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Abstract 
Vaccination policies in Australia need to be scrutinised because the use of a medical 
intervention in the prevention of infectious disease has serious health and social implications. 
Deaths and illnesses to infectious diseases were significantly reduced due to environmental 
and lifestyle reforms prior to the widespread use of most vaccines in the mid-20th century. 
Mass vaccination campaigns were adopted after this time as the central management strategy 
for preventing infectious diseases, with many new vaccines being recommended in the 
National Immunisation Program (NIP). The implementation of mass vaccination programs 
occurred simultaneously with the development of partnerships between academic institutions 
and industry. The Australian government’s NIP, like all member countries of the World 
Health Organisation (WHO), is recommended by the Global Alliance for Vaccines and 
Immunisation (GAVI). This is a partnership with the WHO and UNICEF that includes the 
World Bank, the International Monetary Fund, the International Federation of Pharmaceutical 
Manufacturers and Associations (IFPMA), the Bill and Melinda Gates Foundation (BMGF), 
the Rockefeller Foundation, the United Nations Development Fund (UNDF) and other private 
research institutions. All members of this public-private partnership influence the 
development of WHO global health policies.  
It is important that independent research is carried out to assess whether all the 
vaccines being recommended today are safe, effective and necessary for the protection of the 
community. It is also important to have comprehensive evidence that it is safe to combine 
multiple vaccines in the developing bodies of infants. The framework for undone science is 
used to analyse the Australian government’s claim that the benefits of vaccines far outweigh 
the risks. Whilst the government claims serious adverse events to vaccines are rare this is not 
supported by adequate scientific evidence due to the shortcomings in clinical trials and long-
term surveillance of health outcomes of recipients. A close examination of the ‘Swine Flu’ 
2009 vaccine and the vaccine for human papillomavirus (HPV), intended to prevent cervical 
cancer, shows shortcomings in the evidence base and rationale for the vaccines. This 
investigation demonstrates that not all vaccines have been demonstrated to be safe, effective 
or necessary. It also concludes that the government’s claim that the benefits of vaccines far 
outweigh the risks cannot be sustained due to the gaps in the scientific knowledge resulting 
from unfunded research and the inadequate monitoring of adverse events after vaccination.  
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against antigens such as bacteria, pollen grains and foreign red blood cells and 
foreign protein etc. It is the basis of immunity and allergy. Antibodies are 
globulin type proteins that are classified according to their structure and 
function. 
 Titre  
The extent to which a sample of blood serum containing antibody can be 
diluted before losing its ability to cause agglutination of the relevant antigen. 
It is used as a measure of the amount of antibody in the serum. 
Immune  
Protected against a particular infection by the presence of specific antibodies 
against the organisms concerned. 
 
Immune Response 
 The response of the immune system to antigens. There are two types of 
immune response produced by two populations of lymphocytes. B-
lymphocytes (or B-cells) are responsible for humoral immunity and T-
lymphocytes (or T-cells) are responsible for cell-mediated immunity. These 
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Immune System:  
The organs responsible for immunity. The primary lymphoid organs are the 
thymus and the bone marrow; the secondary lymphoid organs are the lymph 
node and lymphoid aggregates (spleen, tonsils, gastro intestinal lymph tissue 
and Peyer’s patches (ocal masses of lymphoid tissue on the mucous membrane 
lining in the small intestine). 
Immunity   
The body’s ability to resist infection resulting from the presence of circulating 
antibodies and white blood cells. Healthy individuals protect themselves by 
means of physical barriers, phagocytic cells, natural killer cells, and various 
blood-borne molecules. All of these mechanisms are present prior to exposure 
to infectious agents and are part of natural (or innate) immunity. 
Immunity (Active)  
When the body’s own cells produce and remain able to produce appropriate 
antibodies following an attack of a disease or deliberate stimulation. 
 
Immunity (Passive)  
When ready-made antibodies in antiserum is taken from an immune person or 
animal and injected into another individual. This immunity is short lived. 
Babies have passive immunity conferred by antibodies from the maternal 
blood and colostrums to counter diseases for several weeks or months after 
birth.  
Immunisation  
The production of immunity by artificial means. Passive immunity which is 
temporary or active immunity by the stimulation of the body with treated 
antigens to produce its own antibodies (called vaccination or inoculation). 
Immunoassay 
Techniques used for determining the levels of antigen and antibody in a tissue.  
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Immunogenicity  
The property that enables a substance to provoke an immune response 
including foreignness, size, route of entry into the body, dose, number and 
length of exposures to the antigen and host-genetic make-up. 
Immunosuppression   
Suppression of the immune response usually by disease e.g. AIDS or drugs. 
Pathogen  
A microorganism such as a bacterium that parasitizes an animal (or plant) or a 
human and produces a disease. 
Pathogenic  
Capable of causing disease. The term is applied to a parasitic microorganism 
(especially a bacterium) in relation to its host, Pathogenicity. 
Seroconversion  
To produce specific antibodies in response to the presence of an antigen (e.g. a 
vaccine or a virus/bacteria).  
Surrogate  
An object or criteria that functions as a substitute for another object/criteria. In 
clinical trials where it is not logistically practical to use one criteria as an end-
point for the conclusions another suitable substitute is used.   
Vaccination   
The act of receiving a vaccine to stimulate antibody production to produce 
immunity to a disease. 
Vaccine   
A special preparation of antigenic material that can be used to stimulate the 
development of antibodies thus conferring active immunity against a specific 
disease or number of diseases. Many vaccines are produced by culturing 
	   xvii	  
bacteria or viruses under conditions that lead to a loss of their virulence but 
not their antigenic nature. Other vaccines consist of specially treated toxins 
(toxoids) or of dead bacteria that are still antigenic. New vaccines contain 
genetically engineered DNA.  
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CHAPTER 1 
INTRODUCTION 
1.1 Vaccination in Australia 
In Australia many new vaccines have been added to the national vaccination schedule and 
implemented in coercive policies over the last two decades. The aim of this thesis is to 
examine the complex relationship between policy development and scientific knowledge in 
order to assess the adequacy of the Australian government’s National Immunisation 
Program (NIP) in protecting public health. Government vaccination policies are claimed to 
be founded on scientific evidence for the good of the community and this investigation 
provides a critique of the evidence and political decisions that are being used to support key 
claims underpinning current vaccination policies. The project examines the complex issue 
of scientific evidence and health policy development, and the influence of funding and 
political/cultural factors on the design of public policy. Vaccines have been shown to result 
in death and illness in a percentage of the population and, like all drugs, cannot be used 
without risk (AG IAP 2015). In order to protect public health, I argue that Australian 
vaccination policies should be founded on detailed historical and epidemiological 
knowledge of infectious diseases, specific to the Australian situation. This project examines 
whether comprehensive knowledge of infectious disease etiology or selective knowledge is 
being used to underpin the claims of safety, efficacy and necessity for using the vaccines 
recommended in the NIP. Policy development is essentially a political process founded on 
the available scientific evidence hence another aim is to examine the political structures 
that influence the integrity, rigour and completeness of the scientific evidence. The 
information collected will be used to assess the role of vested interests in the development 
of Australian vaccination policies.   
A critique of Australia’s vaccination policies is necessary because the government has 
adopted vaccination as the default position for certain groups in Australian society, even 
whilst claiming vaccination in Australia is not compulsory. Pressure is being placed on 
individuals to use multiple vaccines by linking financial incentives in the form of welfare 
benefits, childcare places and employment to the use of an expanding number of vaccines. 
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Since the introduction of the first vaccine in the late 18th century, this medical intervention 
has been vigorously debated in families and communities. In recent times vaccines have 
been used in global mass vaccination programs directed through the World Health 
Organisation (WHO) in an attempt to eradicate infectious diseases. These programs are 
based on the theory of vaccine-created herd immunity and the need to ensure high 
participation rates in vaccination programs to prevent these diseases. As a member country 
of the WHO, the Australian National Immunisation Program (NIP) has reflected many of 
the directives provided by the WHO for global health policies. Since the early 1990’s the 
Australian government has emphasized the need to increase participation rates in 
vaccination programs. At the same time, new vaccines were added to the schedule and the 
terminology changed so that infectious diseases became known as ‘vaccine-preventable 
diseases’, in line with global policy. The use of vaccines globally is promoted by 
significant vested interests and their adoption in public health policies is an ethical issue 
that requires public discussion and consent from the community. This thesis is an 
examination of the Australian Government’s vaccination policies, including an assessment 
of the underpinning scientific evidence and the stakeholders who have influence in the 
decision-making process.   
Vaccination is a medical intervention that injects weakened pathogens (antigens) and 
chemical substances into the tissues of healthy individuals to stimulate the production of 
antibodies (Stern and Markel 2005). This is different to immunisation which is the process 
of obtaining immunity from the artificial stimulation of antibodies against an antigen 
(Martin 2002). Although these two words are often used interchangeably by the public and 
on the government Immunise Australia Program (IAP) website, they have very different 
meanings and it is not appropriate to use them as synonyms. Receiving a vaccine does not 
always provide immunity and immunity can be gained without receiving a vaccine. 
Individuals can develop immunity to a disease by either natural exposure to the pathogen or 
by receiving a vaccine. Sometimes individuals are vaccinated but do not acquire immunity 
to the disease. This can be a result of the vaccine not working or because an individual is 
exposed to a strain of the disease that is not covered by the vaccine. Conversely individuals 
can have immunity to a disease but not be vaccinated. This is because exposure to the 
pathogen, even without symptoms, results in natural immunity and this immunity is of 
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longer duration (often life-long) than that gained from a vaccine. This is the case for 
whooping cough, hepatitis B and measles (AG IAP 2012).  
Public health reforms successfully reduced mortality and illness from infectious diseases in 
developed countries by the mid-20th century yet vaccines were not used as a major strategy 
for the prevention of disease until after 1953 (CoA 1953). Since that time there has been a 
significant increase in the number of vaccines being recommended to the public, despite the 
prior and ongoing reduction in risk from infectious diseases. In this thesis I examine 
evidence relevant to policy formation, including the role of ‘undone science’: areas where 
funding is not provided to collect crucial evidence relevant to the claims that are made. In 
this thesis I have investigated whether there are political and cultural pressures related to 
considering alternatives to the accepted wisdom.  
In order to assess the founding principles of this policy I have started by clarifying the 
definition of ‘health’ and the way in which health is measured in populations. There are 
many different methods of describing and measuring the health of communities. The 
definition of health is critical to achieving the desired outcomes of a public health policy. 
Health, politics and culture are strongly interrelated and this is reflected in the models of 
health that have been adopted by western and eastern countries. This thesis illustrates the 
Australian government’s priorities in public health policy by its adoption of the scientific 
medical model of health in the mid-20th century to prevent an increasing number of 
infectious diseases. Designing public health policy for the control of infectious diseases 
requires knowledge of the causal factors in the worldwide decline of deaths and illness to 
infectious agents. Hence the thesis investigates the evidence that exists to demonstrate the 
influence of vaccines in the control of diseases. This is done by examining the historical 
perspective in which mortality and morbidity to infectious diseases declined over the past 
one hundred years. Vaccines target bacteria and viruses which exist in an ecological context 
within each geographical region. These infectious agents are an essential part of the 
microflora; the ecological context in which they are found plays a significant role in the 
control of disease. 
Public health authorities have long observed that the characteristics of the environment, the 
host and the infectious agent interact to produce a variety of health outcomes after exposure 
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to an infectious agent. I investigate the causal factors in infectious diseases and examine 
whether full knowledge of them has been used as the foundation for Australian government 
vaccination policies within the Australian context. Vaccination was adopted as the central 
management strategy for infectious disease control in the second half of the 20st century. 
Hence, this thesis includes an investigation of the threat of infectious diseases at the time 
most vaccines were introduced. The partnership between industry and medical science 
flourished at the same time as vaccines were adopted as the main management strategy for 
infectious diseases globally. I have provided a description of this partnership to illustrate 
how the medical-industry model has influenced the production of scientific knowledge and 
the promotion of health in the Australian community. Cultural values and ethics are 
fundamental to health promotion and a description of the ethics adopted in good medical 
practice is also provided to see if they are consistent with the promotion of current 
vaccination policies. The thesis examines the effect of the medical-industry partnership on 
the development of public health policy and the ability of health professionals to provide 
independent health advice to their patients within this cultural context. Public health policy 
always involves value judgments of the available evidence, not simple extrapolation or 
application, and this is explored in the thesis.   
Risk assessment for health hazards is influenced by the interest stakeholders have in 
scientific issues so I have investigated the influence of funding and the perspectives and 
dominance of different stakeholders in policy decisions about vaccines. This also includes 
an assessment of the methodology that is used to determine the risks of infectious diseases 
as well as the risks of vaccines. It is important that these risks are assessed in a systematic 
manner with transparent assumptions to protect public health. The risk of diseases and 
vaccines must then be accurately communicated to the public. Health is not the only 
interest protected in public health policies; the prestige and livelihood of medical 
practitioners and industry are tied up in the design of public health policies. Hence the 
public is entitled to be involved and consulted in debates/decisions about public health 
policy in order to protect their interests in these policies.  
In addition, medical clinicians and environmental health practitioners hold different 
perspectives on health prevention, therefore management strategies for infectious disease 
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will vary according to who is in charge of the policy: environmental health practitioners 
(ecological medicine) or clinicians (scientific medicine). I have described the differences in 
the beliefs held by these professionals. A description of the governance of this policy is 
also necessary to illustrate the interests that are central to policy development. Most 
members of the public believe that claims about the efficacy and safety of vaccines are 
founded on comprehensive evidence that accurately predict health outcomes because this is 
how the government presents this policy. If necessary research to improve knowledge about 
health outcomes has been discussed but not funded, it is termed ‘undone science’; I have 
investigated the undone science relevant to the Australian government’s vaccination 
policies. It is important that the funded studies are designed with appropriate parameters to 
ensure they provide sufficient empirical evidence about the safety and effectiveness of 
vaccines in the community. Research design influences the integrity and rigour of the 
conclusions. If relevant research is left undone the science relevant to protecting public 
health is absent. As policies are founded on value judgments concerning the available 
evidence, the absence of relevant research puts population health at risk due to the 
unpredictable nature of the health outcomes.   
I have included two case studies, the HPV vaccine and the ‘Swine Flu’ 2009 vaccine, to 
illustrate the influence of corporations on the evidence that is being used to promote 
vaccines as being safe, effective and necessary to prevent infectious diseases. The public is 
informed that health policies are founded on the best available evidence but they are not 
informed of the gaps that may exist in the evidence. These case studies examine the reasons 
why there might be gaps in the evidence and it describes the political framework in which 
policy is affected by biased science or undone science. The existence of institutional 
barriers to carrying out independent research, including on topics unwelcome to groups 
with vested interests, underscores the need for transparency and accountability in 
government processes and the accurate communication of health issues to the public. 
Traditionally research institutions have had more autonomy from industry in directing 
medical research, thus providing greater independence in the assessment of which areas of 
science would receive funding. This is essential to making balanced decisions on public 
interest science and health policy design. In this thesis I examine how the privatization of 
science has altered the values of non-profit research institutions and how industry-directed 
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research is impacting on the production of knowledge. Government funding can also be 
aligned with industry interests if structural barriers such as conflicts of interest exist in the 
process of policy development. The information collected in this thesis has been used to 
examine the Australian government’s claim that the national subsidised schedule of 
vaccines produces more good than harm in the population. Such a claim is dependent upon 
the integrity and transparency of the science and whether there is a consensus amongst the 
stakeholders about the evidence that is being used.  
Macfarlane Burnet, Nobel Prize laureate for immunology and Australia’s first Australian of 
the Year in 1960, suggested over half a century ago that genetics, nutrition, psychological 
and environmental factors (ecological medicine) may play a more important role in 
resistance to disease than the assumed benefits of artificial immunity induced by 
vaccination procedures (Burnet 1952 p106). He suggested that in years to come society 
may have to reassess the belief scientists were placing in vaccination. He considered that 
genetic deterioration of the population may be a consequence of universal mass vaccination 
campaigns and he postulated that ‘some of our modern successes in preventative and 
curative medicine may on the longest view be against the best interests of the state’ (Burnet 
1952 p107). Burnet (1952) believed that genetic constitution was the most important hidden 
variable in disease statistics. Gilbert (2004) reinforces this theory with a new definition of 
environmental health that emphasises the importance of genetic potential to health 
outcomes from environmental hazards. This is described in chapter 2. It is possible that the 
genetics and health of the population are at risk if these factors are not considered in the 
preventative strategies that are adopted in the control of infectious diseases. This theory 
needs to be investigated because we have observed a simultaneous increase in chronic 
illness in Australian children, and in children in other countries, as the number of vaccines 
and participation rates in NIP’s has increased (AIHW 2005; PHAC 2007; Burton 2003). 
Allergies have increased in the Australian population with 10% of infants having a food 
allergy and 20% of the Australian population: hospitalisations for anaphylaxis have 
increased 5-fold in the last 20 years (ASCIA 2015). This correlation has not been 
investigated by the Australian government to demonstrate that the Australian vaccination 
schedule is not the cause of this significant increase in chronic illness. See section 7.4. 
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Quality of life is a measure of population health, not just infant mortality rates and 
vaccination coverage, and as the permanent chronic illness in Australian children escalates 
governments have a duty of care to demonstrate that vaccination policies are providing 
more good than harm in the population and that they are indeed in the best interests of the 
community.  
1.2 Research 
I have drawn on publicly available documents to probe the justifications for the use of 
many vaccines to control an increasing number of infectious diseases. The sources I have 
used are government documents and websites, the Australian Government Immunisation 
Handbook, medical and scientific articles, books, and websites. Many older sources have 
been used in reviewing historical knowledge of the decline of infectious diseases and also 
for the investigation into the HPV vaccine. This has been done to assess the knowledge that 
was available to authorities at the time the vaccines were introduced. This is particularly 
important for the HPV vaccine because the etiology of cervical cancer was not firmly 
established until the late 1990’s when new biotechnology was developed and it is possible 
that recent evidence is being interpreted to conform to preconceived ideas. I have used the 
framework of political economy and undone science to examine the government’s claims 
that vaccines are a safe, effective and necessary preventative strategy for preventing 
infectious diseases. The investigation examines the political and economic influences on 
the evidence that is used to make these claims. It examines the government’s vaccination 
policy to determine whether the decisions to use an increasing number of vaccines are 
based on evidence from the Australian context or directives from the WHO in line with 
global health policies. Scientific findings obtained from clinical trials can be biased when 
funding is provided by companies with vested interests in the outcomes. Therefore an 
independent assessment of the evidence is required. This project investigates whether an 
independent assessment of industry sponsored research is included in policy development. 
In a few places in this thesis some exposition at a basic level is needed to cover ideas 
essential for developing the overall arguments. In these places I have drawn on fundamental 
treatments of the subject area. 
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Further, epidemiological studies in populations are limited because they are mainly 
observational and many variables cannot be controlled. This underscores the need to ensure 
that scientific conclusions are founded on all types of evidence. A central feature of the 
methodology was to determine whether epidemiological, animal, clinical, biological and 
ecological studies are all being used to form a consensus about the benefits and risks of 
vaccines. I have examined the risk of infectious diseases from an ecological perspective to 
investigate the justification for using an increasing number of vaccines in Australia’s 
national immunisation program (NIP). The project was limited by the fact that consumers 
in Australia are not encouraged to debate vaccination polices. They are designed by expert 
panels and presented as a ‘medical intervention’ that should be promoted to the public by 
health professionals.  
  
1.3 Thesis Structure 
The thesis is divided into 2 parts: Part 1 Science and Policy (chapters 1-5) is a description 
of the historical development of the policy, and Part 2 Corporate Influence and Undone 
Science in Public Policy illustrates the influence of the medical-industry complex on the 
production of scientific knowledge and the political decision-making process in the era of 
privatisation.  
Part 1: Science and Policy 
Chapter 2 discusses the historical development of Australia’s public health policies and the 
adoption of vaccination as the dominant management strategy for infectious diseases from 
1953 to the present. It examines the control of infectious diseases and the main factors that 
were influential in reducing deaths and illnesses to these diseases. Chapter 3 describes 
Australia’s National Immunisation Program (NIP) and its development within WHO global 
public health policy. Part 1 of chapter 3 presents the influence of WHO in the development 
of Australia’s NIP. It provides the reasons why the number of vaccines and the emphasis on 
participation rates in vaccination programs increased during the1990’s. Part 2 of chapter 3 
describes the development of the NIP over the last three decades and the recent extension 
of Australia’s vaccination policies to mandatory use in many workplaces and in social 
welfare policies. Chapter 4 describes the implementation of the NIP by the Australian 
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states. A description of the control and governance of this policy has been provided as well 
as the methodology for risk assessment for infectious diseases and vaccines. Surveillance of 
disease in the community is also described, as it is essential for measuring the burden of 
disease and communication of risk to the public. This chapter describes the concept of 
artificial (vaccine-induced) and natural herd immunity for community protection and the 
way in which statistics are being presented by the media to communicate the risk from 
diseases/vaccines. Chapter 5 describes the model of health that has been adopted by 
western countries and how it influences policy decisions. It provides a discussion of the 
guiding principles and cultural beliefs/values underlying public health policy in Australia. 
Public health is a complex area that involves many political and ethical decisions. The 
Seedhouse Ethical Grid is presented to illustrate the principles that should guide decisions 
in health promotion and the way in which current vaccination policies are infringing human 
rights. The ethical guidelines for good medical practice in Australia are discussed along 
with the human rights codes that protect our rights in public health policies.  
Part 2 Corporate Influence and Undone Science in Public Health Policy 
Chapter 6 describes the development of the academic–industry model that is influencing the 
production of scientific knowledge in the 21st century. It provides examples of the impact 
the privatisation of science has had on the direction and type of research that is undertaken 
in academic institutions. The corporatisation of science has led to a change in the integrity 
and rigour of scientific research and it has also led to the dominance of technical experts on 
government advisory boards. This chapter explores the effect of corporatizing health on the 
institutional barriers against citizen involvement in policy design. Chapter 7 provides a 
discussion of a number of key claims that are made about vaccines to the public to support 
the government’s vaccination policies. These claims are stated on the Frequently Asked 
Questions (FAQ) page of the Immunise Australia Program (IAP) website. I have discussed 
these claims in light of the evidence that I have found in the historical and medical 
literature. I have also discussed some of the claims made by the Australian Academy of 
Science (AAS) in its document supporting government vaccination policies. Chapter 8 
describes the political economy of public health policies and the political framework that 
results in ‘undone science’. I have described a conceptual framework that assists in 
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assessing the risks and benefits claimed in government vaccination policies. Vaccination 
policies involve political, ethical and social issues; for example the funding of research is 
influenced by companies and governments. These issues and the relevance of ‘undone 
science’ in public policy are discussed with a case study to illustrate the consequence of 
undone science to the community. This chapter concludes with the undone science that is 
relevant to the Australian government’s vaccination policies. The case studies in chapters 9 
and 10 illustrate how industry-funded research is being promoted to medical professionals 
and the public without independent assessment. Chapter 9 provides a case study of the 
Human Papillomavirus (HPV) vaccine to illustrate how vaccines are being developed and 
promoted to consumers in the era of medical-industry partnerships and globalisation. The 
framework for undone science is used to assess the claims of safety and efficacy that 
underpin the use of HPV vaccines. Chapter 10 provides a case study of the ‘Swine Flu’ 
2009 vaccine to illustrate the influence of corporations in WHO/GAVI global health 
policies and the effect of public-private partnerships on national health policies in member 
countries. It illustrates the influence of conflicts of interest on vaccine advisory boards and 
the undone science that exists in the political decisions made in policy design.  
Chapter 11 presents the conclusions that are drawn from this study. I discuss the political 
and cultural influences in the design of public health policies and the institutional barriers 
that prevent public involvement in vaccination debates and policy decisions. The evidence 
collected in this thesis is also used to examine the Australian Government’s claims that:  
I. Vaccines are proven to be a safe, effective and necessary management strategy for 
infectious diseases and 
II. The benefits of vaccines to the community far outweigh the risks of vaccines to 
individuals. 
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CHAPTER 2 
CONTROLLING INFECTIOUS DISEASES  
	  
2.1 Introduction 
This chapter examines the main factors responsible for the decline in the risk of 
infectious diseases in developed countries such as Australia. An understanding of the 
main influences in the reduction of mortality and morbidity due to infectious diseases is 
necessary to assess the benefits and risks of vaccines. This chapter outlines the 
historical strategies that were most successful in reducing illness and death to infectious 
diseases and it illustrates the political influences in policy design. The chapter examines 
whether public health policy has been designed in response to threats to public health in 
Australia or desired political outcomes.  
Infectious diseases have traditionally been referred to as a public health problem 
however from the 1990’s onwards the term environmental health became popular. 
These terms have similar meanings so I have introduced this chapter with a definition of 
these terms. In many countries government public health policies had a change of focus 
in the mid-20th century. This change was a move from strategies founded on a multi-
factorial theory of disease causation (ecological medicine) to the germ theory that 
underpins western medicine. The western medical model of health is founded on the 
concept of ‘scientific medicine’, which includes evidence-based practice, and infectious 
diseases were re-defined in the second half of the 20th century as a problem that could 
be addressed with a medical intervention. This was due to the progress in etiological 
theories based on microbiology. In contrast, the decline in infectious diseases in the first 
part of the century was brought about through political, social and economic 
interventions in behaviour and the environment: termed social or ecological medicine.  
The direction of Australia’s public health policy was influenced by the World Health 
Organisation (WHO) and UNICEF from the 1970’s onwards. This was part of an 
international effort to vaccinate all the children of the world. This WHO/UNICEF 
initiative was known as the Expanded Program on Immunisation (EPI). Its primary goal 
was to achieve maximum vaccination coverage by implementing strategies that were 
recommended by the WHO. Australia adopted many of these strategies. The scope of 
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this program and its implementation globally are described in section 3.2. Whilst 
medical practitioners were influential in policy design during the early 20th century 
when the Commonwealth Health Department was established (1921), they were not the 
dominant influence: social medicine dominated public health reforms until the mid- 
twentieth century. However, from the 1970’s onwards the medical-industry model was 
the dominant influence in the development of public health policy. This resulted in a 
focus on vaccination - a medical intervention - as the main strategy for preventing 
infectious diseases. Yet for decades prior to this, social medicine had been successful in 
reducing the risk from infectious diseases. The scientific medical model of health and 
its adoption in Australian public health policy are described in chapter 5.  
The use of childhood vaccines globally and in Australia rose significantly from the 
1990’s onwards. This was after infectious diseases had become a very low risk to the 
majority of children in developed countries. A description of the development of 
Australia’s National Immunisation Program (NIP) and the directives provided by the 
WHO/UNICEF for implementation of national programs is presented in chapter 3. The 
implementation of this policy into Australian communities is described in chapter 4 and 
the principles and ethics of public health policies and health promotion are discussed in 
chapter 5.  
2.2 Defining Public Health and Environmental Health  
The Australian Federal Government states that environmental health (EH) provides the 
basis for public health. EH is the study of human diseases that are determined by 
physical, chemical, biological and social factors in the environment (AG OEH 2012). 
This includes improvements in sanitation, water quality, nutrition, control of disease, 
and housing standards, all of which have been essential to the significant improvement 
in health and longevity experienced over the last century (Stanley 2001). Yet the 
Australian government provides the following definition of environmental health: 
‘Environmental health addresses all the physical, chemical, and biological factors 
external to a person, and all the related factors that can potentially affect health. It is 
targeted towards preventing disease and creating health-supportive environments. This 
definition excludes behaviour not related to environment, as well as behaviour related to 
the social and cultural environment, and genetics’ (AG OEH 2012).  
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A definition of environmental health that excludes genetics and the social and cultural 
environment is deficient because these factors are strongly linked to the individual’s 
health and well-being (Gilbert 2004 p16; WHO 1986). This is particularly the case in 
the context of exposure to environmental toxins or pathogens (CDC NIOSH). Social 
and cultural factors are strongly linked to environmental causes of disease and in 
particular the stress and fatigue levels of individuals (CDC NIOSH). Infectious diseases 
are caused by microorganisms in the environment that can infect the body and have the 
potential to become pathogenic (AG OEH 2012). One of the main determinants of 
disease expression is the genetic potential of the host (Gilbert 2004 p16). Recent 
advances in the toxicological and genomic sciences, have led to a new definition of 
environmental health that states: 
‘Conditions that ensure that all living things have the best opportunity to reach and 
maintain their genetic potential’ (Gilbert 1999 in Gilbert 2004, p ix).  
The knowledge gained from new molecular biology techniques has enabled scientists to 
examine the coding of genes. This evidence is demonstrating that in order to ensure the 
health and well being of children (and all life) it is essential to protect the genetic 
potential of the individual. Environmental health practice, or environmental medicine, 
addresses emerging health risks arising from the pressure that human development 
places on the environment (BSEM). This encompasses infectious diseases. It is the 
Australian Government’s goal to prevent infectious disease by creating health 
supportive environments (AG OEH 2012). The area of medicine that addresses 
environmental health is called ecological medicine (BSEM). This is a preventative 
medical discipline that examines the interactions between the individual and the 
environment, and the health outcomes that are produced. This includes both the impact 
of environmental factors on the individual and the individual’s action on the 
environment (BSEM). Ecological medicine examines health outcomes that arise from 
five interconnected areas: i) nutrition ii) toxins iii) allergy iv) genetics v) environment 
(BSEM).  
In 2002, the Institute of Medicine (IOM) developed an action model for achieving 
healthy individuals through public health policy. This model, illustrated in Figure 1, 
incorporates five interacting factors to demonstrate the significance of each aspect to 
achieving healthy communities through public health policy.  
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Figure 1: The Individual and Environmental Factors that Determine Health 
 
Source: Institute of Medicine, The future of Public Health in the 21st Century, Washington, DC: 
National Academies Press 2002. 
Many researchers state that wealth and poverty remain the most significant determinants 
of the health status of all populations (Stanley 2001; Naidoo and Wills 2000 p13; Dubos 
1966 p14). It is stated that the large gains in life expectancy in the first half of the 20th 
century were a result of the implementation of environmental reforms where as the 
contribution of medical care to this life expectancy is relatively small (Bunker 2001 
p1262; Mckeown 1979 p52). Well known health commentator Rene Dubos stated: 
‘…until social and economic changes are made no amount of medical and scientific 
knowledge can be of much help’ (Dubos 1966 p14). Genetic traits are also significant to 
the health of individuals and different genetic traits will be an advantage in different 
environments (Dubos 1966 p15; Gilbert 2004). This explains why there is a variety of 
health outcomes after exposure to an infectious agent in different ecological settings. 
Similarly genetics results in a variety of health outcomes after exposure to a vaccine. 
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2.3 The Control of Infectious Diseases  
This section describes the multiple factors known to interact in the etiology of infectious 
diseases. It describes the epidemiological triad that public health authorities use to show 
the relationship between these factors and an introduction to microbiology and the germ 
theory, and the use of vaccines to control disease.  
Vaccination as a preventative public health strategy was first used by Edward Jenner in 
the late 18th century (Hays 2000). It was used in the fight against smallpox for ~150 
years but its efficacy was never tested in controlled clinical trials that exposed a large 
number of participants to the smallpox virus and compared the outcome to a control 
group (Wallace 1898). Consequently there is controversy surrounding the use of 
smallpox vaccine in the control of smallpox epidemics throughout the history of its use 
(Wallace 1898 pp218-315; Bashford 2002 p39; Kleinman et al 2005; Allen 2007; 
Schwenk 2006). Mass vaccination programs against multiple diseases in public health 
policies have only been practiced for the last 60 years and the combined schedule of 
vaccines recommended by the Australian government has never been tested for long-
term health outcomes in animals or humans (AAS 2012). See section 7.4.  
A vaccine is a medical intervention that is promoted to the public as an effective 
strategy for preventing infectious diseases. Yet these diseases are an environmental 
health issue because they are caused by microorganisms that exist within an ecological 
context. Therefore the risk from these organisms varies according to the characteristics 
of the community, the agent and the individual’s lifestyle and genetics (Wallace 1889 
p316; Cumpston 1989; McKeown 1979 p78; Curry 2002 p33; Stanley 2001 p379; Friis 
and Sellers 2004 p402). Developing countries have had mass vaccination programs for 
many decades yet infectious diseases are still prevalent (WHO 2013). Mass vaccination 
in developing countries began in the late 1970’s with the introduction of the United 
Nations Children’s Fund (UNICEF) ‘child survival revolution’. The fact that developing 
countries are still rife with infectious diseases today suggests that depending on 
vaccines to prevent disease in countries with poor environmental and nutritional 
conditions is questionable (McKeown 1979 p61). This is due to the known synergistic 
effect between malnutrition and illness. Diet is a major determinant of infection rates 
and outcomes of disease (McKeown 1979 p61; Gillespie 1991; Gilbert 2004). Disease 
causality is directly related to host and environmental characteristics and consequently it 
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is not just a result of infection with a pathogenic organism. The agent is a necessary 
factor but not a sufficient cause of disease (Friis and Sellers 2004 p402). The expression 
of disease after exposure to an infectious agent is the result of an interaction of multiple 
factors. These factors have been incorporated into a model for causality that public 
health authorities refer to as the Epidemiological Triad (Friis and Sellers 2004 p398). 
This is illustrated in Figure 2. 
Figure 2: The Epidemiological Triad of Agent, Host and Environmental Factors 
 
Source: The Association of Faculties of Medicine of Canada (AFMC), 2007, The Interacting Triad 
of Causal Factors. AFMC Public Health Educators’ Network http://phprimer.afmc.ca/ (accessed 
October 2013). License: Creative Commons BY-NC-SA. 
 
For many decades, this model has been revered as one of the fundamental public health 
concepts of disease causality and the best method for determining the cause of 
infectious diseases (Friis and Sellers 2004 p398). The model illustrates that disease is 
caused by an interaction between the agent (the pathogenic organism), the host and the 
environment. More recently scientists have recognized that this is a complex interaction 
between many variables. Whilst an agent must be present for an infection to occur it is 
known that not all interactions will progress to disease (Friis and Sellers 2004). 
Infections can be ‘subclinical’ which means they do not produce any signs or 
symptoms, but they still confer immunity to future exposure (Friis and Sellers 2004 
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p402; McKeown 1979 p46). There are also many outcomes from infection including 
complete recovery, permanent disability, disfigurement and death. Many diseases are 
self-limiting and complete recovery can be expected in the majority of cases (Friis and 
Sellers 2004 p402). The likelihood of an infectious agent causing clinical signs and 
symptoms of disease is described as its ‘pathogenicity’. This characteristic and many 
others differ from one infectious agent to the next. Therefore the ability of an agent to 
cause disease in any environment is dependent upon the interaction of many variables 
within the ecological context in which it is found. It is commonly recognised that this 
diversity in health outcomes after individuals have been exposed to an infectious agent 
is not highlighted in the germ theory of disease that is adopted in western scientific 
medicine. These diverse health outcomes are a result of differences in the host’s 
immunology, physiology, social and emotional environment as well as differences in 
the ecological and agent characteristics (Doyal and Doyal 1984 p97; Friis and Sellers 
2004; Gilbert 2004). In contrast, the germ theory describes disease as being caused by 
the infectious agent and resulting from internal biological changes. This simplified 
theory, termed a reductionist theory, is a central belief of the scientific medical model 
(SMM) and it lends itself to using a vaccine to prevent disease from infectious agents. A 
more detailed description of the germ theory is provided later in this chapter. 
2.4 Developments in Public Health Policy in Australia  
This section describes the historical control of infectious diseases and the events that led 
to the reduction in risk (mortality and disability) from infectious agents in Australia and 
other developed countries.  
Public health is the discipline of promoting health to the whole population. It involves 
gathering health information and statistics (epidemiology) to support interventions that 
can improve the health of the population (Naidoo and Wills 2000 p183). It is focused on 
communities or groups rather than individuals and mostly involves services and 
directives provided by governments with assistance from private and voluntary 
organisations (Palmer and Short 2010 p22). These services include environmental 
health measures, health promotion, health education and vaccination programs. Public 
health policy is multidisciplinary involving economics, ethics, epidemiology, 
healthcare, sociology and political science. The purpose of public policy is to serve the 
public interest in community living and it is intertwined with individual responsibility to 
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the state and collective action (Pelling 2002 p16). However, as there are many 
influential stakeholders in this policy, policy design results from a power play between 
different stakeholders in the decision-making process (Palmer and Short 2010 p xxvi). 
Hence, political analysis is necessary to understand whose interests are being promoted. 
Public health policy is not designed on a simple application of the current scientific 
knowledge, but rather is a result of complex political factors driven by struggles over 
funding and power within the dominant network of scientists and their theories. 
During the 19th and early 20th centuries Australia’s public health policy was dominated 
more by social reform than scientific medicine. The sanitary reform movement of this 
time involved local governments implementing infrastructure improvements to control 
infectious diseases in crowded and unsanitary slums (Reynolds 2004 p168; Curry 2002 
pp32-33). Sanitary reform was driven by community activists who observed that the 
poorer classes suffered the greatest burden of disease (Pelling 2002 pp24-25) and they 
believed it was the government’s duty to intervene in this cause. The social reforms 
implemented were observed to significantly reduce mortality and morbidity in children 
in England and Australia (Wallace 1889 pp316-324; Feery 1981; Gillespie 1991 p32; 
Stanley 2001 pp368-369). The developments in public health in Australia reflected the 
measures adopted in Britain in the Public Health Act of 1848 (Reynolds 2004 p168). 
Reforms included clean water, adequate waste and sewage disposal, food hygiene and 
housing. Many public health authorities have stated that improvements in health owe 
more to changes to the environment and public health measures than to clinical 
medicine (WHO CSDH 2005; Stanley 2001; Bunker 2001 p1262; McKeown 1979 
pp78-79; Cumpston 1989 p312; Illich 1975 p15; Dubos 1966 p14). When the death rate 
from scarlet fever, diphtheria, whooping cough and measles in Britain from 1860–1965 
for children up to 15 is combined, the majority of the decline (90%) had occurred before 
the introduction of medical interventions. This includes the use of antibiotics and 
widespread vaccination against diphtheria (Illich 1975 p16). This is supported by 
McKeown (1979) who stated that immunization or medical therapies, other than 
smallpox immunization, are unlikely to have had a significant impact on reducing the 
mortality due to infectious diseases (p92). This is because mortality had significantly 
declined before vaccines for most diseases were available.  
The decline of infectious diseases in England followed a similar pattern to tuberculosis 
with the vast majority of the decline occurring prior to the introduction of medical 
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interventions (Winkelstein 1972 p71; McKeown 1979 p92; Doyal and Doyal 1984 p95). 
This experience of the decline of infectious diseases was similar in Australia and it was 
described by JHL Cumpston, the first director-general of health in Australia, in the early 
20th century (Cumpston 1989 p312). He and other prominent public health officials of 
the time observed that the decline in the risk from infectious diseases in Australia 
occurred simultaneously with improvements in public health and prior to the 
introduction of most vaccines (Cumpston 1989; Burnet 1952; Stanley 2001). By 1950 in 
Australia infectious diseases had become something that Australians thought of as a 
problem in other countries. This was due to improved living standards and a lower 
infant mortality rate (Strahan 1994; Baum 2008 p30). At this time in Australia it was 
considered that 97 percent of newborns would be expected to survive to one year of age 
and 96 percent to five years of age (Gandevia 1978 in Goldsmid 1988 p57). In 1956 
public health officials stated ‘as causes of infant mortality in Australia all the infective 
diseases have been overcome’ (Lancaster 1956a p104). The rates of infectious diseases 
in Australia were very low from 1945 to 2000; 80% of the fall in the under 5 mortality 
rates had occurred by 1960, prior to the introduction and widespread use of vaccines 
(Stanley 2001 p379 and p370).  
Lancaster noted that from 1946-1954 ‘pertussis (whooping cough) was an uncommon 
cause of death for children in Australia and there is a significant decline in mortality if 
the age of infection increases’ (Lancaster 1956a p104). The vaccine was not credited 
with the decline of pertussis because vaccination programs with pertussis vaccine were 
not introduced into mass vaccination campaigns in Australia until 1954. Lancaster also 
stated that ‘mortality rates due to pertussis are used as an index of hygiene or social 
well-being’ (Lancaster 1956b p893). Feery stated that the number of deaths to 
whooping cough in Australia fell even in the unvaccinated areas (1981 p174). The most 
significant contribution to the fall in these mortality rates was the decline in infant 
mortality in the first year of life. This occurred before the introduction of widespread 
vaccination programs in Australia (Stanley 2001 p378; Feery 1981 p174; 
Commonwealth Yearbook 1953). This decline is illustrated in Figure 3. 
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Figure 3: Infant Mortality Rates in Australia 
 
Reference - Official Commonwealth Yearbook of Australia, 1973, No. 59, p183 
The decline is explained in part by a decline in virulence of the pathogens as public 
health infrastructure improved and immunity of the population developed. But the most 
important factor that was recognised at this time was nutrition (Illich 1975 p17; 
McKeown 1979 p78; Gillespie 1991 p49). However, the knowledge of the significance 
of nutrition in the prevention of disease would not have been beneficial to the 
population if there was no political will to implement the infrastructure needed to 
improve the nutritional health of all socioeconomic groups. Szreter (1988) recognized 
the critical importance of the state in redistributing the benefits of economic growth to 
all socioeconomic groups (Szreter 1988 pp34-35). In the 1930’s in Australia the state 
was interested in the health of individuals because they believed each individual was an 
asset to the productivity of the state (Gillespie 1991 p39). As clean water and sewerage 
were provided to all Australians in the mid-twentieth century, with the notable 
exception of many Aboriginal communities, the risk from infectious diseases declined 
in direct correlation (Cumpston 1989). Mortality to infectious diseases continued to 
remain high in Aboriginal communities and other socioeconomic groups where this 
infrastructure was not provided (O’Connor 1989) This example demonstrates the 
importance of state involvement in healthy outcomes and it emphasises the need for 
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legislation, political commitment and popular support for public health reform to be 
successful (Baum 2008 p26).     
Public health policies in Australia have been a state responsibility since the 
establishment of the Commonwealth of Australia in 1901. At this time community 
health centres had a strong emphasis on social medicine to improve health outcomes. 
This included changes to political, economic and social aspects of health (Gillespie 
1991 p39; Doyal and Doyal 1984 p92; Baum 2008 p18). The Commonwealth 
Department of Health was established in 1921 and a medical advisory board was 
established in 1937. This board was called the National Health and Medical Research 
Council (NHMRC) and its role was to:  
i) provide medical advice to the Commonwealth on public health policy and  
ii) to allocate funding to medical practitioners and medical research (Gillespie 
1991). This body is responsible for deciding which areas of science will 
receive funding and which will be ignored. 
The establishment of a medical advisory board for public health policy was the 
beginning of the current paternalistic health system that relies on state and federal 
interventions to achieve healthy communities (Hobbins 2011 p1; Freidson 1970 pp1-
17). The early twentieth century was a time of nation building (up to 1940) and this 
period is noted for the increase in state action that was implemented to improve health 
outcomes. Medical health officers in each state usually had military or colonial 
experience and their role was to monitor standards for clean air, water, food and 
immunization services (Baum 2008 p28). Microbiology was taking hold and giving 
medicine renewed scientific authority with the theory that vaccines could be used to 
prevent infectious diseases (Pelling 2002 p32).  
At this time there was also an emphasis on ‘improving the human race’ (Baum 2008 
pp18-26). The dominant attitude of white Australians was the social Darwinist thinking 
that superior races would survive and Aboriginal people would ‘die out’. This political 
orientation included a eugenics movement: the quest for a ‘pure race’. A eugenics 
program was implemented in Germany with forced sterilisation of mental health 
patients and others with intellectual disabilities. These measures occurred in other 
countries such as the US and demonstrate how political decisions in public health policy 
can remove human rights, such as individual autonomy, whilst being presented as being 
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in the community’s best interests. The emphasis in this era was on the fitness of 
individuals, and their duty to the state to be healthy and productive. In contrast the 
emphasis in the second half of the twentieth century was on the responsibility of 
citizens to be vaccinated for the greater good of the community. The political, 
epistemological and economic conditions of the time influence which theories about 
infectious disease control are adopted in public policy and the relationship between the 
individual and the state (Pelling 2002 p16). The multi-factorial causation of disease was 
obscured briefly in the medical dominance of the germ theory in public health policy in 
the twentieth century but it resurfaced in the New Public Health era from the 1980’s 
onwards. The concept that the control of infectious diseases is purely medical is 
incorrect because infectious agents are linked to many industries and professions 
involved with fermentation, agriculture and the environment (Pelling 2002 p16).  
Governments have used public health policies historically as a tool for achieving 
political and economic outcomes (Pelling 2002 p21). This was observed in the late 19th 
and early 20th centuries when the germ (contagion) theory was used to quarantine 
people and products. Evidence that this was used for political purposes is found in the 
treatment of the Chinese migrants in Australia during outbreaks of cholera. In 1832 the 
Quarantine Act in New South Wales was established to control infectious diseases and 
similar acts were implemented in other Australian colonies soon after. This enabled new 
migrants to be isolated if they were suspected of having cholera and this was imposed 
more rigorously on the Chinese than any other group (Reynolds 1995 p161 in Baum 
2008 p20). The political nature of public health policies in the 19th century was also 
observed in the action of British and Australian health authorities who used public 
health policy to control the poor. Poverty was seen to be the cause of disease however 
redistributing the wealth was considered a threat to social order and productivity. 
Hence, public health authorities would address waterborne diseases such as cholera and 
typhoid that crossed to affluent suburbs before addressing the classic diseases of 
poverty, such as tuberculosis, in the poorer regions (Baum 2008 p21). Health authorities 
used the miasma theory, based on spontaneous generation, as the basis for addressing 
these diseases because it supported cleaning up the environment, whereas the germ 
theory, with its implications of person to person infection, potentially led to quarantine 
procedures which could threaten trade and profits (Baum 2008 p21). At this time it was 
already established that the ability to resist disease was directly related to class and 
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social position due to environmental and lifestyle factors. That is, changes to working 
and living conditions were known to have a direct impact in preventing disease. In the 
1980’s the New Public Health movement was founded on the notion that a strong nation 
is built by reforming the education system and linking science with government to 
operate in a more business-like manner (Baum 2008 p28). The development of public 
health policy from the 1980’s onwards was influenced by the WHO and this is 
described in section 2.7.  
2.5 Immunological Theories 
This section discusses the theories of human immunology that developed in the 20th 
century to illustrate the rival theories that fought for dominance in public health policy. 
Political dominance determined the theories that were adopted in public policy. 
Progress in microbiology coincided with Darwin’s theory of evolution in the late 19th 
century. Prior to improved scientific knowledge about microorganisms the etiology of 
infectious diseases was believed to be from a ‘miasma’ created by unsanitary 
conditions: conditions external to the individual (Reynolds 2004 p168; Curry 2002 
p32). Treatments were based on the zymotic theory of contagion that held that it 
generated spontaneously from decaying matter (Curry 2002). Miasma theory contended 
that disease resulted from inhaling bad smells and for political reasons it was portrayed 
to the public as being ‘unscientific’. This theory advocated improved environmental 
conditions to reduce infectious diseases whilst the germ theory or contagion theory held 
that microscopic organisms were responsible for the development of disease. Germ 
theory lent itself to the use of vaccines as a medical intervention for the prevention of 
disease and this was a politically desirable outcome for the medical/industry model of 
health that arose in the late nineteenth century (Pelling 2002 p26).  
In the early twentieth century sanitary reform driven by the ‘miasma’ theory was 
replaced with microbiology and termed ‘sanitary science’ instead of ‘filth diseases’. 
This was sanitary propaganda which relied on a simplification of the causation of 
disease (Pelling 2002 p30).  A change in terminology was necessary to gain popular 
support for the germ theory over social reform in the prevention of infectious diseases. 
The germ theory was adopted in public health policies in Australia from the 1950’s 
onwards and became the foundation for using mass vaccination programs to prevent 
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disease (Baum 2008 p20). Yet in the early nineteenth century there had been many 
debates about the specificity of diseases and how they should be classified. For 
example, at times they were classified on the consistency of the disease from patient to 
patient (ontological theories) and in other classification systems that took a more 
holistic approach, where the differences in disease due to individuality and 
circumstances were emphasised (Pelling 2002 pp22-24). Sydenham, who is described as 
the ‘English Hippocrates’, believed that each case of disease and each epidemic was a 
unique experience resulting from a particular set of circumstances. He described the 
generic disease process as ‘fever’ in which the whole body was affected and there were 
many debates around fever and inflammation at this time. It was commonly believed 
that disease was a febrile crisis in the body involving the production of diseased matter 
that should be resolved by excretion through the pores/orifices. Sydenham and others 
believed that the process occurred naturally and that doctors should not interfere or cut 
it short because it had a specific course that was significant to development (Pelling 
2002 p23).    
The germ theory of etiology was based on the Darwinian concepts of individual species, 
mutation and natural selection (Dubos 1966; Pelling 2002 p23).  The capacity of 
humans to survive in a given environment was described by Claude Bernard as ‘the 
ability to adapt to external changes while maintaining a constant internal environment’ 
(Dubos 1966 p11). This ability was referred to as homeostasis and it was observed that 
infants are not born with the mechanisms of homeostasis. These mechanisms develop 
over time after experiencing the environment (Burnet 1952; Dubos 1966 p11). Burnet 
comments on this feature with the following observation ‘This effectiveness of internal 
pattern and control is as much a product of growth and experience-through-function as 
the skills of a trapeze artist, an orchestra or a statesman’ (p98). Research in 
biochemistry has demonstrated that a constant internal environment in the human body 
is controlled by the autonomic nervous system and endocrine hormones, and this allows 
humans to fight environmental challenges (Dubos 1966 p11; Trottier et al 2009). 
Therefore it is known that an immune response is much more complex than just the 
production of antibodies in the serum which is the surrogate measure of clinical efficacy 
used for recommending vaccines. The complexity of the immune response means that 
the interaction of the immune system with other body systems must be considered when 
introducing each new vaccine. Historical and current immunological theories do not 
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think of the immune system as an isolated system. Scientists believe that it works in 
conjunction with other body systems e.g. the nervous system (Mercae 2003 p28; 
Tomljenovic and Shaw p2634).  
Homeostasis is considered to be well developed in humans by the age of 5 years and 
this is considered ‘the golden age of resistance’: the age at which humans are most 
adaptable to environmental challenges (Burnet 1952 p 98; Dubos 1966 p12). Children 
between the ages of 5–15 years have the highest resistance to infectious diseases (Dubos 
1966 p12). The efficiency of the human metabolism and immune system starts to wane 
after 30–40 years of age and at 70 it is generally 25% lower than in early adulthood 
(Dubos 1966 p12). Burnet (1952) described the ‘fatal infection’ as one that comes too 
soon (p98). By this he was referring to the fact that exposure has occurred before 
effective homeostatic mechanisms have developed. In this sense, disease can be 
described as a failure of homeostasis (Dubos 1966 p13). Consequently the ‘virulence’ of 
an infectious agent, indicated by the severity of the disease in the population, is not a 
standard characteristic like size or shape: it is an expression of the interaction between a 
particular agent and its particular host within a particular environment (McKeown 1979 
p45; Friis and Sellers 2004). A range of health outcomes can be experienced in 
individuals after infection from the same organism. In other words the genetics, gender 
and constitution of the host and the specific characteristics of the agent/environment 
will affect the severity of the infection (Burnet 1952 p106; Magill 1955 p7; Friis and 
Sellers 2004). During the 1800’s it was observed that infectious agents did not always 
cause disease. For example, it was noted that some agents were only contagious under 
some conditions. It was known that infectious agents were modifiable by the 
environment and that their ability to spread was a changeable characteristic. This 
knowledge was not consistent with the specificity described in the germ theory but it 
was consistent with historical observation (Pelling 2002 p24).      
In the 18th century the health of the inhabitants of the Polynesian Islands was severely 
damaged by the introduction of the measles virus (Dubos 1966 p14). These populations 
had never before been exposed to measles and it decimated many previously robust 
communities. This pattern was also observed in the Australian Aboriginal population 
after the introduction of smallpox and measles due to white settlement in Australia in 
1788. The Aboriginal populations suffered severe mortality after their first exposure to 
these diseases (Baum 2008 pp22-3). But not all individuals who were exposed to the 
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pathogens became seriously ill or died. This indicates that causation cannot be simply 
attributed to exposure to the infectious agent. Similar experiences have been observed 
with infectious diseases when first introduced to other populations. The pattern of 
infection is explained by variations in individual genetics and environmental conditions, 
namely the ecological context of the agent. The virulence of infectious agents is 
observed to decline with exposure to populations and with changes to environmental 
and host conditions. For example, the measles virus in a developed country causes 
relatively benign disease in the majority of children but it can have devastating effects 
in developing countries where conditions are conducive to disease transmission and 
children are malnourished (McKeown 1979 p45). The ecological approach to disease 
was adopted from 1920-1962 when the most significant decline in infectious diseases 
occurred in developed countries (Languir et al 1962; Baum 2008 p18). In 1962 
Langmuir et al described measles in the following way: ‘this self-limiting infection of 
short duration, moderate severity, and low fatality has maintained a remarkably stable 
biological balance over the centuries.’ (p1). At this time there were many 
epidemiologists who argued that the ecological equilibrium of measles had a solid base 
that could not be easily disrupted (Languir et al 1962 p1), therefore humans could not 
expect to eradicate this disease with a vaccine.  
In 1962 measles was not considered a significant health problem in developed countries 
because mortality and disability to this disease had already been reduced 
(Commonwealth Year Book 1953; Langmuir et al 1962 p1 and p3; McKeown 1979 
p56). Yet, despite the ecological equilibrium of measles in developed countries, 
Langmuir et al (1962) postulated it would be reasonable to attempt to eradicate measles 
using a vaccine because of the uncomfortable nature of the symptoms and because a 
vaccine was being developed and should be used to achieve this goal if it could be done 
safely (Langmuir et al 1962, emphasis added). Langmuir makes it clear that the reason 
for supporting measles vaccination at this time was not due to a high rate of death and 
illness to the measles virus but because ‘of the uncomfortable nature of the symptoms’. 
The suggestion that a vaccine could be used for measles eradication was also based on 
the assumption that it could be used safely in a genetically diverse population. A 
vaccine for measles was not used in Australia until 1969 (McKeown 1979 p52), after 
the risk from this disease had declined to very low levels. 
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It was known in the mid-twentieth century that environmental conditions influenced the 
virulence of the pathogen and hence the mortality and morbidity from infectious agents 
(McKeown 1979 p45). Examples of conditions that increase mortality to disease agents 
include:  
i) An inadequate diet which lowers the resistance to infections  
ii) Multiple infections and infestations with parasites  
iii) Lack of infrastructure for hygiene and sanitation  
Measles virus is an example of an infectious agent with high pathogenicity. This means 
that most cases of infection by the virus will produce clinical signs and symptoms of 
disease. Measles is an airborne respiratory virus resulting in high infection rates in all 
social classes. However, there is a large reduction in serious cases and mortality in 
developed countries due to improved living standards and better nutrition (McKeown 
1979 p56). Even when measles infection rates in developed countries are high, mortality 
and serious disease are low due to improved constitutional changes resulting from 
interaction with the virus and improved nutrition combined with smaller family sizes 
(McKeown 1979 p56; Trottier et al 2009). The health of the individual (constitution) 
and genetics have a significant bearing on resistance to disease (Burnet 1952 p106; 
McKeown 1979 p56; Gilbert 2004; Friis and Sellers 2004).  
When essential nutrients are deficient, diseases which would be mild or unobserved in a 
healthy child become serious and death can occur (McKeown 1979 p56). In addition, 
death from measles is mostly a result of infection by secondary bacteria. Anti-bacterial 
drugs have been used in Australia and the US since 1935 and antibiotics since the 
1940’s (McKeown 1979 p52; Armstrong et al 1999 p65). Measles has not been a 
serious risk to the majority of children in Australia since 1950 (Com Year Book 1953); 
this cannot be due to vaccination because a vaccine was not introduced until 1969 and 
the acceptance rate did not reach 50% for many years (Feery 1981 p176). After its 
introduction it was observed that the measles vaccine had no significant effect on the 
decline of deaths due to measles which was already low at the time (McKeown 1979 
p52). It is also stated that measles epidemics have been reported with surprising 
frequency in developed countries where measles vaccination coverage is high 
(Obomsawin 1998; Nkowane et al 1987; Boulianne et al 1991; De Serres et al 2011). 
The outbreaks involve from 20% to 80% of fully vaccinated individuals hence we 
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cannot conclude that random vaccine failures are the cause of these outbreaks. The 
limited duration of vaccine-induced immunity is known to be a factor in these outbreaks 
as well as vaccine failures (Ochsenbein et al 2000). Whilst there are reports that measles 
outbreaks are caused by unvaccinated children these need to be substantiated because 
many of the outbreaks are known to occur in fully vaccinated communities. 
When girls have measles in childhood they acquire long-term immunity and this can be 
conferred to their children in the placenta and via breastfeeding during the first 6–12 
months of life (AAS 2012). This protection is not provided by mothers who have 
received the measles vaccine in childhood but not experienced the disease (Papania et al 
1999; Bale et al 2011). Infants in the first year of life are unable to produce high levels 
of interferon and therefore they are more susceptible to measles without this passive 
immune-protection (created by natural exposure) passed on from their mothers 
(Langmuir et al 1962; Wilson et al 1986). It is observed that exposure to the agent 
‘changes the immunological constitution of the herd’ (Magill 1955; McKeown 1979; 
Friis and Sellers 2004) and this interaction between the host and agent has resulted in 
the reduction in prevalence and severity of many previously epidemic infectious 
diseases (McKeown 1979 p47). This adaptation is known as ‘herd immunity’ and it was 
first observed after natural exposure to infectious agents (Colgrove 2006 pp2-5; Friis 
and Sellers 2004). Colgrove (2006) states that herd immunity was first described in the 
1920’s when it was observed that an entire community will be protected against a 
contagion if a large enough proportion of the population is immune. Immunity occurs 
naturally in humans, and without risk, if the exposure occurs at the right time during 
childhood. Herd immunity is discussed in more detail in chapter 4.  
 Disease severity is directly related to the host’s ability to fight off the infectious agent 
(Friis and Sellers 2004 p403). Nutrition, genetics, psychology and environment all play 
a role in the functioning of the immune system and the expression of disease from an 
infection (Burnet 1952; McKeown 1979 p25; Friis and Sellers 2004 p403). In particular, 
this involves the ‘non-specific’ defense mechanisms as well as the ‘disease-specific’ 
defense mechanisms of the human immune system. This knowledge is fundamental to 
the development of a universal management strategy for reducing the risk from 
infectious diseases for any community (Burnet 1955 p106; Cumpston 1989; McKeown 
1979 p24; Curry 2002 p32-34; Friis and Sellers 2004 p401). Effective control of disease 
in the community requires an in-depth knowledge of the multiple factors that interact in 
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the causation of disease in an individual. The germ theory of disease causation in the 
SMM simplifies the many causes of disease from the interaction of multiple factors at 
different levels of complexity e.g. cellular, body organs/systems and genetics, to a 
single cause of disease, such as a microorganism at the cellular level (Rogers 1984 p67). 
By reducing or simplifying the cause of disease to the infectious agent on its own, the 
medical profession claimed that vaccines could be used to prevent infectious diseases. 
This theory is based on Koch’s postulates which have oversimplified the causation of 
disease through the concept of ‘specificity’ (Pelling 2002 p22). Robert Koch (1843–
1910) was a microbiologist who described the steps required to isolate disease agents 
and this led to the belief that if a disease agent was present in a sick individual then this 
was the cause of the disease and the disease was named after the agent, for example, 
measles, pertussis or influenza. By reducing the cause to ‘the microorganism’ the theory 
lends itself to the idea that the disease can be controlled simply by targeting the 
infectious agent. The belief can be further enhanced in society by spreading negativity 
and fear about infectious diseases in the media whilst portraying a positive image of 
vaccines (Pelling 2002 p15). This simplified theory of disease prevention ignores the 
fact that infectious agents do not cause disease alone and that a vaccine cannot be used 
without causing some harm in genetically diverse populations. If the majority of people 
in a community are not at serious risk from the infectious agent, due to improvements in 
the environmental conditions, then many individuals will be at greater risk from a 
vaccine because they were never at risk from the disease agent. This is also the case 
because combining numerous vaccines in the human body results in synergistic and 
cumulative adverse effects that vary according to individual genetics/constitution. 
The germ theory in the SMM, as applied to the etiology of infectious diseases, has been 
subject to critical analysis by many, including Bashford and Hooker (2002) and Pelling 
(2002). The contempory control of infectious diseases has been described as a ‘fantasy 
of controlling contagion’ because society’s efforts fail so often (Bashford and Hooker 
2002 pp2-3). Beliefs about the processes and agents of infectious diseases have been 
contested throughout history and political decisions have determined the dominant 
method of disease control during different historical periods. Bashford and Hooker state 
this is due to the political nature of science. They state that it is necessary to understand 
what else is being governed in public health policy to understand how the changes in 
meaning of concepts can obscure some things and create others. Pelling describes the 
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complexity of infectious disease control as a result of the special relationship between 
science and politics and the need to produce propaganda (2002 p26). Whilst western 
medical professions were in agreement with sanitary reform they were against 
promoting it as an exclusive system. This wasn’t simply a conflict of ideas. There was a 
lot of similarity in the theories; the differences were due to professional investment in 
the promotion of specific methods of causation (Pelling 2002 p26). In the 20th century 
the two main phases of the public health movement were portrayed as being opposite 
viewpoints but in fact there were many similarities. Portraying them as opposites was 
necessary for the medical profession to emphasise the germ theory and microscopy to 
present the decline in infectious diseases as being a result of medical science. In order to 
ensure that the germ theory dominated it was necessary to discredit some ideas and 
concepts by obscuring definitions or creating confusion over theories. Over-
simplification was used as a strategy to force the acceptance of other theories, such as 
the germ theory, and in this manner medical science was able to restrict and manipulate 
the number of factors that were promoted as the cause of infectious disease (Pelling 
2002 p17). Money and power are involved in determining the accepted scientific 
belief’s in society by domination of the media and political voice. The corporate 
influence on public health policy is described in chapter 6.  
Modern science has progressed by selecting some causes and ignoring others. The focus 
on germ theory and vaccination ignores environmental and pre-disposing causes of 
disease and the interaction of etiological factors. Reductionist theories over-simplify 
and encourage the lay person to believe in ‘magic bullets’ as cures or preventions for 
disease (Pelling 2002 p17). It is clear that public health is an inherently political activity 
and this explains why it is surrounded by controversy. The patterns of disease and 
health in a community represent broader social inequities (Baum 2008 p21). 
2.6 Australian Public Health Policy Since 1950 
This section examines the change in direction of Australian public health policy that 
occurred in the mid-twentieth century and the influences that led to the adoption of 
vaccination programs to control disease. It provides an assessment of the decline in the 
infant mortality rates in Australia to see if this decline can be credited to the adoption of 
vaccination in the second part of the twentieth century.  
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Public health involves an assessment of different strategies to create health-promoting 
environments, including the social, economic and physical aspects of the environment 
(WHO CSDH 2005; Stanley 2001 p400). These were the main strategies that were 
emphasised in the first half of the 20th century during which time the threat from 
infectious diseases declined significantly in developed nations (Naidoo and Wills 2004 
p12; Armstrong et al 2011 p64). Illich (1975) states with reference to infectious disease 
mortality ‘it is certain the professional practice of physicians cannot be credited with the 
elimination of old forms of mortality’ (p17). An analysis of disease patterns has 
established that the most important factor influencing the health of any population is the 
environment (WHO CSDH 2005; Winkelstein 1972 p70, McKeown 1979 p78; Stanley 
2001 p369). This includes food, housing, working conditions, community and cultural 
mechanisms affecting the mental well-being of individuals. Basch (1994) states the 
historical record of western countries contains a large body of literature that shows a 
lack of connection between the use of biomedical technology, including vaccines, and 
the health of communities (p56).  
The Australian government’s public health policy up to 1950 was a holistic approach 
that emphasised prevention through nutrition and environmental changes (Feery 1981; 
Gillespie 1991 p49; Cumpston 1989). During this period health authorities used the 
media to achieve changes in behaviour and lifestyle through education campaigns that 
O’Connor (1989) referred to as ‘propaganda publicity’. The campaigns were very 
successful in changing social behaviour to reduce the infant mortality rate of the 
population. Parents were targeted with health information that was recommended by the 
NHMRC to state governments to improve health outcomes. This was presented in radio 
programs, films and newspaper campaigns to advocate changes in diet, national fitness, 
domestic hygiene and breastfeeding. In 1946 the Australian constitution was changed to 
give the Commonwealth government power to provide a complete health service to the 
nation, including medical advice and treatment (Com Yearbook 1953; Palmer and Short 
1994 p18). At this time state and local health authorities were responsible for 
environmental health protection and this included surveillance of infectious diseases 
and the development of disease prevention programs (Palmer and Short 1994 p11). The 
Health Acts of all states included the compulsory notification of infectious diseases. If a 
notifiable disease occurred, the local authority and the Health Department were advised 
and measures were implemented to contain the disease (Com Yearbook 1953).  
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By 1950 the Australian government’s advisory board on infectious diseases, the 
NHMRC, had removed whooping cough (pertussis), influenza and measles from the list 
of notifiable diseases due to the significant reduction in morbidity and mortality that had 
occurred (Com Yearbook 1953 p278). No vaccines were used for these diseases at this 
time. The same trends were observed in all developed nations and in 1966 Dubos stated 
‘Of the 10 leading causes of death in infants and young children in 1850 every one has 
been brought under control….very few persons of any age die of the acute infections 
which used to account for the majority of all deaths’ (p9). At this time mortality due to 
infectious diseases was rare even though cases of these diseases were common (Dubos 
1966). This was observed to be a result of the adaptation process of humans to the 
environment. Environmental and lifestyle changes increased the age of exposure to 
infectious agents and hence reduced the severity of disease (Burnet 1952 p99; Dubos 
1966 p10).   
Mass vaccination programs for most infectious diseases in Australia were not used 
widely until after 1952 (Com Yearbook 1953; McKeown 1979 p50). These programs 
were introduced after deaths and illness to infectious diseases had significantly 
declined. Australia had low rates of mortality and morbidity due to infectious diseases 
from 1950, before most vaccines were introduced. In 1986 the infant mortality rate was 
8.2 per 1,000 live births (Palmer and Short 1994 p14; Stanley 2001 p371) and many 
vaccines were introduced in the 1990’s. An exception to this pattern was the polio 
epidemics of the 1950’s; a full understanding of these outbreaks and the effect of 
vaccination programs on polio mortality and morbidity requires knowledge of the 
ecological context in which the outbreaks occurred and the criteria for diagnosis and 
surveillance of polio at the time. These aspects of disease statistics are described in 
chapter 4 and illustrated in the case study of ‘pandemic’ 2009 influenza in chapter 10. It 
is also significant that vaccination programs implemented from 1953-1993 in Australia 
were completely voluntary: the government did not use mandatory requirements or 
financial incentives to increase participation rates in these programs (Com Yearbook 
1953; AG IAP 2004). At this time vaccination rates varied in different regions of 
Australia, yet the risk of infectious diseases declined in all regions. The tuberculosis, 
whooping cough and polio vaccination programs implemented after 1953 in Australia 
represent the change in focus of public health policies from an environmental/social 
basis to a medical basis in the second part of the twentieth century (Baum 2008 p28).  
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The Australian government has stated that mass vaccination has prevented more 
suffering and saved more lives than any other public health intervention (AAS 2012; 
AG IAP 2013). However, the historical epidemiological evidence of the decline of 
infectious diseases does not support this claim. Most vaccines were not introduced when 
the risk of these diseases was significantly reduced (Cumpston 1989 p312; McKeown 
1979 p52; Stanley 2001 p377). Despite this evidence the Australian government has 
been informing the Australian public since the 1990’s that the success of vaccines in 
preventing disease depends upon high participation rates in vaccination programs (AG 
IAP 2013). Infant mortality rates continued to decline in developed countries as material 
wealth and living standards improved. The majority of the decline in infant mortality 
rates occurred in the first half of the 20th century before the widespread use of vaccines. 
Analysis of the life expectancy figures shows that the most significant increases were 
made before medical interventions were widespread. In Australia, men gained 13.5 
years between 1920-22 and 1953-55 and women gained 14.8 years during this period. 
However, for the next decade from 1953-55 and 1960-62, the gains for men were only 
0.8 years and for women 1.9 years and this was similar in other developed countries e.g. 
US and Europe (Hetzel 1976 p31). It is known that death and illness were reduced 
through environmental and lifestyle changes, and vaccines other than those for smallpox 
and diphtheria, were not in use for most infectious diseases until after 1950 when the 
risk from these diseases had already been reduced.  
As the virulence of infectious agents declined the medical profession’s role in 
developing public health policy increased. There is no other professional body that has 
the same degree of influence in any policy area (Palmer and Short 2010 p25). When 
examining policy content it needs to be understood in the political context within which 
it is developed (Palmer and Short 2010 p33) and in the 1950’s a strong partnership was 
growing between medical science and industry (Krimsky 2003). At this time public 
health policy in Australia and in other western countries became dominated by the 
scientific medical model of health (SMM) (Naidoo and Wills 2000 p185). Consequently 
the definition of health became narrower and vaccines, a medical intervention, rather 
than social medicine became the main focus for health practitioners. The scientific 
medical model of health is described further in chapter 5. After 1950 in Australia 
vaccination policy was driven by the SMM and founded on the ‘germ’ theory and the 
belief that the cause of disease originates from exposure to an agent with subsequent 
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changes within the individual (Freidson 1970 p16; Curry 2002 pp33-34; Stacey 1988). 
This simplified explanation implies that infectious diseases have only one cause and one 
health outcome hence a drug may be useful in the prevention of these diseases (Dubos 
1966 p13; Pelling 2002 p17). In reality most diseases have more than one cause and it is 
the interaction of factors that results in the expression of disease (Friis and Sellers 
2004). This is illustrated in the epidemiological triad and it is the reason why health 
outcomes from infectious agents vary between individuals (Dubos 1966 p13; Gilbert 
2004). Infectious agents are part of the human flora, including pathogens such as 
hepatitis B, influenza, whooping cough etc, but alone they are not sufficient to cause 
disease in humans (Burnet 1952; Dubos 1966 p13; Friis and Sellers 2004 p402). It is the 
ecological context that results in the development of disease.  
The adoption of the SMM resulted in a focus on disease prevention that reduced the 
emphasis on the external determinants of health; the environment, agent and host 
characteristics. In earlier centuries before the medical practice of vaccination was 
introduced it was known that environmental conditions and host characteristics were 
fundamental to the reduction of disease (Feery 1981 p172; Dubos 1966 p14). The 
increase in female literacy at the end of the 19th century was also seen as a significant 
factor in reducing the rates of infant mortality (Stanley 2001; Baum 2008 p21). Public 
health was reframed in the mid-20th century as an area of ‘medical expertise’ with a 
strong alliance between scientific medicine and the government (Freidson 1970 p16; 
Hobbins 2011 p427). Controlling infectious diseases was also reframed from reducing 
illness and death due to these diseases to preventing or eliminating these diseases 
(Langmuir et al 1962 pp1, 3; Hawe 1994 p242; Curry 2002 p34). In areas where the 
transmission of a pathogen had been cleared and an infectious disease had become a low 
risk, the term elimination was used as the reason for introducing a vaccine for the 
disease (Basch 1994 p14). This was the justification for implementing vaccination 
programs in developed countries like Australia, for diseases that were no longer a 
serious risk to the majority of the population. This included hepatitis b, haemopholus 
influenza (Hib) b, pneumococcal, meningococcal, varicella (chicken pox), rotovirus. 
The terminology of vaccination policies changed in the early nineties and infectious 
diseases were labeled vaccine-preventable diseases. This expression implies that 
vaccines are the key to preventing disease and thus serves to increase the uptake of 
vaccines. Framing vaccination in this way assisted governments to promote vaccines to 
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populations in developed countries where the majority of people were not at risk from 
the diseases for the new vaccines being developed. This is discussed further in chapter 
7. 
Around 1950 the focus of public health changed from the environment to individuals 
and a push was made to focus on vaccination as a method of preventing many infectious 
diseases. It was suggested that if enough people could be convinced to vaccinate then 
some diseases could be eliminated due to vaccine-created herd immunity (Curry 2002 
p34). Medical training became necessary to practice in the field of public health and 
vaccination became the specialty of doctors (Naidoo and Wills 2000 p185). Public 
acceptance of vaccination programs during the 20th century was dependent upon 
negotiations between local governments, the Commonwealth and the use of promotional 
campaigns in the media to frame the issues to the public (Hobbins 2011 p427). After 
1950 public health was increasingly described as the control of ‘communicable 
diseases’ whilst environmental health became a reference to the physical environment in 
which individuals live, including housing, transport, sanitation, pure water and pollution 
(Naidoo and Wills 2000 p7). In the 1970’s the medical model was extended further as 
health authorities employed community physicians to replace medical officers (Naidoo 
and Wills 2000 p14). The image of public health had become medicalised even though 
infectious diseases had a low profile at this time due to the decline in mortality that had 
already occurred.  
Further evidence of the low profile of infectious diseases in Australia in 1989-90 is the 
small proportion of the federal budget that was spent on disease prevention at this time. 
Only 4.4% of the total healthcare expenditure of $33 billion was spent on community 
and public health services in 1989-90 (Palmer and Short 1994 p14). This represented all 
expenditure on health promotion and disease prevention at this time. Table 1 illustrates 
the health priorities of the Australian government in 1989 - prior to the implementation 
of many new vaccines in the National Immunisation Strategy (NIS) in 1993. The infant 
mortality rate was very low in 1989-90 and only 7 vaccines were recommended on the 
government childhood schedule at this time – polio, diphtheria, pertussis (whooping 
cough), tetanus, measles, mumps and rubella (AG IAP 2004). The implementation of 
the new National Immunisation Strategy (NIS) in 1993 was estimated to need a budget 
of $53 million to operate with an initial allocation of $9.6 million (Hawe 1994 p242). 
The last year that a breakdown of the health services was provided in a summarized 
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format was in 1989-90 (Palmer and Short 1994 p14). In 1990 the majority of Australian 
children were not at serious risk from any infectious disease yet this is when the 
Australian government expanded its national vaccination program. By 2008-2009 
funding for the essential vaccines was ‘well in excess of $AU400 million’ (Nolan 2010 
A76). The new National Immunisation Strategy (NIS) implemented in 1993 and the 
strategies that were adopted to increase participation rates in vaccination programs are 
described in chapter 3.  
Table 1 A Summarized Representation of Australian Health Expenditure by 
Category in 1989-90 ($ millions) 
Category  Total Funds 
(Commonwealth, State and 
Private)  
Percent of recurrent 
expenditure 
Total Institutional 
Expenditure 
13779 51.6 
Medical services 4878 18.3 
Dental and other professional 
services 
2442 9.1 
Pharmaceuticals 2510 9.4 
Community and public health 
*  
1165 4.4 
Other recurrent expenditure 1933 7.2 
 
* Community and public health includes the categories of health promotion and illness prevention. 
Source: Australian Institute of Health and Welfare. 1993a. In Palmer and Short 1994 p14. 
                  
2.7 The New Public Health Movement (1985 –1995) 
In the mid-twentieth century, the separation of public health medicine from the broader 
issues of social medicine and environmental reforms was a result of the influence of 
WHO/UNICEF in the development of global health policies. Even though it was 
undisputed at this time that social inequalities were a significant cause of ill health it 
became politically unpopular to use a definition of public health that included the social, 
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environmental, cultural and genetic factors of health (Naidoo and Wills 2000 p186). 
This is observed in the Australian government’s definition of environmental health that 
was provided earlier in this chapter. This notion is compatible with the scientific 
medical model which focuses on a mechanistic model of the human body that treats the 
parts separately and ignores external factors as determinants of disease (McKeown 1979 
pp7-8; Doyal and Doyal 1984). Decision-making in health is a complex process that 
involves medical, economic and political influences. In the 1980’s the dominant 
influence was economic analysis due to the rise of neoliberalism globally. 
The period from the mid-1980’s onwards is referred to as the New Public Health era. At 
this time the medical dominance of public health was challenged as the limitations of 
clinical medicine became clear (Naidoo and Wills 2000 p186; WHO CSDH 2005). 
There was a progressive return to multifactorial causation in accordance with traditional 
theories in the eighties after most infectious diseases had declined in developed 
countries (Pelling 2002 p17). McKeown (1979) was one of the most vocal health 
practitioners in the 1980’s providing evidence of the multifactorial nature of disease. 
The first International Conference on Health Promotion was held in Ottawa in 1986 
(WHO 1986) and a charter of goals was presented at this conference aimed at 
empowering people to have control over their health. There were five important 
principles that were recognised in the Ottawa Charter as being necessary to achieve this 
goal: good public policy, developing supportive environments, supporting community 
action, creating personal autonomy in health and restructuring health services – the 
foundation of social medicine. These principles encompassed a holistic approach to 
improving health that included environmental and spiritual factors and greater 
involvement of the community (WHO 1986). During the 1990’s a greater emphasis was 
placed on social interventions to create sustainable health outcomes in the 21st century 
(Stanley 2001 p400). Whilst medicine was removed as the primary focus of public 
health policy in many countries, the prevention of infectious diseases worldwide was 
still dominated by vaccination. At this time the reliance on epidemiology as the only 
valid method of public health research was also challenged and methodology was 
broadened to better reflect the complexity of health issues (Baum 2008 p38).  
The era from the mid-1990’s to the present has been labeled the Global New Public 
Health movement because of the limitations that economic globalization is observed to 
have on the outcomes of government health policies (Baum 2008 p17). Transferring 
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capital, goods, people and ideas around the world depends upon the political 
arrangements between countries (Blume et al 2013 p32). Political will is required for an 
intervention to be adopted. In 1997 the International Health Promotion Conference 
(IHPC) held in Jakarta focused on the development of partnerships in health promotion 
with large corporations to expand the use of new technologies and vaccines in public 
health policies. These were termed public-private partnerships that included sponsorship 
arrangements with pharmaceutical and other multi-national companies (Baum 2008 
p38). From the 1990’s onwards the policies and practices of international financial 
institutions were having an increasing impact on the health outcomes in WHO member 
countries. This was due to the globalization (privatization) of public health policy and 
the diminishing role that governments were playing in the design of public health policy 
(Baum 2008 p19). Infectious disease policy is now designed on complex economical 
models with inbuilt assumptions for global communities, not context-specific 
communities. 
In 2000, after the establishment of the Global Alliance for Vaccines and Immunisation 
(GAVI), the focus of public health at the IHPC in Mexico City was changed to an 
emphasis on new and re-emerging infectious diseases (Baum 2008 p39). It was 
observed that the spread of AIDS in Africa was wiping years off the life expectancy of 
Africans and this was used to focus the global public health movement on bioterrorism 
and increased fear and preparation for pandemic diseases, such as Sars and Swine flu. 
Public health policies in the Global New Public Health Era from 2000 have been 
influenced by the representatives of the GAVI public-private partnerships, and 
presented to member countries through WHO/UNICEF (Blume et al 2013). The 
privatization of health services is a key threat to global public health. Some of the main 
concerns listed in the People’s Health Movement arose due to the new direction of 
WHO/UNICEF policies from 2000. These include the fact that policy is now designed 
by private-public partnerships that advance corporate interests at the expense of the 
public interest. These partnerships are also founded on the voluntary commitment of 
corporations to equity, public health and sustainable environments instead of strong 
regulation through a democratic process (Werner 2005 in Baum 2008 p41). That is, 
there is no accountability for corporations in private-public partnerships and their 
primary interest in health promotion partnerships is profits for their shareholders. This 
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represents a conflict of interest to the purpose of public health policy: protecting public 
health.   
WHO/UNICEF are providing conflicting directives on health promotion. On the one 
hand they are advocating for human rights and community action to address the 
determinants of health sustainably but on the other they are focusing on private 
partnerships in health promotion with profit-making corporations. These contradictory 
strategies are not compatible and increase the health inequities that are detrimental to 
populations (Baum 2008 p41). Economic growth in many developing countries has 
resulted in industrialized areas merging with impoverished rural areas without 
sanitation, hygiene, healthy air quality or housing. Respiratory and enteric infections 
flourish when there is unregulated industrialization (Blume et al 2013 p32). Although 
the WHO established the Commission for Social Determinants of Health (CSDH) in 
2005 global public health policy continues to be more focused on governance by 
technocrats and partnerships with corporations than developing comprehensive 
healthcare that addresses the environmental and social determinants of health (Baum 
2008 42). A focus on profits protects industry interests and not the public interest in 
government health policies. The influence of GAVI on global health policy 
development is explained further in section 3.3.           
2.8 Measuring the Health of Communities 
During the first half of the 20th century it was common practice to use the surrogate of 
age standardised mortality rates as an indicator of the health status of communities 
(Palmer and Short 1994 p16).  This was because the health of communities is difficult 
to measure. There are many variations in the definition of ‘health’ and there are also 
difficulties in measuring different aspects of health. Mortality rates were a useful and 
concrete indicator of survival but they provide limited information about ‘population 
health’ in terms of morbidity, quality of life and human rights. Mortality rates are 
unable to provide information about the non-quantitative issues such as disability, pain, 
stress or family circumstances that are associated with many diseases (Basch 1994 p22). 
From 1995 onwards, public health authorities adopted vaccination coverage as a key 
measure of health in communities (Blume et al 2013 p11). This measure was chosen 
because it reflected the interests and strategies of the dominant stakeholders in global 
policy: the vaccine manufacturers in collaboration with financial institutions (Blume et 
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al 2013 p26). However, this measure is inadequate for informing authorities about the 
burden of chronic disease and disability in populations and it is founded on the 
questionable assumption that high vaccination coverage improves the health of 
communities. It also hides the issue of vaccine safety (McNeill et al 2013 p81). This is 
because there is no systematic surveillance of vaccine safety globally and it is not 
addressed in the cost-effectiveness models being used by GAVI to promote vaccines to 
the WHO. This is described more fully in chapter 6 and with examples in the case 
studies in chapter 9 and 10.    
A key measure of health that could be used if the desired outcome was the health of 
populations is the material well-being of communities. Public health advocates have 
observed a clear ecological relationship between material well-being measured by 
income and the health status of families (Palmer and Short 1994 p17; Stanley 2001 
pp378-9; Baum 2008). Improvements in mortality and morbidity are directly related to 
higher disposable income and higher levels of maternal education. These factors are 
quantifiable indicators of health but they are not used to design global health policy. In 
contrast, the key measures of health adopted in the era of New Global Public Health are 
the Millennium Developmental Goals (MDG). These were established in the UN’s 
Millennium Declaration and adopted in 2000 by all WHO member countries (Blume et 
al 2013 pp25-6). They were designed by the private-public partnerships of the GAVI 
alliance and the Organisation for Economic Co-operation and Development (OECD). 
These goals have been based on investment in health to improve economic growth and 
productivity for private sponsors. Waitzkin describes how this aim reduces the 
importance of the social determinants of health – income, class and power, and 
consequently the importance of health as a fundamental human right - because the 
funding for these public programs that are declared to be for the ‘good of the 
community’ is private capital resulting in private profit (Waitzkin 2003 p523). Although 
the MDG’s were adopted in 2000 they originated in the 1990’s when economic analysis 
became the dominant influence in policy design. At this time the concept of the 
disability-adjusted life year (DALY) was introduced as a measure of health. This was a 
concept developed by the World Bank in 1993 and used in its report “Investing in 
Health” (McNeill et al 2013 p63). It is a concept that measures the overall disease 
burden as the number of years lost to disease, disability or early death and it relies on 
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many assumptions. WHO adopted this key measure in 2000 under the recommendations 
of GAVI.  
Since this time economists have become more influential than health authorities and 
health departments in global policy design (McNeill et al 2013 p63).  The Bill and 
Melinda Gates Foundation (BMGF) and the GAVI alliance represent the private-public 
partnerships that are shaping global health policies through the WHO/UNICEF. 
Sponsors of health programs have the power to influence public health policies in WHO 
member countries. WHO is now perceived as having a sub-contractor role in global 
health policy instead of being responsible for the direction of these policies and being 
influential in protecting population health (McNeill et al 2013 p65). McNeill et al also 
state that statistics have been abused to fabricate evidence of success (p84). This aspect 
of the ‘evidence’ used in vaccination policies is discussed further in chapter 6. 
The initiatives implemented to achieve the MDG’s do not address the causality of 
infectious diseases; they ignore the social determinants of health and focus on the 
technological solution of vaccination. In fact, there is no correlation between the 
achievement of the MDG’s and decreasing inequalities in mortality between wealthy 
and poor nations because the progress between countries is inequitable (Moser et al 
2005 p1181). If the aims of the MDG’s are not decreasing the inequity gap then it could 
be said that they have been designed to fail to improve health (Blume et al p26). The 
goals were chosen because they were quantifiable, robust and could provide a concrete 
measure of performance to justify programs to the international stakeholders. However, 
they were based on an economic analysis of health driven by donor self-interest and not 
the health needs of each country. Hence an equity dimension needs to be incorporated 
into the child mortality MDG (Moser et al 2005 p1181). Examples of the key measures 
of health that were claimed as successes during 2000-2008 include (McNeill et al 2013 
pp75-6): 
1. ‘Prevented a cumulative 3.4 million future deaths 
2. Protected a cumulative 50.9 million children with basic vaccines against DTP3 
3.  Protected a cumulative 213 million children with new and underused vaccines’ 
These achievements provide confidence to the donor countries because they are 
quantifiable measures of health. This increases the funding for GAVI which in turn 
increases the influence it has over WHO/UNICEF policy (McNeill et al 2013 p75-6). 
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The use of these outcomes to measure health is justified with economic modeling 
designed with the underlying assumption that increased vaccination rates improve the 
health of populations. Whilst the influence of wealth and education on health outcomes 
has been known for centuries (Winkelstein 1972 p74; Dubos 1966 p14) this information 
has never been collected in Australia on a regular basis and used in the development of 
government public health policies (Palmer and Short 1994 p17). Yet many studies have 
demonstrated the significant differences in mortality and morbidity rates, particularly 
infant mortality rates, which exist between occupational and socioeconomic status 
groups (Palmer and Short 1994 p17; McKeown 1979 p60; Stanley 2001 p379). An 
example of this is Australia’s indigenous population. Although these communities have 
had vaccination programs since 1958 (O’Connor 1989 p74) the indigenous childhood 
mortality rate from 1994-1996 was 3 times higher than the non-indigenous mortality 
rate (Stanley 2001 p372). Many of these communities were and still are lacking in 
sanitation, good nutrition and hygienic living conditions (O’Connor 1989; Stanley 2001 
p400). This information is relevant to government vaccination policies that recommend 
the universal use of multiple vaccines because outbreaks of disease can be controlled 
through a change in socioeconomic circumstances without the aid of vaccines. This 
would be a significantly more cost-effective strategy as can be seen by Australia’s 
health statistics up to 1989 (see section 2.6).  
2.9 Conclusion 
The epidemiological triad illustrates that infectious diseases are a result of the 
interaction of multiple causal factors in pathogenesis. In other words, infectious agents 
(bacteria/viruses) are necessary but do not always result in disease; exposure to these 
agents can result in a diversity of health outcomes. This is why the assessment of the 
severity of each infectious agent in the community cannot be made outside the 
ecological context. Global public health policies are resulting in a ‘one size fits all’ 
vaccination program that ignores the context in which infectious diseases occur and the 
diversity of outcomes that are expected. There are a range of health outcomes that can 
arise after exposure to an agent – no disease, mild or severe disease, or death - and the 
health outcome is dependent upon the host, environment and agent characteristics. 
Humans develop immunity by adapting to their environment through a process known 
as homeostasis. Homeostasis is part of the process by which humans develop resistance 
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(immunity) to disease and it develops through natural interactions and exposure with the 
organisms in an ecological context. The immune system interacts with the environment 
and other body systems in complex ways to develop long-term protection against 
disease: it is not simply the production of antibodies to an antigen in the process of 
seroconversion induced by vaccination. In this way communities are protected by herd 
immunity developed by natural exposure to the agents.  
The infant mortality rate in Australia declined primarily due to improvements in the 
ecological context including sanitation, hygiene, nutrition, breast feeding, smaller 
family sizes, less crowding and improved infrastructure. The risk of death and illness 
due to infectious diseases had declined by 1950 before most mass vaccination programs 
were introduced. In 1950 only two vaccines were in voluntary use in mass vaccination 
programs in Australia, diphtheria and smallpox, and these diseases did not decline any 
more quickly than other infectious diseases. Whilst outbreaks of infectious diseases still 
occurred after 1950, the risk of death and severe illness was low to negligible to the 
majority of Australian children and long-term herd immunity to the diseases was gained 
by natural infection during childhood. Many mass vaccination campaigns were 
introduced in Australia from 1952–1990 but participation was voluntary and without 
coercive government strategies. Infectious diseases continued to decline as living 
standards and education improved. Despite the low infant mortality rate in the early 
1990’s and the lack of significance of infectious diseases in Australia at this time, the 
government implemented a new strategy to increase the vaccination rates in the 
population and to expand the recommended schedule of vaccines. This policy change 
was in response to WHO global health directives, and not a specific recommendation 
for the ecological context of the Australian situation.   
A decision was made in the mid-twentieth century to medicate all children to prevent 
disease, despite the diversity of outcomes that arise after exposure to an infectious 
agent. At this time the health of Australians was measured using the decline in the 
infant mortality rate and since 1990 vaccination coverage has been used as the surrogate 
measure for ‘health’. These surrogates have been used even though it is known that 
mortality rates and vaccination coverage are unable to inform authorities about the 
illness/disability associated with each disease. The well-being and quality of life of 
individuals in communities cannot be accurately measured using these surrogates. This 
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is relevant to vaccination policies because there has been a significant increase in 
chronic illness in Australian children that has occurred at the same time as the 
government increased the participation rates and the number of vaccines listed on the 
childhood vaccination schedule in the 1990’s. Authorities that depend upon infant 
mortality rates and vaccination coverage alone to inform public health policy will not 
detect or recognize a correlation between vaccines and increased morbidity in the 
population.  
Overview of Chapters  
The expansion of the Australian government’s vaccination program within the global 
framework for public health policy directed by the WHO/GAVI is described in chapter 
3. Chapter 4 discusses the federal governance of the NIP and the way in which risk 
assessment for infectious diseases is performed and communicated to the public. A 
discussion of the principles of public health policies and ethical codes of conduct for 
health promotion is provided in chapter 5. Chapter 6 investigates the rigour of the 
science that is produced in academic-industry partnerships in research institutions and 
chapter 7 provides a discussion of the evidence the Australian government provides to 
support the claims used to promote vaccines to the public. Public health policies are a 
reflection of the cultural and political beliefs of the time. Chapter 8 discusses the 
political framework that results in undone science and how public health policy is being 
designed on political decisions made without complete scientific knowledge. It provides 
the political framework for the existence of undone science and explains the 
consequences of its existence in public policies to population health. These influences in 
the development of global vaccination programs are illustrated in a case study of the 
Human Papillomavirus (HPV) vaccine in chapter 9 and the ‘Swine Flu’ 2009 vaccine in 
chapter 10. An investigation of these vaccination programs demonstrates the political 
and economic environment in which vaccines are being produced in the globalization 
era and the effect this has on the research that is produced in academic institutions. 
Chapter 11 provides the conclusions drawn about the Australian government’s claim 
that vaccines are a safe and effective prevention for many infectious diseases.   
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CHAPTER 3 GLOBAL HEALTH POLICY AND AUSTRALIA’S 
NATIONAL IMMUNISATION PROGRAM (NIP) 
PART 1 GLOBAL PUBLIC HEALTH POLICY 
3.1 Introduction 
This chapter provides an overview of global health politics during the 1990’s when the 
Australian government was developing its National Immunisation Program (NIP). 
Australia’s vaccination policies were part of a global vaccination campaign that was 
directed by the WHO/UNICEF and aimed to increase the vaccination rates of children 
in all countries. Global health politics in the 1990’s provide an explanation for the 
Australian government expanding its NIP at a time when infectious diseases were a very 
low risk to Australian children. See chapter 2. The development of global vaccination 
policies and the Australian NIP from 1990 are described in this chapter. 
This chapter also provides a discussion of the strategies that have been adopted in 
Australia to emphasise the responsibility of individuals to participate in vaccination 
programs. These strategies pressure the public to use a medical procedure ‘for the good 
of the community’. The theory of ‘vaccine-created’ herd immunity has been used by the 
government to suggest that high participation rates in vaccination programs are 
necessary to prevent infectious diseases.  A discussion of the Australian government’s 
reason for emphasising participation rates in vaccination programs is provided here as 
well as the reason for increasing the number of vaccines recommended in the NIP. I 
have also provided a discussion of the ingredients of vaccines because the increased use 
of vaccines increases the risk of adverse events due to the excipients and non-human 
protein combined in the vaccine carrier.   
Recently the government has implemented recommendations for vaccines to be 
mandatory in a number of Australian workplaces. A discussion of the implementation of 
vaccination policies in occupational settings at a time when infectious diseases are not a 
serious threat is provided in this chapter. Policies that use financial incentives to 
pressure individuals to vaccinate for employment and schooling contradict the 
Australian government’s claim that vaccination in Australia is not compulsory. In many 
cases people cannot afford to lose their jobs by choosing not to vaccinate and some 
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parents are also dependent upon childcare facilities and welfare benefits for their 
livelihood.  A discussion of the impact of the government’s vaccination policies on the 
freedom to choose a medical procedure for healthy people has been presented in this 
chapter. Chapter 4 provides a description of the way in which the NIP is implemented 
into Australian communities and the surveillance methods that are used to assess the 
risk of communicable diseases to the community. An overview of the governance of 
Australia’s vaccination policies is provided in Appendix 3. There are many ethical 
implications in a public health policy that recommends a medical procedure to healthy 
people and a discussion of these issues with the guidelines for good medical practice is 
provided in chapter 5.  
3.2 Global Health Policy   
The WHO Expanded Program on Immunisation (EPI) 
This section describes the influence of public-private partnerships with WHO/UNICEF 
that are influential in the development of global and national public health policies. It 
also describes the influence that global health policy has had on the development of 
Australian vaccination policies. I have relied largely on Roalkvam, McNeill and Blume 
(eds) 2013 Protecting the World’s Children: Immunisation Policies and Practice 
because this is the most current and comprehensive text on global health policies. The 
directive to increase the participation rates in Australian vaccination programs from the 
1980’s onwards was part of a global health initiative and a description of how this 
developed is provided below. 
The WHO is a United Nations multilateral agency and is composed of United Nations 
member countries who accept the WHO constitution (WHO Countries). Since the 
1940’s and up to 1990, the WHO and the United Nations Children’s Fund (UNICEF) 
have been the dominant influence in designing international health policy (IOM 1993). 
In 1974, the WHO established the Universal or Expanded Program on Immunisation 
(EPI) through a World Health Assembly (WHA) resolution (WHO ISD). At this time 
the WHO provided policy guidance for people of all ages and UNICEF was involved in 
implementing childhood vaccines into global programs. After the launch of this 
program UNICEF/WHO set vaccination policies and standards for vaccination coverage 
that were to be achieved by each member country (WHO ISD). As of 2014 there were 
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194 member countries (WHO Countries). The goal of this program was to increase the 
vaccination rate of children worldwide to ensure that all children benefit from ‘life-
saving vaccines’ (WGO ISD). It was founded on the belief that vaccination programs 
had been successful in eradicating smallpox globally (WHO ISD). This was despite the 
warning by the WHO director-General, Halfdan Mahler, in 1980, stating that smallpox 
eradication had provided important lessons but claiming that other diseases could be 
singled out for worldwide eradication was not one of them (Blume et al 2013a p7). 
However, the WHO proceeded to recommend that member states develop immunization 
and surveillance programs for some or all of the following diseases according to their 
epidemiological circumstances: diphtheria, pertussis, tetanus, measles, poliomyelitis, 
tuberculosis and smallpox. The program was formalized by the UNICEF-WHO joint 
committee in 1975 with an emphasis on member countries taking ownership of their 
own programs and advice and assistance in obtaining vaccines being provided by the 
WHO/UNICEF (Blume et al 2013a p8).  
In 1976 the WHA assessed progress of the expansion of vaccination programs and 
observed that they were not reaching the majority of children in developing countries. 
At this time another health report by the UNICEF-WHO committee was produced that 
emphasised poverty and ignorance as well as the integration of vaccination in health 
programs in developing countries. This led to the WHO director-general, Mahler, 
establishing the goal of ‘health for all by 2000’ at the WHA in 1976 (Blume et al 
2013a). A conference in Alma-Ata, Kazakhastan in 1978 resulted in the Declaration of 
Alma-Ata that focused on the significance of socioeconomic development and primary 
healthcare, including community participation and lay health advocates as the 
cornerstone of public health, rather than a reliance on biomedical technologies such as 
vaccination (Blume et al 2013a p9). Vaccination programs were seen in this directive as 
part of a larger program of primary health care, not the main focus. Not everyone agreed 
with this strategy. Walsh and Warren, from the Rockefeller Foundation, believed it to 
be unrealistic. They claimed it was impossible to fund the clean water, nutritional 
requirements and basic primary health care for the world’s population (Blume et al 
2013a p9). They suggested that selective primary health care with a major emphasis on 
vaccination was the way to proceed, even though the cost of providing multiple 
vaccines to developing countries in a sustainable manner most likely outweighed the 
cost of providing basic healthcare services. The selective primary healthcare would give 
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priority to ‘high risk’ diseases and focus on measles and DPT vaccination, tetanus 
toxoid for pregnant women, encourage breast feeding, provide chloroquine for malaria-
infested regions and oral rehydration therapy (ORT). This did not provide a direct focus 
on the main cause of deaths in developing countries – diarrhea, and was seen by some 
as a betrayal of the holistic approach agreed to at Alma-Ata in 1975 (Blume et al 2013a 
pp10-11).  
The official launching of the EPI program with an overriding focus on achieving 
maximum vaccination coverage for the world’s children occurred in 1983 (Obamsawin 
1998). This program was implemented despite the critical voices describing the 
destructive effects that EPI was causing at the community level in many countries 
(Newell 1988 p905; Obomsawin 1998). Vaccination coverage therefore became the key 
measure that WHO/UNICEF would use to assess the success of the EPI in achieving 
‘health for all by 2000’. The EPI or Universal Childhood Immunisation (UCI) was 
promoted in 1982/3 on the initiative called the ‘Child Survival Revolution’ established 
by James Grant, the Executive Director of UNICEF, qualified in economics and law, 
not public health (Blume et al 2013a pp11-12). Other institutions and individuals 
involved with this initiative included the Rockefeller Foundation and Robert 
McNamara, former President of the World Bank. In the 1980’s neoliberalism was the 
political and economic model adopted by many countries. This model is based on the 
assumption that economic growth can be stimulated by freeing markets from 
government influence (WHO CSDH 2005). Neoliberalism became the dominant 
influence on global health in the 1990’s and policies were controlled by the 
‘Washington consensus.’ This term is derived from the fact that global health policies 
are dominated by the US government, the World Bank, and the International Monetary 
Fund – all based in Washington (WHO CSDH 2005).    
When neoliberalism was becoming the dominant model in global politics the 
WHO/UNICEF began to present mixed messages in addressing global health. Whilst 
the WHO ‘Health for All’ vision from the 1970’s strongly recognised social and 
environmental determinants of health (SEDH) as the primary influence on health 
outcomes, this approach was abandoned when neoliberalism became dominant. This 
ideology focuses on privatisation, deregulation, free markets and technology-based 
health programs (WHO CSDH 2005). The World Bank had an increased influence in 
global health policy from the early 1990’s onwards. Neoliberal policies were imposed 
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on developing countries by donor organizations and governments through bilateral 
arrangements mostly set up through the World Bank and the International Monetary 
Fund (WHO CSDH 2005). When sponsors provide money for health programs it 
diminishes the control governments have over their health programs. A nation’s 
autonomy over its own health program depends upon the financial status and medical 
expertise of the country (McNeill et al 2013 pp66-67). Donors have a major influence 
on health policies in poor countries.  
In 1983 all political leaders of the WHO member countries, 158 at this time, were 
directed to make a commitment to raising the vaccination coverage in their countries to 
80% by 1990 (Obomsawin 1998). In the discussion of the necessity for this program 
there was no mention of the different risk profiles that infectious diseases had in 
different countries, only that the strategy was building on the success of the global 
smallpox eradication program (WHO ISD). A conference was held at the Rockefeller 
Foundation’s Bellagio Conference Centre in 1984 entitled ‘Protecting the World’s 
Children’; it focused on childhood diseases that could be prevented by vaccination. 
UNICEF became a dominant voice on global health policies at this time and the EPI 
became focused on increasing the vaccination coverage of the world’s children even 
though this strategy conflicted with the emphasis on primary healthcare services 
advocated by the Director-General of the WHO at Alma-Ata (Blume et al 2013a p11).  
As a result of UNICEF’s influence global health policies for infectious disease became 
narrowly defined as selective primary healthcare (PHC) programs which removed the 
focus from the social and environmental determinants of health and targeted only 
Growth monitoring, Oral rehydration therapy, Breastfeeding and Immunisation – 
known by the acronym GOBI (WHO CSDH 2005). In reality these programs were even 
narrower with most countries only addressing oral rehydration and vaccination (WHO 
CSDH 2005). By 1990 the program had achieved its goal of increasing the global 
vaccination rate of children to 80% for all the basic childhood vaccines – polio, 
diphtheria, pertussis, tetanus, measles and tuberculosis (WHO ISD; IOM 1993). The 
Institute of Medicine (IOM) states that the EPI raised the global vaccination levels from 
5% to 80% during the period 1974-1990 (IOM 1993).  
The Child Survival Revolution was celebrated at the UNICEF World Summit for 
Children in New York in 1990. This program was funded by the US Congress even 
though it was rare for foreign aid to be given priority by its members or constituents 
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(Blume et al 2013a pp11-12). The vaccination goal was re-set by the WHO to achieve 
90% vaccination coverage by the year 2000 and the child survival campaign was used to 
continue public support for the program in the political arena. However, vaccination 
coverage doesn’t inform authorities about the burden of disease and disability in a 
population, namely about the health of populations (see section 2.8). This indicator is 
used on the assumption that vaccines prevent disease and that they do this without 
causing serious or frequent adverse health effects in the population. These assumptions 
are hidden to the public because there is little or no surveillance of adverse events 
caused by vaccines in most countries (Obomsawin 1998). See chapters 6, 7 and 9. There 
is no systematic, active surveillance of long-term health outcomes in any country (CDC 
VAERS). In the early 1990’s there was a digression in public health policies from local 
initiatives and community action to a focus on medical technologies using sophisticated 
media campaigns to sell the message. This caused a rupture in political opinion at the 
international and national level. GOBI was criticised as being poorly conceived and a 
simplistic approach to complex health problems (Basch 1994 pp45-6).  
The Children’s Vaccine Initiative (CVI) and GAVI (1990-2015) 
Globalisation changed the processes of vaccine development and production from 1990 
onwards. In the 1980’s there was a realisation that many of the countries that needed 
vaccines would not be able to afford them. There is little incentive for vaccine 
manufacturers to invest in the development of vaccines if there is limited commercial 
value (Basch 1994 p8). This problem was solved with the establishment of public-
private partnerships in the 1990’s. Prior to globalisation, the vaccine market was 
unstable and virus strains and production processes were not protected by patents, 
therefore fewer companies were competing to develop vaccines (Blume et al 2013b 
p31). A new Children’s Vaccine Initiative (CVI) was launched in the 1990’s to harness 
nascent technologies in the development of new combination pediatric vaccines and to 
continue to reach the 20% of children in developing countries who were not receiving 
vaccines (IOM 1993). This initiative had a wider range of stakeholders supporting its 
implementation than the EPI. Whilst the stakeholders still included the WHO and 
UNICEF they were now joined by the Rockefeller Foundation, the World Bank and the 
United Nations Development Program (UNDP) (IOM 1993). These organisations 
worked together with private industry providing directives for global public health 
policy through the WHO. The CVI consultative group included commercial vaccine 
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manufacturers, public-sector vaccine manufacturers, donors and national development 
assistance agencies, research institutes, representatives of national immunisation 
programs, the US Food and Drug Administration (FDA), US Agency for International 
Development (USAID) and the US Centers for Disease Control and Prevention (CDC). 
Rising costs and the complexity of vaccine development were hindering the research 
and production of new combination vaccines however the new financial partnerships 
with industry in the CVI, supported by the Vaccine Fund, overcame many of these 
problems (Muraskin 2004 p1922).  
An example of private-public partnerships is the Program for Appropriate Technology 
in Health (PATH). This group was set up as a non-government organization (NGO) in 
1977 and it received 4 of the 20 largest individual grants from the Bill and Melinda 
Gates Foundation (BMGF) from 1999-2007 (McNeill et al 2013 p68). The new 
partnerships resulted in global policy being designed in a manner that was contrary to 
the WHO charter (Muraskin 1998 pp43-5). The WHO has a mandate to promote global 
health according to the charter for health promotion adopted in Ottawa in 1986. This 
charter emphasises autonomy and promotes community input and ownership of public 
health policies. It is required to promote a bottom-up model not a top-down model. 
Consequently, the goals of private and public organizations are very different and the 
CVI was constantly in disagreement about global health policy and the WHO 
controlling the CVI. Private organizations whose goal is profit provided the funding to 
support the development and research of new vaccines in the CVI that were promoted to 
governments through global health policies. This initiative resulted in new vaccines 
being implemented into countries without input from the community and local health 
authorities. When the health needs of countries are determined by outside experts they 
do not always fulfill the needs of the community (Basch 1994 p9). Although the CVI 
consultative group met annually at an international forum many of the organisations 
were from the USA. The influence of the new stakeholders in the WHO advisory board 
for global health policy resulted in agendas for national immunisation policies reflecting 
US interests (IOM 1993 p22).  
The US provided assurance for the funding of the CVI through UNICEF in 1991/2 even 
though the Europeans, particularly the Nordics, did not approve of this sponsorship. 
They believed that the development, testing and introduction of new vaccines into 
government programs should be secondary to the support for the EPI. This is because 
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there was uncertainty about the sustainability of the fundamental vaccines provided to 
developing countries in the EPI (Muraskin 1998 pp49-50). Hence, UNICEF became the 
funder for all activities that did not involve research and development. It funded the 
infrastructure that facilitated the implementation of the vaccines yet at the outset of the 
design of the initiative UNICEF was seen as the vehicle for funding to be channeled 
into vaccine product development. This initiative was seen by Europeans as a creation 
of the US to support multinational corporations in the biotechnological revolution. The 
WHO also had concerns about working with industry to create the resources needed for 
vaccine development. For example, the low prices of vaccines offered to countries 
through the EPI could only be provided because of the profits generated from the 
commercial market. Companies could pay off the initial capital investment through 
private sales to make a reasonable profit and this enabled the pharmaceutical companies 
to sell the vaccines to the public sector at a lower cost than production: a two-tiered 
pricing system. The mass ordering of vaccines for the public sector resulted in 
economies of scale that lowered the prices for the private and public sectors. However, 
the WHO was compromised in this arrangement that allowed companies to gain 
significant private profit (Muraskin 1998 p62). There was also concern over WHO 
receiving royalties from private organisations that used WHO research. This included 
patents, licenses, technical knowledge, trademarks and copyright. It was felt that this 
conflict of interest in working with private industry would compromise its goals 
therefore it chose to participate only in joint research projects and not cooperative 
market agreements.  
In the late 1990’s the shortage in funding for the CVI resulted in the development of the 
Global Alliance for Vaccines and Immunisation (GAVI). This alliance was initiated by 
the Head of the World Bank in 1998 at a summit for the WHO, UNICEF, the 
pharmaceutical companies, international agencies, health ministers and academics 
(GAVI HoG). The agenda was driven by the fact that there was no incentive for 
pharmaceutical companies to supply vaccines to the developing countries because they 
were unable to afford the 6 new vaccines that had already been introduced into 
developed countries. The Bill and Melinda Gates Foundation (BMGF) donated US $750 
million to the cause and this was matched by the governments of developing countries 
resulting in US $1.67 billion (McNeill et al 2013 p69). The BMGF joined the GAVI 
alliance advisory board and the collaborative venture was launched at the World 
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Economic Forum in 2000 (GAVI HoG). As stakeholders in the alliance, the BMGF, the 
Rockefeller Foundation and pharmaceutical companies were influential in shaping 
global public health policies (McNeill et al 2013 p73).  
3.3 The Influence of GAVI in Global Policy  
After the GAVI alliance was established a working party that included the International 
Federation of Pharmaceutical Manufacturers and Associations (IFPMA) designed 
policies with a global focus on new vaccine production and implementation. This 
direction in public health policy conflicted with the priorities that some countries 
wanted to choose for their health agendas. Many donor and recipient countries were 
critical of the singular focus GAVI had on vaccines (Muraskin 2004 p1922). It operates 
on a top down model that undermines community action and its focus on vaccines is not 
formed by a consensus in the international public health community. There was 
discussion that GAVI should be an independent organisation however it became an 
alliance with the WHO working party issuing global directives from 1998-2008. GAVI 
increased its governance powers and took over many of the WHO functions in member 
countries (McNeill et al 2013 p75). Global public health policies are now focused on 
technocratic governance and technologies and not traditional primary health care. The 
increased emphasis on vaccination programs has been to the detriment of programs 
targeting nutrition, sanitation, health education, clean water, child and maternal health, 
prevention and control of endemic disease and medicines (Obomsawin 1998; Blume et 
al 2013 p27). This focus on vaccination policies could not have occurred without 
private partnerships with the Gates Foundation, the input from the IFPMA and the 
Vaccine Fund supported by the developed nations (Muraskin 2004 p1922). Global 
public health policies promoted by the WHO are being designed by a governing board 
that includes the World Bank and members of many commercial vaccine manufacturers 
whose products are promoted by GAVI (GAVI HoG). Further, GAVI provides 
representatives to ‘educate and financially entice’ countries to accept GAVI’s 
vaccination goals (McNeill et al 2013 p82). GAVI has also established vaccine advisory 
committees to advise governments about the recommendations for policy. These are 
known as the National Technical Advisory Groups for Immunisation (NTAGI) and their 
stated purpose is to provide ‘informed’ and ‘transparent’ policy advice (WHO ITAG 
2008). They are composed mainly of scientific and medical experts, usually with one 
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consumer representative. The advice provided by GAVI/WHO is influenced by the 
IFPMA and pharmaceutical companies whose representatives can attend meetings and 
present information (Gessner et al 2010 A2).   
These conflicts of interest in the design of public health policies for the ‘good of the 
community’ are hidden from the global population. During the 1990’s the WHO 
distrusted the profit motives of the private sector and there was conflict over the 
direction of these policies (McNeill et al 2013 pp70-75). This was solved by the 
establishment of private-public partnerships through NGO’s. When Gates became a 
partner in the GAVI alliance with many transnational corporations he moved the centre 
for policy development from Geneva to Seattle. In addition to these conflicts of interest, 
the majority of members of the WHO, UNICEF and EPI advisory boards that are 
involved in developing vaccination programs come from professional backgrounds with 
financial links to industry; many are scientists and administrators from developed 
nations (McNeill et al 2013 p69). Conflicts of interest and the composition of 
stakeholders on vaccine advisory boards play a significant role in the direction of global 
and national health policies in the New Public Health era. These are discussed further in 
chapter 6.  
Global health policies have targeted children in both the developing and developed 
countries with vaccines, even though deaths and illness to infectious diseases had been 
significantly reduced in developed countries by 1950. Hence the narrow focus on 
vaccination programs did not address the different risk profiles that infectious diseases 
had in different countries. They have also been promoted with moral authority to 
policy-decision makers and the global community. They are framed as ‘saving 
children’s lives’ in campaigns that are akin to a crusade (McNeill et al 2013 pp67-68). 
This is because the GAVI alliance has been founded on the claim that ‘if a vaccine is 
available on the international market, to not make it available to all children, 
particularly those whose poverty makes them most vulnerable, is a form of moral 
neglect on the part of the international community’ (Sandberg and Justice 2013 p87). 
This policy claim is given further credibility as a ‘social justice’ program by the Johns 
Hopkins School of Public Health and the London School of Health and Tropical 
Medicine (McNeill et al 2013 p68).  
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GAVI skewed the direction of WHO funding to universal recommendations on 
vaccination coverage in all WHO member countries despite the knowledge that public 
health officials had of the etiological factors involved in disease outcomes from 
infectious agents. It has also funded new vaccine producers in India, Brazil and 
Indonesia to compete with the large pharmaceutical companies. This presents a further 
conflict of interest between vaccine producers and WHO global policy directives; GAVI 
recommends vaccines to the global community that some of its members profit from. 
GAVI claimed that funding new vaccine manufacturers would result in significant price 
reductions for vaccines but according to McNeill et al (2013 p69) this never eventuated. 
In addition, vaccines cannot be used without harming a percentage of the population but 
this harm is not being systematically monitored or factored into the economic modeling 
for key measures of health. Vaccine producers and patent holders that profit from 
vaccines are represented on both global and national vaccine advisory boards (McNeill 
et al 2013 p69) and this conflict of interest is not made transparent to the public in the 
recommendations of global health policies by the WHO. Vaccines are described in the 
1986 US National Childhood Vaccine Injury Act as ‘unavoidably unsafe’ (Holland 
2011 p12) and the increased risk from the use of an increasing number of vaccines and 
achieving higher vaccination rates is not quantified in a risk/benefit analysis for each 
country in the implementation of this global policy (WHO ISD; Obomsawin 1998).  
Since the CVI initiative was first launched the policy has expanded to target many more 
diseases. The vaccines have been introduced in developed countries for diseases that 
were a low risk to the majority of the population at the time they were introduced. They 
have also been introduced without discussion of the context in which people get these 
diseases (AG IAP 2004; Mercae 2003 p197). GAVI is using economic modeling 
influenced by industry to show health problems that governments are not aware of, and 
using financial incentives to create the ‘political will’ for governments to implement 
new vaccines as the solution. This is despite the health problems not being a priority 
and it results in unnecessary vaccines with increased risk of adverse health outcomes for 
some individuals. The cost-effectiveness data for new vaccines is produced by industry 
- not the WHO - and it is being presented to enhance the possible benefits of vaccines 
whilst ignoring the risks (McNeill et al 2013 p78-9). In other words, advocacy from 
GAVI representatives using manipulated statistics and hidden assumptions is being used 
to ensure countries commit to new vaccines. Chee et al state that GAVI does not always 
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have strong scientific evidence or universal support for its strategic policies, for 
example, the introduction of Hib vaccine, and therefore it is perceived to push new 
vaccines inappropriately (Chee et al 2008 p19).   
3.4 National Immunisation and Technical Advisory Groups (NITAG) 
The WHO/GAVI alliance places high priority on establishing vaccine advisory boards 
in member countries for the development of national immunisation programs (Duclos 
2010 A18). These groups are referred to as national immunisation and technical 
advisory groups (NITAG). In Australia this group is called the Australian National 
Technical Advisory Group on Immunisation (ATAGI). WHO/GAVI assist in their 
establishment and influence the advice they provide in the following ways (Duclos 2010 
A23-24): 
• Providing technical guidance in the formulation of immunisation policies 
• Providing global and regional policy recommendations and providing the 
evidence for these recommendations 
• Providing the latest developments on vaccines to the chair of ATAGI 
• Guidance in providing sources of financial support 
• Developing training and educational materials 
• Facilitating exchange between global NITAG’s and participation of the chair 
in regional immunisation meetings  
These activities are influenced by the US Centers for Disease Control and Prevention 
(CDC), the ProVac Initiative launched in 2006 and the Supporting Independent 
Immunisation and Vaccine Advisory Committees (SIVAC) through WHO/GAVI. 
(Duclos 2010 A24). The influence of pharmaceutical companies in the advice provided 
by the Australian vaccine advisory board (ATAGI) and in the production of scientific 
evidence in clinical trials is described further in chapter 6.  
The role of NITAG’s ‘is to facilitate a systematic, transparent process for developing 
vaccination policies by making evidence-based technical recommendations to the 
national government’ (WHO ITAG 2008 pp2-3). Over the last 15 years evidence-based 
policy making (EBPM) has been formalised as the foundation for developing public 
health policy (Belague et al 2009). This is a system of knowledge that aims to use 
clinical evidence obtained from systematic research to support policy decisions. It 
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gained prominence in the 1970’s due to Archie Cochrane’s emphasis on the need for a 
systematic evaluation of the safety and efficacy of innovative interventions/products in 
medicine. The Cochrane Collaboration was established in 1993 and the evidence-based 
methodology is now being applied to many non-clinical areas of policy development 
such as education, public policy and public health. EBPM implies that the methodology 
is based on scientific evidence. However, this needs to be examined in the broader 
political context where the interpretation of research findings can be shaped by the 
research donor (Belague et al 2009 p1539).  EBPM is a move away from the use of 
common-sense and local knowledge in the formation of policy. This is significant in 
public health policy design where environmental context plays a significant role in 
health outcomes and where the scientific knowledge is often not complete. See chapter 
4 for the significance of non-technical information in the risk assessment for health 
hazards. 
EPBM is being used by governments to justify new policies that are replacing 
established policies of proven benefit. This results in a narrower approach to health that 
does not offer comprehensive solutions to context-specific health issues (Behague et al 
2009). Whilst contextualisation of globally recommended policies is acknowledged as 
being an important factor in promoting health (WHO ITAG 2008) it cannot be achieved 
in practice because research activities are being dominated by a focus on achieving 
internationally set agendas. In the New Public Health Era of public-private partnerships 
local researchers who are familiar with a country’s specific health issues do not have 
access to the government health department. Governments are framing policy on the 
advice of global sponsors and economic modeling influenced by industry, and not local 
needs. This is observed in the adoption of the Millennium Developmental Goals 
(MDG). Many countries are achieving the MDG’s at the expense of primary health care 
and community input into health policies. The interventions being recommended in 
many countries are reflecting the sponsor’s needs and not the local context (Behague et 
al 2009 p1542). The use of the EB methodology without non-technical input is resulting 
in limited healthcare practices that have been detrimental to health and environmental 
outcomes in many countries (Behague et al 1009 p1540; Baum 2008 p101; Basch 1994; 
Obomsawin 1998). 
In Australia the childhood schedule has expanded to include vaccines to protect against 
16 diseases with 11 vaccines recommended before an infant is one year of age (AG IAP 
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2013). This schedule has expanded in line with GAVI’s directives in the first phase of 
its program (2000-2005) to ‘save children’s lives’ and ‘protect people’s health through 
widespread use of vaccines’ (McNeill et al 2013 p75-6). GAVI uses many strategies to 
implement its directives. One of them is to provide financial support to each country’s 
vaccination services through a performance-based reward system (Chee et al 2008 p41). 
Other strategies include supporting the financial sustainability of programs at country 
level and influencing vaccine supply and demand.  
Global health strategies have resulted in a decline in the authority of governments over 
the control of population health even though governments formally have the right to 
decide health policies for their own regions and populations (Sandberg and Justice 2013 
p88). This is a fundamental principle of the international community and transgressing 
this principle results in a loss of authority over human rights for individuals. 
Vaccination is a technological procedure and its adoption in government public health 
policy, using coercive and mandatory strategies, infringes on the fundamental human 
right to bodily integrity and informed consent. This right is protected in the Geneva 
Declaration which includes the physicians oath declaring that they will not use their 
medical knowledge to ‘violate human rights and civil liberties, even under threat’ 
(WMA 1948). Ethics and vaccination programs are discussed further in chapter 5. The 
EPI has been proven to be ineffective in the long-term in preventing outbreaks of 
infectious diseases in global communities because the program does not target the social 
and environmental determinants of health (WHO CSDH 2005 p19; Mercae 2003 p210). 
In addition, there is no obligation for governments to provide financial and technical 
resources to support capacity-building (Fidler and Gostin 2006 p88). This situation 
could undermine the new International Health Regulations (IHR). 
Well documented outbreaks of infectious diseases continue to occur in highly 
vaccinated populations. (Nkowane et al 1987; Boulianne et al 1991; De Serres et al 
2012; Lee et al 2004; Lopez et al 2006; Dayan et al 2008; Witt et al 2012; Mercae 2003 
p198). This evidence clashes with the claim that vaccine-created herd immunity can 
prevent infectious diseases. The fact that unexpected outbreaks continue to occur in 
vaccinated populations has led some health professionals to question the theory of 
vaccine-created herd immunity that vaccination policies are founded on (Obomsawan 
1998). In addition, it is the severity of the disease and not just the occurrence of disease 
that is significant to the health of populations.  
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The WHO states that an estimated 83% of children less than 1 year of age globally have 
received 3 doses of Diphtheria-Tetanus-Pertussis (DTP) vaccine (WHO IC 2013). Yet 
there have been many epidemics of pertussis (whooping cough) reported in highly 
vaccinated populations over the last two decades (Beherman 1998; Wendelboe 2005; 
Klein et al 2012; Mihalovic 2012). This includes outbreaks in Australia, the United 
Kingdom, and the USA where vaccination rates for pertussis have been above 90% 
since 1995 (Wendleboe et al 2005; Burgess et al 1998). This evidence suggests that 
vaccine-created herd immunity to whooping cough is not sufficient to prevent whooping 
cough outbreaks in many populations. Infectious disease epidemics have been reported 
with surprising frequency in developed countries where vaccination coverage is high 
due to the EPI (Obomsawin 1998). Muraskin (2004) describes GAVI’s focus on 
vaccination as a major flaw in public health policy. He states that the only reason 
countries are using so many vaccines is because of the major financial enticements. The 
core constituencies, including field workers and governments of developing countries, 
do not prioritise this goal and European bilateral donors have strong doubts about 
vaccines being the best strategy for achieving healthy outcomes in the developing world 
(Muraskin 2004 p1925). 
3.5 The International Health Regulations (IHR) 
Since the mid-19th century governments have maintained international agreements to 
protect their borders against the spread of infectious diseases. The IHR came into force 
on 15 June 2007 as an international legal instrument binding on the 194 member 
countries of the WHO (WHO IHR 2008). The aim of the IHR is to help nations prevent 
and respond to acute public health risks of global significance.  By 1995 the 
WHO/UNICEF had decided that globalization required a new framework for health and 
security. Public health, security and democracy were stated to be intertwined in the IHR 
and the changes were described as ‘moving humanity towards larger freedom’ (Fidler 
and Gostin 2006 p85). These changes occurred after private-public partnerships began 
to dominate WHO policy in 1995 and the new IHR are observed to reflect industry 
needs and not those of national governments (Sandberg and Justice 2013 p93). Changes 
to the international regulations in 1998 had allowed data for global health policy to be 
obtained from non-government sources, including data from industry. WHO was 
systematically using non-government surveillance information from the Global 
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Outbreak Alert and Response Network (GOARN) before the new IHR’s were 
completed in 2005 (Fidler and Gostin 2006 p93). The IHR allow the WHO to maintain 
the confidentiality of NGO sources of data where it is ‘duly justified’. However, there 
are no guidelines to specify when this condition applies (Fidler and Gostin 2006 p88). 
In 2005, the IHR changed after 10 years of discussion and WHO/UNICEF announced a 
new global strategy at the same time as the changes to IHR. This policy was to expand 
current vaccination programs to more populations and new demographics beyond 
childhood (WHO/UNICEF 2005 p24 in Blume et al 2013a p2).  
The WHO supported the IHR’s under the belief that timely and open reporting of public 
health events would make the world a safer place (Flynn 2010). The IHR’s gave new 
powers to the Director-General of the WHO to set up an Emergency Committee (EC) in 
response to a possible pandemic. Members of the EC are to remain undisclosed to the 
public. The EC’s purpose is to advise the Director-General when to declare the 
pandemic (WHO IHR 2008). The functioning of the EC in the response to the 
declaration of a ‘Swine Flu’ pandemic in 2009 is described in chapter 10. Whilst the old 
regulations required governments to inform WHO about the transfer of diseases that 
might be of global concern, the new IHR’s require nations to give priority to issues that 
are of global concern over domestic issues. The new IHR’s were stated to be a balance 
between maintaining the right of governments to protect their people whilst avoiding 
unnecessary interference with traffic and trade. Essentially the changes implemented 
were made on the grounds that the IHR’s were ineffective against new emerging 
diseases that presented the threat of pandemics, e.g. AIDS, SARS and Swine Flu. The 
new IHR’s changed the international legal context for the implementation of national 
public health programs and gave new powers to the WHO (Fidler and Gostin 2006 p86-
94). 
The new IHR’s include the following requirements: 
1. An obligation to notify WHO of all events that may lead to a global public 
health emergency, not just the specific diseases that were previously listed. The 
list was expanded to include all infectious diseases and biological and chemical 
warfare. Public health is connected to security concerns because of the potential 
for terrorism from weapons of mass destruction.  
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2. Countries must notify WHO of an illness or medical condition irrespective of 
origin or source that presents or could present significant harm to humans.  
3.  Increased surveillance of diseases, including the whole territory and not just 
points of entry and exit. 
4. Notifications can be provided to WHO by any source including mass media, the 
internet and NGO’s. This information only needs to be ‘verified’ by the 
government concerned. 
These changes to the IHR’s ensure that global health governance, in partnership with 
corporations, has authority over national governments, if they choose to accept them. 
The choice to accept these policies is removed for countries that depend upon 
sponsorship or performance-based reward systems for their health programs. Financial 
enticements can bind governments to policies. It is noted that the USA has submitted a 
reservation regarding the acceptance of the IHR’s by stating it will implement the 
regulations in a way that is consistent with American federalism (Fidler and Gostin 
2006 p91). The WHO/UNICEF claim that this centralised global strategy is the only 
way to prevent the threat of emerging pandemic diseases in a way that minimises the 
disruptions to international trade (Fidler and Gostin 2006 p86). Whilst the WHO claims 
the strategy is compatible with human rights and state sovereignty, the opposite is true. 
Global policies are a top-down model that are not driven by community ownership and 
involvement; a feature that is also contrary to the principles established in the New 
Public Health statement, declared at the Ottawa Conference in 1986, to address the 
social determinants of health. See section 2.7.   
When the IHR’s came into force in 2007 national governments were required to fulfill 
their obligations by 2012 (Fidler and Gostin 2006 p88). In 2010 Bill Gates declared a 
‘decade of vaccines’ and pledged $10 billion to support this initiative. This led to a 
Global Vaccines Action Plan that was supported by the WHO, UNICEF and the US 
National Institute of Allergy and Infectious Diseases (NIAID), a body that is part of the 
US National Institutes of Health (NIH) (Blume et al 2013a p1). It was claimed in 2011 
that the global vaccine market was expected to reach US $34 billion in 2012 with a 
growth rate of 14% expected for the next 5 years (CVEP 2011 in Blume et al 2013a p2). 
The growth of the vaccine market has been described as the ‘vaccine paradox’: a 
situation where governments control the demand and provision of vaccines (Horton and 
Das 2011 p296 in Sandberg and Justice 2013 p98). Governments are being advised by 
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GAVI, an alliance with vaccine manufacturers that profit from the vaccines they 
promote with financial incentives to governments through the WHO. An example of the 
influence of corporations in the decisions by governments regarding the declaration of a 
‘Swine Flu’ pandemic in 2009 is provided in chapter 10.  
The introduction of global vaccination programs has not been based on evidence of the 
epidemiology of infectious diseases in each country, their case-fatalities and limited 
consequences, but on industry economic modeling and international considerations 
(Sandberg and Justice 2013 p109). Whilst these programs claim to be ‘evidence-based’ 
in high income countries, it is necessary to ask ‘who is providing the evidence that is 
underpinning these policies and how has it been produced?’ This question is addressed 
in chapter 6 and in the case studies provided in chapters 9 and 10.   
3.6 Global Preparations for a Pandemic  
Under the 2005 International Health Regulations most countries were required to 
develop Pandemic Preparedness Plans (PPP) (WHO GIP). New and improved tools to 
prepare and respond to pandemics have become available to the Global Influenza 
Surveillance Network (GISN) and these have been used by WHO since the emergence 
of avian influenza A (H5H1) in 1997, to prepare a global pandemic response plan 
(WHO GIP).  
The new tools and technologies that are available include (WHO GIP):  
I. Antivirals  
II. Nascent technologies to speed the development of pandemic vaccines. These 
are new patented methods for producing vaccines in a shorter time. 
III. Improved molecular and genetic techniques to analyse and track the 
evolution of influenza viruses 
IV. Mathematical methods to model the evolution and spread of a pandemic 
virus, estimate incidence and prevalence and assess the impact of 
pharmaceutical and non-pharmaceutical measures on disease transmission 
and associated morbidity and mortality  
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The WHO member countries have spent 10 years under the guidance of the IHR’s 
preparing their PPP’s for a possible pandemic. Many scientists have expected a 
pandemic of influenza for a long time and they believe a possible mutation of the swine 
flu virus poses the biggest danger to the population because it makes existing flu 
medication and vaccines ineffective (Flynn 2010). Yet there is disagreement on the 
efficacy of current antiviral medications and influenza vaccines (Cohen and Carter 
2010) and their effectiveness in an epidemic is undetermined. The PPP’s established by 
governments globally included strategic stockpiles of antivirals, antibiotics, influenza 
vaccines and personal protection equipment (WHO GIP). In addition, the IHR’s 
included the surveillance and reporting of all events to the WHO that may represent a 
public health emergency of international concern. For example, cases of new sub-types 
of influenza, which were never previously monitored, must be reported (WHO IHR).  
A stated milestone for the IHR’s was the assessment of member countries’ surveillance 
and response capacities by June 2009 (WHO IHR). Notably the global ‘Swine Flu’ 
pandemic was declared on June 11 2009 when the EC changed the definition of a 
pandemic and removed the requirement for the need to show how severe the impact of 
the virus would be on the population. Without this change to the definition it would not 
have been possible to declare a level 6 pandemic. Under the IHR’s governments had 
PPP’s that were termed ‘sleeping contracts’ with pharmaceutical companies, which 
were to take effect when the WHO declared a pandemic. These contracts required 
national regulatory authorities to license vaccines developed by various vaccine 
manufacturers (sometimes following accelerated procedures) to ensure vaccines were 
available more rapidly than for seasonal flu (Flynn 2010). The events that led to the 
2009 ‘fake’ pandemic are described in chapter 8.  
3.7 Global Vaccination Policies and Human Rights 
The IHR’s gave new powers to the WHO. This included: 
 i) The power to decide if a disease event reported by state parties fits the criteria for 
declaring an international public emergency and  
ii) If an event of international concern is declared, the WHO can recommend non-
binding measures for addressing the health risk in each country – temporary or 
permanent measures.  
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This gives WHO influence in health measures and in human rights in national policies. 
The IHR’s require that health measures against persons are appropriate to the risk and 
no more intrusive than available alternatives that would achieve a similar health 
outcome (Fidler and Gostin 2006 p87). They also require that the measures are applied 
in a transparent and non-discriminatory way. When implementing compulsory measures 
for medical examinations governments must apply the least intrusive measure but this is 
not stipulated in the IHR’s for the prevention of disease which include vaccinations, 
isolation, quarantine or the use of other prophylactics. When governments apply 
compulsory health measures the IHR’s do not require due process protections. There are 
binding limits on the strategies that governments can take against public health risks and 
generally they cannot require invasive medical examinations, vaccination or use of other 
prophylaxis as a condition for entering a country (Fidler and Gostin 2006 p88). 
However, the IHR’s mechanisms for forcing governments to comply with the 
recommended health measures are weak which means that in practice the ‘binding 
limits’ are not enforceable. 
3.8 Contraindications to Vaccines 
The EPI has been implemented in many countries with little attention to the known 
contraindications to vaccines. There are many factors known to put individuals at risk 
from vaccines. These are termed contraindications, for example, a family history of a 
genetic disease (Obomsawan 1998). An example of this is provided with the whole-cell 
whooping cough vaccine that was linked to neurological adverse events (Feery 1981 
p174; Zeigler et al 1991; NHMRC 1954-86; NHMRC 91). In 1978-1990 a family 
history of neurological disease was considered a contraindication to vaccines (NHMRC 
1978-86; NHMRC 91). In 1980 a British survey (The British Childhood 
Encephalopathic Study [NCES]) estimated the risk of having a severe neurological 
reaction with persisting sequelae from whooping cough vaccine to be 1 in 310,000 
vaccinations (Feery 1981 p174). This data was re-analysed a decade later using different 
assumptions and criteria to conclude ‘the risk of encephalopathy with permanent brain 
damage was close to zero’ (NHMRC 1991). However, the Australian College of 
Pediatrics (ACP) stated in 1991 that most neurological events (febrile seizures and non-
febrile seizures, encephalopathy and other neurological symptoms) occur in children 
that do not have known risk factors. They also stated that infants/children who have a 
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history of convulsions in immediate family members (siblings and parents) have a 3.2-
fold increased risk for neurological events compared to those who do not have a family 
history of the condition (Zeigler et al 1991 p17). 
In the 1990’s there was disagreement between the contraindications for whooping 
cough vaccine stated by NHMRC, the American Academy of Pediatrics, the Australian 
College of Pediatrics and vaccine manufacturers (Zeigler et al 1991; NHMRC 1991). In 
1994 the NHMRC adopted the guidelines of the American Academy of Pediatrics 
which did not include a family history of neurological disease as a contraindication to 
WC vaccine (NHMRC 2003). Contraindications were stated to be encephalopathy 
within seven days of vaccination (not including febrile convulsions) and immediate 
severe allergic reaction, for example, anaphylaxis (NHMRC 2003).     
3.9 Vaccine Ingredients 
In the US, the Vaccine Injury Compensation Program (VICP) has paid over $2 billion in 
damages to over 2,500 families since 1988: and these are only the cases that were 
allowed and were voluntarily reported within 4 hours of the vaccination (Habakus and 
Holland 2011 p2; Obomsawin R preface). Many other claims were refused based on the 
criteria for acceptance. Although exemptions to vaccination in the US are allowed 
doctors can be punished if they grant too many and parents are not made award that 
exemptions exist (Habakus and Holland 2011 p2). Even though vaccines are described 
in US law as ‘unavoidably unsafe’ (Holland 2011 p12) Australians are not informed of 
the ingredients of vaccines or all the known risks from this procedure. The ingredients 
of Australian vaccines are presented in Appendix 1. In addition, Australia does not have 
a compensation scheme for its National Immunisation Program (NIP). This is the case 
even though coercive practices, such as financial incentives, have been introduced to 
encourage Australians to use an increasing number of vaccines. Medical practitioners do 
not describe the ingredients of vaccines to Australian consumers before they vaccinate 
and the ingredients have not been provided to parents on the Immunise Australia 
Program (IAP) website (AG IAP 2014). Instead the ingredients are listed as 
‘components of vaccines’ in Appendix 3 of the Australian Government Immunisation 
Handbook (AG IH 10th Ed 2014). Most vaccines contain preservatives, antibiotics and 
adjuvant (aluminium compounds) that are described on the IAP website as being in 
‘trace’ amounts.  
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The Australian Government’s vaccination policies are considered coercive because they 
pressure individuals to use vaccines by providing financial incentives for both parents 
and doctors. They are also coercive because they require individuals to fill out an 
exemption form signed by a doctor if they choose not to vaccinate. This is being 
required of parents who wish to claim the government welfare benefits or childcare 
places and of employees in some workplaces (AG IAP 2014). These requirements place 
pressure on parents to be ‘responsible’ by ensuring their children are ‘fully vaccinated.’ 
When parents are not informed of the ingredients of vaccines or the potential health 
hazards of vaccines it is a breach of their right to fully informed consent. Good medical 
practice requires that doctors fully inform patients about the risks and benefits of 
medical procedures and they must recognise and respect a person’s right to make their 
own decisions on healthcare (MBA 2010). See chapter 5.  
The community is informed that diseases on the childhood vaccination schedule are not 
a public health risk because vaccines prevent these diseases (AAS 2012). Medical 
practitioners state that vaccines are one of medicine’s greatest achievements (Offit 
2003), even though the historical data shows that the most significant fall in mortality 
and morbidity due to infectious diseases occurred prior to the use of all vaccines other 
than diphtheria and smallpox. This was discussed in Chapter 2. Patients place their trust 
in doctors to be acting with integrity, truthfulness, dependability and compassion (MBA 
2010). If a public health policy includes a medical intervention on the basis of claims 
that are not supported by scientific evidence it is a breach of the public’s trust. It also 
breaches the ethical code of good medical practice that has been adopted by Australian 
doctors (MBA 2010). Doctors in Australia are required to ensure that any procedures 
they recommend to patients are necessary and beneficial to their patients (MBA 2010). 
In 2006 the World Health Organisation (WHO) recognized that many non-infectious 
diseases pose as serious a threat to world health as infectious diseases (WHO CD 2013). 
Chronic illness is now the leading cause of death in the world resulting in 63% of all 
deaths. The scientific community is also aware that a large proportion of the chronic 
illness is due to autoimmune diseases (WHO CD 2013). Vaccines contain aluminium 
adjuvants which have been associated with causing autoimmune diseases for many 
years (Greville 1966; Shoenfeld and Agmon-Levin 2011).  
The chemicals in vaccines include mercury (mostly prior to 2000), formaldehyde, 
aluminum adjuvant, antibiotics, stabilisers and preservatives. However, it wasn’t until 
	  
	  
67	  
1999 that the FDA finally stated that the mercury in vaccines exceeds the Federal Safety 
Guidelines (FDA Thimerosal). Government officials admitted they had not considered 
the cumulative effects of the increased number of vaccines (FDA Thimerosal). Herbert 
Needleman’s research on the effects of lead in children has led to claims that there is 
substantial evidence that environmental toxins (even in trace amounts) are implicated in 
behavior change resulting from disturbances to the prefrontal lobes in the brain 
(Needleman 2000). In particular, researchers have linked heavy metals with affects on 
neurotransmitters – chemical substances needed for the proper functioning of the 
nervous system (Needleman 2000). Alteration of the prefrontal lobes affects decision-
making, choices and resisting impulses (Needleman 2000). Autism is a result of 
immature development and organization of the brain, in particular of the frontal and 
temporal lobes (Coulter 1990) and mercury is a heavy metal that has been in many 
childhood vaccines for decades. See Appendix 2. Mercury and aluminium are described 
as ‘neurotoxins’ and they are combined with many other compounds in vaccines. When 
chemicals are combined they are known to have cumulative and synergistic effects with 
other chemicals and they are known to be particularly toxic in infants and young 
children. Toxicity also increases when they are injected into the tissues as opposed to 
entering the body through natural routes of exposure (Gilbert 2004).   
In 2000 the Australian Commonwealth Government issued a directive to remove the 
mercury-based preservative thimerosal from all childhood vaccines. Since then the 
government has claimed that there is no mercury (other than a trace amount) in any 
vaccine on the schedule for children less than five years of age (AG IAP 2012). 
However, in 2013 thimerosal was still listed as an ingredient in the Energix B vaccine 
for Hepatitis B given at birth and also for the influenza vaccine Fluad and Fluarix (AG 
IH 9th Ed 2013). In addition, thimerosal was still present in the infanrix-hexa vaccine, 
the new 6-in-1 vaccine that will be used most frequently in infants to replace 6 separate 
vaccines (Austin et al 2010). A ‘trace’ amount of a toxin is not a quantitative measure 
and parents have a right to be informed truthfully about the quantities of the ingredients 
in vaccines. This is particularly the case when parents in Australia are being pressured 
into using many vaccines under the benevolent claim that it is the responsible thing to 
do for the community.  
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PART 2 DEVELOPMENT OF AUSTRALIA’S NATIONAL 
IMMUNISATION PROGRAM (NIP) 
 
3.10 The Australian National Immunisation Strategy (NIS) (1993) 
In 1993, under the WHO’s declaration of health for all, the World Health Assembly 
called on WHO to establish partnerships with the commercial sector to assist in the 
development of national vaccination strategies (Buse and Waxman 2001 pp1-2). Public-
private partnerships were outlined as a core function of WHO’s corporate strategy to 
achieve the goal of health for all and this created industry incentive for the research and 
development of drugs and vaccines. National vaccination programs were designed by 
partnerships between industry and intergovernmental organisations from this time 
onwards and referred to as National Immunisation Programs (NIP) (Buse and Waxman 
2001). Partnerships with industry gave the UN access to more resources and industry’s 
involvement in the promotion of public health messages gave the commercial sector an 
improved corporate image that encouraged new investors and markets.    
A milestone in the promotion of global vaccination programs was the 1986 report from 
the Institute of Medicine (IOM) of the US National Academy of Sciences. This report 
described the diseases of importance in the US and in the developing countries (IOM 
1986 in Basch 1994 p12). The report listed three categories of pathogens of importance 
to global health - high, medium and low - for which vaccines could be developed. The 
report placed a vaccine against childhood diarrhea in the category of highest importance 
because of the high burden of this disease in developing countries, not the developed 
countries, and vaccines for pathogens of lesser significance into category 2 or 3, 
including hepatits B virus and Haemophilus influenza type b virus (Basch 1994 pp12-
13). Research and development on vaccines was revitalised in the 1990’s because it was 
recognised that new biomedical technologies might improve the existing vaccines and 
could be used to create new vaccines for other infectious diseases (Basch 1994 p182). A 
new globally coordinated effort was initiated to achieve the common goal of Universal 
Childhood Immunisation (UCI). This brought together national, regional and 
international development agencies, private foundations, voluntary organisations, 
academic institutions, and industrial companies. Global and national vaccination 
programs became a coordinated initiative at this time where the needs of a global 
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community were established in advance of the development of vaccines. This program 
could not have been achieved and is not sustainable without significant financial 
support from the World Bank, the International Monetary Fund, private foundations and 
developed nations. The program has been promoted by global and national decision-
makers on a belief in the value and cost-effectiveness of vaccines and a push for social 
equity where all populations should have access to the benefits of vaccines. This 
enabled vaccination to be promoted as a public good, like education, and it was 
considered unethical to prevent a child from receiving a ‘life-saving vaccine’. Thus 
vaccines were prevented from being framed as a commercial commodity linked to 
corporate profits (Basch 1994 p182). 
Despite the low mortality and morbidity rates in developed countries, achieved by 1950 
through environmental and lifestyle reforms, governments globally promoted the idea 
that ‘vaccines prevented infectious diseases’ and that ‘high participation rates in 
vaccination programs are necessary to control infectious diseases’ (AG IAP FAQ 2013; 
CDC; Stanley 2001 p380). It has been well established that deaths and illness to 
infectious diseases were reduced in developed countries before the widespread use of 
vaccines (Stanley 2001 p370). See chapter 2. Therefore, ‘vaccine-created herd 
immunity’ was not responsible for the decline in these diseases. Yet in the early 1990’s 
the Australian government decided to increase the vaccination rates in the population on 
the basis that ‘vaccine-created herd immunity is necessary to control infectious 
diseases’ (AG CDIJ 1997). This was in response to WHO directives for global health 
policies. The Australian government justified this strategy on the premise that it might 
be possible to eliminate outbreaks of these diseases if vaccination rates were 85-90% 
(Hawe 1994 p241; Curry 2002 p34). This was despite the Australian College of 
Pediatricians (ACP) stating in 1991 that the prediction that whooping cough disease 
could be eradicated by achieving an uptake of the vaccine of 95% was probably wrong 
(Zeigler et al 1991 p16). This paper (Zeigler et al 1991) was authored by Margaret 
Burgess who became the founding director of the NCIRS in 1997 and Peter McIntyre 
who became the director of NCIRS from 2004 until the present time. The risk from 
these diseases had already been reduced so increased vaccination rates were emphasised 
in an effort to prevent these diseases. Hence the new terminology: vaccine-preventable 
diseases. This was part of a WHO directive that claimed to be ‘building on the success 
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of the smallpox eradication program and ensuring that all children globally benefited 
from vaccines’ (WHO EPI; IOM 1993).  
The conclusion that higher vaccination rates would be cost-effective was founded on the 
theory of vaccine-created herd immunity. It was theorised that vaccination rates of 94–
97% could interrupt the transmission of the pathogenic organisms and make it possible 
to eliminate many infectious diseases, particularly measles (Hawe 1994 pp241-2). As 
measles is a more contagious disease than smallpox it was argued that vaccination rates 
needed to be much higher than the 50% rate required to eliminate smallpox (Hawe 1994 
p241). This theory was based on the observed herd immunity that was obtained after 
natural infection that resulted in the reduction in the risk of infectious diseases by 1950. 
The new NIS did not just emphasise higher vaccination rates for measles vaccine but 
higher vaccination rates for all the vaccines recommended on the government schedule; 
even new ones that had not yet been introduced. It was a ‘package deal’ (Hawe 1994 
p242). In other words, even though the vaccines listed on the national schedule were 
implemented after deaths and illnesses from infectious diseases greatly declined in 
Australia, the government included all of them (plus new ones) in a new national 
campaign insisting that ‘high participation rates (90%) in vaccination programs are 
necessary to control infectious diseases.’ The NIS was a strategy that was estimated in 
the 1990’s to cost $53 million to operate (Hawe 1994 p242). At this time the infant 
mortality rates in Australia were low at 8.2 per 1,000 live births and infectious diseases 
were not considered to be a serious risk.                                                         
 Although the WHO stated in 1989 that measles ‘was not eradicable’ the new NIS was 
promoted by the Australian government on the claim that ‘measles could be eliminated’. 
This was defined as meaning ‘constant vigilance could prevent outbreaks’ and measles 
could be controlled (Hawe 1994 p243). The Australian Government claimed that highly 
contagious diseases such as whooping cough and measles could be eliminated if very 
high vaccination rates were achieved. However, the strategy in the early 1990’s also 
involved introducing new vaccines to the schedule and ensuring that the uptake of these 
vaccines was also above 90% (Hawe 1994 p242), for example, the triple antigen MMR 
vaccine, Haemophilus influenza type b (Hib) and hepatitis B (AG CDIJ 2007). When 
the NIS was implemented in 1993 infectious diseases were re-named vaccine-
preventable diseases and the public was informed through the media that high 
	  
	  
71	  
participation rates were needed for all vaccines to prevent death and illness from 
infectious diseases (AG IAP 2004).  
In the early 1990’s a new pertussis vaccine was developed using novel technologies. 
This was an acellular pertussis formula developed without thimerosal (a mercury 
compound and preservative) to reduce the adverse events that were associated with 
whole-cell pertussis vaccination (Basch 1994 p196). The acellular pertussis vaccine was 
introduced into Australia’s national program in 1999 and the whole-cell pertussis 
vaccine phased out over a number of years. The measles vaccine was reformulated to 
enhance the immunogenic quality in younger infants because maternal antibodies 
neutralise the live vaccine virus as well as the ‘wild’ disease-causing virus (Basch 1994 
p15). New biotechnology was also used to improve the oral polio vaccine by increasing 
its tolerance to heat. These vaccines had an assured market because they were approved 
for universal use in all populations. 
3.11 Australia’s National Immunisation Program (NIP) (1997-2012) 
In 1997 the initiative to increase vaccination rates was formalized and re-named the 
Immunise Australia Program (IAP) (AG IAP 2004). This strategy had been gradually 
implemented since 1993 and aimed to coordinate activities across many areas in order 
to control epidemics through higher childhood vaccination rates. This included an 
emphasis on a range of different strategies to attract parents to vaccination and on 
building infrastructure to improve access and delivery of vaccines. Essentially it 
required more cooperation between public and private sector interests with the removal 
of financial barriers to vaccination (Hawe 1994 p241). A ‘Seven Point Plan’ was 
implemented to attract parents to vaccination and encourage the uptake of the 
recommended childhood vaccines. It was believed that the reason vaccination rates 
weren’t high enough was because parents were complacent (Hawe 1994 p242). The 
vaccines recommended on the NIP schedule were subsidized by the government 
because they were claimed to be essential for community health. Vaccines to prevent 9 
diseases were listed on the NIP in the early 1990’s and were provided free of charge in 
the public and private sector from 1997-2000 in all jurisdictions (AG CDIJ 2007). 
Vaccination was promoted to parents as being a safe and effective way of protecting 
children against targeted diseases. It was also stated that the risks of these diseases are 
far greater than the very small risk of vaccination (AG IAP FAQ 2013).  
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3.12 Strategies Adopted in the Seven-Point Plan  
The strategies adopted in the Seven Point Plan (1997–2013) include initiatives for 
parents to increase the timeliness and coverage of vaccination as well as education 
campaigns for the general public and health professionals. The following points have 
been referenced from the Australian Government’s Immunise Australia Program (IAP) 
website.  
1. Central features of this strategy include a contribution from the Commonwealth 
Government to provide subsidised childhood vaccines, improved standards of 
maintaining vaccine quality and improved surveillance and reporting of vaccine 
preventable diseases.  
Although contraindications to vaccines are a significant area of concern for 
health providers (Obomsawin 1998; Hawe 1994 p242) the focus of the 
government’s concern when the new initiatives were introduced was more about 
‘marginal cost and marginal benefit’ (Hawe 1994 p242). In other words, the 
contraindications due to genetic predisposition were secondary to economic 
considerations from a ‘one size fits all’ policy.  
2. A General Practice Immunisation Incentive Scheme (GPII) was established to 
encourage doctors to participate in the program. Until 2013 the GPII scheme 
offered a Service Incentive Payment (SIP) to medical practitioners who notified 
the ACIR of children who had completed the vaccination schedule according to 
the National Immunisation Program. This payment changed in May 2013 and it 
is now paid to medical practices that monitor, promote and provide appropriate 
immunisation services to children under 7 years of age. A service provider 
education strategy is also provided in the seven-point plan. This is aimed at 
increasing the service provider’s commitment to actively promoting age 
appropriate childhood immunization.  
3. An Outcomes Payment was introduced in 1997 to practices that achieved 90% 
or greater vaccination coverage of children less than seven years of age who 
attended their practices. This is now called the GPII described above. 
4. There was also an Immunisation Infrastructure Fund that provided funding for 
divisions of general practice, state-based organisations and funding for a 
	  
	  
73	  
National GP Immunisation Coordinator to increase the proportion of children 
who are vaccinated at local, state and national levels.  
5. Further incentives to increase the vaccination rates included the establishment of 
the Australian Childhood Immunisation Register (ACIR). This is a national 
register that is administered by Medicare Australia to monitor children’s 
vaccination status and to notify parents when a vaccine is required. It also 
provides a database to inform the government who is eligible for immunisation 
welfare benefits. 
The ACIR is used to administer the GPII effectively. The GPII is an incentive 
payment to GP practices to encourage all practices to fully vaccinate at least 90 
per cent of children under seven years of age that attend their practices. By 
registering children on the ACIR the vaccination status of children can be 
followed and the required amount can be paid to GP practices when the target 
vaccination rates are achieved. GP’s are also expected to consider each 
consultation with a child as an opportunity to update vaccination status. 
Medicare Australia subsidizes private consultations that involve vaccination.  
6. Children’s vaccination status is linked to the eligibility for family assistance 
payments to remind parents to keep up-to-date with vaccination. In 1997 this 
payment was called the Maternity Immunisation Allowance (MIA) and it was 
paid to parents when a child was aged between 18 months and 24 months of age. 
Parents of unvaccinated children could still receive this benefit if they filled out 
a conscientious objector’s form signed by a doctor. Exemptions were provided 
for medical, religious or philosophical reasons. Since 2009 the MIA has been 
provided to parents in two payments. The first payment ($129) is when the child 
is aged between 18–24 months old and the second payment ($129) is between 4-
5 years old. This benefit ceased on 1 July 2012 and was replaced by the Family 
Tax Benefit Part A supplement.  
This benefit was increased to $2,100 and from July 2012 has been paid to 
parents in three installments of $726 (AG IAP 2013). In order to obtain this 
welfare benefit parents are required to have their children assessed by the Family 
Assistance Office (FAO) at one, two and five years of age. Children must be 
either fully vaccinated, be on a recognised vaccination catch up schedule, or 
have a signed exemption form for parents to be eligible to claim this benefit. The 
assessment of the vaccination status of children must take place during the 
	  
	  
74	  
financial year that each child turns one, two and five years of age in order to 
receive the benefit.  
 
After increasing the welfare payment linked to vaccination in 2012 the 
government added three more vaccines to the recommended schedule for a child 
to classify as ‘fully vaccinated’. The three new vaccines were meningococcal C, 
pneumococcal and varicella (chickenpox). Although these vaccines were 
available to parents for several years prior to 2012 they were not recommended 
on the NIP. These diseases are a low risk to the majority of children in Australia, 
however as of 1 July 2013 these vaccines are required for children to be 
described as ‘fully vaccinated’ in order to obtain the government welfare benefit.  
The definition of ‘fully vaccinated’ in 2013 means inoculation against 11 
diseases before a child is 12 months of age. See Appendix 3. 
 
Another welfare payment that was introduced in 1997 was the Child Care 
Benefit. This payment is to assist with the cost of day care centres and other 
childcare facilities. Again the benefit applies to children who are fully 
vaccinated or have an approved exemption from vaccination. The Childcare 
Rebate was worth approximately $7,500 per child in 2014. This benefit is to 
assist with childcare and is adjusted according to family income. In 2015 the 
Australian government proposed removing the right to philosophical and 
religious exemptions to vaccination. This would be implemented from 1 January 
2016 and it means that vaccination will no longer be a choice for parents who 
depend on welfare payments or childcare benefits for their livelihood (AG DHS 
2015). Vaccination with the full schedule of vaccines would be mandatory to 
receive childcare and welfare payments in 2016. Only medical exemptions will 
be accepted if this legislation is passed. 
7. Regulations have been introduced to require parents to present evidence of their 
child’s vaccination status when they enroll in schools. The regulation requires 
that a child that is not vaccinated due to medical or conscientious objections can 
be asked to stay home during outbreaks of an infectious disease. In NSW in 
2013, the Public Health Act of 2010 was changed to ban unvaccinated children 
from childcare centres if parents do not provide an up-to-date certificate of 
vaccination or a valid exemption form signed by an approved doctor (Gerathy 
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2013). Exemption forms are allowed for medical, religious or philosophical 
reasons but they must be signed by an approved doctor.    
Educational materials for doctors and other immunisation providers are supplied by the 
Immunisation Action Coalition (IAC) (IAC 2012). This is a non-profit organization set 
up by the US CDC with health professionals to distribute information globally on 
vaccination. The IAC assists in raising vaccination rates globally by facilitating 
communication about the safety, efficacy and use of vaccines to health professionals 
and the public (IAC 2012). The IAC receives funding from pharmaceutical companies 
in the form of ‘educational grants’ (IAC 2012). In 1997 the seven-point plan was 
promoted through an ‘Immunise Australia’ media campaign that targeted parents of 
children aged 0-6 years of age. The campaign aimed to raise awareness of participating 
in vaccination programs to control infectious diseases. Other sources of funding for this 
program, apart from the government, include the pharmaceutical companies. Vaccine 
manufacturers are providing funding to health professionals to increase the number of 
children they vaccinate. One example of this type of funding was the Infanrix 
Immunisation Awards that were presented at the National Public Health Association of 
Australia in 2006 (PHAA 2006). GlaxoSmithKline, the manufacturer of the Infanrix 
combination vaccine for diphtheria, tetanus and acellular pertussis vaccine, offered 
$10,000 to commend professionals who had implemented programs to successfully 
achieve the following outcomes: 
• An increase to 90% coverage in the 4 year old cohort 
• An increase in vaccination coverage in populations of hard-to-reach children 
and/or adolescents 
 
3.13 The Reason for Increased Incentives in 2012 
The government believes vaccination is the safest and most effective way to protect 
against infectious diseases. It is stated that vaccination reduces the spread of the disease 
so that individuals who are not vaccinated will also be protected by the vaccine through 
the establishment of ‘vaccine-created’ herd immunity. The government states that 
‘immunization rates in 2012 are at the highest on record and as a result notification rates 
of vaccine-preventable diseases are low’ (AG IAP 2012). Sixty-six cases of measles in 
children under 10 are cited as the reason for the need to increase incentives for 
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vaccinating (AG IAP 2012). The government has not provided supportive information 
on the vaccination status of these measles cases, their severity or the context (e.g. 
socioeconomic status) in which these cases occurred. This is significant for 
understanding the factors contributing to the risk from measles that exists in Australia 
for the majority of children. 
This evidence is also inconsistent with the epidemiological literature that indicates there 
are significant problems with the vaccination campaigns to control measles in the 
developing countries. Despite high measles vaccination coverage in many countries due 
to the EPI there are regular epidemics of measles in these countries (Obomsawin 1998). 
Australian parents are informed by the government that ‘measles can have serious 
consequences including death’ (AG IAP 2012). This is the reason provided for the 
increased incentives to vaccinate in 2012. This statement does not represent 
comprehensive information about the risk of measles to the majority of children in 
Australia. Poverty and nutritional status influence the risk of this disease and these 
factors need to be considered when designing public health policies for the good of the 
majority of the population. 
In addition, the government claims parents who do not vaccinate their children are 
risking their child’s health as well as the health of other children. Again the government 
does not quantify or even identify all the factors contributing to the risk from infectious 
diseases, yet the statement has been used to justify increasing the incentives for parents 
to vaccinate. In addition, the government has not provided a risk/benefit assessment for 
each vaccine to justify implementing strategies that make vaccination the default 
position for all the diseases for which there is a vaccine. This default position is 
enforced by requiring parents to get a vaccine exemption form signed by a healthcare 
provider in order to choose not to vaccinate.      
3.14 The National Immunisation Program (NIP) Since 2012  
Whilst the Australian government states ‘vaccination is not compulsory’, the 
recommended schedule of vaccines has now been linked to government welfare 
benefits, some workplace requirements and school entry. Many Australians feel 
pressured to vaccinate their children because they are required to get a doctor’s 
signature to refuse a vaccine. Participation is further emphasised by encouraging the 
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public to believe that it is their responsibility for the ‘community good’. See chapter 7. 
This has the effect of increasing the vaccination rate of the Australian population. The 
NIP schedule since 2013 now includes vaccines against 16 diseases. See Appendix 3. 
This is an increase from 7 at the program’s inception in the early 1990’s. Children are 
now recommended to have 7 vaccines by 2 months of age and 14 vaccines by 4 years of 
age. This results in approximately twenty-four inoculations/doses to complete the full 
vaccination schedule at four years of age. Varicella became available in a new 
combination vaccine - Priorix-Tetra - at 18 months of age from July 2013 in Australia. 
This vaccine includes measles, mumps, rubella and varicella combined in one vaccine. 
The vaccines that have been introduced into the NIP schedule since 1990 are for 
diseases that at the time posed only a low risk to the majority of children. Therefore it is 
incorrect to claim that high-participation rates are needed to protect community health 
for these vaccines. See chapters 4 and 7.  
Funding for the NIP is provided by the Australian Government and industry sponsors to 
establish the following services (AG IAP 2013; PHAA 2006): 
1. Free vaccines recommended in the NIP 
2. The Australian Childhood Immunisation Register (ACIR) that records details of 
vaccines given to children under seven years of age 
3. Notification payments to immunisation providers that report vaccines 
administered to the ACIR 
4. The General Practice Immunisation Incentives (GPII) Scheme to provide 
financial incentives for monitoring, promoting and providing immunisation 
services to children (ended May 2013). 
5. A facilitation and reward payment to states and territories to deliver the NIP in 
their jurisdictions. 
 
3.15 Vaccination in the Australian Workplace 
In 2006 the Federal government implemented a new Policy Directive requiring students 
studying health at tertiary institutions to be fully vaccinated before commencing or 
completing their practical work (NSW DH 2005). This was a mandatory directive 
requiring the updating of vaccination status against 10 diseases. The policy directive 
states that all health students who are affiliated with the hospital system or with NSW 
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Health are required to be vaccinated. In 2007 this initiative was extended to include all 
health professionals and employees of the NSW health system and in 2008 this was 
extended to other Australian States (AG IH9 2012). See Appendix 3. The Australian 
Government recommends that employers in occupations where workers are at 
significant risk of infectious diseases should implement a vaccination program. This 
program should include a vaccination policy, current staff vaccination records, 
provision of relevant information about infectious diseases and the management of 
employees who refuse vaccination (AG IH9 2012). The government emphasizes that 
this policy should include reducing the risk of a healthcare worker transmitting disease 
to a patient (AG IH9 2012). It is recommended that employers should take all 
reasonable steps to encourage unvaccinated workers to be vaccinated and if an 
unvaccinated person is exposed to a vaccine-preventable disease then they should be 
given any agent (prophylaxis) that prevents the development of the disease (AG IH9 
2012).  
 
The reason for extending vaccination programs to healthcare workers, childcare centres, 
schools and emergency services is the belief that individuals are at greater risk from 
infectious diseases in these occupations (AG IH9 2012). There has been no evidence 
provided of a heightened risk of these diseases to Australian workers in these 
occupations. However, it is stated that these professionals have greater capacity to 
transmit these diseases to other individuals because they work in close contact with 
communities. Public policies are based on ‘best judgment’ and the current thinking is 
that individuals in some workplaces are at greater risk from infectious diseases therefore 
vaccination policies should be enforced.  Academic institutions are insisting that health 
students be vaccinated to complete their courses, even though the Australian 
Government policy states that vaccination in Australia is not compulsory and that these 
directives are recommendations, not regulations or legislation (AG IH9 2012). Since 
2012 some childcare centres, schools and institutions have been discriminating against 
healthy individuals by selecting against their enrolments or by preventing their 
placement in clinical situations in the workplace because they are not fully vaccinated. 
Parents and health professionals are losing welfare benefits and work/school placements 
if they do not follow the recommended procedures and several court cases have arisen 
due to the pressure placed on individuals to vaccinate (Hansen 2012).  
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3.16 The Evidence for Workplace Vaccination Policies 
I have relied on Sepkowitz 1996 and Sepkowitz and Eisenberg 2005 for this information 
because these are the only sources cited by the government in the Australian 
Immunisation Handbook to support this policy. 
The Australian Government has based its vaccination policy for the Australian 
workplace on evidence that has been collated from US workplaces and not Australian 
workplaces (AG IH9 2012). Statements about this policy in the Immunisation 
Handbook are based on evidence provided in two documents: 
1) An analysis of occupationally acquired infections in healthcare workers in the 
US in 1996 and 
2) The recommendations that were provided by the US Advisory Committee on 
Immunisation practices (ACIP) in 1997 (AG IH9 2012).  
With reference to occupationally acquired infections in the US, the literature states that 
the last assessment of this issue occurred in 1986 (Sepkowitz 1996). There are few 
historical studies that have examined the incidence, prevalence or exposure-associated 
rates of infection in any country. Prior to 1996 the issue of preventative measures to 
improve worker safety had not been a matter for consideration (Sepkowitz 1996). 
Although there is a recognised risk to healthcare workers, a system to track fatal, 
occupationally acquired infections to determine an accurate estimate of the risk to 
healthcare workers had not been established in any country by 2005. Consequently, the 
actual occupational death rate from infections acquired in the workplace in any country 
was unknown when this policy was introduced (Sepkowitz and Eisenberg 2005).  
In 2005, the CDC performed another analysis of the risk to US workers and estimated 
that 17 – 57 per million US healthcare workers die annually from occupational 
infections and injuries (Sepkowitz and Eisenberg 2005). However, the researchers admit 
that this figure is an educated guess at best. The figure was based upon ‘the projected 
potential consequences’ of only 4 diseases based on the prevalence, transmission rate 
and natural history rates of these infections (Sepkowitz and Eisenberg 2005). The 4 
diseases were hepatitis B, hepatitis C, HIV and tuberculosis.  These diseases are 
relevant to specific environments and the risk characterisation from these studies should 
not be assumed to represent the risk to all US and Australian healthcare workers. The 
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risk is dependent upon the social and environmental context in which the diseases are 
observed. In addition, the risk assessment includes the risk from HIV, which cannot be 
prevented with a vaccine, and it does not include diseases that present a risk to 
Australian workers.  
This death rate was also based on data with significant limitations so it is impossible to 
know if the figure was an over- or underestimation of the risk to US healthcare workers 
(Sepkowitz and Eisenberg 2005). In 2005, there was no national tracking system in any 
country to define the need for extra measures for healthcare worker protection. This also 
means that it was not possible to estimate the cost-effectiveness of introducing 
mandatory vaccination policies for any occupation – either in Australia or the US - at 
this time. Vaccination polices in Australian workplaces have been implemented before 
the size of the risk that workers face has been quantified, therefore preventative policies 
for healthcare workers cannot be claimed to be evidence-based practice. These policies 
have been based on the current belief in the necessity for vaccines as opposed to 
empirical evidence of risk established by a national tracking system of worker’s health.  
In 2005, the CDC recommended that national organisations introduce nationwide 
tracking systems to determine the magnitude of the problem resulting from acquired 
infections and death in healthcare workers (Sepkowitz and Eisenberg 2005). This 
demonstrates that the introduction of this policy in Australia in 2006 was based upon 
unrepresentative data from another country, and the Australian government had not 
quantified the risk that infectious diseases in Australia pose to healthcare workers. The 
US data uses the example of experiences with SARS and smallpox vaccination in the 
early 2000’s to illustrate the potential risk of infectious diseases to healthcare workers. 
These are interesting examples to use particularly as the risk of smallpox was greater 
from the vaccine than from the disease itself (Sepkowitz and Eisenberg 2005). In 2003, 
the US government was concerned about bioterrorism and implemented a policy 
requiring all healthcare workers to be vaccinated against smallpox in case of a terrorist 
attack. This program had to be aborted after vaccinating only tens of thousands of 
workers because of the significant side-effects (including death) caused by the smallpox 
vaccine.  
Healthcare workers were refusing to get this vaccine because of the known fatal 
reactions. As a result of this harm, the US government extended financial compensation 
for workers to include those who have become disabled from a vaccine in the line of 
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duty (Sepkowitz and Eisenberg 2005). A compensation scheme is not available to the 
Australian public and this represents a safety issue for employees who are harmed by a 
vaccine in the line of duty. The lack of information regarding the magnitude of risk due 
to infectious diseases in the workplace has been confirmed by an Australian doctor who 
commented ‘I can’t recall a single case of a student or clinician getting tetanus, 
diphtheria or mumps from a patient. The diseases we do fear catching – HIV, hepatitis 
C and most viral respiratory diseases – have no vaccines’ (Iannuzzi 2012). This doctor 
also commented that he now gets numerous visits from a ‘new category of patient’: 
healthy young adults. These students are visiting doctors to get forms signed and to 
update with multiple vaccines in order to complete their practical placements for their 
tertiary courses (Iannuzzi 2012).  
In addition to the lack of information on the risk of infectious diseases to healthcare 
workers there is a lack of information on the magnitude of the risk from the required 
vaccines for occupational use. Due to the lack of adequate surveillance of post-
vaccination adverse events there is no quantitative data on the risk that is imposed on 
healthy adults by updating with a combination of 10 recommended vaccines. It is 
known that vaccines present a serious risk to some individuals yet Australia, unlike the 
US, does not have a vaccine compensation scheme for the victims of vaccine adverse 
events. Hence, introducing mandatory directives regarding the use of vaccines in the 
Australian workplace should have been preceded by the collection of evidence of the 
necessity for this action, a public debate on the pros and cons of this regulation and a 
compensation scheme for individuals who are harmed by this mandated medical 
procedure. 
 
3.17 The Impact of Coercive Strategies in Vaccination Policies   
Whilst government welfare benefits are also available for parents who choose not to 
vaccinate their children, there are certain requirements they must meet in order to 
receive these benefits. In 2013 these requirements include a certificate from a healthcare 
provider that states one of the following reasons (Ag IAP 2013): 
• ‘There is a medical reason why the child should not be vaccinated 
• The child has already had the disease or has natural immunity 
• A particular vaccine is unavailable’ 
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• Conscientious objection   
To obtain the welfare allowance without vaccinating their children parents need to 
complete the Immunisation Exemption: Medical Contraindication form or the 
Conscientious Objector’s form that is available on the Health Department website. The 
Conscientious Objector’s form can be used by parents choosing not to vaccinate their 
children for personal, philosophical or religious reasons. To refuse vaccination parents 
must complete the form with the assistance of an approved healthcare provider. This 
means the government has set a default position of vaccinating rather than not 
vaccinating in Australia. The significance of this is that healthy children are now 
recommended to use multiple vaccines before their first birthday yet doctors are not 
obliged to inform parents of the ingredients of these vaccines.  
The Conscientious Objector’s form became known as the ‘vaccine refusers’ form in 
June 2013 (Hartley 2013). Many parents experience difficulties in getting GP’s to sign 
refusal forms in order to claim the government welfare benefit of $2,100 (Bradley 
2013). One poll found that 54% of doctors would only sign ‘vaccine refusers’ forms on 
medical grounds (Bradley 2013). The Australian Medical Association (AMA) has stated 
there is ‘no legal obligation to do so’ (Woodhead 2013). Brian Morton, chair of the 
AMA’s Council of General Practice, states that his decision not to sign refusal forms is 
backed by advice from the medical defence organisations (Woodhead 2013). Although 
the government’s official line is that vaccination in Australia is not compulsory, in 
reality it results in financial and employment penalties for individuals who choose not to 
vaccinate.  
 
There is currently confusion over whether doctors are obligated to sign conscientious 
objector’s forms. The government provides a directive to doctors requiring them to 
counsel parents about the pros and cons of vaccines before signing the forms. The 
expectation that doctors will sign the forms is also supported by the government’s 
statement that ‘vaccination is not compulsory’ and the fact that welfare benefits are 
linked to the signing of this form. However, the Australian Medical Association (AMA) 
informs doctors that if they do not feel they have adequately explained the risks and 
benefits of vaccination during the consultation then they are within their rights to not 
sign a conscientious objector’s form (Woodhead 2013). Consequently many parents and 
employees in Australia feel pressured to vaccinate by doctors who will not sign the 
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vaccine refusal forms and by employers that require employees to update with the 
recommended vaccines. This is resulting in discrimination in some aspects of Australian 
society on the basis of vaccination status, even whilst the government continues to 
claim vaccination in Australia is not compulsory. As of 2015 the Australian government 
has proposed removing the conscientious objector’s form and the right to refuse 
vaccines on philosophical and religious grounds. Only medical exemptions will be 
accepted in the new legislation for social welfare policies to be implemented in 2016 
(AG DHS 2015).    
3.18 Conclusion 
The Australian government’s NIP has been set within the framework and directives of 
the WHO’s global health policy. It has not been developed within the specific 
environmental context of the Australian community but to comply with directives from 
the WHO on global vaccination policies. These policies have been developed by 
WHO/UNICEF since the 1970’s and inspired by the campaign to eradicate smallpox. 
Although there was disagreement at this time about the value of vaccination in 
eradicating diseases, WHO/UNICEF decided to expand the program to many other 
infectious diseases. This was initiated as the Expanded Program on Immunisation (EPI) 
and since the 1970’s has developed through many phases in all WHO member 
countries, both developing and developed. The campaign has been promoted on the 
moral principle of ‘saving the world’s children with life-saving vaccines’. During the 
1980’s the influence of neoliberalism resulted in economic and political experts 
dominating the development of global health policies. Mixed health messages began to 
be presented through WHO directives as neoliberalism focused public health policies on 
technology-based interventions such as vaccination. This was done in many developing 
countries at the expense of primary healthcare programs that targeted the social and 
environmental determinants of health. In the 1990’s the World Bank, the International 
Monetary Fund and the Rockefeller and Gates Foundations became partners with the 
WHO/UNICEF to sponsor global vaccination programs. A shortage of funding in the 
1990’s for the research and development of vaccines led to the development of public-
private partnerships that were influential in the direction of global health policies in 
WHO member countries.  
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Economics and politics began to dominate the design of public health policies from this 
time, with health statistics obtained from non-governmental economic models of the 
cost-effectiveness of implementing vaccination programs. Global health directives were 
based on industry modeling for global communities instead of the specific ecological 
conditions of each country. In 2000 the direction of global public health policies 
changed with the establishment of the Global Alliance for Vaccines and Immunisation 
(GAVI), a body that consists of public-private partnerships with governments and 
corporations jointly influencing global health policy decisions. At this time vaccines 
became the sole focus of global policy: GAVI promoted vaccines to WHO member 
nations using financial incentives as well as by controlling the supply of vaccines to 
these countries. This resulted in the ‘vaccine paradox’ where governments, in alliance 
with corporations, control the supply and demand of vaccines. This represents a clear 
conflict of interest that is not transparent to the public. Since 2000 global public health 
policies have protected industry interests through the sole focus on vaccination 
programs and many authorities within the WHO, and developed nations, have expressed 
concern at these technology-based health programs. This has been at the expense of 
broader primary healthcare needs. 
Australia’s NIP expanded in the 1980’s and 1990’s according to WHO goals for 
achieving high participation rates for all the recommended vaccines. The goals were set 
to increase childhood vaccination rates to ninety percent for all the vaccines in Australia 
even though there was no significant threat to the majority of the population from the 
targeted infectious diseases. The decision to use vaccines for many diseases was a 
universal directive to both the developed and the developing countries, without 
risk/benefit assessments for the use of each vaccine in specific countries and 
populations. In addition, national governments did not provide an adequate surveillance 
system for the accurate determination of the frequency of causally related adverse 
events from vaccines. The harm caused by vaccines, either individually or in the 
combined schedule, has not been included in the economic modeling for the cost-
effectiveness of vaccination programs. These programs have been based on the 
assumption that vaccine-created herd immunity can prevent infectious diseases, if 
enough people participate in these programs, without causing significant harm to the 
population. The lack of empirical evidence for these assumptions is discussed in 
chapters 4 and 7.  
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During the 1990’s government’s re-labeled infectious diseases as vaccine-preventable 
diseases, a label that implies vaccines can prevent infectious diseases. The public has 
been informed through the mainstream media that high participation rates in vaccination 
campaigns are needed to prevent infectious diseases but the empirical evidence to 
support this claim has not been provided. The evidence the Australian government 
provides to support vaccination policies is discussed in Chapter 7. The government has 
introduced many new vaccines since the 1990’s and emphasised the need for high 
vaccination rates for all infectious diseases for which there is a vaccine. New vaccines 
are continually added to the national recommended schedule. Each vaccine carries a risk 
to some individuals yet the Australian government does not provide a separate 
risk/benefit assessment for each disease and vaccine, nor for the combination of 
vaccines that are recommended in the children’s schedule. The vaccines have been 
added to the recommended schedule without public consultation or participation in 
policy development, and without informing the public of the ingredients of vaccines. 
Financial incentives have been used to pressure parents and doctors to use all the 
recommended vaccines and to assist the government to track the vaccination status of 
children.  These strategies were implemented in 1993 and formalized in 1997 as the 
Immunise Australia Program (IAP). These coercive practices have increased in 2015 
with many employees now being required or expected to vaccinate even though the 
government continues to claim that vaccination in Australia is not compulsory. 
The Australian Government’s program does not make any reference to the historical 
evidence of the control of infectious diseases in Australia or the risk/benefit of using an 
increasing number of vaccines in children/adults. Mainstream media has been used 
since the 1990’s to influence public behaviour by informing the public that high 
participation rates in vaccination programs are important in controlling infectious 
diseases without providing evidence for this claim. In contrast, the media was used in 
the early 20th century to successfully promote social (ecological) medicine to the public 
to reduce the threat of infectious diseases through environmental and lifestyle changes. 
The media message changed in the second half of the century when the focus of public 
health was directed to vaccination policies. Since this time the mainstream Australian 
media has emphasised the benefits of vaccines, without providing empirical evidence, 
and without informing the public of the known risks associated with each vaccine or the 
long-term health effects of the combined schedule of vaccines. 
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Overview of later Chapters 
Chapter 4 provides a discussion of the implementation of vaccination policy in 
Australia and the methodology used for assessing environmental health risks in 
infectious disease law. It examines the way in which health risks for vaccines and 
infectious diseases are being characterized and framed to the public. Chapter 5 
examines the principles that underpin good medical practice and health promotion in 
public health policy. A description of the influence of corporations in the supply and 
demand for vaccines in government vaccination policies is provided in chapter 6 and 
chapter 7 is a discussion of the evidence the government provides to the public on the 
Immunise Australia Program (IAP) website to support vaccination policies. Chapter 8 
describes the concept of undone science and the political framework that increases areas 
of undone science in public policy. In chapters 9 and 10, I have provided examples of 
the corporate influence and undone science in two global vaccination programs, the 
Human Papillomavirus (HPV) vaccine and the ‘Swine Flu’ 2009 vaccine. In chapter 11 
I have drawn conclusions about the development of Australia’s vaccination policies and 
the integrity of the scientific evidence being used to make claims about the safety and 
efficacy of vaccines.  
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CHAPTER 4  
IMPLEMENTATION OF THE AUSTRALIAN GOVERNMENT’S 
VACCINATION POLICIES  
	  
4.1 Introduction 
This chapter describes the development and governance of infectious disease control in 
Australia. It provides an overview of the federal committees responsible for developing 
government policy and the responsibilities of the states and territories in implementing 
these policies. The strategies for assessing the risks and surveillance of infectious diseases 
in Australia are also described. More information on the governance of the policy can be 
found in Appendix 3. There are two different perspectives on assessing the risk posed by 
infectious agents and hence two different theories regarding the best method for reducing 
the risk:  
1. An ecological perspective of risk from infectious agents. This risk is assessed by 
environmental health practitioners and addressed by social (ecological) medicine. 
This includes an assessment of the external causes of infectious diseases e.g. 
environmental, economic, cultural and political factors. These practitioners 
recognize that disease outcomes from infectious agents are associated with the 
environmental context and that the risk and health outcomes from an agent will vary 
between geographical regions and genetically diverse populations. 
 
2. A medical perspective of risk from infectious agents. The risk of disease is 
addressed in the scientific medical model using the germ theory of disease. This 
theory focuses on the internal biological cause of disease and uses a medical 
intervention to control infectious diseases, regardless of the environmental context. 
The risk of infectious diseases to the community is assessed by medical 
practitioners and it is addressed by mass vaccination campaigns that assume all 
individuals are at the same risk from an infectious agent/vaccine in all geographical 
regions. 
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This chapter explains the difference in the practices of these practitioners and the 
management strategies they promote. The strategy that is adopted in public policy is a 
result of political decisions that are influenced by the dominant scientific network and 
current cultural beliefs and values. The policy of universal vaccination treats all individuals 
as being at the same risk from an infectious agent and from a vaccine. This is not the case 
in reality due to the environmental and genetic diversity of different geographical regions 
and communities. See Chapter 2. These risk factors are discussed in this chapter to address 
the question of whether universal vaccination policies can produce more harm than good in 
the population if the majority of individuals in the community are not at serious risk from 
the infectious agent. Vaccines also cause adverse health outcomes and death in some 
individuals and the genetic diversity of the population is a determining factor in the risk 
associated with both infectious agents and vaccines.  
Herd immunity is discussed in this chapter in the context of naturally-obtained herd 
immunity and vaccine-created herd immunity. The type of evidence the government is 
using to support the claim to the public that vaccine-created herd immunity prevents 
infectious diseases is discussed in Chapter 7. A description of the factors that influence 
disease statistics is presented and illustrated with the example of the 2009 swine flu 
pandemic. This is further illustrated in a case study of the ‘swine flu’ 2009 pandemic in 
chapter 10. The case study has been chosen because it is a recent example of how 
information can be produced and framed by the media to create fear of a disease in the 
community. Communication and the framing of risk to the public in the media is a major 
consideration for public health policy because this is the main channel for influencing 
social behaviour. In this chapter I have discussed the consequences to human population 
health if risk is not presented in an honest and transparent manner with the participation of 
the community upon which the policies will be enforced. Chapter 5 presents the ethical 
code for medical practitioners and the values that are used to guide health promotion in the 
community and chapter 6 describes the influence of corporations in the production of 
scientific knowledge and public health policy in the era of privatisation.   
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4.2 The Governance of Vaccination Policies in Australia  
In this section I have relied largely on information from the text by Cromar, Cameron and 
Fallowfield (2004) because this is the first comprehensive text that describes current 
environmental health risk assessment (EHRA) and management practices in Australia and 
New Zealand. The text is titled Environmental Health in Australia and New Zealand. The 
methodology that is being used in Australia to address public health issues is representative 
of current global practices and these methodologies have been described by local 
contributors in the Cromar et al edited version. Financial support for the text was provided 
by the Public Health Education and Research Program and it was approved by the 
Commonwealth Department of Health and Ageing to further education in environmental 
health in Australia. 
Australia’s National Immunisation Program (NIP) has been developed by the Office of 
Health Protection within Australia’s Federal Department of Health and Ageing. This 
program is recommended to the states and territories for the control of infectious diseases 
(AG IAP 2013). The National Immunisation Committee (NIC) develops the policy through 
the Communicable Diseases Network Australia (CDNA) and this is communicated to the 
Minister for Health by the Australian Technical Advisory Group on Immunisation 
(ATAGI) (AG IAP 2013). The responsibilities and composition of ATAGI are described in 
more detail in chapter 6 and Appendix 4. State Governments in Australia are responsible 
for implementing vaccination policies through the state public health acts which are guided 
by the federal NIP. Local government is the third level of governance and it provides the 
infrastructure for implementing policies at the community level. Inspection and action 
against infectious diseases involves environmental health practitioners in local government 
as well as the provision of education and health promotion programs to the community 
(Stoneham et al 2004 p128).  
State and territory public health acts specify the regulations for the control of infectious 
diseases. This includes the requirement that medical practitioners and pathology 
laboratories notify relevant public health authorities of any case of a notifiable disease. The 
acts also list a subset of diseases called ‘controlled notifiable diseases’ which are subject to 
more specific controls. When cases of these diseases are identified health authorities have 
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powers to carry out compulsory medical examinations and place restrictions on an affected 
individual’s activities. Authorities can also place them under surveillance if their behaviour 
is considered a risk to the community. Environmental health issues are effectively managed 
by three key factors - legislation, funding and education. The development and 
implementation of environmental health policy changed significantly at the state level in 
the mid 1990’s. At this time corporate partnerships were introduced into government 
policies and a purchase-provider model of administration was adopted. This model 
involves the separation of the purchaser of health services from the funding and provision 
of these services to the community. Corporatisation in this model has been defined as the 
restructuring of public health services into public sector and private (not for profit) 
corporations (Dwyer and Eagar 2008). Many government administrations globally have 
adopted this form of service delivery for health promotion.  
There are two components of this purchase-provider model:  
i) A purchasing agency that ensures the needs of the population are met (e.g. 
government committees) and  
ii) A service provider that delivers the service and has some autonomy and 
responsibility over the delivery of the service (e.g. public or private (not for 
profit) corporations) (QDH).  
The corporate planning process ensures that community needs that do not come into core 
legislation are included in policy development (Stoneham et al 2004 p136). Examples of 
these types of issues include vaccination, physical activity, sun protection, food safety and 
other education programs. The corporate plan sets goals to be achieved over a specified 
time period with outcomes set for the providers. State governments have mandated 
legislation to ensure community needs are incorporated into the planning process for local 
governments. In these models, it is important that regulations exist to ensure the funding for 
these health promotion campaigns is transparent to the public. This is because public health 
is put at risk if community education campaigns can be influenced by corporations that 
profit from the products they are promoting. One strategy adopted under this corporate 
planning model includes establishing partnerships with organizations to access funding for 
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health promotion programs. The roles and responsibilities of the purchaser and the 
providers are described in the contracts that are drawn up between the partners. 
4.3 The National Environmental Health Strategy  
Traditionally public health policy has been managed by the states and territories, however, 
changes in the nature of environmental hazards in the 20th century led to the belief that a 
national environmental health policy would be a more effective in addressing these issues. 
Australia’s first national environmental health (EH) strategy was implemented in 1999 
(CoA 1999 in Stoneham et al 2004 p131). Environmental health policy encompasses any 
policy decision in any level of government that directly involves health impact concerns 
and accountability for the community. The Australian government’s definition of 
environmental health has been provided in Chapter 2. EH policy is multidisciplinary 
because health outcomes are affected by all aspects of our lifestyle. The national strategy is 
also stated to be designed to increase public participation in the health outcomes of the 
community. Prior to 2000 the federal government did not have a significant role in public 
health legislation other than quarantine, directives provided in international health treaties 
and controls on the use of chemicals (Stoneham et al 2004 p130).  
The National Environmental Health Strategy (NEHS) has been developed in Australia by 
the enHealth Council, a subcommittee of EH authorities from government and 
environment/public health sectors who have collaborated to produce a national approach to 
risk assessment (AG EHRA 2012). These guidelines provide an outline of the principal 
roles and responsibilities that are fundamental to achieving good health outcomes in the 
community. Guidelines for the assessment and management of environmental health issues 
have been set in the NEHS for implementation by the states and territories. The guidelines 
present a general methodology for EHRA that focuses on chemical, physical and 
microbiological hazards. This methodology is described in the Health Impact Assessment 
Guidelines (2001) and Environmental Health Risk Assessment Guidelines (2002).  
The main objectives of the guidelines provided to the states and territories for EHRA are: 
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• Involvement and agreement from all stakeholders 
• Establishing partnerships to bring about change 
• Creation of energy and empowerment to change 
Public health law was extensively reformed from 1985-1997. Prior to this time control of 
infectious diseases and environmental legislation were regulated under the same legislation 
and implemented by the states and territories (Reynolds 2004 p171). The new reforms 
placed the regulation of infectious diseases under different sections of the Public Health 
Law Act. The new regulatory sections are: 1) public and environmental health law 2) 
infectious disease control law 3) food law 4) drugs and therapeutic law 5) tobacco law 
(Reynolds 2004 p169). This separation was significant because traditionally the control of 
infectious diseases was a result of public health reforms to the environment. That is, control 
of the environment resulted in the control of infectious diseases. In this new classification 
the control of infectious diseases has been separated from the control of the environment 
and other environmental health problems.  
Sanitation and hygiene are now regulated under public and environmental health law and 
communicable diseases are covered under infectious disease law (Reynolds 2004 p171). A 
consequence of this new separation is that the risk assessment for infectious diseases is not 
determined by the systematic methodology of the EHRA framework that is applied to many 
other environmental health hazards in Australia. This is consistent with global practice 
whereby the risk and cost-effectiveness of infectious diseases is determined by computer 
modeling and not a systematic methodology (Habakus 2011). The EHRA framework is 
accepted by environmental health practitioners globally to be the most systematic and 
transparent methodology for assessing the health risks of environmental hazards yet it is not 
adopted for the determination of risk from infectious diseases and vaccines.  
Another consequence of the separation of infectious diseases is that infectious disease law 
is founded on a different set of values and principles (Reynolds 2004 p171). An example of 
one principle that has been adopted in public and environmental health law but not in 
infectious disease law is the precautionary principle (PP) (Reynolds 2004 p172). In 1992 
the use of the PP in public policy was described in the United Nations Conference on 
Environment and Development (UNCED). It was stated that whenever there is doubt about 
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the impact of an activity (or a procedure) then the responsibility for managing the impact 
lies with the proponent and not the general public (UNCED 1992 in Stoneham et al 2004 
p134). Population health requires that regulators use caution when basing policy decisions 
on toxicological data. This is because political decisions can be made in policy design and 
future research may prove the data to be wrong or misleading. The PP is relevant to 
vaccination policy because there is a risk from the chemicals used in vaccines as well as a 
risk from infectious agents. It is important that the characterisation of risk - for vaccines 
and infectious agents - that is used in computer modeling for policy development is 
determined by a transparent and systematic process. Currently the most transparent and 
systematic process used by environmental health practitioners is believed to be the EHRA 
framework. This methodology is used for many environmental health hazards in Australia 
but not for infectious disease control. The PP is also adopted for environmental protection 
in Australia but not for infectious disease control.  
Adopting the PP in infectious disease law in the format stated by the UNCED would 
require the medical profession to prove that the combined schedule of vaccines does not 
cause harm before the vaccines are recommended to the public in government policies. 
When the onus of proof is on the public and not the proponent of the procedure it is not 
necessary for governments to provide proof that the procedure is not harmful. This is 
because funding can be directed away from appropriate studies that may find evidence of a 
causal link. When the onus of proof is not on the proponent, it is possible for governments 
to claim ‘there is no proof of harm and therefore no action needs to be taken’. This claim 
can be made on a lack of evidence because the appropriate studies have not been carried 
out. This is discussed further in chapter 8.  
Whilst the Federal Government has little responsibility in implementing control measures 
in the states and territories it is involved with the national surveillance of diseases and 
designing the framework and legislation for the control of diseases in the states and 
territories (Cameron 2004 p204). Surveillance systems assist authorities to develop public 
health policy and they must also be used to evaluate the changes that are introduced as a 
result of government policy. The EHRA framework requires that management strategies 
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that are implemented to reduce health risks to the population are constantly evaluated to 
provide evidence that the policy is achieving the outcomes that are set.  
The body which oversees all environmental and public health policy in Australia is the 
Australian Health Protection Committee (AHPC). Advice is provided to this body by the 
CDNA, the enHealth Council and the Public Health Laboratory Network (PHLN) (AG IAP 
2013). The CDNA is a national body that informs state and territory governments about 
changes to disease patterns in their area. Local government is then responsible for 
implementing preventative strategies that are recommended in the NIP to reduce the 
incidence of disease in the states and territories. Whilst the health impact from most types 
of environmental health hazards are being assessed using the systematic methodology of 
the EHRA framework and a set of values, risk assessment for infectious diseases is being 
analysed by computer models (Cameron 2004 p207). Computer models are dependent upon 
the assumptions and parameters that are chosen by the research scientists and these are not 
always made transparent to policy advisers (Michaels 2008). It is essential to know if an 
accurate estimate of the harm from vaccines has been included in the computer modeling of 
cost-effectiveness for their use in infectious disease control.  
4.4 Measuring the Risk of Disease to the Community  
There are two very different viewpoints in determining the risk presented by an infectious 
agent to the community. These are the viewpoints of the medical practitioner and the 
environmental health practitioner (Cameron 2004 p202):  
1. Environmental Health Practitioner: This viewpoint contends that many 
infectious agents circulate through subclinical infections that do not produce much 
(or any) obvious signs of disease. Environmental health practitioners acknowledge 
the influence of the environment and host characteristics in the expression of 
disease in the community. These practitioners use ecological (social) medicine to 
control disease. Risk from infectious agents is assessed by observing the severity 
and age-incidence of the disease in the community, not just the incidence or 
notifications of cases regardless of the severity.  
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2. Medical Practitioner: This viewpoint is consistent with the scientific medical 
model that considers ‘health’ restricted to the action of the microorganism on the 
human body. In this model the influence of the external environment in the 
expression of disease are reduced and the focus is placed on a universal medical 
intervention for all individuals. This viewpoint emphasizes the need to record all 
cases of the disease regardless of the severity and pattern of the disease in the 
community. 
In the environmental health viewpoint the incidence of infection is only a valid indicator of 
the risk of disease if the majority of cases are severe or fatal. In situations where the 
majority of cases are mild or sub-clinical, it is necessary to weigh up the benefits of longer-
term community protection from natural exposure against the shorter term protection of a 
vaccine that comes with a risk for a percentage of the population. The two viewpoints 
described above are important in the development of public health policy. Different 
strategies will be recommended depending upon which group of practitioners has the most 
influence in policy design. Clinicians and environmental health practitioners will have 
differing viewpoints about the monitoring of different pathogens because one examines the 
ecological context and severity of cases and the other examines incidence rates of infection 
without regard to context and severity.  
 4.5 The Australian Government’s Environmental Health Risk 
Assessment (EHRA) Framework 
This section draws especially from the Australian government’s document titled 
Environmental Health Risk Assessment: Guidelines for assessing human health risks from 
environmental hazards (June 2002). The document was compiled by the Environmental 
Health Council (enHealth Council). 
The purpose of health risk assessment is to provide comprehensive health information to 
risk managers, policy-makers and regulators in order to implement the most effective 
measures of mitigation. To achieve this goal, both scientific and non-scientific information 
is required. Gaps in the scientific knowledge can lead to incorrect assumptions about safety 
if they are not addressed in a transparent manner with technical and non-technical input.  
	  
	  
96	  
The various elements that need to be considered in the risk assessment are:  
• the source of danger (hazard) 
• the uncertainty of outcomes 
• possible adverse health outcomes 
• the target 
• the time-frame and  
• the importance of the risk for the people that are affected by it.  
The US National Research Council (NRC) emphasises the need to include a broad 
representation of participants in the risk assessment process. In particular, the needs of the 
community and affected parties must be included in the analysis: ‘The process must have 
an appropriately diverse participation, or representation of the spectrum of interested and 
affected parties, of decision-makers and of specialists in risk analysis, at every step’ (NRC 
1996 p3). This is to ensure that all risks are included in policy decisions and that vested 
interests cannot be protected in the policy. It is observed that experts and consumers often 
disagree over the degree of risk involved in a situation (Finucane 2004 p151). However 
differences can be a result of access to different information or it can depend upon the 
financial or political interest the stakeholder has in the selected management strategy. 
Financial interests, livelihood or status can affect a stakeholder’s view on policy. Therefore 
conflicts of interest are required to be declared if individuals are participating on policy 
advisory boards. This information is required to be publicised because it is relevant to the 
validity of the knowledge used in political decisions. See chapter 6 for a discussion of COI 
in Australian policies. 
The suggestion by some that the public should just trust the experts puts public health at 
risk because the public is dependent upon health being the primary interest in the 
development of public policy. Other interests in public policy include profits and prestige 
and experts with financial ties to industry may be influenced by these connections in the 
decision-making process. Research and experience have shown that risk assessment that is 
approached without the proper involvement of the public will not provide the best outcome 
for the community (Finucane 2004 pp151-153). There are three main principles that 
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environmental health (EH) authorities accept are necessary for the successful 
implementation of public health policy (NRC1996 p7): 
1. Broad support from the public in the decision-making process.  
2. Decisions must not be based on technical (expert) advice alone. It must 
include non-scientific value judgments.  
3. The government requires consent from the community on whom the policy 
will be enforced and they have the right to full participation in the decision-
making process. 
These three principles emphasise open and transparent debate of the underpinning 
knowledge that public health policies are designed on. Acceptance of the policy by the 
public depends upon free and informed debate about policy decisions as opposed to an 
authoritarian policy that is based on selective and controlled information. The government’s 
EHRA framework provides the most comprehensive and transparent assessment of all the 
known and perceived risks to ensure that the management strategies that are implemented 
for environmental hazards do not result in more harm than good to the community. The 
framework for this methodology is set out in Figure 4.  
EH Risk Assessment can be defined as ‘the process of estimating the potential impact of a 
chemical, biological, physical or social agent on a specified human population under a 
specific set of conditions and for a certain timeframe’ (Langley 2004 p93). This process is 
necessary for informing the decisions made by EH risk management teams. The decision-
making process incorporates scientific, technological, social, economic and political 
information which underscores the need for a diversity of participants on advisory boards, 
not just technical experts. Traditionally it has been believed that risk management decisions 
are subjective and founded on value judgments on the tolerability of the risk weighed 
against the cost-effectiveness of the preventative action (Langley 2004 p93). An essential 
part of the risk management process is to monitor and audit the efficacy of the selected 
strategy to evaluate health outcomes. This feedback is essential for ensuring that the 
implemented strategy is kept updated and remains effective.  
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Figure 4: An Australian Environmental Health Risk Assessment Framework 
 
Source: Australian Government, Department of Health and Aging, Environmental Health Risk 
Assessment Guidelines for assessing human health risks from environmental hazards, 2002 
  
In infectious disease law the health risks from infectious diseases and vaccines are 
determined by computer modeling and not the EHRA framework. Eduljee (2000) states that 
computer modeling techniques have transformed risk assessments in the last few decades 
but they have also conferred a false sense of overconfidence in the statistical analysis. 
Computer modeling has led to an elitist culture where technical experts dominate the 
process and other stakeholders are excluded from contributing. Bias can enter the risk 
assessment obtained from computer models through the choice of model, the 
implementation of the mathematical equations, the parameter values chosen or the 
interpretation of the results. These aspects of computer models involve value judgments 
and the underlying assumptions are not always explained to non-experts with the risk 
assessment that is provided.  
A model of the relationship between RA and RM is provided in Figure 5. This model is 
comprised of four interconnected components and can be altered for adaptation to 
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microbiological risk assessment. This is necessary because the specific characteristics of 
each microorganism need to be included in the risk assessment process and described 
within an ecological context in a given time frame. This has been done for RA involving 
microbiological agents involved with food contamination in Australia but not for the 
control of communicable diseases.  
Figure 5: The Relationship of Risk Assessment and Risk Management 
 
Source: Adapted from P/CCRARM, 1997; Patton, 1998; NRC, 1983 as cited by the Australian 
Department of Health and Ageing, 2004 (AG EHRA 2012) 
Many variables must be considered in assessing the health risks from vaccination policies 
due to genetic variability of the population, the diversity of the environment and the 
combination of multiple chemicals found in vaccines that are injected into the body. The 
risk assessment must include any issue that alters an individual’s well being, quality or 
potential in life; it is not just about death and physical disability (Gilbert 2004). In the case 
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of vaccination policies the risk from the chemical exposure in vaccines must also be 
considered in the RA for infectious diseases. The Australian government states that current 
risk assessment methods cannot make ‘accurate quantitative estimates of risk for low levels 
of exposure to environmental hazards’ (AG EHRA 2012). It is noted that the uncertainties 
that exist in toxicological and exposure data prevent the authorities from providing feasible 
numerical estimates of the risk from many low level exposures. This is particularly relevant 
to vaccination policies because all vaccines contain low levels of toxins that are injected 
into the body. This method of entry allows toxins to have greater access to the organs and 
body systems than typical natural exposure to these toxins. See Appendix 6.  
The uncertainties that can exist in risk assessment, and that can lead to bias, arise from 
several areas including inadequate knowledge, parameter uncertainty due to measurements, 
errors arising from incorrect modeling and uncertainty arising from difficulties interpreting 
predictions (AG EHRA 2012). Uncertainty in the risk assessment also arises when a single 
number is used to describe individual responses that have multiple variables. Examples 
include the use of a single value to represent body weight or the susceptibility to adverse 
effects (Gilbert 2004). Both uncertainty and variability must be discussed in risk 
assessment recommendations. These uncertainties exist in the number and frequency of 
vaccine doses given to children as well as the genetic variation in the response. Yet genetic 
variability is not considered in the risk assessment process for infectious diseases. The 
management strategy is a one-size fits all. Risks need to be weighed against the benefits of 
a prevention or treatment particularly when strategies are being implemented for 
populations. This is because the risk can be greater in sub-populations, such as ethnic 
groups or those that are genetically pre-disposed to diseases.  
Risk assessment needs to be founded on a systematic analysis of all the hazards of a 
procedure. This allows an evaluation of the biological properties and an ability to identify 
the toxic effects that are statistically and biologically significant as well as the undone 
research that may exist in a particular area of the policy. The Australian government’s 
EHRA framework recommends that the first step in any risk assessment process is 
consultation with the affected community. This is to ensure that the consumer’s perception 
of risk is included in the decisions about the best management strategy to implement. Other 
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reasons for involving the public include the importance of local knowledge and concerns 
that may be missed by generic risk assessments and models. Ultimately a value judgment is 
made by policy-makers based on the tolerability of the risk to affected individuals and the 
cost-effectiveness of the selected strategy. Risk assessments must be a realistic analysis of 
the hazards and they must provide an explanation of the default positions that have been 
adopted based upon the evidence. In order to be realistic the framework for decisions about 
RA must reflect the natural variation in the environment and the population (Eduljee 2000). 
If these factors are not considered in the risk assessment process the estimate of risk will be 
unrealistic and the harm caused by the hazard will be unknown.  
Currently, most RA models have an endpoint that is focused on the hypothetical individual 
and they do not account for the genetic variability of the population. This is a concern for 
Australian vaccination policies that have set a default position of using a universal medical 
procedure in genetically diverse populations. Universal vaccination has been adopted for 
many diseases in Australia even though the exposure pattern for the chemicals in the 
vaccines for different individuals has not been determined (FDA Thimerosal; PHAC 2002; 
Burton 2003). Default values that are based upon modeling on the hypothetical individual 
often contain assumptions and extrapolations which can be seriously flawed (AG EHRA 
2012), particularly in the case of low doses of toxins and antibiotics present in vaccines that 
are injected into the body. This is because the effects of low doses of toxins in combination 
with other chemicals have not been determined in humans. This is an example of undone 
science. See chapter 8. Assumptions or extrapolations in default values are also dependent 
upon the assessor and will therefore vary according to their constructed perspective of the 
risk. If the default values have been determined by technical experts without a diversity of 
stakeholder input, they can become too rigid and the mitigation action can result in more 
harm than good in the community.  
4.6 Clinical Disease and Subclinical Disease: The Iceberg Concept  
Scientists postulate that infections resulting in active clinical disease account for a 
relatively small proportion of the actual infections that occur in communities. This concept 
is illustrated in Figure 6 and is described as the iceberg concept.  
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Figure 6: The Iceberg Concept of Infection 
 
Source: US CDC, Forrester FT, The Iceberg Concept of Infection, Public Health Image Library 
 
If the vast majority of exposure to a potential pathogen causes subclinical infections or mild 
disease then this can result in natural herd immunity for the community. This is because a 
subclinical infection produces immunogenicity through natural exposure but without signs 
or symptoms of the disease in the individual. The immunity achieved in this way is known 
to provide longer-term protection than immunity obtained from vaccines. There is a large 
variation in the clinical presentation of viral infections. For example, the vast majority of 
polio infections are subclinical as compared to infection with rabies which is largely 
clinical and highly virulent (Friis and Sellers 2002 pp 402-3). An important determinant of 
the severity of infection is the host’s ability to fight off the disease. Genetics and 
environment play a large role in this characteristic. The improvements in nutrition and the 
trend back to breast feeding in the early 20th century (1920-30’s) combined with other 
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social medicine strategies played a significant role in the ability to control infectious 
diseases in developed countries. See sections 2.3 and 2.4. 
The shorter-term immunity produced by vaccines, using altered and genetically engineered 
proteins and DNA, results in the need for several booster shots throughout life (DHA IAP 
2013) and the effects of vaccines in the interaction with other body systems have not been 
fully explored. Whilst natural immunity is not always life-long, it can reduce the severity of 
re-infection by the pathogen later in life (Wendelboe 2005; Behrman and Kliegman 1998). 
Many diseases are known to be more severe when first exposure occurs in adolescence or 
as an adult, rather than in childhood (Burnet 1952; Wendelboe et al 2005). Thus, natural 
infection in childhood can provide greater protection (and cost-effectiveness) to the 
community for diseases where the majority of individuals are not at risk of severe disease 
after exposure.   
4.7 Herd Immunity  
Public health authorities emphasise to communities that the control of infectious diseases 
depends upon the creation of ‘herd immunity’ by vaccination (DHA IAP 2013). This 
concept suggests that when a sufficient proportion of the community is immune to a 
disease, for example >50% (depending on the disease), this provides protection for the 
unimmunized individuals by interrupting the transmission of the agent. Herd immunity is 
known to be created by natural exposure to the infectious agent and it is theorised that 
vaccines can also create herd immunity (Colgrove 2006; Habakus 2011 p25). However, 
there are several reasons why herd immunity created by vaccination may not be achieved in 
practice: 
I. There can be more than one strain of an organism that causes the disease which 
may not be included in the vaccine (Behrman and Kliegman 1998).  
II. Humans may not be the only reservoir for the disease. The virus/bacteria may be 
found in other animals therefore transmission is not interrupted (Friss and Sellers 
2004).  
III. The virus/bacteria can mutate and the vaccine may not contain the mutated strain.  
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These problems place doubt on the ability of vaccines to provide herd immunity for some 
infectious diseases. The claim that a vaccine can prevent the transmission of pathogens 
between individuals and create herd immunity only applies to pathogens that do not have a 
non-human reservoir, such as dogs or other animals, and where there is only one strain of 
the pathogen in circulation (Basch 1994 p15). Herd immunity will not be created for a 
pathogen where many strains of a pathogen exist in the environment, where the life-cycle 
includes other animals or where spores of an agent are common in the soil (tetanus). In 
these circumstances the vaccine may provide some protection to the individual but cannot 
provide herd immunity (Basch 1994). Therefore governments should be required to provide 
empirical evidence that vaccine-created herd immunity is possible before recommending an 
increasing number of vaccines and claiming they are necessary for community health. 
Target vaccination levels of 80-90% have been accepted by the community on faith and not 
evidence (Colgrove 2006 p158). The duration of immunity gained from natural exposure 
and from vaccines should also be considered for each infectious disease when deciding 
whether a vaccine is the best management strategy for a disease. Diseases that produce 
long-term immunity from natural infection include measles (Friis and Sellers 2004) and 
whooping cough (Wendelboe et al 2005). These diseases are also known to be less severe 
when individuals are exposed as a child (over 1 year of age) than as an adolescent or adult 
(Burnet 1952; Behrman and Kliegman 1998; Wendelboe et al 2005). The ability of a 
pathogen to produce a high proportion of subclinical or mild infections and the influence of 
the environment and host characteristics in pathogenesis must also be considered in 
decisions regarding the use of vaccines to control a disease. The evidence provided by the 
government to the Australian community to support the theory of herd immunity and 
participation in vaccination programs is discussed in chapter 7. 
Herd immunity for vaccines is determined using mathematical modeling (Basch 1994 
pp71-72). These models use the transmission pattern of pathogens in the community and 
rely on parameters and assumptions chosen by the researchers/sponsors. This is a non-
transparent assessment that is not inclusive of all stakeholders. Pathogens are not 
transmitted in a predictable manner to all individuals so it is essential that all stakeholders 
know what criteria are being used in mathematical models to determine the transmissibility 
or risk of an infectious agent to the community. This fact was emphasized by the eventual 
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success of smallpox eradication programs. The success of eradicating smallpox was 
attributed to a change in strategy from ‘vaccinate every person in the world’ to a strategy of 
surveillance and containment (Basch 1994 p72). It was realised that it was unnecessary to 
vaccinate every person because not everyone was at the same risk of getting smallpox, even 
if exposed to the virus. The new strategy depended upon tracing cases of disease and 
isolating the individuals who had been exposed to the virus. It is stated that only those who 
were contained were vaccinated (Basch 1994 p72) however it is debatable whether the 
vaccine would have been necessary because smallpox is only transferrable by direct skin-
to-skin contact. It is not transmissible through the environment or until the symptoms 
appear. Therefore, isolation of the cases alone could have stopped the circulation of the 
virus and eradicated this disease. This is particularly that case because of the improved 
environmental conditions due to public health reforms in the twentieth century. A vaccine 
for smallpox was in use for 150 years before the disease was finally eradicated by the 
isolation of cases in the mid-twentieth century.    
4.8 Surveillance of Communicable Diseases  
This section provides information about the surveillance of infectious diseases in Australia 
to illustrate the variables that influence the characterisation of risk associated with 
infectious agents and vaccines. It also describes the practices that are utilised in the 
collection and analysis of the data to illustrate whether government policies are 
communicated to all stakeholders in a transparent and accountable manner.  
When monitoring the incidence or notifications of a disease it is important that the data is 
presented to authorities and the public in a transparent manner (AG EHRA 2002). This is 
because incidence data can be manipulated to increase or decrease the reported occurrence 
of a disease. There are two main ways in which surveillance data can be used to 
demonstrate an increase or decrease in a disease. These are:  
i) Changing the definition of a disease and  
ii) Altering the way in which the disease is monitored.  
If either of these variables changes, without informing the public or government authorities, 
then the statistics can be reported in the media in a way that misrepresents the risk of the 
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disease to the community. For example, a change in the criterion for diagnosis of a disease 
can achieve a reduction in cases simply by excluding some cases based on different criteria. 
Similarly if the surveillance of a disease is altered or the surveillance is stopped then it can 
appear that the incidence of the disease has changed when in fact it is a result of a change in 
the monitoring of the disease. Media reports of disease etiology seldom reveal the way 
incidence statistics are used in mathematical models. Furthermore, the media is not 
accountable to the health department for the information it provides to the public. 
Information on surveillance is collected from the public and health professionals. The 
primary sources of information on surveillance are from doctors who notify authorities on 
suspicion or confirmation of a case of disease. The analysis of notifications is completed by 
computer models. Data from this modeling is put into context by the researchers who 
design the models. In other words, researchers interpret the data before they provide it to 
the government and the public (Cameron 2004 p205). Disease statistics are dependent upon 
the truthful reporting of the classification of the disease notification. This is because some 
notifications are not confirmed but are only suspicions and also because some are mild 
cases and the proportion of mild notifications is significant to the management strategy that 
is adopted for mitigation. Examples of the different types of notification that are reported to 
authorities include (Cameron 2004 p206): 
i) Definitive: the case conforms with the surveillance case definition  
ii) Presumptive: it is likely to become a confirmed case if more data becomes 
available 
iii) Possible: there is little supporting data.  
Disease incidence is often reported to the public through the media and it is possible to give 
a false or misleading impression of the risk of a disease by selectively reporting 
information about the cases. Some of the variables in disease statistics that are relevant to 
the risk of the disease include socioeconomic status (environmental context), identification 
of the causal pathogen (suspicion or confirmed) and vaccination status of the cases. 
Statistics that are reported without this contextual information are liable to misrepresent the 
risk of the disease to the majority of the population. 
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Focusing on the overall incidence of a disease in the population is not of any significance 
because it does not inform about the age-incidence of the disease or the socioeconomic-
incidence of the mortality and morbidity from the disease (Burnet 1952; Cumptson 1989). 
Burnet (1952) also stated that case-fatality rates will vary greatly in different investigations 
because of the different criteria that can be used in diagnosing and reporting diseases. It is 
an inexact science. Stewart stated that notifications are incomplete indicators of prevalence 
and are in no way indicators of the severity of the disease to the population (Stewart 1977 
pp234-237). Governments are using computer models to determine the risk however this 
system is dependent upon the integrity of the researchers and the assumptions they are 
using. This is because the variables in disease statistics are not transparent to the public or 
government officials and the validity of assumptions cannot be verified (Cameron 2004 
p205). Hence government authorities and the public are expected to trust the researchers 
and their statistics and assume that they are making decisions in the public interest. The 
influence of these variables in the reporting of disease statistics to the public is illustrated in 
the media reporting of the ‘swine flu’ pandemic in Australia in 2009.  
4.9 Case Study: A new strain of ‘Swine’ Influenza (Type A H1N1) or a 
change in surveillance? 
In 2009 the Australian Government prioritized a vaccine for community use against a new 
strain of influenza. This preventative action was notable as there was little evidence that 
suggested this influenza strain was more virulent than previous strains that occur regularly. 
In fact, the World Health Organization (2009) stated the majority of people who contract 
this disease experience the milder form of influenza and recover without requiring 
treatment (WHO Swine Flu 2009). An examination of evidence provided by the Western 
Australian Health Department regarding deaths to swine influenza Type A H1N1 shows 
that it is possible that a change in the surveillance of influenza in 2009 resulted in the 
creation of hysteria over a new strain of influenza virus. Influenza is caused by many 
different strains of virus. These viruses spread easily and new strains develop regularly 
(Jefferson et al 2008). A vaccine against influenza is designed to protect against only one to 
three strains depending on the type of vaccine used (GWA CDCD 2009). For example, the 
2008 seasonal influenza vaccine protected against Type A (H1N1), Type A (H3N2) and 
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Type B (3). Influenza Type A H1N1 is a strain that has been covered in influenza vaccines 
for many years and it would be expected that humans would have some immunogenicity to 
similar Type A strains.  
The new strain of flu in 2009 was commonly called ‘swine flu’ by the media and it was 
described as being a recombination of genetic material from human Type A H1N1. This 
was stated to be a combination of one strain of bird flu and two strains of pig flu (WHO 
Swine Flu 2009). When this new strain was first detected in April 2009 the WHO stated 
‘there are no known instances of humans getting this strain of influenza from pigs or other 
animals’. It was also stated that this strain is not known to be endemic in pigs (WHO Swine 
Flu 2009). Yet this flu was promoted to the public through the media as ‘swine flu’ even 
though it was a strain that had never been found in pigs. The official medical term for this 
strain of flu was ‘Influenza Type A, H1N1, human strain’ (WHO Swine Flu 2009). It needs 
to be asked whether this strain of flu would have caused so much panic in the population 
and with authorities if it had been described by its medical name. The community may have 
been less fearful if they had been known that the virus was not transferred from pigs and 
that Influenza Type A H1N1 is a strain of flu that humans have been exposed to for many 
years - even though this strain had a different genetic make-up. The World Health 
Organisation stated in 2009 that influenza A (H1N1) was a new virus and one to which 
most people would have little or no immunity (WHO Swine Flu 2009). Yet in a study 
conducted by the CDC soon after the virus appeared it was shown that individuals between 
the ages of 18-64 had antibodies present that reacted to the swine flu virus (Schuchat in 
Katz et al 2009 p521-524). Whilst this does not indicate clinical protection it does suggest 
that some individuals may have had immunity from previous exposure to H1N1. There was 
no reason for public health authorities to assume in 2009 that that the population would 
have no immunity to this new strain when it was immunologically similar to previous 
H1N1 viruses (Schuchat in Katz et al 2009 p521-524).  
H1N1 is a strain of influenza that has been covered for many years in the seasonal influenza 
vaccine. Therefore it would be expected that the Australian Health Department would have 
mortality data for seasonal H1N1 from previous years. After all vaccines are introduced to 
reduce the deaths and illness from infectious diseases and it is necessary to evaluate the 
	  
	  
109	  
effectiveness of vaccination campaigns in the population. But this was not the case. The 
Western Australian Health Department stated this data was never collected in previous 
years (GWA CDCD 2009), even though Type A H1N1 has been one of the most virulent 
and prevalent strains and regularly covered in the influenza vaccine for many years. In 
2009 the Australian Health Department changed the surveillance of influenza in the 
community (GWA CDCD 2009) to monitor the new strain of ‘swine’ influenza. The WA 
Department of Health stated the reason there is good data on the mortality associated with 
influenza H1N1 2009 is because of enhanced surveillance systems that were put in place 
specifically to monitor the incidence of this virus (GWA CDCD 2009). Prior to 2009 
influenza that was notified by GP’s and laboratories was not systematically followed up or 
linked to hospitalization/death data to determine outcomes. In addition, post-mortem 
victims were not routinely tested for sub-types of influenza. In previous years deaths were 
listed as ‘influenza’ and were not routinely sub-typed for the strain. The Australian Health 
Department also stated ‘hospitals were less likely to routinely test admitted patients with 
respiratory viruses, including pneumonia, for influenza, so (in previous years) many cases 
remained undiagnosed or were assumed to be primary bacterial infections’ (GWA CDCD 
2009).  
Yet in 2009 most cases of influenza notified by labs or GP’s were followed up to see 
whether the cases led to hospitalization or death. The Australian Health Department was 
also systematically testing hospitalizations/deaths for H1N1. As a result, the health 
department was able to claim that 90-95% of laboratory proven influenza cases were due to 
‘swine’ H1N1 (GWA CDCD 2009). However they could not produce the morbidity or 
mortality statistics for previous strains of seasonal H1N1. It has been known for many years 
that incidence figures for a disease can be inflated by monitoring a disease in a more 
systematic manner. This knowledge is not always beneficial because it can include sub-
clinical or mild infections that give a false representation of the burden of the disease to the 
community. A more sensitive or systematic test will identify cases that would previously 
have gone unidentified, so a greater recorded incidence of a disease does not always 
indicate greater severity (or burden) to the population (Burnet 1952 p93; Cumpston 1989). 
This is the case with a disease such as influenza which has a high incidence in the 
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community but epidemics are known to be mild for the majority of people (Heikkinen et al 
2006).  
Members of the public could not easily assess whether this new strain of ‘swine’ H1N1 was 
more virulent than the regular seasonal H1N1 if the testing and surveillance of influenza 
had changed, particularly as there was no evidence of a ‘pandemic’ in the community. The 
changes in surveillance in 2009 meant that even though influenza Type A H1N1 was 
prevalent in previous years there was no data on the number of deaths associated with this 
strain in previous years because it wasn’t monitored. The Health Department also stated it 
was unclear to what extent ‘swine’ H1N1 infection contributed to the deaths it was 
associated with because there were usually several infections present and in most cases 
underlying medical conditions (GWA CDCD 2009). Disease diagnosis and cause of death 
is an inexact science and it is up to the medical practitioner to state the primary cause of 
death. The Health Department did not produce statistics that demonstrated the overall death 
rate for influenza in 2009 was significantly worse than in previous years but the media did 
not report this to the public (GWA CDCD 2009). This fact was supported by the 
Therapeutic Goods Association in the statement ‘the experience in Australia of the disease 
is mild in most cases’ (AG TGA 2009).  
The evidence presented above illustrates how using different surveillance methods can 
enhance the apparent incidence of disease in the community. This leaves the cause of the 
increase in incidence open to interpretation. For this reason the government should be 
required to publicize any changes to surveillance practices. This will ensure that the 
information the public receives can be interpreted in an open and transparent fashion and 
will lead to appropriate responses. The public was misinformed by reporting this strain of 
Influenza A (H1N1) virus as ‘swine flu’ and by exaggerating the risk from this new strain 
(AG TGA 2009). However, the health department states it is not responsible for the way in 
which the media reports on health issues to the public. This situation compromises public 
health if the media is not required to report accurately on all the variables that characterise 
the risk of diseases and vaccines to the public. See chapter 10 for a more detailed 
description of the ‘swine flu’ pandemic in 2009. 
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4.10 Communicating Risk to the Public  
Risk assessment is an inexact science therefore honesty and transparency are essential 
qualities in the determination of risk (Langley 2004). This approach is crucial to the 
establishment of trust by all stakeholders and in the adoption and acceptance of an 
appropriate management strategy by the public. In order to promote a desired outcome in 
the population it is helpful for managers to understand the different ways in which humans 
make judgments about complex issues. There are various factors that determine an 
individual’s perception of risk and these must be assessed before a judgment is made about 
the management of the risk. These include the hazard, the possible benefit/harm gained by 
implementing a particular management strategy, the trustworthiness of the proponents and 
potential responses to the management of the risk. Due to the large number of hazards the 
community is exposed to public members cannot assess all these factors in-depth for every 
hazard. Therefore, individuals use heuristics or rules of thumb to make opinions on 
complex information (Finucane 2004 pp148-9). 
There are two heuristics in particular that are commonly used: 
1. The availability heuristic: the more frequently a person experiences or hears of an 
event the more easily it will be recalled. This results in an inaccurate perception of 
risk if the media reports on this issue in a one-sided manner. If the focus is only on 
the benefits of the issue then individuals do not recall the few times that they hear 
about the risks. People also give more weight to concrete information as opposed to 
abstract information, therefore the more irrelevant detail that is added to the story, 
the more believable it becomes.  
2. The affect heuristic: an intuitive feeling people get after long-time experience with 
particular situations. In this case, individuals, including experts make judgments 
from a gut or emotional level even though deliberate and logical analyses are more 
appropriate. Emotion blinds people to the risk. 
In order for the public to make an accurate assessment of risk regarding a hazard it is 
recognized that the potential risks need to be emphasized and made more vivid so people 
will recall information other than the benefits of the activity or product. In the case of 
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vaccines the media continually reinforces the benefits of vaccines and the risks of the 
infectious diseases. The risks of vaccines are rarely reported on and when they are, they are 
downplayed and stated to be ‘very rare’ (AG IAP 2012). Another way to influence 
behaviour is through labeling. In the vaccination debate the terms ‘anti-vax’ and 
‘conspiracy theory’ are used to suggest that the ideas are not mainstream attitudes. People 
have strong affective reactions to labels and it is known that statistical or factual evidence is 
often ineffective in changing risk perceptions if these attitudes have been stigmatized 
(Finucane 2004 p149). These affective associations are strong and it is difficult to change 
someone’s perception once the association has been established.  
In a similar manner the framing of information by the media is extremely important. It is 
known that the wording and structure of the information has a large influence over people’s 
risk perception. This is known as the framing effect and it can make a big difference to the 
outcome of decisions. In many cases it may result in confusing the information for lay 
people. When this happens lay people will make decisions based on the trust that they place 
on proponents or institutions, rather than a true judgment of the information. In addition, 
humans are ‘risk avoiding’ so presenting the statistics as the number of lives lost as 
compared to the number of lives saved can strongly influence perceptions and behaviour. 
This can be seen in the promotion of vaccines to the public. Even though the majority of 
people in developed countries are not at serious risk from any infectious disease the vaccine 
is promoted on the small number of deaths or cases that do occur – without the context in 
which they occurred. For example, deaths to whooping cough or measles may be a result of 
the socioeconomic circumstances of the individual but these contextual factors are not 
reported with the number of cases that occur. Fear is a significant factor in human 
behaviour and disease statistics can be framed to maximize the fear of a disease and 
minimize the side-effects of vaccines. The framing effect is used by both experts and lay 
people and particularly by the media in advertising campaigns. Lay people have difficulty 
perceiving when the frame has been manipulated by experts and this has serious 
consequences in risk management when the manipulation goes undetected (Finucane 2004).  
This illustrates how risk perception is a social and cultural construct. Risk perception is 
composed from two types of risk judgment: the technical judgment made on expert 
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scientific information of the frequency or magnitude of the issue and the non-technical 
judgment guided by qualitative information based upon the sociopolitical views, cultural 
norms, and environmental characteristics (AG EHRA 2012). The public also places trust in 
the government and medical institutions to be acting in the public interest and this 
information will be weighted more highly in the individual’s perception of risk. There are 
many factors that influence a person’s perception of risk and these are listed in Table 2.  
Table 2: Factors Affecting Individual Perception of Risk 
More Acceptable Risk Less Acceptable Risk  
Benefits understood Benefits unclear 
No alternatives Alternatives available 
Risk ahead Risk affects few 
Voluntary Involuntary 
Individual control Uncontrollable 
Familiar Unfamiliar 
Low dread High dread 
Affects everybody Affects children 
Naturally occurring Human origin (synthetic) 
Little media attention High media attention 
Understood Not understood 
High Trust Low trust 
 
Source: Gilbert 2004, A Small Dose of Toxicology: the health effects of common chemicals, Boca Raton 
Fla, CRC Press, p33.  
	  
A major factor that has been left out of this table is the influence of financial rewards. If a 
decision affects an individual’s livelihood, status or financial arrangements it can influence 
their behavior and alter their perception of the risk involved in a procedure or technology 
(Krimsky 2003). See chapter 6. In societies that adhere to a model in which the ‘expert 
knows best’ risk assessment is very narrow and excludes the social and psychological 
aspects of risk assessment. In 1996 the US National Research Council supported a move to 
ensure risk management was addressed in its full social complexity (NRC 1996). This 
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means including public perceptions of risk which put value on the gaps in scientific 
knowledge. For example, values that can affect our perception of risk where gaps in the 
knowledge exist include controllability, dread, catastrophic potential and the 
trustworthiness of proponents. Public perceptions are based upon legitimate value laden 
aspects of risk and it is essential to include these risks in policy decisions to ensure the 
public’s health is prioritized in the management decisions that are made. These aspects of 
risk assessment are included in the EHRA framework but they have not been made 
transparent in computer modeling. For the last two decades there has been a reliance on 
quantitative risk assessment, yet intuitive risk assessment has been fundamental to human 
survival for centuries (Gilbert 2004). Therefore, it is essential that social and political 
factors are not eliminated from the risk assessment equation by relying only on economic 
modeling. These qualities are important in preventing judgment decisions being made on 
assumptions rather than empirical evidence in cases where there is uncertainty or ignorance 
in the risk assessment.  
Russell (1986) stated that the available information on the risks of diseases and their 
prevention rarely provides precise estimates of these risks and they are often very 
imprecise. It is often not clear which is riskier, the disease or the preventative measure. But 
he concluded that the true benefit of any preventative action was the value individuals 
placed on the outcomes produced by the procedure and how they valued them in 
comparison with alternative outcomes (Russell 1986 in Basch 1994 p81). Media campaigns 
play a large role in shaping the perceived risks of infectious diseases and their prevention 
for the public. The media emphasises the perceived benefits of vaccines and minimises the 
risks. An example of the minimisation of vaccine risks is the smallpox vaccine. In the 
1960’s compulsory smallpox vaccination in the US was stopped because it was realised that 
more harm was being caused by the vaccine than from smallpox disease (Basch 1994 p81). 
In many countries globally, both developing and developed, there is a low public 
understanding of the procedures for clinical trials and the processes intended to ensure their 
integrity in their conclusions (Basch 1994 p82). Government decision-makers and the 
public are expected to trust that the claims about safety and efficacy of vaccines have been 
produced with integrity. Clinical trials are very complex and developed nations often work 
with developing countries in trialing new vaccines. This can lead to claims of ‘cultural 
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imperialism’ or unethical conduct if there is an appearance that populations are being 
selected because they are uninformed about the risks/benefits of the procedure (Basch 1994 
p83). Local communities in developing countries are often suspicious of the real motives 
for clinical trials because they are introduced by western nations and sponsored by 
pharmaceutical companies.  
4.11 Conclusion 
Australia’s National Immunisation Program (NIP) has been developed by the Federal 
government as a recommendation to the states and territories under the Public Health Acts. 
The public health laws were reformed in 1999 and the regulation of infectious diseases was 
placed under infectious disease law and separated from other public health issues - 
sanitation and environmental control – that were traditionally associated with infectious 
disease control. This resulted in the use of different methodologies for determining the 
health risk for infectious diseases and many other environmental health hazards. Risk 
assessment for infectious diseases is performed by computer modeling however for many 
other environmental health hazards, including the microbiological risk from food 
pathogens, it is determined using the Environmental Health Risk Assessment (EHRA) 
Guidelines. See Appendix 6. This framework for risk assessment is believed by 
environmental health practitioners to represent the most systematic and transparent method 
for assessing health risks for environmental hazards in genetically diverse communities.  
Risk assessment for environmental hazards must include both technical and non-technical 
information. This is to address the limitations and uncertainty in the science. Gaps in 
scientific knowledge result in incorrect value judgments about safety and this can be 
countered with caution and non-technical input if the gaps in the science are acknowledged.	  
The EHRA framework also ensures that the community is consulted regarding their 
perceptions of the risk of a hazard. A rigorous risk assessment can stand up to scrutiny by 
all stakeholders and the public must be encouraged to openly debate vaccination policies to 
maintain population health. The public perception of risk is essential to policy development 
to ensure that health is the primary focus of the policy. There are many variables and 
assumptions in computer modeling that are not made transparent to the public or 
government ministers. In addition, the precautionary principle (PP), with the onus of proof 
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on the proponent and not the general public, has not been adopted in infectious disease law. 
When the PP is not implemented with the onus of proof of harm on the proponent instead 
of the general public, it is possible for governments to claim there is no evidence of harm 
therefore no action needs to be taken, based on a lack of scientific evidence due to 
appropriate studies not being funded. The public cannot be provided with definitive 
evidence if the studies have not been funded.  
A universal management strategy that carries a risk to sub-groups in the population needs to 
be openly debated by the community. The dominance of scientific experts in vaccination 
policy is questionable because of the increasing gaps in scientific knowledge due to undone 
science. This can synchronise with a lack of transparency in risk assessment to compromise 
health management strategies. A dependency on scientific experts and elite knowledge 
from computer models results in the exclusion of public participation in policy debate. Yet 
the existence of unfunded research in the underpinning knowledge (see Chapter 6) needs to 
be debated and addressed with non-technical information in policy decisions. The corporate 
model of health that was adopted by the states and territories in the 1990’s allows 
corporations to fund health promotion programs, such as vaccination, to the public in media 
campaigns. If industry funding is involved in health promotion campaigns it is possible for 
vaccine manufacturers to influence public behavior through the selection or framing of 
information. The case study of the Swine Flu Pandemic in 2009 illustrates how the framing 
of disease statistics in the media can misrepresent risk and influence public behavior 
regarding the use of vaccines. 
Surveillance statistics can be misrepresented to the public by changing the definition of the 
disease or changing the surveillance of the disease without publicising the changes. This 
information can then be promoted to the public in health promotion campaigns in the media 
that are funded by corporate partnerships. The media is not accountable for the information 
it provides to the public and the community is expected to trust that the information 
provided is in the public’s best interest. This situation can compromise public health 
because industry promotes industry interests which are not always compatible with the 
public interest. Industry became more involved in health research and promotion in the 
latter part of the twentieth century with the development of the medical-industrial 
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partnership in institutions and public-private partnerships to sponsor health programs. 
These have been discussed in Part 2 of the thesis: Corporate Influence and Undone Science 
in Public Policy. 
Chapter Overview 
Chapter 5 describes the scientific medical model of health and the ethical values inherent in 
health promotion and chapter 6 discusses the influence of corporations in the production of 
scientific knowledge. In chapter 7 I discuss the information the government provides to the 
public to support its claims about vaccines. Chapter 8 introduces the concept of undone 
science and the political framework that leads to its existence. Examples of undone science 
and industry influence in government vaccination polices are provided in case studies in 
chapters 9 and 10. Chapter 11 presents the conclusions drawn from this investigation.  
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CHAPTER 5 PUBLIC HEALTH POLICY AND HEALTH 
PROMOTION ETHICS 
5.1 Introduction 
Investigating government vaccination policies requires an analysis of the value system and 
beliefs underpinning the policy. This can be achieved by examining the health model that 
has been adopted for health promotion and the cultural environment in which it is 
implemented. Public health policy involves ethical issues regarding the balance between the 
health of individuals and community health. It is a political process that is influenced by 
many stakeholders who have interests other than health in these policies. Examining the 
main influences in the development of vaccination policies will help to assess whether the 
policy has been driven by the health needs of the population or economic and political 
interests in these policies.   
This chapter examines the adoption of the scientific medical model (SMM) as the main 
foundation for Australia’s public health policy. It provides an outline of the main features 
of this model with a comparison to the holistic model of healthcare. A description of the 
partnership between medicine and industry that developed over the 20th century is also 
provided. This medical-industry complex has significantly influenced society’s beliefs 
about health and has shaped our modern beliefs about the prevention of infectious diseases. 
In particular this partnership has influenced the education of doctors regarding the benefits 
and risks of medical procedures. Moral decisions in healthcare require ethical guidelines. A 
discussion of the Seedhouse ethical framework is presented here with the standards that 
have been set by the Medical Board of Australia for the registration of medical 
practitioners. The Good Medical Practice Guidelines that are set by the Medical Board of 
Australia (MBA) for the registration of medical practitioners requires that practitioners 
support the government’s NIP. Under these guidelines medical practitioners are also 
required to be vaccinated against infectious diseases. 
In this chapter I outline the ethical guidelines that exist for the registration of doctors in 
Australia and the implications this has for informing the public about the risks and benefits 
of vaccination. I describe the ways in which mandatory vaccination policies violate human 
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rights and the human rights covenants that protect these freedoms. This section also 
provides an analysis of the political and social forces that are influencing government 
decisions to use a medical intervention in the prevention of disease. I have started by 
providing a definition of health for public health policy because this is fundamental to the 
expected health outcomes and evaluation of vaccination policies. In Part 2 of the thesis, 
Corporate Influence and Undone Science in Public Policy, I describe the influence of 
industry in the development of global and national vaccination policies.     
5.2 A Definition of Health for Public Health Policy 
Of the many definitions of health that have been used over the centuries, the one I will use 
for this research is derived from the Old English word for heal (hael meaning ‘whole’). 
This definition states that ‘health is a concern for the whole person and his or her integrity, 
soundness, or well-being’ (Naidoo and Wills 2000 p6). This definition of health is 
consistent with the definition that has been adopted by the World Health Organisation 
(WHO) since 1948.  In the WHO constitution it is stated that ‘Health is a state of complete 
physical, mental and social well-being and not merely the absence of disease or infirmity’ 
(WHO 1948). Traditionally, the health of the community and control of infectious diseases 
have been measured by the decline in the infant mortality rate (Palmer and Short 1994). 
However, health is more than just longevity because this measure does not reflect the 
morbidity in the population. Also important are the quality of life and the ability to function 
effectively within a given environment. (Dubos 1966 p10; McKeown 1979 p5). As 
environments keep changing, good health is a continual process of adapting to the 
multitude of microorganisms, the pollutants from our activities and the pressures of society. 
It can be considered that all living things are diseased and it is only the pattern of disease 
that changes with time and culture (Dubos 1966 p9; Burnet 1952 p106). It has been stated 
that the most fundamental cause of disease and health inequalities are the social conditions 
in which people live (WHO CSDH 2005 p4).  
In contrast the meaning of health that has been utilized in the scientific medical model 
(SMM) adopted by most western countries is narrower and refers only to health ‘as the 
absence of disease or illness’ (Naidoo and Wills 2000 p6). Western medicine, also referred 
to as scientific medicine, is essentially based on a mechanistic approach to health arising 
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from an understanding of the structure and function of the human body and of the disease 
processes that occur in each separate part (McKeown 1979 p3). Whilst it is known that 
environmental changes play a role in the risk of disease, the scientific theory of disease 
prevention assumes that protection from disease can be achieved primarily through internal 
intervention and without knowledge of the ecological context of disease. That is, it is 
founded on the belief that the major determinants of health are internal mechanisms, not 
external environmental and lifestyle factors, and these can be targeted with medical 
interventions to prevent disease (McKeown 1979 p5). An illustration of the main 
determinants of health outcomes is provided in Figure 1. The core of the diagram represents 
the determinants of health that are the main focus of scientific medicine – the health 
dimensions within the individual – and the outer rings represent the wider determinants of 
health that arise from environmental, social, cultural and political factors. The WHO 
definition of health is inclusive of all the interacting factors in Figure 1: society structure, 
economic and political factors, infrastructure and the impact from physical, biological and 
chemical aspects of the environment (WHO 1948).  
Another definition of health describes humans and the environment as a system and 
‘health’ as a process of this ecological interaction (Friis and Sellers 2004; McKeown 1979 
p45; Illich 1975 p26). This concept is inconsistent with the definition used in the scientific 
medical model which focuses on the health of the individual as a separate entity. A model 
of health that focuses on disease etiology within the individual excludes the wealth of data 
demonstrating that ecological factors are the primary determinants of health and disease 
(WHO CSDH 2005; Winkelstein 1972 p74; McKeown 1979 p78). Good health is defined 
differently for people living in different social and occupational environments. This is 
because their physical needs, food requirements and stress levels vary and they are not 
equally vulnerable to all diseases or infectious agents (Gilbert 2004; Dubos 1966 p10; 
Burnet 1952). The Good Medical Practice guidelines for Australian doctors also include a 
broad definition of health that encompasses social determinants. Doctors are required to 
acknowledge the social, economic, cultural and behavioral factors that influence health at 
both individual and population levels (MBA 2010).   
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5.3 The Scientific Medical Model of Health  
This section describes the beliefs inherent in the model of health that has been adopted by 
western countries and it describes how medical education is now controlled by the industry-
medical partnership which influences the belief system of medical practitioners.  
The scientific medical model of health was adopted by western countries as the main belief 
system for modern medicine in the mid-20th century (Doyal and Doyal 1984 p90). It arose 
in the middle of the 18th century and was known as ‘allopathy’. It is defined as ‘treatment 
that counters illness with a treatment which opposes the illness’ (Walker 1993 p3). The 
identification of germs in the 19th century led to the belief that illness was caused by 
specific biological pathogens and it became plausible to look for treatments in isolation of 
how a patient thought or felt (Doyal and Doyal 1984 p90; Stacey 1988 p71). If there was a 
problem with the body it could be treated with a chemical (such as a pharmaceutical drug) 
to destroy the organism or to immunize people against the effects of a harmful agent (Doyal 
and Doyal 1984 p90). In this model the human body is conceptualized and treated as if it 
were a machine (Doyal and Doyal 1984 p85; Walker 1993). The machine analogy is 
developed further to suggest that all the parts are interconnected but capable of being 
treated separately (Doyal and Doyal 1984 p.92). 
 Allopathy rejects the theory that the mind, the emotions and the soul are involved as causal 
agents in the development of illness or its treatment (Walker 1993 p3; Doyal and Doyal 
p85) and this places it in conflict with models in eastern countries which are founded on a 
holistic approach to health. Holistic medicine is founded on the belief that all parts of the 
body are interconnected in the cause of disease and a change in one part affects other parts 
(Walker 1993 p4; Stacey 1988 pp15-47). Many scientists believe that health is the 
interaction of the mind and body. These systems are believed to be linked so that the stress 
under which a person lives finds its expression in physical illness (Burnet 1952; Dubos 
1966 p15: Doyal and Doyal 1984 p97). In the scientific model it is assumed that the 
etiology of disease is mainly biological, therefore social and economic factors are not given 
high significance in patterns of mortality and morbidity (Doyal and Doyal 1984 p93; Stacey 
1988 pp71-77). This model objectifies human beings with its mechanistic analogy and 
narrow focus on etiology and bodily symptoms (Doyal and Doyal 1984 p99). It also 
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encourages the notion that ‘passive’ compliance is required to cure disease. Patients are 
required to ‘trust’ the medical experts because of the complexity of their specialized 
knowledge. Consequently patients become dependent and dehumanized (Illich 1975 pp31-
61; Doyal and Doyal 1984 p99; Stacey 1988). Another criticism of this model is its 
inability to explain why there is a range of health outcomes associated with each infectious 
agent (Doyal and Doyal 1984 p96). For example, if an agent, such as influenza virus, is 
known to cause an illness it would be expected that all individuals exposed to the agent 
would get the illness. But this is not the case. Only a few exposed individuals show signs 
and symptoms of disease and these symptoms vary in severity.  
An individual is more than just the sum of its parts; there is a continual interaction between 
the internal biology and the external environment and the organism is changed by this 
interaction (Birke and Silverton 1984 p3). The biology of the organism is not necessarily 
the primary cause of this change and in some cases the biology itself is changed by the 
environment (Birke and Silverton 1984 p3). The diversity of health outcomes that results 
from interaction with the environment and infectious agents was described in chapter 2.  
Since the origins of the scientific medical model there has been a continual struggle in 
many countries for dominance between the holistic health industry and scientific medicine 
(Stacey 1988 pp15-59; Walker 1993). Whilst the importance of social factors and treating 
the whole person has taken greater prominence since the late 20th century, the western 
scientific medical model has underpinned the training of doctors and health workers in 
most western countries for the last century (Doyal and Doyal 1984; Stacey 1988 pp47-59).    
In the scientific model the terms ‘disease’ and ‘illness’ have been allocated specific 
meanings (Naidoo and Wills 2000 p7). ‘Disease’ implies an objective state of health that 
isn’t always distinguished by visible symptoms. Instead, abnormalities in the functioning of 
the body can be detected by pathology or screening practices and the significance of these 
changes is interpreted by a medical professional (Naidoo and Wills 2000 p7). ‘Illness’ 
however is a subjective feeling of loss of health and is identified by the symptoms that are 
experienced. The symptoms may lead to further investigations using diagnostic tools such 
as blood tests and screening until the disease is diagnosed. In the scientific medical model 
an individual can be diagnosed with a disease without experiencing any symptoms and this 
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is why health can be viewed as a socially constructed entity (Naidoo and Wills 2000 p7). 
This has been termed ‘medicalising the body’ (Curry 2002 p29). Medicine is a powerful 
institution controlled by professional associations with vested interests (Walker 1993 p5; 
Naidoo and Wills 2000). It is a social enterprise that is linked to professional power 
(Friedson 1986 p185). Although scientific medicine is competing with a rise in self-help 
and holistic therapies it still remains a powerful institution because of its role in defining 
health and illness in society. This is also due to the elite and autonomous nature of the 
medical profession (Friedson 1986; Stacey 1988).  
Doctors are in a powerful position due to their role in diagnosing disease and this power is 
controlled by professional associations who are protecting their own vested interests 
(Freidson 1986 p185). Bodies of scientific knowledge are considered to be a source of 
power over the lives of individuals. Therefore authorities who control this knowledge are 
able to have social control over people’s lives (Friedson 1986 p1). Medicine has been 
described as a social activity that concentrates professional power amongst an elite group 
(Naidoo and Wills 2000 p15). In other words it can be described as supporting a particular 
type of economy: capitalism and/or patriarchy (Naidoo and Wills 2000). When biological 
knowledge is controlled by ‘experts’ with an appearance of benevolence, then individuals 
can become dependent upon the ‘experts’ for advice in all areas of family life (Friedson 
1986 p1).   
5.4 Culture and Medicine 
Political processes that operate in policy development are moulded by the values and norms 
of society and by economic factors (Palmer and Short 2010 p31). The melding of medicine 
and industry resulted in a research focus of disease based on the internal biological 
structure of individuals and divorced from the environment: biomedical research (Naidoo 
and Wills 2000 p9). Industry believed the environment was irrelevant to the disease process 
(WHO CSDH 2005; Walker 1993 p8). This focus is in strict contrast to the older belief of 
holistic medicine that is practiced in many eastern countries and sees the health of the 
person within the context of their surroundings (WHO CSDH 2005; Stacey 1988; Walker 
1993 p8). In recent decades practitioners and the community have become divided over the 
best strategies to adopt in managing health. There has always been a division between 
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curative medicine and preventative medicine (Stacey 1988 pp15-60; Naidoo and Wills 
2000 p11). This division in society is thought to exist because doctors in western countries 
are being educated on the benefits of medical treatments without an equal emphasis of the 
risks (Rogers pp64-65; Naidoo and Wills 2000 p12). In addition, there is a lack of emphasis 
on the social, environmental and nutritional links to illness that would assist in the 
prevention of disease (WHO CSDH 2005).  
A broader conception of health that includes the social and environmental determinants of 
health and recognition that all medications have side-effects provides strategies for 
reducing both infectious disease and chronic illness in the population. The prevalence of 
chronic illness has been increasing in western populations since infectious diseases 
declined in the mid–20th century (Illich 1975 p17; WHO 2013). During this time the use of 
medical interventions in the prevention of disease has significantly increased. Cochrane 
stated that most medical interventions used in 1972 had not been proven effective prior to 
their widespread use and he advocated for the evaluation of medical interventions in 
controlled clinical trials (Cochrane 1989 pp431-432). There was a significant increase in 
pharmaceutical drug use from 1950-77 and the negative consequences of frequent drug use 
were being recognised by 1984 (Rogers 1984 p65). Until the 1960’s there was a lack of 
research on the effectiveness of western medicine. This was because research techniques to 
objectively evaluate interventions had not been developed. The randomized control trial 
was introduced in 1952 but few medical interventions had been evaluated even in the 
1960’s (Cochrane 1989 p432). The Chinese have continued to use medicinal herbs 
extensively because they are considered less toxic than pharmaceutical drugs and some are 
more effective (Rogers 1984 p65; Garrett 2012a). Some natural remedies are biologically 
successful and through years of trial and error they have been tested in many more 
individuals than modern drugs at the time of their release (Rogers 1984 p65). In 2012, the 
Council on Foreign Relations stated there is a lack of independent testing on many 
pharmaceutical drugs and vaccines and also many natural remedies. Many pharmaceutical 
drugs/vaccines have a high risk of side-effects and no proven efficacy (Garrett 2012a).  
Even in 2008 the European Commission (EC) was estimating that adverse drug reactions 
(ADR) kill 197, 000 European Union citizens annually at a cost of €79 billion (EC 2008). It 
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was also estimated that ADR’s represent 5% of hospital admissions and are the fifth most 
common cause of hospital deaths (EC 2008). Clinicians and scientists stated in 2011 that 
ADR’s have reached epidemic proportions and are increasing at twice the rate of 
prescriptions. This is in part a result of a lack of adequate evaluation before drugs are 
approved for the market (Archibald et al 2011 p1915). Obomsawin observes that the 
universal childhood immunisation program (EPI) has never addressed the need for effective 
monitoring and proper evaluation of potential side-effects from vaccines (Obomsawin 
1998). He states: 
‘Past estimates on the degree of adverse reactions are unreliable and optimistic since actual 
monitoring efforts are generally negligible.’ And 
‘Overall, the evidence strongly suggests that the chronic underreporting of vaccine-induced 
morbidity, disability and mortality is in fact the norm, whether in the Developing or the 
Developed Worlds. The first definitive policy statement on this issue by the World Health 
Organisation (issued on April 1991) indicates the WHO’s recognition of the significance of 
this problem’ (Obomsawin 1998 p2).  
Culture plays a significant role in the belief systems adopted by different countries as can 
be seen in the use of the scientific medical model in western societies. These societies use 
capitalist markets to encourage the maximum production and consumption of goods 
(Fitzgerald 2001 p73). The ideology of the market presents a dilemma when applied to 
health because many health outcomes are dependent upon a change in behavior, diet or the 
environment that operate largely outside the value of the markets. Furthermore, many of the 
medications that can be purchased are increasing illness in the population through adverse 
reactions and interactions in body systems (Archibald et al 2011).  
5.5 Ethical Guidelines for Health Promotion 
In today’s society codes of ethics provide only a general guide to moral decisions on health 
because people live longer and quality of life needs to be recognised in the decisions that 
are made. Different groups have different perspectives on the risks and benefits of different 
procedures. This is due to their values, and what they stand to gain or lose in the decision-
making process (Palmer and Short 2010 p51). It is also a product of their education. There 
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are two levels at which ethics needs to be addressed: micro-level ethics between patients 
and doctors and macro-level ethics in policy decisions that involve the rights and 
responsibilities of governments, communities and individuals (Palmer and Short 2010 p51).    
The ethical principles that have been utilised for decades by health practitioners to guide 
moral decisions have been illustrated in the grid developed by David Seedhouse (2009). 
This is illustrated in Figure 7. 
Figure 7: The Seedhouse Ethical Grid 
 
Source: Seedhouse 2009 p144 
 
This grid provides a tool for making value judgments about medical procedures. It 
represents elements that should be part of a thorough reasoning process in the development 
of public health policy (Seedhouse 2009 p144). The core rationale of health ethics is found 
in the blue layer at the centre of the grid. These four boxes represent a simplification of the 
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key elements of the foundations theory of health: i) create autonomy ii) respect autonomy 
iii) respect all persons equally iv) serve needs before wants.  
Seedhouse (2009) states ‘All plausible theories of health equate work for health in some 
way with the creation of autonomy’ (p144). He claims health work has always been driven 
by the goal of autonomy. In addition, the WHO’s definition of health, described earlier, is 
only achievable by creating autonomy in individuals.  
Autonomy underpins healthcare in the following ways (Seedhouse 2009 p145): 
I. Under western law consent is essential in any healthcare intervention. Practitioners 
are required to provide clients with sufficient information about treatments to 
enable them to make an informed decision. In western countries it is a civil or 
criminal offence to provide an intervention without consent. This is also required 
conduct in the Good Medical Practice Guidelines for Australian doctors (MBA 
2010). 
II. As health problems are no different to other problems that affect people, a 
healthcare professional has no special training or right to force their ‘judgment’ of 
the correct procedure onto a patient. The only situation where this may be 
acceptable is when an individual’s welfare is demonstrated to be seriously at risk 
or if an action will be harmful to the public interest. But the latter must be 
supported by a consensus from all stakeholders.  
III. Health work should enhance human potential and not diminish human potential - 
unless the procedure is to prevent a worse harm from occurring. Autonomy is 
created by enhancing human potential. 
Interventions that make no attempt to increase autonomy (or even remove autonomy) are 
not health work (Seedhouse 2009 pp144-45). There are two definitions of autonomy 
provided by Seedhouse (2009):   
1) Being able to do 
2) Being able to have one’s choices 
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The principle of autonomy includes both respect for patient welfare and allowing patients 
to be in control of decision-making. These elements cannot be separated because autonomy 
is a personal quality and both aspects are necessarily connected (Seedhouse 2009 p147). It 
means that a person is able to ‘do anything rather than nothing’. Therefore you might have 
a small degree of autonomy or a lot of autonomy.  
All healthcare work should aim to provide patients with as much autonomy as possible 
(Seedhouse 2009). The foundations theory of health states that health is supposed to 
remove obstacles that stand in the way of human potential (Seedhouse 2009 p151). For 
example, practitioners need to remove ignorance by providing adequate information for 
clients to make an informed decision or to remove restrictions that are created by the 
desires of others and not the welfare of the patient. Creating autonomy by removing these 
obstacles can be seen as a pre-requisite for respecting autonomy (Seedhouse 2009). Health 
workers are limited by their training and understanding of health issues so their duty to 
create autonomy may be limited (Seedhouse 2009 p149). Health education can become 
indoctrination if practitioners do not create and respect autonomy (Seedhouse 2009 p159). 
The knowledge gap between healthcare workers and patients makes patients susceptible to 
‘trusting’ their doctor hence respect of autonomy is necessary to ensure that patients are not 
manipulated into certain procedures without good evidence and reason. The question of 
whether welfare should ever take precedence over the right to choose is dependent upon the 
situation. In scientific medicine there is a tendency towards paternalism where doctors 
present their perception of what is in the patient’s best interest and this can often be given a 
higher priority than the patient’s right to choose (Seedhouse 2009 p157).  
The Seedhouse Ethical Grid includes six main principles that practitioners should respect 
when providing healthcare advice to patients. These are: 
1. Respect for autonomy: a respect for the rights of individuals and their right to 
determine their lives. 
2. Beneficence: doing good 
3. Non-malfeasance: doing no harm 
4. Justice: being fair and equitable   
5. Duty to care 
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6. Duty to be truthful 
These principles form a framework to ensure there is a moral foundation in the decision-
making process regarding health promotion. Healthy outcomes for individuals and the 
community depend upon the inclusion of these values. If a medical procedure is adopted in 
a public health policy, the evidence for its use must be in accordance with these ethical 
guidelines. This will ensure that more good than harm will be produced by this action.  
5.6 Conduct for Australian Medical Professionals   
The Australian Medical Association (AMA) has a code of conduct for medical practitioners 
that combines the 2,500 year old Hippocratic Oath with the guidelines presented by the 
World Medical Association (WMA) in the Declaration of Geneva (AMA 2006). The 
Hippocratic Oath is an oath taken by new physicians that requires them to uphold ethical 
standards (US NLM 2002). This oath is not required by most modern medical schools and 
has been re-written by many schools to suit the different cultural values and issues in the 
21st century (NLM 2002). The Hippocratic Oath states that doctors will ‘do no harm or 
injustice’ to their patients (NLM 2002). Under the AMA’s code of conduct new medical 
practitioners take a vow to abide by the principles that have been set by the WMA (AMA 
2006).  
Guiding principles are adopted by the AMA to ensure that the actions taken by doctors are 
in the best interests of the client. These principles include the following two commitments 
and many others (AMA 2006):  
• The health of my patients will be my first consideration. 
• I will not use my medical knowledge to violate human rights and civil liberties even 
under threat.  
In Australia, the Medical Board of Australia (MBA) has set a national code of conduct for a 
medical practitioner that complements the Code of Ethics developed by the Australian 
Medical Association. This code is set out in a document titled Good Medical Practice to 
inform the community of the principles underpinning the ethical and professional conduct 
of doctors (MBA 2010). It is a framework to guide professional judgment and it states that 
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the principles should not be compromised. Every doctor is required to adhere by these 
ethical standards to maintain their medical registration (MBA 2010 p1).  
The guidelines of good medical practice encourage doctors to recognise and respect the 
rights of patients to make their own decisions about healthcare, which is compatible with 
the Seedhouse ethical grid. Doctors are directed to encourage patients to take responsibility 
for their own health and to support them in this endeavor (MBA 2010 p3). Decisions 
should be a shared responsibility between the doctor and the patient. In particular, the guide 
emphasises the need for informed consent regarding any medical intervention. It states that 
an examination, investigation or treatment should not be provided without obtaining 
informed consent or other valid authority (MBA 2010 p6). The Australian Immunisation 
Handbook (ed 10) (section 2.1.3) also states that informed consent for vaccination ‘must be 
given voluntarily in the absence of undue pressure, coercion and manipulation’ and ‘it can 
only be given after the potential risks and benefits of the relevant vaccine, risks of not 
having it and any alternative options have been explained to the individual’. This is 
compatible with the statement in the Good Medical Practice Guidelines. However, there 
are many serious risks to vaccines listed on the Product Information for each vaccine that 
most Australian parents are not informed about before they give their consent. Most parents 
are also not shown the list of vaccine ingredients in the Australian Immunisation Handbook 
(Appendix 3) before they give their consent. Furthermore, they are required to get a 
doctor’s signature to refuse this medical intervention instead of giving their consent to 
receive it. This is contrary to the MBA guidelines and the Australian Immunisation 
Handbook. 
The Good Medical Practice guidelines emphasise the right of Australian doctors to choose 
not to provide or participate in treatments if they do not support them (MBA 2010 p3). 
However, vaccination is not considered to be a treatment but rather it is intended to be a 
preventive measure. Another directive states that doctors must be aware of their obligations 
in disease prevention, screening and reporting of notifiable diseases (MBA 2010 p10). A 
doctor’s ‘obligation in disease prevention’ is to support government vaccination policies 
because they are an accepted medical practice of western medicine. Doctors ‘must be 
aware’ of the guidelines set for the promotion of government vaccination policies and ‘they 
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must immunise themselves against relevant communicable diseases’ (MBA 2010 p16). The 
code of conduct states that doctors must adhere to these guidelines or they risk being de-
registered from the medical profession. Academic freedom to speak the truth on medical 
issues is curtailed when the knowledge is linked to a person’s livelihood. Ziman (2000) 
states ‘science cannot be expected to speak truth to power unless power is forbidden to talk 
back’ (p162). Hence requiring doctors to support government vaccination policies to 
maintain their registration has consequences for the health of society if they are unable to 
speak openly about the risks of vaccines without fear of de-registration.  
Doctors encourage patients to use vaccines because they are educated, with influence from 
industry (see chapters 6 and 7), to believe that vaccines were the most important 
intervention in the decline of risk from infectious diseases. They are also informed that 
serious adverse events to vaccines are rare (AAS 2012). Current vaccination policies 
transgress two principles of western medicine (Obomsawin 1998): 
1. Preventions and treatments should be individualized, particularly when injecting 
substances into the human body that carry the potential for disease, disablement 
and death. 
2. The objectively informed patient (or parent) should always have absolute freedom 
to accept or reject any given measure or therapy and have reasonable opportunity 
to consider alternatives. 
5.7 Public Health Policy and Human Rights 
In this section I describe the international human rights covenants that protect the right to 
privacy (including bodily integrity) and non-discriminatory social welfare policies. 
Governments have a duty to uphold international human rights covenants in the design of 
public health policies. If a policy infringes upon human rights the government is required to 
show that the action is for a legitimate public health purpose, that it is proportionate to the 
risk and that it is formalised in law. The information discussed here is largely referenced 
from the Parliamentary Reports published by the Australian Human Rights Commission.  
McGavin (2001) suggests that if the principal differences in risk estimates for an 
environmental hazard are value-based one has to seek consent or at least ensure that actions 
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do not transgress the rights of others before an intervention is adopted (Hicks 2004 p163). 
Government public health policies are always value-based because they are made on 
political decisions from the available scientific evidence. Australian vaccination policies 
are linked to social welfare benefits and employment. These policies coerce individuals, 
with financial incentives, to use a medical intervention and this infringes upon the healthy 
individual’s right to choose how they maintain their own health without coercion or 
manipulation. The International Health Regulations (IHR’s) require that health measures 
against persons are appropriate to the risk and no more intrusive or invasive than 
reasonably available alternatives that would achieve the desired level of health protection 
(Fidler and Gostin 2006 p87). The Australian government states that public health policy 
can infringe on human rights if it is demonstrated to be for a legitimate public health 
purpose, proportional to the risk and done by law (HRC 2013).  
Human rights are covered in many international covenants. The International Covenant on 
Economic and Cultural and Social Rights (ICECSR) protects the individual’s right to 
autonomy over their own body (bodily integrity) as well as the community’s right to non-
discriminatory social welfare policies. Article 17 of this covenant is the Right to Privacy 
that includes ‘the right to personal autonomy and physical and psychological integrity over 
one’s own body’ (AG APb p58) and Article 9 is the Right to Social Security that includes 
the requirement that social security ‘is accessible (providing universal coverage, without 
discrimination and qualifying and withdrawal conditions that are lawful, reasonable, 
proportionate and transparent’ (AG APb pp105-6). Under the ICECSR covenant the 
Australian government has a duty to ensure that the right to social security is available to 
Australians in a non-discriminatory manner or to justify this violation of human rights.  
The government’s vaccination policies discriminate against some healthy children/adults on 
the basis of vaccination status and these have been implemented despite the government 
continuing to claim that vaccination in Australia is not compulsory (AG IAP 2015). This 
has also occurred even though there is no requirement in any Australian health act or in 
regulations or legislative health instruments under these acts that compel a person to accept 
the administration of a vaccine (AG DHA 2013). The increased use of coercive measures in 
vaccination policies corresponds with government recommendations to use an increasing 
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number of vaccines in the Australian population (AG IAP 2013). See chapter 3. These 
policies are not equitable because they expose some groups in society to a greater risk from 
vaccines than others. This applies especially to individuals who depend upon social welfare 
benefits and in some professional areas of employment. The government has also not 
informed the Australian community that government vaccination policies are guided by 
directives from the GAVI/WHO alliance under global public health policies that are 
developed with influence from pharmaceutical companies. See chapters 3, 6 and 8. These 
features of government vaccination policies arguably conflict with the principles of the 
Seedhouse Ethical Grid (respect for individual autonomy, truthfulness and justice) that are 
used to guide moral decisions in health promotion. Seedhouse states that all plausible 
health policies that are designed to promote health should include the creation of individual 
autonomy, not its removal (section 5.5). 
The Australian government’s Immunise Australia Program website also carries a disclaimer 
that states (AG DH IAP 2015): 
All the material published on the Immunise Australia site is for information 
purposes only. The information contained on this site is not a substitute for, and is 
not intended to replace, independent professional advice. Users should consider the 
need to obtain any appropriate professional advice relevant to their own particular 
circumstances.  
The material contained on this site may include the views or recommendations of 
third parties, and does not necessarily reflect the views of the Commonwealth of 
Australia, or indicate a commitment to a particular course of action.  This site may 
contain references to other sites and these are provided for convenience only and 
should not be construed as an endorsement by the Commonwealth of Australia; 
conversely omissions should not be construed as non endorsement.  
The Commonwealth of Australia does not warrant or represent that the information 
contained on this site is accurate, current or complete. Users should exercise their 
own independent skill or judgment or seek professional advice before relying on it. 
The Commonwealth of Australia does not accept any legal liability or responsibility 
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for any injury, loss or damage incurred by the use of, or reliance on, or 
interpretation of, the information contained on this site. 
This disclaimer clearly states that the government does not accept responsibility for the 
information it provides to the public to support vaccination programs, either as being 
accurate or complete. In particular, the government directs members of the public to use 
independent advice that is specific to their own circumstances. The government states that 
the actions recommended on the Immunise Australia Program website may be from a third 
party and they do not necessarily ‘indicate commitment to a particular course of action’ by 
the Commonwealth Government of Australia. Yet the Australian government is using the 
recommendations on the IAP website to legislate mandatory vaccination in social welfare 
policies. This course of action infringes on human rights even though the Commonwealth 
of Australia is not stating that it supports the recommendations provided on the IAP 
website. In particular, mandatory vaccination in social welfare polices contradicts the 
government’s statement above that ‘Users should exercise their own independent skill or 
judgment or seek professional advice before relying on it.’ The recommendations on the 
IAP website are stated to be for a legitimate public health purpose yet the government is not 
claiming that the information is accurate, current or complete or that it supports the course 
of action recommended. 
5.8 Conclusion 
In the mid-20th century there was a change in focus in Australia’s public health policies 
from the social and environmental determinants of health to the use of vaccines, a medical 
intervention, as the main focus for disease prevention. This was in line with progress in 
scientific (western) medicine that considers most causes of infectious disease to be 
biological and initiated from within the individual. Consequently it has a narrower focus on 
etiology that discounts the influence of environmental, political and social causes of 
disease. The central aim of the scientific medical model of health is to reduce morbidity and 
mortality in the population by increasing the use of medical interventions. This is evidenced 
in the development of Australia’s vaccination policies which show an increase in the 
number of vaccines recommended by the government, and an increase in coercive 
measures, as the threat from infectious diseases declined.  When powerful associations 
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shape medical knowledge they can influence the behaviour of individuals in society 
through public health policies. In Australia the medical profession and the pharmaceutical 
industry have a major role in determining areas of health policy with limited input from 
other interest groups, particularly the public on whom this policy is enforced. This situation 
can result in the appearance of a scientific consensus on vaccination because these 
professional bodies can choose the research topics that will be funded. When evidence is 
selected to support a desired outcome in a health policy the status quo can be maintained. 
The political framework that enables evidence to be selected for government policies is 
described in chapter 8. This outcome is also achieved by the professional medical 
associations through the regulation of doctors’ education and by the standards set through 
the Good Medical Practice guidelines. Medical practitioners in Australia can be de-
registered from the profession if they do not comply with the standards and regulations set 
by the Medical Board of Australia (MBA). This means doctors are not free to present their 
personal assessment of the risks and benefits of vaccination because their professional 
regulations require them to support government vaccination policies. 
Vaccines were adopted as the primary preventative strategy for infectious diseases from the 
1950’s onwards. The sales of drugs and vaccines increased in the 1980’s when the free 
market economic model was adopted in Australia even though the safety of many of these 
products had not been established in properly designed clinical trials. In this political model 
industry can provide financial incentives to doctors to increase the sales of their products. 
They can also provide sponsorship for doctors’ education. When financial incentives are 
provided to enhance a doctor’s livelihood the ethical guidelines for health promotion can be 
overlooked and this puts patient health at risk. Gaps may exist in the scientific knowledge 
that are essential to predicting health outcomes, yet these can be ignored if information is 
presented to doctors and patients in a selective manner or if conflicts of interest exist in 
decision-making boards. Doctors trust that they are getting a balanced education and in 
general patients trust the advice provided to them by doctors. Patients and doctors are 
dependent upon the information they receive to make an informed decision on a medical 
procedure. Consequently, maintaining patient autonomy and informed choice regarding 
medical interventions is fundamental to maintaining the health of populations. This is 
particularly important when the integrity of medical science, and sponsorship of education, 
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can be influenced by political and cultural factors. A policy that removes these values 
contravenes the guiding principles stated in the Seedhouse Ethical Grid for the promotion 
of health in the population. 
Estimating the risk from an infectious agent depends upon the method of measuring disease 
burden in the community – case-fatality or incidence of the disease (see chapter 4). These 
methods are value-based and ethical guidelines imply that governments should seek the 
consent of the community before value-based interventions are implemented in public 
policy. When policies are presented in a benevolent manner, infringements on human rights 
can be overlooked if the community places unwarranted trust in the medical profession and 
the government. The public’s interest in these policies should not be compromised by the 
economic or political interests of special groups. The Australian government has not 
provided adequate evidence for coercive measures in vaccination policies or that the 
recommended actions are proportionate to the risk of infectious diseases in Australia. These 
actions are also not included in any laws under Australian health acts. In addition, they are 
being implemented whilst the government states that vaccination in Australia is not 
compulsory. When certain political structures exist, governments can claim a procedure is 
safe simply because there is a lack of evidence for the public to prove otherwise. This is 
termed ‘undone science’ and the political structures that lead to areas of unfunded research 
relevant to public health policy are described in Part 2 of this thesis ‘Corporate Influence 
and Undone Science in Public Policy’. 
Part 2 Chapter Overview 
The influence of corporations in the production and promotion of science is described in 
chapter 6 and a discussion of the government’s claims about the safety and efficacy of 
vaccines is provided in chapter 7. In chapter 8 I describe the political framework that allows 
increasing areas of undone science to exist in the design of public health policy. Chapters 9 
and 10 provide case studies of the HPV vaccine and the ‘Swine Flu’ 2009 vaccine to 
illustrate the influence of politics and corporations in the development of global and 
national vaccination policies. Chapter 11 provides the conclusions to this investigation.  
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 CHAPTER 6  
INDUSTRY INFLUENCE IN RESEARCH AND POLICY 
6.1 Introduction 
Cultural and political changes that have occurred since the mid-to late 20th century have 
resulted in government public health policies that have been increasingly influenced by 
corporate lobbying and sponsorship of research and education. The expansion of industry-
sponsored university research during this time has led to a shift in the way knowledge is 
produced and published by academic institutions. There has been a decline in the autonomy 
over the production and transparency of academic knowledge. The commercialisation of 
scientific knowledge has changed the structure of academic institutions and this has been 
accompanied by a change in the traditional culture and values under which scientific 
knowledge is produced. The biggest area of commercialization in science has been in the 
biomedical and health sciences. In the era of globalisation research is being driven 
primarily for profit and not just for its contribution to knowledge.  
 
This chapter describes the changes that have occurred to research institutions over the past 
fifty years and the way this has altered the culture and integrity of the scientific knowledge 
that is produced. I have provided specific information about the corporate influence in 
medical research from the US because this is where it is best documented but drugs are a 
global industry and these practices are occurring in (and affecting) many countries. The 
vaccine industry has expanded rapidly over the last two decades and regulatory processes 
have not kept pace with vaccine production. The effects of this rapid expansion on the 
regulatory processes for vaccines are described in this chapter. I have also described the 
conflicts of interest (COI) in medical research and policy development that can lead to a 
bias in the underlying science in the medical literature and in government public health 
policy. As there is no formal enforcement of values in medical research the public is 
dependent upon the honesty and integrity of the peer-review process to validate scientific 
knowledge. This chapter describes the influence of academic-industry partnerships on the 
peer-review process of scientific knowledge. Doctors are dependent upon their medical 
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education to make the best value judgments for their patients. To achieve healthy outcomes 
the information they receive should not be influenced by corporations that make a profit out 
of health interventions. I have described how industry sponsorship of the education of 
medical professionals influences the treatments that doctors provide to the community and 
also the direction of government public health policies.  
 
This information is not a criticism of the involvement of industry in medical research per se 
or to suggest that capitalism cannot produce good science. It is to recognize that these 
influences can result in biased science and that transparency and patient autonomy in the 
use of all medical interventions are the key principles in maintaining healthy communities. 
The problems described in this chapter are still rife today even though it has been claimed 
that many of them have been addressed (Goldacre 2012 pxi). 
 
6.2 The Academic-Industry Partnership  
This section is informed especially by Marcia Angell because of her role as former chief-
editor of the New England Journal of Medicine (NEJM) for 20 years. Her vast experience 
as the editor of this prestigious medical journal has led to many conclusions that are 
supported by other prominent authorities that are also cited in this section.  
 
In the era of globalisation industry is providing funding for academic institutions, medical 
institutions and government bodies (Krimsky 2003; Angell 2005; Michaels 2008). The new 
image of a ‘scientist’ in the 21st century is the person who can make contributions to 
knowledge while participating in converting the new knowledge into a product for the 
market (Krimsky 2003 p1). This is termed knowledge or technology transfer. To facilitate 
technology transfer, university-industry partnerships have been established to direct 
research towards profit. In this new structure of academic institutions research ideas are 
patented by the industries that sponsor the research (Krimsky 2003 p30). Consequently it is 
possible for ambition and career success to bias the assessment of the research. This can 
erode the integrity of scientific institutions and eventually produces mistrust and scepticism 
in the general public (Krimsky 2003 p2). Partnerships with industry became common after 
the 1970’s and 80’s when universities needed to diversify their funding sources to remain 
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competitive. At this time there was an anti-regulatory atmosphere in the governments of 
many countries that facilitated the pathway to privatisation (WHO CSDH 2005). It became 
popular for universities to partner with the private sector and generate wealth by selling 
their knowledge and licensing discoveries (Krimsky 2003 pp28-9). The process of 
commercialising universities required changes to the laws. In the USA several 
congressional Acts, such as the Patent and Trademark Amendments Act (Bayh-Dole Act) 
and the Technology Innovation Act of 1980, were passed and tax incentives were provided 
by the government to encourage partnerships (Krimsky 2003 p30).  
 
Many of the laws that were passed in the US Congress in the 1980’s were designed to 
speed up the ‘technology transfer’ of government funded research into useful products. In 
particular, the Bayh-Dole Act granted patents to universities, small businesses and non-
profit institutions from the research sponsored by the US National Institute of Health (NIH) 
(Angell 2005 p.202; Krimsky 2003 p30). This gave institutions title to the inventions made 
with federal research funds. It enabled exclusive licenses to be granted to drug companies 
for these patents. Prior to this Act, tax-payer funded research was in the public domain. 
Universities could subsequently patent and license their discoveries and also charge 
royalties (Angell 2005 p202). Sponsors can also own the clinical data, a practice that results 
in censorship of the medical literature (Goldacre 2012 p39). These political changes were a 
significant boost to the biotechnology and pharmaceutical industries and encouraged the 
establishment of many new biotechnology companies (Angell 2005 p202). It is now 
common for both academic researchers and their institutions to own equity in the 
biotechnology companies they are collaborating with. Therefore when a patent that is held 
by a university or a small biotechnology company is licensed to a drug company, the 
shareholders and employees will benefit financially from this publicly funded research. In 
medical schools prior to 1980 academic investigators who carried out industry-sponsored 
research rarely had conflicts of interest (COI) with their sponsors. However, since 1980 the 
medical schools themselves have a variety of deals with industry and are therefore not in a 
position to object to researchers behaving in the same way (Angell 2009). Conflicts of 
interest in industry funded research result in a systematic bias towards industry interests 
(Goldacre 2012 p38). 
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The Bayh-Dole Act transformed the ethos of medical schools and teaching hospitals to 
capitalize on research discoveries in medical schools. Many lucrative financial deals were 
established with drug companies in the 1990’s and this has led to a significant ‘pro-industry 
bias’ in the medical research that is presented to governments for use in public health 
policies (Angell 2005 p202). This situation was demonstrated in a survey of medical 
schools in 2003 which showed that the majority held equity interest in companies that were 
sponsoring the research within the same medical institution (Angell 2009). An investigation 
of the department chairs also found that the majority received income from pharmaceutical 
companies for the department and most received personal income as well. Although 
medical schools were issuing guidelines in the 1980’s about conflicts of interest, they were 
variable, permissive and loosely enforced (Angell 2009). In the 21st century, there is not ‘a 
single sector of academic medicine or medical education in which industry relationships are 
not ubiquitous’ (Stamatakis et al 2013 p469).  
 
The academic–industry partnership spread globally in the late 20th century and this has 
meant that pharmaceutical companies do not rely on their own research for new drugs. 
Consequently the production of prescription drugs tripled from 1980–2000. Prior to this, 
sales of drugs were static but the corporatization of medicine paved the way for the 
pharmaceutical industry to become the most profitable industry in America (Angell 2005 
p203). The global pharmaceutical industry is a $600 billion industry ‘rife with corruption 
and greed’ (Goldacre 2012 p x). In 1980, the US Patent Act was altered to remove the 
requirement that patentable inventions should be ‘novel, useful and non-obvious’. This 
change opened the door to acquiring patents for many more ‘inventions’ (Angell 2005 
p176). The monopoly rights for brand-name drugs were further extended with the 1984 
Hatch-Waxman Act. This meant that copies of the drug (generics) can only be placed on 
the market when the rights expire (Angell 2005 pp178-179). In addition, generic drugs do 
not require clinical trials to test for safety and efficacy before they are licensed by the FDA 
if they contain the same active ingredient as the brand name drug (Angell 2005 p179). 
Further, half the drugs approved in the US by the FDA from 2005-2011 were approved 
without companies having to demonstrate a measurable benefit of the drug (Downing et al 
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2014). The FDA did not require proof of the benefit of drugs that had innovative chemical 
structures, termed New Molecular Entities (NME). The risk-benefit profiles for drugs are 
not properly determined because active placebos, surrogate end-points and small sample 
sizes are being used in many clinical trials (Downing et al 2014).   
 
The Act extending the monopoly rights on drugs through the US Patent and Trademark 
Office (USPTO) ensured that creating a monopoly and extending it for as long as possible 
was a very profitable activity (Angell 2005 p173). Industry could also increase its profits by 
obtaining exclusive marketing rights from the FDA. The monopoly rights for blockbuster 
drugs, those that earn over a billion dollars per year, such as the HPV vaccine, are golden 
for the pharmaceutical companies and can now extend for more than 20 years (Angell 2005 
pp174-178). Pharmaceutical companies can extend this patent by licensing the drug for 
other diseases. Throughout the 1980’s there was a rapid growth of US university-industry 
relationships particularly in the area of biotechnology. This type of sponsorship was 20% 
higher in biotechnology than any other sector and nearly 50% of biotechnology companies 
were sponsoring university research at this time (US Congress OTA 1988 in Krimsky 2003 
pp31-32). During this decade at least 11 multimillion-dollar contracts for research in 
biotechnology were issued. Sponsorship by biotechnology companies in US universities 
reached $120 million by 1984. This figure represented 42% of all industry-sponsored 
university research (Krimsky 2003 pp31-32). This is relevant to vaccination policies 
because nascent biotechnology is being used to produce new vaccines for many 
communicable and non-communicable diseases and also new combination vaccines for 
childhood diseases. 
6.3 The Influence of Industry Sponsorship on Medical Research 
In the US and many other countries, university scientists play a crucial role in providing 
evidence for laws and policy. In the 21st century science is being produced with industry 
funding and goals which mean that ‘expert’ opinion can now be bought with a point of 
view (Michaels 2008 p47; Krimsky 2003; Angell 2005). Bias has affected the outcomes of 
all stages of the scientific process. This has significant consequences for policies and laws 
that are implemented in the public interest because these should be founded on a balanced 
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assessment of the body of research on a topic. The commercialisation of science has led to 
the pharmaceutical industry selling drugs to the community without performing properly 
designed randomised clinical trials (Kleinman 2005 p13; Angell 2009 pp109-114; Garrett 
2012; Goldacre 2012 p2; Downing et al 2014). Industry-sponsored studies downplay the 
side-effects of drugs, with only the benefits being emphasised to doctors and the 
community (Stamatakis et al 2013 p470; Goldacre 2012 p2). This situation has been made 
possible because of the influence of industry funded sponsorship in research grants and 
clinical trials, and in medical education. Industry funds, designs and controls a large portion 
of the most influential medical research and education (Stamatakis et al 2013 p470). 
 
There is increasing direct evidence of the manipulation of results in industry funded trials 
(Stamatakis et al 2013 p470; Goldacre 2012 p21). Ioannidis (2005) concluded that nearly 
half of published articles in scientific journals contained findings that could not be 
replicated by independent researchers. In fact, he showed that most research findings are 
false. This problem is noted to be particularly widespread in medical journals where peer-
reviewed articles can be crucial in influencing multi-million dollar spending decisions. 
Conflicts of interest in these journals compromise the neutrality of published research 
(Epstein 2011; Angell 2005; Krimsky 2003). Drug companies can select which clinical 
trials they will publish and the suppression of trials with negative results is producing 
medical literature with false positive findings (Goldacre 2012 p2). In biomedical research, 
COI are very common but they are rarely reported (Ioannidis 2005). The bias can be 
financial or just a commitment to their own findings (Ioannidis 2005; Goldacre 2012). It is 
observed that the peer-review process can be used by prestigious researchers to suppress 
the publication of findings that refute their research (Krimsky 2003 p10; Ioannidis 2005; 
Michaels 2008; Angell 2005). This results in the perpetuation of false claims. Ioannidis 
(2005) states that the more popular the scientific field, the less likely the research findings 
are to be true.  
Medical journals are involved in COI because 50% of their income is derived from 
pharmaceutical advertising and reprint orders (Angell 2009). Many journals are also owned 
by companies who operate as medical publishers but in effect provide a marketing service 
	  
	  
143	  
to the pharmaceutical industry (Angell 2009; Goldacre 2012 p38). Another COI in 
published studies is the financial ties many authors now have with the companies that 
sponsor their research. In the 1990’s the decline in US government funding for medical 
research left medical scientists dependent on pharmaceutical companies to fund their work 
(Bosely 2002). Sponsors continue to control the data even when lead authors declare that 
researchers had full control over publishing decisions (Goldacre 2012 p41). Industry has 
gained unprecedented control over trial data and this has increased the opportunities for 
company employees to draft research papers and it has led to the practice of ‘ghostwriting’ 
and ‘honorary authorship’ (Bosely 2002).  
The practice of ghostwriting is very common in the commercialised era of science 
(Krimsky 2003 p115; Peterson 2008; Seife 2012). This practice involves doctors being paid 
to put their names on a paper they haven’t written. In this way credibility due to apparent 
independence is conferred on the findings of industry funded research. It is a deceptive 
practice akin to plagiarism that has become common in the marketing of scientific and 
medical research (Krimsky 2003 pp115-117). Many pharmaceutical companies now market 
drugs through a PR firm that hires a freelance writer to write an article and a doctor to put 
their name on it (Krimsky 2003 p116). The doctor can be paid $1,000-$10,000 for their 
contribution (Bosely 2002). It is then presented for publication in a peer-reviewed journal. 
Industry can also influence which research is published in the most influential medical 
journals by using ghostwriters (Stamatakis 2013 p471). The status of industry trial results 
can be raised by listing academically affiliated investigators as the first or second authors of 
the articles (Stamatakis 2013 p471). This has been done for publications regarding the HPV 
vaccine and is described in Chapter 10. This practice is deceptive to researchers and 
consumers and should be considered scientific fraud. However, much of the medical 
community has accepted the practice and participates in it for the financial rewards 
(Krimsky 2003 p115). It is also a hidden practice. In many cases, it is alleged that the 
authors will not have seen the raw data they are writing about – only tables of data prepared 
by industry employees (Bosely 2002). Originally ghostwriting was only found in medical 
journal supplements sponsored by industry but it is now widespread in all the major 
journals (Bosely 2002).  
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Ghostwriting or honorary authorships erode the integrity of science. Doctors are also 
presenting talks on ghostwritten papers at drug-company sponsored symposiums and 
receiving money for the talk, airfares and accommodation (Bosely 2002; Angell 2005; 
Peterson 2008). To combat the ghostwriting of articles, the editors of medical journals 
claimed they would introduce a system requiring scientists to sign a declaration that the 
papers they submitted to peer-reviewed journals were their own work. However, the 
practice of ghostwriting continued (Seife 2012). Many journals have also denounced drug 
companies for restricting the access of scientists to the raw data of clinical trials 
(Stamatakis 2013 p471; Bosely 2002). In addition, it is known that drug companies do not 
publish trials with negative findings. Researchers can do many trials but they are free to 
choose which ones they will publish (Goldacre 2012 p7). This results in ‘publication bias’ 
and it is endemic in medical and academic institutions. Regulators have failed to address 
this problem. Incomplete data on the safety and efficacy of drugs in the medical literature 
misleads doctors, patients and policy-advisors resulting in harmful decisions in patients 
(Goldacre 2012 p27). Dr. Richard Horton, chief editor of the Lancet, stated at a symposium 
on biomedical research at the Wellcome Trust in London that half of the scientific literature 
is unreliable and much is fraudulent (Engdhl 2015). He says pharmaceutical companies are 
manipulating the tests on the safety and efficacy of drugs/vaccines and these studies are 
being used to train and educate doctors: COI, lack of transparency, invalid analyses and the 
funding of fashionable trends, such as innovative biotechnologies, are facilitating this 
situation.  
The integrity of health promotion organisations is threatened by the influence of industry 
sponsorship (Krimsky 2003 p79). Sponsors fund and influence all aspects of research, 
evidence synthesis, cost-effectiveness evaluation, formation of clinical guidelines, 
conferences, grants, healthcare professional education and healthcare professional decisions 
(Stamatakis 2013 p471). These pathways for influencing medical practice and healthcare 
are illustrated in Figure 8. 
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Figure 8 An outline of the main pathways through which the industry influences 
medical practice and the focus of the healthcare systems. 
 
Source: Stamatikis E, Weiler R, Ioannidis J. 2013. Undue industry influences that distort healthcare 
research, strategy, expenditure and practice: a review. European Journal of Clinical Investigation. May. 
43: 5: p470. 
 
Financial involvement in these areas provides an opportunity for industry to influence every 
aspect of medical institutions. But the areas of most significance are the sponsorship of 
doctor’s education and the direction of research (Krimsky 2003 p31). These directly impact 
on the ability of doctors and scientists to protect the public interest. Doctors and scientists 
now participate in the following activities that represent a conflict of interest to their 
professional guidelines (Angell 2005): 
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• consult for companies whose products they are researching  
• join company and government advisory boards 
• become members of speakers bureaus for drug companies 
• have patent and royalty arrangements 
• agree to be listed as authors of articles ghost written by interested companies 
• promote drugs and devices at company-sponsored symposiums 
• accept expensive gifts and trips 
• have equity interest in the companies sponsoring the research  
 
Examples of these practices are illustrated in the case study of the HPV vaccine in chapter 
9. Many research institutions and medical bodies receive large amounts of money from 
pharmaceutical and biotechnology companies that the public is not made aware of. Exact 
amounts of sponsorship are unknown to the public (Krimsky 2003). Industry funding can 
aid the development and progression of science but it is imperative that industry 
partnerships are managed in a transparent process. This is necessary to maintain the 
integrity of the scientific/medical profession and ultimately the authority of medical doctors 
in the community (Stamatakis 2013 p.473; Goldacre 2012 p45). Integrity, objectivity and 
independence are central to the translation of evidence-based knowledge into clinical 
guidelines (Stamatakis 2013 p471). It is now common in the medical field for doctors to 
receive money or gifts from drug companies (Krimsky 2003; Angell 2005 p115; Peterson 
2008). This includes funding for conference travel, accommodation, shares, consultancy 
fees, honoraria for speeches in drug promoting events and other products (Stamatakis 2013 
p471). Between 56-87% of the authors for clinical practice guidelines have at least one 
conflict of interest (Norris et al 2011). Research in social psychology suggests that large 
gifts to doctors can influence behaviour and small gifts can influence attitudes towards the 
company and its products (Krimsky 2003 p33).  
 
Research on the influence of gifts to doctors was used by a subcommittee in Congress in 
the 1990’s to recommend against COI in drug evaluations. The committee requested that 
the Department of Health and Human Services (DHHS) ‘immediately promulgate Public 
Health Service regulations that clearly restrict financial ties for researchers who conduct 
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evaluations of a product or treatment, in which they may have a vested interest’ (Krimsky 
2003 p33). However, this request was never acted upon (Krimsky 2003 p33). The boundary 
between industry and academia has become blurred and clinical guidelines are now 
founded on costly interventions instead of the available evidence (Stamatakis 2013 p472).  
The bias in clinical research is enhanced when financial incentives are provided to doctors 
or policy advisors (Krimsky 2003 p7). Drug companies subsidise the majority of meetings 
of professional organizations thereby influencing the content of these meetings. In addition, 
they fund the continuing education of doctors to maintain their licenses (Angell 2005 
p135). This enables the drug companies to influence doctors’ views about drugs. Side-
effects can be down played and benefits enhanced when the drugs/vaccines are promoted at 
industry funded conferences (Stamatakis 2013 p472; Angell 2009; Goldacre 2012). 
Consequently, in an unregulated environment, the health advice provided to consumers is 
strongly biased towards industry priorities (Stamatakis 2013; Goldacre 2012). Angell 
(2009) estimates that drug companies pay US physicians tens of billions of dollars a year 
which gives them enormous control over the way in which doctors practice. In particular, 
they have control over the way doctors evaluate and use pharmaceuticals. Drug companies 
have significant influence over the results of research, the way medicine is practiced and 
the definition of what constitutes a disease (Angell 2009; Stamatakis 2013). This is all 
possible because of the financial ties they have to doctors and in particular, senior 
academics at prestigious medical schools (Angell 2005 pp142-147). It has also been 
demonstrated beyond doubt that studies funded by industry produce positive results more 
often than independently funded studies (Goldacre 2012 p1). This is called the funding 
effect. 
 
In order to carry out clinical trials, drug companies need access to human subjects therefore 
many of these trials occur in medical schools to provide access to hospitals. Alternatively 
they are done through private research companies. By utilizing the medical schools for 
clinical trials the drug companies can work with highly influential academic physicians 
(Angell 2005 p142). These doctors are referred to as ‘thought-leaders’ or ‘key opinion 
leaders’ (Angell 2005 pp142-147; Peterson 2008). Many of these doctors write text books, 
medical journal papers, issue practice guidelines (treatment recommendations), sit on the 
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FDA and government advisory committees, head professorial societies and speak at many 
conferences for clinicians about prescription drugs. Access and gifts to these physicians 
benefit pharmaceutical companies and provide many opportunities to influence medical 
practices (Krimsky 2003). The growing number of scandals in which the dangers of 
prescribed drugs have been discovered too late led a group of scientists and clinicians to 
write an open letter to the UK Prime Minister (Archibald et al 2011). The letter stated that 
adverse drug reactions have reached epidemic proportions and are increasing at twice the 
rate of prescriptions. This leads to the question of whether drugs/vaccines are being 
adequately trialed and tested for adverse reactions before being approved by boards 
dominated by individuals affiliated with industry (Stamatakis 2013 p471). Data from a 
litigation trial against a pharmaceutical company suggested the manufacturer intentionally 
altered the presentation of trial safety data and trained sales representatives to avoid 
questions from doctors about safety (Stamatakis 2013 p471). Goldacre (2012) states that 
manufacturers test drugs in poorly designed trials that use analytic techniques that 
exaggerate the benefits and downplay the risks and they do not publish trials that represent 
the body of scientific data on a topic (p21).  
 
The harmful effects of drugs are being minimised by choosing incorrect parameters and 
selective criteria in the design of clinical trials. Primary data that is not independently 
assessed by the scientific community can be massaged to produce the desired result through 
the choice of methodology and criteria (Michaels 2008 p53; Goldacre 2012 p2). The 
sponsor of the trial can then claim ‘there is no evidence of harm’ simply because the study 
did not use the parameters that might have revealed harm from the drug/vaccine. This is 
biased or misleading science and it is being used in public health policies. In the new 
structure of university funding and governance the available evidence can be influenced at 
all stages by the sponsor to prevent vital evidence from being collected.  
 
6.4 Australian Examples of Academic-Industry Partnerships 
 
An example of the academic-industry partnership in Australia is found at Murdoch 
University, which has recently collaborated with many corporate partners to form the 
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Institute for Immunology and Infectious Diseases. This is an international medical centre 
with over 30 collaborations and significant international funding, including $12 million 
from the Bill and Melinda Gates Foundation. Other partners include the Royal Perth 
Hospital, Fiona Stanley Hospital, biotechnology industries, Microsoft Corporation, 
GlaxoSmithKline, Merck, Roche and other pharmaceutical industries. The research 
program at the new medical institute is titled ‘The Genesiis Campaign’. This is in reference 
to a new era in the fight against infectious diseases based upon recent research in the 
understanding of human genetics and differences in individual gene patterns. The institute 
aims to open the door to new treatments and vaccines for infectious diseases. Its goal is to 
be a top international multidisciplinary research centre focusing on contemporary issues 
such as AIDS research and clinical and diagnostic care. In achieving this goal, intellectual 
property and commercial benefits will be secured to Western Australia. In 2011 there were 
two patents being developed in the international phase (Murdoch University 2011).  
 
Another Australian example of academic-industry collaboration is the University of 
Queensland (UQ) and CSL Ltd (Uniquest). UQ collaborates with Uniquest Pty Ltd, a 
company that manages the university’s commercial interests such as the sale of products 
that are based upon UQ technology. According to Uniquest, innovations that it has licensed 
have sales of $3 billion per year, putting it in the top 10% of universities worldwide for 
technology transfer (Uniquest). This partnership is described further in chapter 9.  
 
6.5 The Global Regulation of Vaccines 
In the era of globalisation many pharmaceutical products such as medicines and vaccines 
are no longer being produced and regulated in the countries in which they are used. As a 
result there is now a vast international network of production and distribution. However, 
the industry has expanded rapidly and the distribution problems are resulting in sub-
standard vaccines. The increased demand has resulted in criminal, false products in some 
cases (Garrett 2012b). There is concern that the regulatory processes are not keeping up 
with changes in the industry and it is alleged that organised crime is increasingly involved 
in the production of medicines. Regulators are over-whelmed or non-existent in many 
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countries. The WHO does not have the legal framework to effectively address these 
problems so the Council on Foreign Relations (CFR) is looking to the G8 and G20 
countries for solutions (Garrett CFR 2012).  
Government regulators of drugs/vaccines for many countries are funded by the industry 
whose products they approve (Goldacre 2012 p128). This includes the European Medicines 
Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) (UK 
regulatory board), the US Food and Drug Administration (FDA) and the Australian 
Therapeutic Goods Administration (TGA). The situation where government regulators 
promote the interests of the industries they monitor instead of the public interest is 
described by sociologists as ‘regulatory capture’. This is now a global practice even when 
regulatory boards state ‘members of the Management Board shall not have financial or 
other interests in the pharmaceutical industry which could affect their impartiality’ 
(Goldacre 2012 p126). Despite this requirement many of the representatives on EMA 
boards come from pharmaceutically funded companies, including on their management 
board. It is observed that regulatory decisions in the US FDA have been influenced by 
political pressure because of this practice. The FDA has even been described as an ‘agent of 
industry’ to the US Senate Committee on Finance (Goldacre 2012 pp127-8). Dr. Lucija 
Tomljenovic, at the University of British Columbia’s Neural Dynamics Research Group in 
the Department of Ophthalmology and Visual Sciences, has been quoted as saying ‘vaccine 
manufacturers, pharmaceutical companies and health authorities have known about 
multiple dangers associated with vaccines but chose to withhold them from the public. This 
is scientific fraud and their complicity suggests that this practice continues to this day’ 
(Enghahl 2015).  
6.6 Conflicts of Interest in the Regulation of Vaccines in Australia   
The information provided in this section regarding the Australian Therapeutic Goods 
Administration (TGA) has been largely sourced from the Australian government’s website 
and a WHO review of the functioning of advisory boards for vaccines funded by the Bill 
and Melinda Gates Foundation. 
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The Therapeutic Goods Administration (TGA) was established in 1989 and it is the 
Australian government regulator of therapeutic goods such as medicines, vaccines and 
blood products. This board, like the vaccine regulatory bodies in governments globally, is 
conflicted by being 100% funded by the industry whose products it monitors (AG RWAR 
2010 p10). This funding system is known as Cost Recovery (or User-Pay) and it means that 
the TGA recovers the full cost of its regulatory activities by charging the sponsors and 
manufacturers of the products that are regulated. The pharmaceutical and manufacturing 
industry funds the TGA even though this government board has the dual role of approving 
drugs for its sponsor and monitoring the safety of these same drugs in the Australian 
population (AG TGA 2012). In order to effectively regulate in the public interest the TGA 
would need to be independent from industry funding. Regulations that provide incentives 
for producing profit and not health in government policies, compromise all participants in 
health promotion – doctors, researchers and policy advisors. These regulations encourage 
individuals – even those with integrity - to participate in decisions that cause significant 
harm to patients and the community (Goldacre 2012 pxi).  
The activities of the TGA in the cost-recovery program include: 
• Registration and approval of drugs/vaccines 
• Issuing exclusive rights, licenses and privileges 
• Monitoring ongoing compliance with regulations  
• Monitoring ongoing safety of the products 
• Investigation and enforcement of regulations 
At present the processes of the TGA are not transparent to the public and funding 
arrangements for this government body illustrates that pharmaceutical companies are 
influencing the approval and monitoring of drugs/vaccines in the population. In addition, 
consumers whose health is invested in these policies are not properly represented in the 
decision-making processes of the TGA or on vaccine advisory boards for public health 
policy. The fact that the TGA is funded by the pharmaceutical companies and 
manufacturers of medical devices creates an incentive for bias towards industry interests. 
Funding arrangements and COI for committees that control the health of the population 
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should be transparent to the public. The TGA justifies the COI in funding arrangements and 
policy decisions by suggesting that ‘it requires commercial companies that apply for 
marketing approval to pay for the cost of the review of the application on a cost recovery 
basis’ (AG RWAR p10). But this arrangement does not explain why the TGA has the 
responsibility for monitoring the safety of these products in the population when their 
procedures can be influenced by the industry that manufactures the product and sponsors 
the TGA. A regulatory body, to protect the public interest, needs to be independent of 
commercial interests (Gessner et al 2010 A4). The current funding situation for the TGA 
does not provide incentive to implement an effective monitoring system for vaccines 
because the TGA is monitoring the very drugs it has approved for its sponsors for 
commercial gain. Whilst the TGA states that it rigorously enforces conflict of interest 
requirements there is no evidence of this and up to 2015 the conflicts of interest of 
members of vaccine advisory boards have not been disclosed to the Australian public. The 
clinical trials used by government regulators to approve drugs are being funded by industry 
and performed by researchers who are voting members on vaccine advisory boards for the 
Australian government (Nolan et al 2010).  
The Influenza Specialist Group (ISG) that provides advice on influenza policy in Australia 
is also fully funded by industry (Sweet 2011). The ISG justifies this situation by claiming 
that ‘they (the ISG) are helping promote public health messages, not pushing specific 
brands of vaccine’ (Finch and Burson-Marsteller in Sweet 2011). However, this does not 
justify the position of the ISG because the committee makes decisions affecting the 
financial interests of industry, specifically whether a vaccine is used as a preventative 
strategy against influenza: a multi-million dollar decision. The consequences of this 
decision make a significant difference to the profits of vaccine manufacturers. Therefore, it 
is essential that this public health decision is determined independently of the 
manufacturers. Whilst the existence of a conflict of interest does not automatically lead to  
bias it is important they are made transparent to the public if they are allowed to exist in the 
decision-making process. This allows consumers to judge the value of the information they 
are receiving, particularly when decisions are made that are contrary to the evidence. If 
boards are not truly independent of commercial interests the health information can 
potentially be influenced by these interests and COI need to be transparent to the public. 
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Value judgments made in political decisions can have serious implications for public 
health. In 2008 at least two members of the ISG believed that the advice given by the ISG 
regarding influenza policy was questionable. Associate Professor Michael Whitby, an 
infectious disease physician, decided not to be actively involved on the ISG committee 
because: 
‘He was concerned about the organization promoting influenza vaccination for indications 
not supported by national guidelines, especially the promotion of vaccination of children’ 
(Sweet 2011).  
Professor Peter Collignon and colleagues expressed similar sentiments in an article that was 
published in the British Medical Journal (Collignon et al 2010). Collignon has also been 
quoted saying ‘The TGA made that decision (about risk-benefit to children) without any 
evidence to back it up’ (Corduroy 2010). At this time there were members of the ISG that 
had financial COI that had not been disclosed to the public. One member of the Influenza 
Specialist Group (ISG) had been the previous Research and Development Manager at 
Commonwealth Serum Laboratories (CSL), Australia’s only flu vaccine manufacturer 
(Dean 2009). Another member had shares in CSL and was in charge of the WHO influenza 
laboratory in Melbourne at the time the ‘Swine Flu’ pandemic unfolded (Bita 2011). The 
Australian government states that committee members are required to declare any conflict 
of interest and this is ‘taken into consideration at meetings’ (Bita 2010). If these conflicts of 
interest are unavoidable then it is important that they are made transparent to the public 
because it is known that financial connections can affect policy decisions. This information 
is needed by the public to make informed decisions about their health otherwise they are 
left to trust that government decisions are in the public’s best interest. Some public health 
experts have called for an independent body to monitor drug safety because it is clear that 
self-regulation of the industry is not in the public interest (Stokes 2010; Baxter 2010; 
Moore in Corderoy 2010).  
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6.7 Conflicts of Interest in Government Vaccine Advisory Groups  
(ATAGI) 
A sustainable vaccination program recommending many new vaccines, most of them free, 
cannot be provided to Australians without an effective funding mechanism. The cost of 
Australia’s vaccination program by 2008-2009 was well above $AU400 million (Nolan 
2010 A76). During 1990-1997 the recommendations for the funding of vaccines in 
Australia were made by a sub-committee of the NHMRC. This committee was also 
responsible for developing the Australian Immunisation Handbook: a government 
document outlining national clinical guidelines for all health professionals. The governance 
of this sub-committee was brought under government control in 1997 when it was moved 
into the Department of Health and Ageing (DHA). At this time the board was re-named the 
Australian Technical Advisory Group on Immunisation (ATAGI) and its main roles were to 
provide confidential advice to the Health Minister and to develop guidelines for health 
professionals in the Australian Immunisation Handbook (Nolan 2010 A76-77). In 
producing the guidelines for health professionals in Australia, ATAGI is required to adhere 
to the NHMRC’s guidelines for the levels of evidence and ethical behaviour in healthcare 
and medical research.  
ATAGI is an example of the many National Immunisation Technical Advisory Groups 
(NITAG) that have been set up with the assistance of WHO, in member countries, to 
develop government vaccination programs founded on WHO recommendations (Bryson et 
al 2010 A13). See chapter 3. These boards provide information for the government to make 
decisions regarding recommendations on vaccination schedules and the implementation of 
new vaccines.  They also provide advice on research priorities, vaccine formulations, high-
risk groups and the implications of adverse events (Gessner et al 2010 A2). Representatives 
on ATAGI include medical and public health practitioners, technical experts, ex-officio 
members (government bodies e.g. NCIRS, OHP, TGA, NIC, CDNA) and one consumer 
representative (AG IAP 2012).  In fact, WHO has stated that the inclusion of a civil/public 
representative is optional and only ‘if needed’ (WHO ITAG 2008 p5). This contradicts the 
statement that these boards are ‘independent’ and representative of all stakeholder interests. 
Australian government vaccination policies are developed on the advice provided by these 
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expert technical advisors who are selected to ATAGI by the Health Minister through an 
informal nomination process (Nolan 2010 A79). Given that vaccine advisory boards 
include experts associated with industry, the boards should also include representatives of 
the public. This is because the public is the stated beneficiary of public health policies: the 
major stakeholder. If a major stakeholder is not properly represented in policy development 
then their perspective of risk can be minimised in policy decisions. In this way, a one-sided 
consensus can be achieved when there is insufficient dissent to oppose the dominant 
interests on the advisory board. A stakeholder’s perspective can be further side-lined if they 
are not properly represented in the media, in the political domain or involved in public 
debates on the topic. A lack of balance in the media removes the stakeholder’s voice from 
the debate and synchronises with a lack of political power. When there is only one 
representative of a stakeholder on the advisory panel I believe it is also possible to choose a 
representative who is in agreement with the desired perspective and/or influence their 
opinion by ensuring they gain financially from their participation. It is possible for policy 
decisions to be founded on biased or ‘selected’ information when specific political 
structures such as COI exist. See chapter 8.  
In Australia members of ATAGI hold their positions for many years. The term is set for 4 
years but can be extended at the Minister’s discretion (Nolan 2010 A79). For example, 
Terry Nolan was the chair of ATAGI for 9 years from 2005-2014, Peter McIntyre (2004-
2015) and Robert Booy (2005-2015), co-directors of the National Centre for Immunisation 
Research and Surveillance (NCIRS),  have been members/ex officio members of ATAGI 
during this time (AG NCIRSn). Conflicts of interest are a concern on the ATAGI board 
because the decisions made have significant implications for vaccine sales for 
pharmaceutical companies. It is stipulated that committee members of ATAGI must be 
independent of pharmaceutical industry influence (Gessner et al 2010 A3) and the 
Australian regulations state that a detailed agenda is sent to each representative before each 
meeting to update relevant COI (Nolan 2010 A79). However, declaring a COI does not 
remove it and it is the public that needs to be informed of these relationships to protect their 
interests in these policies. COI on the ATAGI board were not publicised prior to 2015. The 
COI policy for ATAGI members has variable consequences that are determined by the 
chair of ATAGI in consultation with the chair of the PBAC and other government members 
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(Nolan 2010 A79). Depending on the level of COI, members can participate and vote, 
participate and not vote, attend meetings but not contribute or be prevented from attending 
meetings altogether (Gessner et al 2010 A3). The chair’s own COI and decisions about the 
consequences of COI are not transparent to the public. It is stated that in general ‘personal 
remuneration of other forms of direct or indirect financial or other benefits for marketing or 
promotional activities are inconsistent with ATAGI membership’ (Nolan 2010 A79). Over 
the last decade, 2005-20014 many ATAGI representatives had COI with vaccine 
manufacturers that were not revealed to the public. During this time many new vaccines 
were added to the recommended schedule of vaccines that are paid for by the government 
and provided free to the community.  
The chair of ATAGI from 2005-2014 was also the deputy chair of the research committee 
of the National Health and Medical Research Council (NHMRC): the committee that 
allocates funding for research projects (DHA 2012). Nolan states that involvement in 
industry-sponsored vaccine research is generally not considered a conflict of interest that 
requires exclusion if the payment is made to the institution and not the individual (2010 
A79). However, industry grants for vaccine trials are not provided to institutions to allocate 
to projects of their choice. They are usually provided to specific researchers for specific 
vaccine trials. Over the last decade many members of ATAGI, including the chair and co-
directors of NCIRS, have been chief investigators on vaccine trials that are funded by 
GlaxoSmithKline, Merck, Pfizor, Novartis, Sanofi, BioCSL, Baxter, Wyeth, Merck, 
Janssen &Janssen (Crucell) (AG ATAGI 2015; Nolan et al 2010). Many members have 
also been representatives of vaccine advisory boards at some time and received individual 
payments (honoraria) from vaccine manufacturers for their attendance at conferences 
(Nolan et al 2010). In addition, there is no funding provided by the NHMRC for vaccine 
clinical trials or research that is independent of vaccine manufacturers. 
 
NITAG’s, such as ATAGI, are described as consisting of independent experts with the 
technical capacity to evaluate new and existing immunisation interventions. The premise of 
these groups is to provide a systematic, transparent process for developing immunisation 
policies by making ‘evidence-based technical recommendations’ to the national 
government (WHO ITAG 2008). Their role is described as being ‘technical’ and ‘advisory’ 
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and it is intended to bring ‘increased scientific rigour and credibility to the complex process 
of making immunisation policies, free of political or personal interests’ (Bryson et al 2010 
A13). Yet it is clear from the governance of Australia’s vaccination policy that vaccine 
advisory boards such as ATAGI are not using a systematic framework of assessment or 
evidence from the local community and they are not independent from vaccine 
manufacturers, government influence or transparent in their processes and assumptions. See 
chapter 4. Bryson et al state that the credibility of NITAG’s relies on ‘true independence 
from the government’ (2010 A16) yet ATAGI is heavily influenced by government 
representatives from NCIRS, NIC, PBAC, OHP.    
 
There is global concern about the significant influence of government in NITAG 
committees and the lack of independence from political interference (Gessner et al 2010 
A4). Gessner et al (2010 A4) state that scientific information from pharmaceutical 
companies should be presented through documents or via telephone and not through 
industry representation and participation in NITAG meetings. This is particularly the case 
as the public is not invited to attend these meetings or to present information to the 
committee. The US Government justifies the use of expert panels by claiming it cannot 
assemble, from its own staff, the expert knowledge necessary to address the diversity of 
technical issues under the government’s responsibility (Krimsky 2003 p92). Hence the 
government suggests that it is broadening the knowledge base that is used in the decision-
making process by using external expert advice. A government report even stated 
‘Advisory committees continue to represent part of federal efforts to increase public 
participation’ (US Government Report in Krimsky 2003 p92). For decades university staff 
and academics have been encouraged to work with industry in equity arrangements. 
Therefore regulations prohibiting experts with COI from participating in policy decisions 
would remove many well qualified people from the assessment process and it would also 
be hard to find experts without COI. Hence this regulation is difficult to enforce (Goldacre 
2012 p128). This indicates that the solution lies in having a decision-making board that has 
transparent COI and has proper public representation and scrutiny, without financial ties to 
industry or government influence.    
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6.8 The Approval Process and Funding for Vaccines 
 
 ATAGI consults with other government advisory boards and it provides advice to the 
government’s pharmaceutical benefits scheme (PBS) on the strength of evidence for the 
funding of new vaccines. One member of ATAGI doubles as a member of the 
pharmaceutical benefits advisory committee (PBAC) (Nolan 2010 A79). The government 
funded National Centre for Immunisation Research and Surveillance (NCIRS) also plays a 
significant role in the advice provided by ATAGI and in setting up working parties. (Nolan 
2010 A79).  See Appendix 4. Recommendations for the funding of vaccines made by the 
PBAC to the health minister are based on the manufacturer’s submission and ATAGI/ 
NCIRS advice.  Whilst pharmaceutical companies do not have formal representation or 
voting rights on the NITAG committees, industry representatives are allowed to attend 
meetings and provide information yet in Australia these meetings are not open to the public 
to attend or to present information (Gessner et al 2010). There is no transparency in who 
has been allowed to provide ‘factual’ information or to participate in decisions at ATAGI 
meetings.   
ATAGI does not use a systematic process for collating and assessing data for the decision-
making process. Some criteria used in making recommendations include the mortality and 
disability data attributed to the disease but not always local mortality or disability data. 
Other data that is used is disability-adjusted life years lost (DALY), hospitalizations, 
epidemic potential and the potential for disease eradication. Local data is relevant for all 
infectious diseases and also for the outcomes for vaccines in different populations but this 
is not always used in the economic modeling for new vaccines in many countries (Gessner 
et al 2010 A3). Decisions regarding the inclusion of a new vaccine on the Australian NIP 
are determined by an ATAGI sub-committee ahead of the licensure of the vaccine. Nolan 
states that considerations for the suitability of a new vaccine include the implications for 
herd immunity but this (herd immunity) is ‘neither necessary nor sufficient for a positive 
recommendation for NIP suitability’ (Nolan 2010 A79). This is of note because the 
government is using claims about vaccine-created herd immunity to justify its use of 
coercion to promote vaccination.  
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 Data that is used to develop recommendations is sourced from WHO documents, journals, 
other NITAC’s and regional/ local sources. The final decisions made by NITAG 
committee’s for national programs are often influenced by WHO recommendations. Most 
committees adopt all of the WHO recommendations and some adopt them with 
modifications to local priorities. Whilst the recommendations made by the committee are 
only advisory and not legally binding, Australian health ministers depend upon ATAGI 
advice. Nolan (2010 A81) stated that the assumptions and economic principles 
underpinning the recommendation process were still being debated but that they were 
widely accepted by industry and healthcare professionals. There is no mention that they 
have been examined or accepted by consumers. All ATAGI working parties are chaired by 
an ATAGI member and supported by one or more scientific officers from the NCIRS who 
are responsible for writing the report (Nolan 2010 A82). Nolan states that the policy branch 
of the NCIRS is critical to the quality of the advice provided to the government and health 
professionals.  
Since 2005 funding applications for new vaccines have been addressed by a sub-committee 
of the PBAC, not by ATAGI (Nolan 2010 A79). The methodology for determining the 
cost-effectiveness and funding for vaccines is based on price per disability-adjusted life 
year (DALY) saved (Nolan 2010 A78). The cost-effectiveness of vaccines is determined by 
examining the evidence of the benefit of the vaccine from large clinical trials. This can then 
be used to estimate the cost of saving one quality-adjusted life year (QALY) which 
translates to the number of doses that need to be given at the vaccine cost to gain one extra 
year of full quality life (McIntyre 2012). This economic modeling, which relies on many 
non-transparent assumptions about the effectiveness and safety of vaccines, has resulted in 
the recommendation of many new vaccines into the Australian population since the 1990’s. 
Unlike the UK there are no specific cost-effectiveness cut-offs for making 
recommendations for vaccines in the Australian NIP (Gessner et al 2010 A3). It is also of 
note that the price of vaccines funded by the Australian government is not made available 
to the public even on request (AG DHA 2013).  
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The recommendations for vaccine funding are included in the PBAC framework for all 
drugs marketed in Australia. The PBAC receives submissions mostly from pharmaceutical 
companies on the cost-effectiveness of new vaccines/drugs. Vaccine sponsors may request 
that a vaccine be recommended on the NIP, and subsidized by the government, or listed on 
the PBS where a co-payment is required from consumers (Nolan 2010 A82). The general 
criteria for vaccines to be recommended on the NIP are defined in the Vaccine Appendix of 
the PBAC submission framework which has been developed with significant influence 
from the Medicines Australia Vaccine Industry Group (MAVIG), a sub-committee of 
Medicines Australia that represents the pharmaceutical companies. Whilst the ATAGI 
recommendations are founded on input received from many different professional, industry 
and government groups, the general public does not actively participate in ATAGI 
discussions and ATAGI does not conduct open forums for debate (Nolan 2010 A82). In 
addition, the unabridged ATAGI working party reports on vaccine recommendations are 
not made public. This is stated to be because they contain unpublished clinical trials that 
have restrictions on releasing the data. If this is the case it also means that the material has 
not been peer-reviewed by independent scientists and its integrity is questionable. Public 
health is at risk if the scientific data cannot be viewed and debated by all stakeholders 
before new vaccines/drugs are approved in government public health policies. The 
existence of COI on decision-making boards and the use of non-transparent science 
facilitate policies that can be developed on selective science of questionable integrity 
chosen by the dominant network of scientists. See chapter 8.  
6.9 Conclusion                                                                                                                                                                             
In the 21st century universities and research institutions are operating in partnerships with 
industry and directing research into profitable technology. Universities receive large 
amounts of money from industry that are not transparent to the public. COI are ubiquitous 
in financial relationships involving researchers in university faculties. Consequently 
industry has unprecedented influence over the type of research that is performed and the 
outcomes achieved. COI also exist in relationships involving the medical profession, media 
and government. These relationships play a significant role in the way drugs/vaccines are 
promoted to the community. When industry funds the research it leads to less public 
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interest science being investigated because it might not serve industry interests. This is 
termed ‘undone science’ and the political framework for this practice is described in 
chapter 8. Vaccines/drugs are being approved for the market without properly designed 
clinical trials. The side-effects of drugs are being down-played to doctors and consumers 
and the benefits are over-emphasised. Many peer-review journals now depend upon 
industry funding for their profits and this increases the publication bias towards positive 
trial results and the suppression of negative results. Pharmaceutical companies are also 
sponsoring lobby groups that appear to be advocating for consumer interests but in fact are 
fronts for drug companies. This influence synchronises with pharmaceutical marketing to 
doctors which is presented as ‘education’ and the media promotion of vaccines influenced 
by corporations. Consequently there is a systematic bias towards industry interests in 
medical research and public health policy and promotion. 
A lack of acknowledgment by governments of an important area of research is easier to 
maintain if the stakeholder whose interests are affected is removed from the political 
decision-making process. This is observed in the development of Australia’s vaccination 
policies as the community is not consulted or encouraged to participate in public debate on 
vaccination and there is only one consumer representative on the government vaccine 
advisory committee (ATAGI). In addition, pharmaceutical representatives can be invited to 
ATAGI committee meetings to provide information but these meetings are not open to the 
public and the information is not available for public scrutiny before vaccines are approved. 
A lack of political power and financial support also has the effect of reducing the consumer 
voice in the mainstream media. These factors are synchronising to remove an independent 
consumer perspective from the risk assessment process of policy development. They are 
also resulting in non-transparent policy decisions being made by ATAGI/NCIRS members 
in an unsystematic assessment of the risks.  
The lack of independent regulation of the global vaccine market is resulting in sub-standard 
vaccines. Vaccines are a global production and they can be automatically approved in many 
countries based on clinical trials that were performed in another country. Manufacturers in 
the US have less incentive to develop safe and effective vaccines because they are exempt 
from liability when harm is caused. This legislation ensures that there is a stable vaccine 
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market but it does not provide incentives to protect the health of the population. 
Government regulators in most countries are 100% funded by industry under a Cost-
Recovery (User-Pay) system. This means they approve their sponsor’s vaccines/drugs for 
the market and monitor these same products for safety and efficacy. In effect they are 
indirectly monitoring their own products. Large political donations from pharmaceutical 
companies are also being allowed to influence government policy. Funded lobby groups are 
targeting policy decision-makers, medical practitioners, educational boards and mainstream 
media with selective information. Vaccine advisory boards are rife with conflicts of 
interest, enabling industry to influence the direction of government funding in health policy 
research and policy decision-making. National vaccine advisory committees such as 
ATAGI have been established in many WHO member countries and they receive advice 
and financial support from the WHO in the development of national vaccination programs. 
Recommendations for new vaccines are not always founded on local data and cost-
effectiveness is being determined using economic models that rely on non-transparent 
assumptions about the safety and efficacy of vaccines. Although the importance of vaccine-
created herd immunity is used to promote vaccines to the community, the chairman of 
ATAGI for the last decade states that the implications for herd immunity for new vaccines 
are ‘neither necessary nor sufficient for a positive recommendation for NIP suitability’ 
(Nolan 2010 A79). This indicates that vaccines are being promoted to the community on a 
false premise that has serious implications for population health. Further, the cost-
effectiveness of vaccines is being determined on evidence produced in clinical trials that 
are funded by pharmaceutical companies and carried out by researchers/chief investigators 
who are representatives on government vaccine advisory boards such as ATAGI and the 
NCIRS.  
This arrangement is very profitable for universities, governments, researchers and 
representatives on vaccine advisory boards but it is extremely costly to public taxpayers 
and to population health. In 2008-2009 the cost of providing vaccines ‘free’ to Australians 
was well above $AU400 million (Nolan 2010 A76). However, the actual cost of these 
programs is unknown because the figures are not released to the public (even when 
requested) and they do not include the cost to the community of the deaths and disability 
that are a known side-effect of vaccines. This cost to the community is unknown because 
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the TGA has not established an active surveillance system that can make causal 
relationships to vaccines. A regulator that is 100% funded by industry has no incentive to 
accurately monitor the adverse events from its own products. This demonstrates the need 
for vaccination policies to be independent from commercial and political interference in 
order to protect public health. In Australia policy decisions for vaccination programs are 
based on research (often unpublished) that is performed by government representatives on 
vaccine advisory boards who receive honoraria and funding for their clinical trials from 
pharmaceutical companies. The findings from such research are being used in policy 
decisions for vaccination programs without public scrutiny or assessment by independent 
researchers. 
In chapter 7 I discuss the evidence the Australian government is providing to the public to 
support the claims about vaccine safety and efficacy. Chapter 8 presents a description of 
undone science and the political framework that leads to a lack of integrity and rigour in 
medical science. Chapters 9 and 10 are case studies of the HPV vaccine and ‘Swine Flu’ 
2009 vaccine, showing the influence of corporations in the development of global 
vaccination policies. Chapter 11 presents the conclusions for this investigation. 
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CHAPTER 7  
THE EVIDENCE UNDERPINNING CLAIMS ABOUT VACCINES 
7.1 Introduction  
The aim of this thesis is to assess the rigour of the claims supporting the efficacy, safety 
and necessity for the use of an expanding number of vaccines in the Australian 
Government’s National Immunisation Program (NIP). I have provided here an examination 
of the key claims that the Australian government has presented to the public to support 
current vaccination policies. The information provided to the public discusses vaccines in a 
general non-specific way yet it is necessary to examine the scientific evidence for each 
vaccine separately to determine its safety and effectiveness in protecting community health. 
This is because there are many variables that influence pathogenesis that are specific to 
each disease agent. The risk/benefit equation for each vaccine varies according to the 
ecological context of the infectious agent and the interaction of multiple variables in 
pathogenesis. This has been described in chapter 2. This chapter investigates whether the 
government promotes vaccines to the public in an ecological context recognizing the 
variables that contribute to the ‘risk’ of disease to different individuals (due to environment 
and genetic differences) or in a general way implying that all vaccines are safe, effective 
and necessary in the prevention of infectious diseases.  
In particular, this chapter provides an assessment of key information that is provided to the 
public to support vaccination policies. I have assessed the Australian government’s claims 
made in the Frequently Asked Questions (FAQ) on the Immunise Australia Program (IAP) 
website (See Appendix 6) and in the Australian Academy of Science’s 2012 document The 
Science of Immunisation: Questions and Answers.  
My critical analysis of the claims made by the government includes: 
1. Exposing misleading statements (such as equating vaccination and immunisation) 
and /or 
2. Illustrating where the government has not provided (here or elsewhere) evidence to 
back up its statements, or where there is contrary evidence and/or 
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3. Illustrating where research has not been done to support the conclusions and/or 
4. Illustrating undeclared or unsupported value judgments embedded in or associated 
with statements. 
7.2 Terminology: Vaccination, Immunisation and Vaccine-Preventable 
Diseases: 
On the IAP website the government has used the word immunisation to answer public 
concerns although the correct term is vaccination. I have explained the meaning of these 
terms here and I will use the correct term ‘vaccination’ for this discussion. This is 
significant to the vaccination debate because receiving a vaccine does not always provide 
immunity and using the word ‘immunisation’ implies that immunity has been achieved. 
Similarly I have explained why the term vaccine-preventable disease is also a misleading 
term.  
Vaccination is a medical intervention that injects weakened pathogens (antigens) and 
chemical substances into the tissues of healthy individuals to stimulate the production of 
antibodies (Stern and Markel, 2005). This is different from immunisation which is the 
process of obtaining immunity from the artificial stimulation of antibodies against an 
antigen (Martin 2002). These two words are often used interchangeably by members of the 
public and on the government Immunise Australia Program (IAP) website although they 
have very different meanings and it is misleading to use them interchangeably. Individuals 
can obtain immunity to a disease by either natural exposure to the pathogen or by receiving 
a vaccine. Sometimes individuals are vaccinated but do not obtain immunity to the disease 
(AG IAP 2012). This can be a result of the vaccine not working or because an individual is 
exposed to a strain of the disease that is not covered by the vaccine. Conversely individuals 
can have immunity to a disease without being vaccinated. This is because exposure to the 
infectious agent can result in natural immunity which is usually of longer duration (often 
life-long) than that gained from a vaccine, as in the cases of whooping cough, hepatitis B 
and measles (AG IAP 2012).  
The government defines vaccination and immunization on the Immunise Australia Program 
(IAP) website. It states:  
	  
	  
166	  
• Vaccination means having a vaccine - that is actually getting the injection.  
• Immunisation means both receiving a vaccine and becoming immune to a 
disease, as a result of being vaccinated.  
Most people use the terms 'vaccination' and 'immunisation' interchangeably but their 
meanings are not exactly the same. The term 'immunisation' is used in this website, as it 
is most commonly used in the community (AG IAP FAQ 2012).  
The government is misusing the word immunisation and misleading the public in the 
benefits gained from using vaccines. The information discussed on the government website 
refers only to the physical act of receiving a vaccine therefore the correct word for the 
government to use is vaccination. The government’s language incorrectly implies that all 
individuals who get vaccinated have gained immunity. This is known to be a false 
assumption; some vaccinated individuals do not gain immunity so the correct term to use 
for the act of receiving a vaccine is vaccination. In addition, the US Centers for Disease 
Control and Prevention (CDC) and governments globally are now referring to common 
infectious diseases as vaccine-preventable diseases (CDC 2012). Again this terminology 
suggests that vaccines create immunity in all individuals and that vaccines can prevent 
infectious diseases. Infectious diseases can only be described as ‘vaccine-preventable’ if it 
is demonstrated that protection from disease is a direct response to the use of the vaccine. 
Epidemics of some diseases are still occurring in areas where vaccines have been used for 
many years (WHO CSDH 2005 p19) and it is known that a percentage of recipients do not 
gain immunity after vaccination. Therefore it is necessary to establish that any protection 
from disease is a direct result of the use of vaccines before these diseases are labeled as 
‘vaccine-preventable diseases’. This empirical scientific evidence can only be provided 
from correctly designed randomized controlled clinical trials of vaccinated and 
unvaccinated participants. These trials control the variables involved in disease prevention 
and therefore offer definitive conclusions about the best method of prevention.  
The Swedish government regulator for medicinal products, the Medical Products Agency 
(MPA), states that many conventional vaccines that have a long history of use have never 
been tested in formal controlled clinical trials to demonstrate their efficacy in preventing 
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disease (MPA 2007 p5). The Agency states that whilst there are no formal controlled 
clinical trials demonstrating efficacy in preventing disease ‘there is a well demonstrated 
relationship between human serum antibody titre and protection against infection’ (MPA 
2007 p4). In other words, it is common practice to trial vaccines for efficacy using the 
surrogate of seroconversion. This end-point is the level of antibody titre in the blood that is 
believed to be necessary to protect the individual from disease (AG IAP 2012). Whilst 
antibody titre is used as a surrogate for disease protection, proof that ‘vaccine induced’ 
seroconversion protects against disease still requires evidence from randomized controlled 
clinical trials to demonstrate that the artificially induced level of antibody titre is protective 
against disease and that it was produced by the vaccine. Antibody seroconversion is also 
achieved by natural infection – with or without clinical symptoms. That is, asymptomatic 
infections (or sub-clinical infections) also produce seroconversion and immunity to disease. 
See Chapter 4. Proof that ‘vaccine-induced’ seroconversion results in immunity to disease 
has not been demonstrated in controlled clinical trials presented by the Australian 
government on the IAP website, the Australian Academy of Science in the Science of 
Immunisation document or the MPA in the discussion of vaccine efficacy in the Public 
Assessment Report for Afluria (MPA 2007).  
The public is expected to accept that vaccine-induced seroconversion is responsible (and 
necessary) for disease protection. Yet it is known that whilst there is a general correlation 
between antibody titre and disease protection, a high antibody titre does not always protect 
against disease and vice versa: individuals with a low antibody titre do not always get the 
disease (Ryan et al 1998; Granoff and Rappuoli 1997; Smith A 1999; CDC MMWR 2009). 
This fact is observed with respect to the whooping cough vaccine and it indicates that other 
factors play a role in immunity to disease. Therefore, without a controlled clinical trial 
between vaccinated and unvaccinated participants demonstrating protection against the 
disease, it is only an assumption that the person who doesn’t get sick was protected by the 
antibody titre induced by the vaccine. There is no empirical proof that the vaccine provided 
protection against the disease because there are other vaccinated children who still get the 
disease. It may have been the strength of the child’s immune system, natural exposure with 
a sub-clinical infection or lack of exposure to the wild virus that resulted in the absence of 
disease.  
	  
	  
168	  
When epidemics of a disease do not occur there are many factors that could play a role, 
including the vaccine, but without the qualifications noted above, the term ‘vaccine-
preventable disease’ is misleading. This term implies that vaccines can prevent infectious 
diseases but the fact that formal controlled clinical trials demonstrating that vaccines 
prevent infectious disease have not been done represents ‘undone science’ in this policy. 
Hospitalization statistics are another method that could be used to evaluate the effectiveness 
of vaccines in the population. Recording the vaccination status of individuals hospitalized 
with infectious diseases indicates whether the most serious cases of disease are vaccinated 
or unvaccinated. This data, collected in a transparent manner by an independent authority, 
could be used to promote vaccines to the public, yet it is not presented by the government 
on the IAP website or in the AAS supportive document.  
In the discussion below I have used the terms vaccination and immunisation according to 
their correct definitions. I have also used the term infectious disease instead of the 
government’s terminology of vaccine-preventable disease to provide clarity to the 
discussion.  
7.3 The Government’s Answers to FAQ on the IAP Website 
In the presentation of this discussion I will provide government statements in bold italics 
followed by a discussion of the claims. A complete list of the FAQ’s on the government 
website can be found in Appendix 6. 
Statement 1  
All forms of immunisation work in the same way. When a person is vaccinated, their 
body produces an immune response in the same way their body would after exposure to a 
disease, but without the person suffering symptoms of the disease. When a person comes 
in contact with that disease in the future, their immune system will respond fast enough 
to prevent the person developing the disease.  
Discussion: The scientific literature does not support the claim that all forms of 
immunisation work the same way. For example, artificial immunity produced by 
vaccination with inactivated agents is of shorter duration than that produced from natural 
infection (AAS 2012; AG IAP 2013; NCIRS Fact Sheet VC 2009). This shows that all 
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forms of immunization – artificial and natural - do not work in the same way. The 
attenuated, inactivated or genetically engineered pathogen in a vaccine is injected directly 
into the tissues of the body – as opposed to ingestion or respiration - along with many 
excipients in the vaccine carrier: preservatives, antibiotics, and adjuvant. Many of these 
excipients are not inert substances and this means they will have an unpredictable effect in 
the human body (Pifferi and Restani 2003; Shoenfeld and Agmon-Levin 2011; FDA). The 
body’s defense mechanisms are stimulated in a different way due to the fact that the 
vaccine is injected into the tissues as opposed to entering the body naturally via the 
respiratory or digestive systems. Absorption of substances is increased when they are 
injected into the blood vessels or the tissues as opposed to inhaled or digested (Gilbert 2004 
p26). There are also many other factors that come into play in the prevention of disease - 
host, environmental and agent characteristics – and this interaction of factors must be taken 
into account when predicting health outcomes (Burnet 1952 p107). Immunity is not just the 
production of antibodies stimulated by an infectious agent it is a reaction in the body that is 
produced by a number of integrated systems (Behrman et al 1998).  
The human body has many first-line defense mechanisms (non-specific defense) to prevent 
micro-organisms from entering the body (Friis and Sellers 2004 p403; AAS 2012). Whilst 
it is true to say that a newborn infant is regularly exposed to multiple pathogens in the first 
year of life they rarely pass the infant’s non-specific defense system. The route of entry 
plays a fundamental role to the health outcomes that result from exposure to toxins (Gilbert 
2004 p25). Outcomes are also affected by the duration and frequency of the exposure. If 
there is little absorption of the substance/agent then there will be little response. 
Metabolism and excretion can also have a modifying effect on the absorption of some 
substances (Gilbert 2004 p26). Other influential factors include gender, age and genetics 
which determine the rate at which a person metabolises substances. Some individuals are 
unable to metabolise substances at all due to their genetics or age. These factors apply to 
the expression of disease after exposure to an infectious agent and also to exposure to 
foreign antigens from the injection of vaccines. Mercury, an ingredient that was used in 
some vaccines for many years, is a good example of the differences between the effects 
from ingestion and injection of substances and this has been described in Appendix 4. 
When the body is exposed to a pathogen naturally the first line of defense is the skin and 
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the lining of the lungs (AAS 2012 p4; Friis and Sellers 2004 p403). Mucous, cilia, stomach 
acid, phagocytes and other white blood cells are the first line of defense against foreign 
particles (antigens). These tissues are referred to as the innate immune system; the white 
blood cells in these regions (guardian cells) have sensors that detect the antigens (AAS 
2012 p4). The guardian cells then activate lymphocytes to produce B-cells and T-cells. It is 
the B-cells that produce the antibodies that target specific antigens in a lock and key 
fashion to prevent infection (AAS 2012).  
In contrast, a vaccine is injected into the subcutaneous or intramuscular tissues with the 
excipients of the vaccine, including the foreign proteins and DNA of the altered pathogen 
and contaminants of the manufacturing process (Eldred 2006; NCIRS VC 2009). The 
animal-derived protein in the manufacturing process can be calf serum, monkey kidney 
tissue, chick or human diploid cells, all of which are similar in structure to human proteins 
(La Rosa 2002; Eldred 2006). Hence the antibodies that are produced in the vaccinated 
animal can cross-react with its own tissue proteins in a process similar to autoimmunity 
(Greville 1966; La Rosa 2002; Shoenfeld and Agmon-Levin 2011; Tomljenovic and Shaw 
2011). This demonstrates that all forms of immunisation do not ‘work in the same way’ as 
stated in the FAQ. Vaccination induces auto-antibodies in animal models (including lupus-
associated ones) and these are a known cause of autoimmune diseases (La Rosa 2002; 
Molina and Shoenfeld 2005; Shoenfeld and Agmon-Levin 2011; Tomljenovic and Shaw 
2011). The link between vaccines and the autoimmune response has been known for 
decades (Greville 1966). It has also been known that this response can occur weeks, months 
or years after exposure (Shoenfeld and Agmon-Levin 2011; Gilbert 2004 p.27; FDA 
Thimerosal). The immune system functions together with other body systems and 
interfering with one system can have unpredictable health outcomes. There is evidence that 
artificial immunity caused by vaccination causes accelerated autoimmunity and 
inflammation and many scientists consider that individuals with a family history of these 
diseases are genetically pre-disposed to these conditions after vaccination (NHMRC 1954–
1986; Obomsawin 1998; NCIRS VC 2009; Shoenfeld and Agmon-Levin 2011 p6).  
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Statement 2: 
The two main reasons provided by the government for vaccinating every child in Australia 
are:  
i. Immunisation is the safest and most effective way of giving protection against the 
disease. After immunisation, your child is far less likely to catch the disease if 
there are cases in the community. The benefit of protection against the disease far 
outweighs the very small risks of immunisation.  
ii. If enough people in the community are immunised, the infection can no longer be 
spread from person to person and the disease dies out altogether. This is how 
smallpox was eliminated from the world and polio has disappeared from many 
countries.  
Discussion: To conclusively support these claims further research needs to be done.  
I. The government states that after immunisation your child is far less likely to catch 
the disease. This statement is not correct because not all vaccinated individuals gain 
immunity. The correct word to use in this statement is vaccination and not 
immunization. Some individuals still get the diseases they are vaccinated against 
and the observation that artificial immunity is different to natural immunity (see 
statement 1 above) means that the claim cannot be sustained. Formal controlled 
clinical trials using an inert placebo to demonstrate efficacy in preventing disease 
have never been performed for most conventional vaccines (MPA 2007) to 
conclusively support the claim that ‘the benefits of immunity gained from vaccines 
far outweighs the very small risks of immunisation (vaccination)’.  
 
There are many factors and body functions that interact in health outcomes and a 
public health policy should not be justified using incorrect statements such as all 
types of immunisation (artificial and natural) work in the same way. In addition, 
vaccines have side-effects in some individuals and whilst the FAQ has described 
these risks as ‘very small’ the fact remains that the frequency and nature of side-
effects from vaccines are not fully known because government monitoring systems 
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are not designed to make causal links regarding the types and frequency of adverse 
events that occur after vaccination. The statement that the risks are ‘very small’ is a 
value judgment that is not supported with adequate scientific studies. In other 
words, this is an area of undone science.  
 
II. The statement that smallpox and polio were controlled by ‘immunisation’ (meaning 
‘vaccination’) is a simplistic description of the control of infectious diseases. 
Pathogenesis results from a complex interaction of many factors (see chapters 2 and 
4) that relate to the host, the agent and the environment. The eradication of smallpox 
was significantly influenced by the specific nature of the smallpox virus and public 
health reforms that occurred in the early 20th century (Wallace 1989; Curry 2002; 
Kleinman et al 2005; Disease Warriors 2005). A vaccine against smallpox was 
available for 150 years prior to its eradication in the mid-twentieth century. 
Kleinman et al (2005) ask why the disease took so long to be eradicated if the 
vaccine was effective (p312). One strategy that has been credited with assisting in 
the eradication is case tracing epidemiology (or the ‘ring strategy) (Disease 
Warriors 2005). This strategy involved identifying and isolating cases of the disease 
and it was successful because the smallpox virus is only communicable once the 
symptoms have appeared (Curry 2002; Kleinman et al 2005). This isolation of cases 
prevented transmission of the disease. Consequently only 50% of the global 
population was vaccinated. The fact that the disease is only transmissible after the 
symptoms appear was fundamental to the interruption of the life cycle of the virus 
and this factor combined with improvements in sanitation and hygiene enabled the 
disease to be eradicated 150 years after the vaccine was first used. Since smallpox 
has been eradicated scientists have raised serious questions about the safety and 
efficacy of smallpox vaccine which was never tested in randomized controlled 
clinical trials prior to its use in the 19th and 20th centuries (Wallace 1889 p217; 
Kleinman et al 2005). In 1889 Wallace commented on the numerous deaths and 
injuries caused by smallpox vaccine and described its use as ‘one of the scandals of 
the 19th century’ (p219). After a trial in US healthcare workers in 2003 it was 
established that the smallpox vaccine can cause neurological adverse events that 
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included meningitis, encephalitis, Bell palsy, seizures, Guillain-Barre syndrome and 
death. The documentation of these events in the smallpox vaccine trial on healthcare 
workers in 2003 resulted in an early end the trial (Schwenk 2006). 
 
There are many contextual issues surrounding the decline of infectious diseases that 
are significant to their ability to be eradicated. The variables that are involved in the 
incidence of an infectious disease include characteristics of the pathogen and host, 
environmental factors and any changes to case definitions or surveillance methods 
that occur at the same time as the incidence of disease declines. The government has 
not discussed any of these factors. Herd immunity was a concept that was first 
observed after communities were exposed naturally to infectious agents. For many 
infectious agents this can offer better community protection because exposures can 
be sub-clinical (asymptomatic) or mild and provide longer-lasting immunity than 
artificial immunity produced by vaccination. The theory of herd immunity is 
discussed in chapter 4.  
Statement 3 
Immunisation protects people against harmful infections before they come into contact 
with them in the community. Immunisation uses the body’s natural defense mechanism - 
the immune response - to build resistance to specific infections. Immunisation helps 
people stay healthy by preventing serious infections. 
Discussion: This statement is misleading because it is not true if the correct word, 
vaccination, is used. Vaccination does not always produce artificial immunity and it 
sometimes causes illness and disability (AG IAP 2013). Hence the use of the word 
‘immunisation’ in this statement is misleading. The statement assumes that immunity 
(without any harmful effects) will always be produced by vaccination. Statements about the 
lack of evidence for vaccine efficacy and safety are often listed on the package inserts or 
product information (PI) for vaccines. For example, the Commonwealth Serum 
Laboratory’s (CSL) package insert for influenza vaccine (Fluvax/Afluria), a vaccine that 
has been produced in Australia since the 1960’s, states: 
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‘There have been no controlled clinical studies demonstrating a decrease in influenza 
disease after vaccination with Fluvax/Afluria’ and ‘Vaccination with Fluvax/Afluria may 
not protect all individuals’ (CSL Fluvax PI 2007). 
Efficacy is defined by the US Congress Office of Technology Assessment (OTA) as ‘the 
probability of benefit to individuals in a defined population from a medical technology 
applied for a given medical problem under ideal conditions of use.’ Vaccine efficacy trials 
use the measure of seroconversion as a surrogate for vaccine efficacy in preventing disease 
in the population (Basch 1994 p69). In addition, the government does not publish 
independently assessed data of vaccinated and unvaccinated individuals (including 
socioeconomic status) who are hospitalized due to infectious diseases to promote vaccines 
to the public. Cases that are hospitalised are the more serious cases of disease and 
transparent data on vaccination status is needed to evaluate the influence of a vaccine in 
reducing the disease. This has not been presented by the Australian government on the IAP 
website to support current vaccination policies (AG IAP 2013).  
Statement 4 
Vaccines contain either:  
• a very small dose of a live, but weakened form of a virus;  
• a very small dose of killed bacteria or virus or small parts of bacteria; or  
• a small dose of a modified toxin produced by bacteria.  
Vaccines may also contain either a small amount of preservative or a small amount of an 
antibiotic to preserve the vaccine. Some vaccines may also contain a small amount of an 
aluminium salt which helps produce a better immune response. 
Discussion: This statement is misleading because it uses the word ‘small’ to imply that it 
would not cause significant harm and it does not list all the possible ingredients of the 
combined schedule of vaccines. The government has used qualitative descriptions of the 
amount of each ingredient and not actual ‘quantities’ with the known effects of these 
substances in humans. Yet it is known that ‘very small’ amounts of many toxic substances, 
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including antibiotics and preservatives, can have severe health effects in humans, 
particularly in children and infants (Gilbert 2004 p21). The Australian government even 
states in its framework for risk assessment for environmental health hazards that the health 
effects of low doses of many toxic substances have not yet been established (AG EHRA 
2013; Gilbert 2004 Preface). These effects are often synergized when injected into the body 
in combination with other chemical compounds (Gilbert 2004 p32). Yet this knowledge 
about the risks of vaccines is not provided in the government’s discussion about the 
ingredients of vaccines. The exact ingredients of vaccines are not provided to consumers on 
the IAP website. The government has listed ‘components of vaccines’ in Appendix 3 of its 
Immunisation Handbook (10th Ed) (DHA IH 2013). Most community members would not 
access this handbook for information and doctors are not required to provide it to patients.  
Statement 4 also omits to mention the serious adverse events that are known to be caused in 
some recipients by vaccines. These include allergies, hypersensitivity, anaphylaxis and 
autoimmune diseases that are discussed in the medical literature and in the product 
information sheets for vaccines (NCIRS VC 2009; NHMRC 1954-86; Obomsawin 1998; 
Tomljenovic and Shaw 2011; CSL PI Afluria /Fluvax 2007). These possible adverse events 
are often not discussed with doctors before vaccination and this is particularly the case now 
that vaccines are being administered in schools. A family history of these conditions was 
traditionally a contraindication to some vaccines (NCIRS VC 2009; NHMRC 1954-86; 
Obomsawin 1998) but these conditions were removed as a barrier to universal vaccination 
in school programs in the 1990’s (AG NHMRC 1991; Obomsawin 1998). The possible 
serious adverse events that are listed on the CSL package insert for the influenza vaccine, 
Fluvax (2007), include allergic reactions (including anaphylactic shock), neuralgia, 
thrombocytopenia, paresthesia, encephalopathy, neuritis (neuropathy), transverse mylitis 
and Guillain-Barre Syndrome (GBS), vasculitis, pruritus, urticaria, influenza-like illness, 
partial facial paralysis and brachial plexus neuropathy (CSL PI Afluria/Fluvax 2007). Yet 
neither these, nor adverse events from other vaccines are mentioned in the FAQ’s on the 
government’s website.  
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Statement 5  
Thimerosal (or thimerosal) is a compound used in small amounts to prevent bacterial 
and fungal contamination of vaccines. Thimerosal is partly composed of mercury in the 
form of ethyl mercury. Mercury causes a toxic effect after it reaches a certain level in the 
body. Whether or not it reaches a toxic level depends on the amount of mercury 
consumed and the person’s body weight. As a result of these concerns, in particular for 
newborn babies and very young children, thimerosal was removed or reduced from 
vaccines. 
Currently, all vaccines on the National Immunisation Program for children under 5 
years of age are now either thimerosal free or have only trace amounts of Thimerosal. It 
is not possible to completely remove thimerosal from all vaccines; some vaccines like 
Energix-B are still most effectively manufactured using a trace amount of thimerosal as 
a preservative. 
Discussion: This information is selective and it justifies the use of a toxic substance in 
infant vaccines whilst confirming that thimerosal is not demonstrated to be safe in infants.  
1. The statement does not provide evidence that any level of thimerosal in vaccines is 
safe; indeed it specifically states that mercury has toxic effects. It also downplays 
the significance of mercury in vaccines. Parents have a right to be fully informed 
about the ingredients of vaccines and thimerosal should be correctly defined to 
parents as a compound that is made up of 49% ethyl mercury which is a known 
neurotoxin (FDA Thimerosal).  
In the 60 years that vaccines have been used this knowledge has never been 
provided to parents before they gave consent for their children to be vaccinated. The 
government states that the toxicity of thimerosal ‘depends on the amount of 
mercury consumed and the person’s body weight’. It does not say what amount of 
mercury is safe. The safety of this ingredient will vary for each infant/child 
according to body weight and with the number of vaccines that are used. A safe 
level in humans has never been determined because establishing a safe level of a 
known neurotoxin in humans would be unethical (FDA Thimerosal). However the 
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government does not consider it unethical to use mercury compounds in infant 
vaccines without knowledge of its safety, and without the consent of parents. 
 
The Public Health Agency of Canada (2002) states ‘High dose, acute or chronic 
mercury exposure of children and adults can cause neuro- and 
nephrotoxicity…..there are limited data examining the effects of low-dose, 
intermittent mercury exposure in infants immunised with thimerosal-containing 
vaccines’.  
 
This statement was made after many thimerosal-containing vaccines had been used 
in infants for 60 years and particularly in the 1990’s when the number of 
thimerosal-containing vaccines increased significantly (AG IAP 2012; PHAC 
2002). There were over 20 vaccines that had been licensed that contained thimerosal 
in quantities ranging from 0.005%-0.01% (Varughese and Calver 1999 in PHAC 
2002). The amount of mercury is cumulative with each vaccine that is given. 
  
2. The US Food and Drug Administration (FDA Thimerosal) revealed in 1999 that the 
cumulative exposure of American infants (6 months of age) to ethylmercury from 
vaccines exceeded the recommended US Environmental Protection Agency (EPA) 
guidelines that were established for the closely related organic mercury compound 
methylmercury (AAP 1999 in PHAC 2002). It is also documented that exposing the 
feotus or infant in the first 6 months of life to organic mercury compounds poses a 
risk of neurological damage due to mercury toxicity (PHAC 2002). The symptoms 
of neurological damage due to mercury toxicity are similar to those of autism 
(Kirby 2005; PHAC 2002). A case study on mercurial toxicity and its links to 
autism has been discussed in Appendix 2.  
 
3. Energix-B is the hepatitis B vaccine given to babies at birth (day 1 – 7) (DHA IAP 
2013). It is a vaccine manufactured by GlaxoSmithKline (GSK) and the prescribing 
information states that the ‘pediatric formulation contains a trace amount of 
thimerosal (< 0.5 mcg mercury) from the manufacturing process’ (GSK 2005). This 
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trace amount of mercury is combined with aluminium hydroxide, sodium chloride 
and phosphate buffers in the Hepatitis B (Energix-B) vaccine and given to infants 
before their excretory systems and the blood brain barrier have developed. The 
government does not address these issues in the FAQ even though the scientific 
literature does not provide a consensus that it is safe to combine these substances in 
developing infants and adults. 
 
A study to investigate the health effects of using Hepatitis B vaccine in neonates 
(infants under 4 weeks of age) was carried out in 2010 on children born before 
1999. This was before thimerosal-free vaccines were available. The study reported 
that male neonates had a 3-fold increased risk for autism diagnosis than males never 
vaccinated or vaccinated after the first month of life. Non-white boys bore a greater 
risk than white neonates (Gallagher and Goodman 2010 p1671). Universal 
vaccination with hepatitis B vaccine was recommended to all neonates in the US in 
1991 and findings from studies regarding the safety of this vaccine have been 
mixed. Until 2000 this vaccine contained thimerosal and some studies have shown 
links between hepatitis B vaccine and autism, neurodevelopmental disorders, central 
nervous system inflammatory demyelination in childhood, liver problems, chronic 
arthritis and receipt of early education intervention services (Gallagher and 
Goodman 2010 pp1665-6). Yet the Institute of Medicine (IOM) stated in 2004 that 
there was no link between thimerosal-containing vaccines (TCV) and autism based 
on a selection of studies from countries that did not have recommendations for 
universal vaccination with hepatitis B vaccine for neonates (EUVAC.net, 2010 in 
Gallagher and Goodman 2010 pp1671). Some of the risk factors that have been 
identified for autism diagnosis include a family history of an autoimmune disorder, 
aberrant metabolic dysfunction, impaired methylation, early antibiotic use, genetic 
variants among subjects of European ancestors, porphyrin biomarkers of metal 
inhibition of the heme synthesis pathway and jaundice (Gallagher and Goodman 
2010 pp1672).  
Statement 6 
Another reason why children get many immunisations is that new vaccines against 
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serious infections continue to be developed. The number of injections is reduced by the 
use of combination vaccines, where several vaccines are combined into one shot. 
Discussion: The government does not mention that since 1950 the introduction of vaccines 
in the Australian population has been for diseases that represent a small risk to the majority 
of children (Com Yearbook 1953; Stanley 2001). The introduction of most vaccines in 
Australia was not to control epidemics of disease but to see if these diseases could be 
eliminated. See Chapters 2 and 3. This claim by the government implies that it is 
worthwhile to combine an unlimited number of vaccines in the infant body and that this can 
be done without producing significant side-effects or chronic illness. Yet the risks are not 
mentioned in the FAQ’s and the long-term safety of using multiple vaccines has not been 
established. The chronic illnesses that have increased in the Australian population as the 
use of vaccines has increased include autism, asthma, allergies, anaphylaxis, neurological 
damage (learning and behavioural difficulties), speech delay and autoimmune diseases, e.g. 
arthritis and type 1 diabetes mellitus.  
Statement 7 
Many children experience minor side effects following immunisation. Most side effects 
last a short time and the child recovers without any problems. Common side-effects of 
immunisation are redness, soreness and swelling at the site of an injection, mild fever 
and being grizzly or unsettled. You should give extra fluids to drink, not overdress the 
baby if hot and may consider using paracetamol to help ease the fever and soreness.  
 
Serious reactions to immunisation are very rare, however if they do occur consult your 
doctor immediately. It is important to remember that vaccines are many times safer than 
the diseases they prevent. 
Discussion: This information is misleading because it does not describe the serious side-
effects that are listed on the PI inserts for all vaccines (WAVE). For a significant but 
unknown number of children, vaccines will not be safer than the disease they are designed 
to prevent. This is because of genetics but also because the majority of children in 
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developed countries, like Australia, are not at risk of getting the disease. Some of the 
serious side-effects that are not listed by the government include neurological disorders 
such as encephalopathy, convulsions, seizures, Guillain-Barre syndrome, autoimmune 
diseases, allergies and anaphylaxis are possible adverse events to vaccines (Coulter 1995; 
Shoenfeld and Agmon-Levin 2011; CSL PI Fluvax/Afluria, PI MMR). These conditions are 
listed in the PI for vaccines yet not mentioned in the government’s FAQ. Furthermore 
doctors are not required to provide this information to parents.  
The claim that ‘serious reactions to immunisation are very rare’ does not provide the 
frequency or probability of a child being harmed by individual vaccines. The government is 
unable to provide accurate statistics of the risk of adverse reactions because the clinical 
trials for vaccines that are funded by the vaccine manufacturers do not compare vaccinated 
children with unvaccinated children using an inert placebo (Downing 2011; Future II 2007; 
CSL Fluvax PI 2007) and they do not establish the long-term health effects (5-20 years) of 
using vaccines in humans (AG TGA 2013). The passive post-vaccination surveillance 
systems used by government regulators globally are unable to determine the frequency and 
types of causally related adverse events linked to vaccines – in the short-term or the long-
term – because they are dependent upon ‘voluntary’ reporting of health outcomes and not 
the mandatory reporting of all health outcomes for vaccinated individuals (AG TGA 2013; 
US CDC VAERS 2013).  
Whilst the government FAQ states ‘it is important to remember that vaccines are many 
times safer than the diseases they prevent’ this cannot be sustained because the appropriate 
studies and surveillance systems have not been funded. Information on the government 
website downplays the side-effects of vaccines and over-emphasizes the benefits without 
definitive evidence. Vaccines and drugs can cause serious damage, or even death and it is 
known that phase III clinical trials are not large enough to characterize the risk from the 
vaccine/drug (Basch 1994 p93). The monitoring of vaccines/drugs and acceptance of 
adverse events linked to these products is influenced by the pharmaceutical companies that 
sponsor the trials, employ many of the researchers and fund the government regulators to 
monitor the safety of these drugs in the population after they are approved. See chapters 6, 
9 and 10. This illustrates that public safety is dependent upon government regulators 
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establishing an active post-approval surveillance system that can make causal links between 
vaccines and adverse events. 
Statement 8 
Natural immunity and vaccine-induced immunity are both natural responses of the 
body’s immune system. The body’s immune response in both circumstances is the same. 
In some cases, vaccine-induced immunity may diminish with time; natural immunity, 
acquired by catching the disease is usually life-long. The problem is that the wild or 
natural disease has a high risk of serious illness and occasionally death. Children or 
adults can be re-immunised (required with some vaccines but not all) if their immunity 
falls to a low level. It is important to remember that vaccines are many times safer than 
the diseases they prevent. 
Discussion: This information does not address all the differences between natural and 
artificial immunity, it is selective (See Statement 1 above). There is no risk/benefit analysis 
of immunity gained naturally and immunity gained artificially with the probability of risk 
for each disease. There is a risk on both sides of this equation – from the disease and the 
vaccine - and it will vary for each disease. The government has not provided quantitative 
evidence of the risk presented to the majority of individuals from both the infectious agent 
and the vaccine. In developed countries like Australia, the majority of children are not at 
serious risk from infectious diseases even when they are exposed to the infectious agent. 
The reasons for this are discussed in chapters 2 and 4.  
The placebos used in safety trials always contain all the adjuvants and often neomycin (an 
antibiotic and known neurotoxin and allergen) that are also in the vaccine (Virtanen et al 
2000). This means that comparing the safety of the vaccinated group to the unvaccinated 
group does not provide complete information about the safety of the vaccines in the human 
body. It assesses the safety of the vaccine when compared to the adjuvant (and/or 
antibiotic) in the human body and these substances are known to be non-inert meaning they 
are known to cause adverse events, immediate and delayed, in the human body (Shoenfeld 
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and Agmon-Levin 2011; Tomljenovic and Shaw 2011). Therefore it cannot be sustained 
that ‘vaccines are many times safer than the diseases they prevent’.  
Statement 9 
The FAQ about ‘Overloading the Immune System’: 
No. Children and adults come into contact with many antigens (substances that provoke 
a reaction from the immune system) each day, and the immune system responds to each 
antigen in specific ways to protect the body. Without a vaccine, a child can only become 
immune to a disease by being exposed to infection, with the risk of severe illness. If 
illness occurs after vaccination, it is usually insignificant. 
Discussion: This statement is inaccurate because it fails to address the different ways that 
children/adults come into contact with multiple antigens naturally and artificially by 
vaccination. As described in statement 1 above, the route of entry for pathogens has a 
major influence on the health outcome of the individual. The risk of severe illness due to 
natural exposure to infectious agents in developed countries is very low. Again the claim 
that ‘if illness occurs after vaccination, it is usually insignificant’ is questionable if it is not 
supported by evidence. Vaccination stimulates a different chain of events than natural 
exposure due to the injection of substances into the body where components have access to 
the organs and body systems. The final sentence of the FAQ answer could be re-written in 
the following way: ‘Without a vaccine a child can become immune to a disease by being 
exposed to infection with little risk of severe illness in Australia. However, in genetically-
diverse populations there is real risk that many children will suffer severe adverse events 
after vaccination’.  
Statement 10 
The government’s statement for ‘why vaccines are still necessary’:  
Many diseases prevented by immunisation are spread directly from person to person, so 
good food, water and hygiene do not stop infection. Despite excellent hospital care, 
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significant illness, disability and death can still be caused by diseases which can be 
prevented by immunisation. 
Discussion: This statement is misleading because it generalizes the risks of all infectious 
diseases. Whilst it is true that illness and disability can still be caused by infectious diseases 
in developed countries, vaccines are being introduced for diseases that are not a risk for the 
majority of people in these countries. If the government is implementing a management 
strategy to prevent death and disability and the adopted management strategy also causes 
death and serious disability, then it is deceptive not to address the risks of the management 
strategy as well as the risks of the disease. Public health policy should be beneficial to the 
majority of individuals in that community.  
The government’s statement also ignores the fact that vaccinated children can still get the 
diseases they are vaccinated against. Therefore if the appropriate studies have not been 
funded to provide empirical evidence of the influence of vaccines in preventing disease, 
then the weight of evidence for the benefits of vaccines has not established.  
7.4 A Discussion of the Australian Academy of Science Document The 
Science of Immunisation  
The Australian Academy of Science (AAS) produced a supportive document for the 
Australian government’s vaccination policies in 2012. At this time many parents were 
questioning the number of vaccines being recommended by the government and this 
document was developed to address parental concerns (AAS 2012). I am addressing the 
AAS claims in this chapter because this document represents another example of the type 
of information used to promote vaccines to the public.  
In the following discussion AAS statements are in bold italics followed by discussions of 
the claims. The terms ‘vaccination’ and ‘immunisation’ have been conflated by the AAS; I 
will use the correct terms in my discussion.  
1. Immunisation has transformed human health by preventing the deaths of 
hundreds of millions of people. 
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2. The widespread use of vaccines has been highly effective globally in reducing the 
incidence of infectious diseases and their associated complications, including 
death. 
3. As a result of vaccination several infectious diseases have been controlled or 
eliminated in Australia which would never have occurred just due to 
improvements in healthcare, sanitation or nutrition. 
4. Vaccines are the most successful form of disease prevention available and will 
continue to be an essential tool in controlling infections and complications. 
Discussion: 
These four claims from the foreword and summary (pp2-3) are about the achievements 
of vaccination programs. The claims have been made by ignoring the historical 
evidence that infectious diseases declined prior to the use of the majority of vaccines in 
all developed countries (Commonwealth Yearbook of Australia 1945–1986; Stanley 
2001). This historical decline has been described in chapter 2. The claims have been 
made without providing historical data to support the statements and without definitive 
evidence to demonstrate the influence of vaccines in reducing infectious diseases. This 
is because definitive studies of the efficacy and safety of vaccines have not been 
funded.  
Statements 1 and 2 claim hundreds of millions of deaths have been prevented by 
vaccines but the claims do not address the many deaths and cases of illness that have 
been caused by vaccines (Wallace 1889; Allen A 2007; Habakus and Holland 2011; US 
VICP). Value judgments about the benefits of vaccines must be founded on the weight 
of evidence not selective evidence for the use of the procedure. This was discussed in 
FAQ 9 above.  
In statement 3 the AAS claims ‘As a result of vaccination several infectious diseases 
have been controlled or eliminated in Australia’. This is a general statement and it does 
not list any disease that has been controlled or eliminated by a vaccine. Similarly, the 
claim in statement 4 that ‘vaccines are the most successful form of disease prevention 
available’ is not sustained by evidence. The AAS has not provided empirical evidence 
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of the influence of vaccines in controlling specific diseases. This could be done by 
providing independent data on the number of vaccinated and unvaccinated individuals 
in the Australian population, with their socioeconomic status, that are hospitalized in 
outbreaks of a disease.  
The Commonwealth Yearbook of Australia (1953) and prominent public health 
authorities clearly illustrate that the infant mortality rates declined significantly before 
the introduction and widespread use of all vaccines except diphtheria. Voluntary mass 
vaccination programs in Australia were not strongly promoted in Australia until after 
1954 (NHMRC 1954). This evidence has not been discussed or countered by the AAS 
to make the general claim above. Although diphtheria vaccine was used prior to 1950 
prominent public health officials such as Lancaster and Cumpston noted that the rate of 
the decline for diphtheria was no greater than the decline for all the other infectious 
diseases for which there was no vaccine (chapter 1). Proof of the influence of diphtheria 
vaccine in the control of this disease would also require data on the percentage of the 
susceptible population that had been vaccinated. This has not been provided. 
5. Immunisation is based on scientific knowledge. 
Discussion: 
This claim implies that the information presented as scientific knowledge to support this 
claim is proof that vaccines are safe, effective and necessary. This ignores the processes by 
which science is produced and assumes that all scientific knowledge is produced with 
integrity and rigor. This is not the case and the cultural and political influences on the 
production of scientific knowledge have been described in chapters 6 and 7. Much 
scientific knowledge is distorted by vested interests and the knowledge base is incomplete 
due to undone science. Furthermore, there is scientific knowledge that does not support 
vaccination and this has not been provided in this AAS document. 
6. We know there are a very small number within a vaccinated population who can 
have adverse reactions as a consequence of vaccination. No medical intervention 
is completely without risk. 
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7. Immunisation with each vaccine protects an individual from a serious infectious 
disease and from associated long-term complications.  
Discussion: 
These statements fail to mention that many people are not at risk from the infectious 
diseases they are being vaccinated against in Australia, even if they are exposed to the 
infectious agent. The claims also do not address the fact that accurate knowledge about the 
health risks of vaccines is unknown because the appropriate studies and monitoring systems 
have not been funded. The statements are based on selective information and are therefore 
misleading the public on the risks and benefits of using multiple vaccines to protect the 
community.  
8. Before release for use in the population a vaccine must undergo a series of 
rigorous clinical trials each of which involves a greater number of participants. 
Discussion: 
There are no formal controlled clinical trials of vaccines that compare the safety and 
efficacy of vaccines against the disease or against an inert placebo. In addition, the recent 
introductions of HPV vaccines and the ‘Swine Flu’ 2009 vaccine have demonstrated that 
comprehensive testing was not carried out before the vaccines were used in the population. 
See chapters 9 and 10. HPV vaccines were fast-tracked for approval by the FDA before the 
clinical trials for efficacy and safety against cervical cancer were completed. Similarly, the 
influenza vaccine was recommended to Australian children under 5 years of age in Western 
Australia in 2008 without being tested for long-term safety and efficacy in children prior to 
its recommendation (Jefferson et al 2008; AG TGA 2010). When companies can make 
significant profit from the research they sponsor it is known that they can influence the 
design and hence the outcome of the clinical trials. See chapter 6. This throws into question 
the claim that vaccine trials are rigorous. An independent assessment of the clinical trials is 
necessary before the claims stated by vaccine manufacturers are accepted.  
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9. Vaccines undergo stringent monitoring once they are in widespread use in the 
community to ensure their ongoing safety and effectiveness. 
Discussion: 
This claim is incorrect. There is no stringent monitoring of adverse events or evaluation of 
the effectiveness of vaccines in the population that would provide meaningful data on their 
effects in the population. This is because all countries use a ‘passive’ or voluntary post-
vaccination surveillance system that is unable to provide data on causal relationships 
between vaccines and the frequency of adverse events that are observed in the population 
(US FDA; AG TGA).  
10. There is no credible evidence to suggest that any vaccine in current use can 
cause these particular diseases (multiple sclerosis and diabetes 1) (AAS Box 9 
p.12). 
Discussion: 
Whilst the AAS claims there is no credible evidence of a link between vaccines and 
autoimmune diseases, they have made this statement by ignoring the studies that are 
showing this link – not by addressing why the studies are not credible. They have also 
made this claim without providing evidence from a properly controlled long-term clinical 
trial (5 or more years) of the health effects of using the combined schedule of vaccines 
(against 16 diseases) in infant animals or infant humans. A link between vaccines and 
autoimmune diseases has been postulated in the medical literature for over fifty years and 
the combined schedule of vaccines is a plausible cause of these diseases. The Medical 
Journal of Australia reported the link between vaccines and autoimmune diseases in 1966 
(Greville 1966) and Burnet discussed the association between hypersensitivity and vaccines 
in 1952 (Burnet 1952). There are also many recent studies that have demonstrated this link 
(La Rosa 2002; Shoenfeld and Agon 2011; Tomljenovic and Shaw 2012) and in particular 
the link with multiple schlerosis (Fourrier et al 1999; Marshall 1998, Confavreux et al 
2001; Geier et al 2005) and diabetes mellitus (Blumberg et al 1993; Feery 1982; Stewart 
1977). The AAS has made the claim that ‘there is no credible evidence’ without stating why 
these studies are not ‘credible’. In fact there is clear evidence from animal studies from 
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1965 that foreign protein and adjuvants produce auto-antibodies which are a known cause 
of autoimmune diseases. Burnet and Mackay stated in 1965 ‘There is no doubt that 
conditions basically resembling certain human autoimmune diseases can be produced in 
originally healthy experimental animals by injections of normally inaccessible autologous 
antigens’ (in Grigor 1965 p83). Whilst there are studies in the medical literature that 
discount a causal link between vaccines and autoimmune diseases, there are no studies that 
have discounted this link using empirical evidence from properly designed RCT’s in 
animals or humans. In addition, a public hearing into the adverse events associated with 
HPV vaccines held in Paris in 2014 included this statement: 
 ‘Current scientific knowledge and progress has revealed that aluminium is responsible for 
what can be called vaccine-induced illness or illnesses that did not naturally exist pre-
vaccination and which the individual therefore contracted through aluminium 
toxicity.’ (Vanlangendonck P. 2014). Aluminium adjuvants are also found in most 
childhood vaccines. 
Here is a description by Basch of the knowledge scientists had of adjuvants and their 
effects in 1994 when the use of vaccines was expanding. This information gives an insight 
into the potential effects of adjuvants and is relevant today in light of recent knowledge 
about the effects of aluminium adjuvants in the functioning of the human body. Adjuvants 
enhance the immune response of the body. That is, they operate to increase the production 
of antibodies in vaccine recipients (Basch 1994 pp227-8). Vaccines that are not made with 
the complete organism (bacteria/virus) are known to be less immunogenic. These vaccines 
require more adjuvant to raise the antibody titre to the protective level. Many of the 
vaccines produced with new biotechnology are made without using the whole organism as 
the antigen. These vaccines use acellular components, chemical synthesis or recombinant 
DNA as the antigen and therefore they require more adjuvant to raise the antibody level of 
the vaccine recipient. Adjuvants also influence the class of immunoglobulin antibodies that 
are produced in the body (Basch 1994 p227). One class of antibody produced is 
immunoglobulin E which plays a major role in allergic diseases; asthma, hayfever, 
dermatitis, gastroenteritis and anaphylaxis (Martin 2002). These conditions have increased 
5-fold in Australian children over the last decade (ASCIA 2015). See section 1.1.  
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Examples of novel vaccines include hepatitis B, acellular pertussis (DTap) and HPV. The 
HPV vaccine has three times as much aluminium adjuvant as any other vaccine and three 
times as many adverse events (chapter 9). The most common adjuvants used in vaccines are 
aluminium hydroxide and aluminium phosphate. In 1984 it was stated that the complexity 
of vaccine adjuvants means that they produce a variety of responses in the host some of 
which are irrelevant to the immunogenic effect. The immune response is a multistep 
process and can occur through a variety of pathways therefore they can theoretically act in 
unknown ways on many cells in multiple pathways. These processes are not fully known 
and understanding of the immune response is unclear (Bomford 1984 in Basch 1994 p228). 
It is also known that there are significant differences in the effect of adjuvants from species 
to species and between individuals within a species. Basch (1994) stated that the extent of 
genetic variability with respect to adjuvant function is unknown but believed it may be 
significant to health outcomes in human populations (p228).    
11. The vast majority of people (mainly adults) who develop autoimmune diseases 
have no recent history of being vaccinated (AAS p12).  
Discussion: 
This statement is misleading for two reasons. Scientists know that the autoimmune diseases 
show a delayed response (Eldred 2006; Shoenfeld 2011; Gilbert 2004; FDA). Autoimmune 
diseases and hypersensitivity (allergies) can develop months or years after exposure so even 
if patients do not have a ‘recent history’ of vaccination, vaccination could still be 
responsible. The statement also ignores the fact that autoimmune diseases such as diabetes 
1 and autism are rapidly increasing in children - not just adults. This increase has occurred 
at the same time as the number of vaccines has increased (AIHW 2005). Two diseases that 
the AAS admits have increased due to vaccines are Guillain-Barre syndrome and idiopathic 
thrombocytopenic purpura (ITP). The suggestion that they are less of a risk than the 
infectious diseases is a value judgment that is not sustained with specific evidence of the 
risks and benefits of different vaccines and infectious agents.  
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7.5 Political Decisions in Government Policy 
The discussion in this chapter illustrates that there is credible evidence for a causal link 
between vaccines and many serious and debilitating diseases that are increasing in the 
population. Yet political decisions are being made in government policies that do not 
acknowledge the medical literature supporting these links. This allows those with vested 
interests in vaccination programs to downplay the risks of vaccination. This is possible 
because governments have reversed the precautionary principle to place the onus of proof 
of harmfulness on the general public and not the proponent. It is difficult for the public to 
prove with ‘hard evidence’ that vaccines are causing many diseases in the population 
because governments have not funded the studies that might establish causal links with the 
vaccines. This allows political decisions to be made that ignore the evidence from small 
scale studies that harm is being caused by using multiple vaccines. Decision-makers use 
political and scientific criteria in deciding whether a procedure should be implemented and 
these decisions can include transient and subjective (value-based) reasons regarding the 
evidence. Not all evidence is of equal value or produced with equal integrity and rigour 
(Basch 1994 p79). The evidence that is used in policy decisions is provided by the 
dominant network of scientists that gains power through the cultural and institutional 
structures that exist in the prevailing political ideology. See chapter 8. 
After the considerable public concern about the safety and efficacy of hepatitis B vaccine in 
the 1990’s, due to its association with multiple-sclerosis, the Virus Hepatitis Prevention 
Board reviewed these safety issues. Several members authored a paper to downplay the 
risks and to promote the vaccine in neonatal and adolescent vaccination programs in many 
countries. This was done by promoting the studies, mostly funded by industry, that do not 
show a link between vaccines and chronic illness. The other studies showing links to 
diseases were ignored. This allowed the authors to claim ‘no scientific data currently allow 
the conclusion that hepatitis B vaccine or other childhood vaccines represent a significant 
risk……’ (Guido et al 2005 p958). This is the type of value judgment that is being made to 
develop vaccination policies and it is not the same as stating ‘vaccines do not cause 
significant harm in the population’. The claim can be re-framed ‘it has not been proven that 
hepatitis B vaccine is not the cause of autoimmune and other diseases in the population’. 
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Scientists are succeeding in hiding the possibility of causal links because the relevant 
research is not carried out. Governments have not funded the studies that might provide the 
evidence showing vaccines are causing many chronic diseases in the population. See 
chapter 8.  
The article concludes that the media should be seen as ‘reliable key partners in countering 
vaccination scares and the anti-vaccination movement’ (Guido et al 2005 p958). The 
authors claim that ‘cultivating optimal professional working relations with them is 
imperative’. They continue ‘Open debate about vaccine safety issues and the performance 
of sound scientific studies are powerful instruments to be used against vaccine scares and 
should be encouraged’ (Guido et al 2005 p958). However in Australia the public is not 
encouraged to participate in debates on vaccination. Powerful pro-vaccination lobby groups 
such as the Australian Skeptics and Stop the Australian Vaccination Network (SAVN) 
influence politicians and the media. They also use social blogs to ridicule and abuse 
individuals, including academics and professionals, who are questioning the safety and 
efficacy of vaccines (Martin 2015). There is evidence that lobby groups in many countries 
are being funded by industry to promote industry interests (Michaels 2008). These groups 
discredit people’s reputations and promote disinformation to suppress scientific debate.   
7.6 The Evidence not Provided by the Government and AAS  
Evidence for the Necessity of each Vaccine Recommended in Australia  
• The diseases for which vaccines are recommended have not been demonstrated to 
be a serious risk to the majority of children in Australia. 
• Quantified data of the risks of vaccines and the risks of each infectious disease to 
the majority of children have not been provided to demonstrate the weight of 
evidence for the necessity and safety of each vaccine. 
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Evidence for the Efficacy of each Vaccine Recommended in Australia 
• There is no definitive evidence from formal controlled clinical trials comparing 
vaccinated participants to unvaccinated participants and demonstrating the efficacy 
of each vaccine against the infectious disease they are designed to prevent.  
• The surrogate of seroconversion has been used for proof of efficacy of each vaccine 
but the models of seroconversion demonstrating a protective level of antibody titre 
against the disease have not been provided. 
• Many vaccinated individuals still get the diseases they are vaccinated against and 
the government has not provided complete evidence, including SES, of the 
percentage of vaccinated individuals who are still getting the diseases.  
Evidence for the Safety of each Vaccine Recommended in Australia 
• There is no definitive evidence from formal controlled clinical trials comparing 
vaccinated participants to unvaccinated participants, using an inert placebo that 
demonstrates the safety of each vaccine or the combined schedule of vaccines. 
• Definitive evidence of vaccine related causal adverse events and their frequency in 
the population has not been provided. 
• A post-vaccination surveillance system that can establish the short and long-term 
causal events and their frequency in the population is not used by government 
regulators.  
• The known link between a family history of autoimmune diseases and 
allergies/anaphylaxis is not discussed and is no longer presented as a 
contraindication for vaccination programs implemented in school settings. 
• The correlation between mercury poisoning and autistic symptoms has not been 
acknowledged by governments even though the US Government regulator, the 
FDA, admitted that the cumulative level of mercury in infants under 6 months of 
age had exceeded the EPA’s guidelines in the 1990’s. This correlation needs to be 
acknowledged and investigated to demonstrate that vaccines are not causing autism. 
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• Adverse events that are listed on the Prescribing Information (PI) for each vaccine 
are not mentioned to parents. E.g. encephalopathy, convulsions, seizures, Guillane-
Barre Syndrome, autoimmune diseases, allergies and anaphylaxis. 
• The risk of each disease and vaccine in genetically diverse communities has not 
been provided. 
7.7 Conclusion  
The evidence provided by the Australian government and the AAS for vaccinating with 
multiple vaccines does not include an assessment of the ecological complexity of the cause 
of infectious diseases or account for the genetic diversity of the population. It also does not 
provide direct evidence of the influence of vaccines in controlling any infectious diseases. 
In addition, the adverse events from using multiple vaccines in infants/adults should be 
considered in the adoption of a management strategy that is implemented in public health 
policy. The government information analysed here does not provide estimates of the 
frequency and type of risk associated with each vaccine - or with the combination of 
vaccines. It also does not provide evidence that policy-decisions about infectious diseases 
are being made for the benefit of the majority of the community. The value judgments 
made by policy advisors in Australia are emphasising the assumed benefits of vaccines and 
downplaying the risks. This is illustrated in the selective evidence and misleading 
statements that are used to promote vaccines to the public in the FAQ and by the AAS. 
Conflated terminology has been used to mislead the public about the efficacy of vaccines. 
The government has not provided evidence that the ‘best judgments’ for public policy are 
being made on comprehensive and independent evidence. Australia’s vaccination policies 
include undone research and a lack of transparency in the rigour of scientific trials and the 
assumptions used in the evaluation of vaccines. This is a consequence of a culture that 
promotes scientific research for ‘profit’ as opposed to its contribution to progressing 
knowledge. In the 21st century industry is sponsoring vaccine clinical trials without 
evaluation from independent experts. This is not disinterested science and it is being 
promoted in public policy by experts with vested interests. 
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The culture in which research and policy development is occurring in Australia is described 
in chapters 6 and 8. An example of the influence of corporations in global vaccination 
policies is provided with the HPV vaccine in chapter 9 and the ‘Swine Flu’ 2009 vaccine in 
chapter 10. These case studies demonstrate how vaccines can be implemented into global 
vaccination polices even though the underpinning science is incomplete. Chapter 11 
presents the conclusions to this investigation. 
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CHAPTER 8 POLITICS AND UNDONE SCIENCE 
IN PUBLIC POLICY  
8.1 Introduction 
This chapter introduces the concept of undone science and the increase in undone science 
that occurs when policies are designed pre-dominantly on the advice provided by technical 
or ‘expert’ advisors with specific agendas. I have provided here a description of undone 
science, a case study, a summary of the political framework that fosters undone science and 
the undone science relevant to government vaccination policies. Many of the sources I have 
used refer to practices in the US and I have described here the relevance of these practices 
to the Australian situation.    
8.2 Undone Science 
Undone science is the research that is not conducted because institutional barriers are 
constructed in the political process to prevent it from being done (Hess 2007 p22). These 
are the areas of science that are left unfunded, incomplete or ignored although many 
scientists consider them to be worthy of further research (Frickel et al 2010 p445). The 
relevance of undone science to government policy is that gaps exist in the scientific 
knowledge that underpins the value judgments made by policy-makers. Nearly all new 
scientific research depends upon funding therefore if the research is not prioritized by 
academic institutions, governments, industry or civil society organisations it can be left 
unfunded. This situation affects the on-going contribution of knowledge which is 
fundamental to the decisions made by politicians in public health policy. The political 
sociology of science describes the power play involved in the prioritising of research 
agendas and the institutional barriers that can be constructed in governments and research 
institutions to produce areas of ignorance in particular fields. This lack of knowledge can 
prevent social movements from challenging public policies that are not seen to be 
beneficial to the public interest (Frickel et al 2010 p446). Hess (2007) describes this 
situation in the following way: ‘The prioritization of research tends to create huge pockets 
of undone science that result in the systematic nonexistence of selected fields of research’ 
(p22).  
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Scientific leaders play an important role in allocating the funding for research agendas and 
they are also in a position to be influenced by economic and political leaders. These 
scientists can also be influenced by social movements and public opinion but this occurs to 
a lesser extent if the area of science is unfunded. It is also less likely to occur if the 
advocates for the science do not have political power (Hess 2007; Gross 2007). Even when 
the undone science is completed it is observed that the scientists and their research can be 
discredited if they are not part of the dominant network of scientists (Hess 2007). These 
political barriers to the production of knowledge arise when the interests of political, 
economic and industrial leaders synergise to control the direction of funding for scientific 
research. In many governments political decisions are determined by the dominant network 
of scientists who advise the government through representation on policy-advisory boards. 
These ‘technical advisors’ are influential in validating the assumptions and extrapolations 
that are inherent in the accepted scientific practices and innovations that are promoted 
(Frickel et al 2010). Whilst science is a social institution that forms the foundation of many 
political outcomes it is noted that most politicians do not have an in-depth understanding of 
scientific issues (Hess 2007 p21). The legitimacy of political outcomes therefore depends 
upon the values inherent in the production of science and in the use of science that has been 
accepted by all stakeholders.   
When the production of science and the ‘selection’ of science for government policy is 
influenced by industry sponsors, the resulting policies may serve the interests of industry 
but not necessarily the public interest. The research agendas of industrial sponsors are 
determined by motives to improve industry profits (Krimsky 2003; Angell 2005). In these 
situations the production of knowledge can rest on the material interests and cultural 
assumptions of privileged groups in society (Frickel et al 2010). In situations where 
universities partner with industry it is observed that the research environments reflect 
industry needs rather than the interests of society. The dominant research areas that are 
selected for funding are technology and the production of goods for profit. When academic 
institutions, governments and industry are aligned it is noted that sponsors (with vested 
interests) have control over the design of studies and the areas of study that are selected for 
funding (Hess 2007; Michaels 2008; Angell 2005; Krimsky 2003). This occurs at the 
expense of public interest science. The existence of undone science illustrates how cultural 
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factors and societal beliefs can mould the science that is produced in scientific institutions. 
In a capitalist economic model of health the science is shaped by profit and not public 
interest because this is a fundamental cultural value inherent in this system. See Chapter 5. 
In the era of globalisation political outcomes can be achieved because industrial 
sponsorship has converged in university partnerships and government funding agendas 
have aligned with corporations (Krimsky 2003 ch5; Hess 2009 p311). Political outcomes 
from epidemiological studies can be achieved by sponsors selecting the study criteria and 
the mathematical models that will be used to analyse the data (Michaels 2008 pp60-78). 
Whilst it is possible for social movements and the public to influence government research 
agendas, this influence is reduced by institutional bias constructed by powerful coalitions 
(Frickel et al 2010). This structural bias can result from the following practices (Michaels 
2008; Angell 2005; Smith 2005; Krimsky 2003): 
I. Conflicts of interest (COI) in government and academic institutions 
II. A lack of community representation on government advisory boards  
III. Financial control of the peer-review system of validating scientific knowledge  
 
These structures within the political and academic system can act as a barrier in preventing 
some important areas of science from being acknowledged and funded. This type of bias is 
hidden from the public. In the globalisation era it is observed that the peer-review process 
and production of validated scientific knowledge is being influenced by vested interests that 
control the financial channels of the peer-review process (Angell 2005; Hess 2007; 
Michaels 2008; Krimsky 2003). When global market mechanisms are uncontrolled they 
nurture the COI that generate bias and unreliability into research and medicine. According 
to an Italian editor of an international medical journal: ‘Members of corporate driven 
special interest groups, in virtue of their financial power and close ties with other members 
of the group often get leading roles in editing medical journals and in advising non-profit 
research organizations’ (cited in Krimsky 2003 p10).  
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In this culture corporate members are acting as reviewers and consultants of scientific 
research and they systematically prevent the dissemination of scientific research that may 
be in conflict with their vested interests (Krimsky 2003 p10). This statement is supported 
by the previous editor of the New England Journal of Medicine, Marcia Angell. She states:  
 
‘It is simply no longer possible to believe much of the clinical research that is published, or 
to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no 
pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as 
an editor of the New England Journal of Medicine’ (Angell 2009 p2). 
 
The COI that the public hear about are only the tip of the iceberg (Krimsky 2003 p9).  The 
validity of scientific knowledge that is used in the risk assessment framework for a public 
health policy should be formed from a consensus of all the stakeholders and not just 
technical experts. See Chapter 4. But this is not possible if journals are selecting against 
some areas of science and if important stakeholders are removed from the academic and 
political process. Each stakeholder in a scientific issue will be affected by policy decisions 
in a different way therefore decisions must be made on a consensus of all the stakeholders 
in the issue. A consensus that does not include all the stakeholders allows selective science 
(which excludes undone science) to be used as the foundation for public health policy.  
 
The structure and hierarchy of academic institutions have changed with the 
commercialisation of academic research and development. In the US, university research is 
considered a source of economic and technological innovation and new professional 
groups, including technology-licensing officers, exist on university campuses to link 
research to industry. Whilst there have been formal university/industry relationships in the 
past, the new model is a merger of two cultures and has resulted in extensive structural 
change in university processes (Kleinman and Vallas 2006 p40). These changes have been 
described as ‘revolutionary’ and the rapid acceleration of innovative research to 
technology-transfer is referred to as ‘the golden goose that is responsible for the nation’s 
economic resurgence’ (Owen-Smith 2006 pp63-4). The change in norms around public and 
commercial science is re-positioning the relevance of universities with respect to other 
	  
	  
199	  
institutions – the government, the market, the citizenry and other constituencies. The 
‘enterprising’ university represents the merging of two institutions, industry and academia, 
built on different values. In the US, in many fields with commercial relevance, the changes 
in norms and practices within the university are resulting in new structures for the 
production of knowledge (Kleinman and Vallas 2006 pp35-38). This has been described as 
‘asymmetrical convergence’ because the driving force for the production of knowledge is 
profit and not public knowledge. In this system, some sectors of industry are adopting 
characteristics of academic culture to enhance their credibility, and the codes and practices 
of universities are changing to those of the commercial sector. This has resulted in tension 
due to the contradictory nature of the co-existing cultures.  
 
Whereas universities were once seen as having collegial and open workplaces, with a high 
degree of researcher autonomy, they are now viewed as offering less autonomy over 
research direction. Research is increasingly driven by commercial agendas and data 
secrecy. University-industry relationships (UIR) are hindering the sharing of data and 
stronger competitiveness for professional recognition is a barrier to the free flow of 
knowledge. There is a commitment to the hoarding of information instead of the traditional 
commitment of knowledge to ‘scientific communalism’ (Kleinman and Vallas 2006 pp45-
6).  Further, in many technical fields the conditions and resources needed for traditional 
research are now mostly found in corporate laboratories. This has resulted in a blurring of 
the lines between ‘academic’ and ‘industrial’ science in the US (Kleinman and Vallas 2006 
pp35-38), a change in culture that significantly impacts on the structure and integrity of 
knowledge production. It has resulted in a hybrid knowledge structure. Intellectual property 
is now a factor in the production of knowledge in addition to publishing in the most 
prestigious journals (Kleinman and Vallas 2006 p40). In this system universities have 
retained their image of being committed to the education of students and producing 
curiosity-driven, public interest science, whilst at the same time becoming enterprising 
businesses driven by profit. The over-riding goals of the commercial university are capital 
and economic competitiveness. Industries are the main sponsors of UIR’s and they drive 
the research agenda. There is less curiosity-driven research to find the answers to questions 
of interest; the drive for knowledge is subordinated to the drive for profit. US universities 
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are justifying this structural change in the knowledge base on the potential benefits of 
technology-transfer to the public (Kleinman and Vallas 2006 p43).  
 
8.3 Examples of Undone Science 
Undone science is a lack of knowledge that arises when a specified area of science is not 
researched or when uncertainty exists in the science due to the assumptions and 
extrapolations that have been used (Gross 2007 pp747-8; Frickel et al 2010 pp444-473). 
The existence of undone science can be a result of a lack of funding or it may be a result of 
difficulties in publishing findings or a lack of career opportunities in this area of science. 
Particular research areas can remain unfunded because the likely answer would not support 
the political objectives of the sponsor. It may be detrimental to profits or it may be an 
embarrassment to the sponsor (Hess 2009 pp306-327). An example of undone science is a 
situation where a new technology or procedure is not tested for long-term safety and 
efficacy in a specific population. Examples include the long-term effects of genetic 
engineering, vaccines or nanotechnology in products that are marketed to the public. This 
information is valuable to the community and essential for safeguarding population health 
in the development of public health policy. When these technologies/procedures are 
implemented into the population before the long-term health effects are known it represents 
an experiment on the population: one that requires adequate monitoring to safeguard 
population health. The question of whether the long-term health effects are established 
prior to the introduction of a new technology or after the introduction of the technology or 
never, revolves around whose interests the government is protecting. This also reflects how 
governments interpret and use the precautionary principle in policy development.  
Undone science also includes science that is founded on assumptions and extrapolations as 
opposed to direct empirical observations. An example of this type of undone science is the 
development of safety standards for the use of chemicals in humans and the environment. 
The majority of data that is used to establish safety standards for toxic chemicals is 
collected from observations in animal studies or naturally occurring accidents rather than 
controlled clinical trials on humans. This is because it is unethical to perform dose-response 
experiments on humans (Michaels 2008 pp60-78). This data includes assumptions and 
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estimations in the extrapolation process that represents undone science. Extrapolation 
produces uncertainty from both ‘known’ and ‘unknown knowledge’. This uncertainty is 
illustrated in extrapolations of data from substances or animals that are similar in structure 
but not the same as the substance/animal in question. Unknown processes can influence the 
results in these cases. In some cases this uncertainty arises because the sponsor has chosen 
to ignore researching this area for political reasons. An example of this type of undone 
science is the extrapolation in humans of risk data for ethylmercury from observations of 
methylmercury in humans. These substances are related in structure but not exactly the 
same therefore value judgments about the safety of ethylmercury are being founded on the 
assumption that the biological reactions are similar. However, these assumptions might be 
demonstrated to be false if an empirical study was performed in years to come. For 
example, many chemicals have been found to have harmful effects in lower doses than was 
originally assumed. An example of an assumption concerning undone science was the long-
held belief that the only serious consequence of lead exposure to children was death from 
high exposure. Further research determined that even small concentrations of lead can 
cause permanent brain damage to children (Gilbert 2004 p19). 
8.4 The Consequences of Undone Science  
When government funding is directed towards research fields that enhance national 
competitiveness or shift towards applied science and technology then there is a trend of 
increasing undone science (Hess 2007 p40). In particular, it is observed that when there is a 
switch to patenting and licensing in a research field then funding will shift from public 
sources, (federal government grants) to industrial sources. This reduces the opportunities 
for alignment with research projects in the public interest as they are generally not in line 
with industrial goals. This will occur even when there isn’t an increase in direct support 
from industry if the government has aligned its research goals with those of industry 
innovation (Hess 2007). Scientists who research the environmental and health risks of new 
technologies are often acting against the interests of industry and its government allies and 
therefore find themselves with limited budgets and opportunities for career development. 
These scientists become marginalized and rather than dedicating their resources towards 
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prestige within the field they find themselves dedicating their resources towards 
investigating the undone science: a career path of anonymity (Hess 2007 p40).   
 
Undone science has resulted in uneven development of different disciplines throughout 
history with greater investments in military and industrial interests than into public interest 
research (Hess 2007). By de-funding particular areas of research and engaging in political 
suppression of information, industry and governments can prevent causal links from being 
established. An example of a government being directly involved in the suppression of 
research was the US government under George W Bush (2001-2009) when global warming 
science was opposed and suppressed (Kleinman et al 2005). Research investment during 
this era and today focuses on research topics within fields that are of special interest to 
corporations, such as information technology (IT), biotechnology (BT) and nanotechnology 
(NT) (Hess 2007 p46). The aggressive commercialization of universities has resulted in 
effects on communities that have only become obvious with time (Krimsky 2003 pp73-87). 
These problems generally result from the stifling of academic freedom to pursue public 
interest research activities. That is, the integrity of the academic process to be able to speak 
the truth in the interests of society is curtailed. Essentially when universities and 
government supported non-profit research institutions become commercially orientated 
they lose their status as impartial and balanced centres of learning. An example of the 
dilemma that is created by commercialised research is when an academic publishes a study 
that is critical of a product in which the university has an investment. The question is - will 
the university punish the academic and suppress the research or will they support them? 
(Krimsky 2003). 
The main areas of focus in the current scientific era are the creation of profitable new 
products that enhance economic and military interests (Hess 2007 p24). Among the pockets 
of undone science that are created in this research agenda are those essential to protecting 
public health. Government policies that are being developed despite a lack of full scientific 
evidence prevent civil society organisations from confronting the policies that are not in the 
public interest (Frickel et al 2010). This is a result of industrial and political leaders 
requesting that the public provides ‘proof of a causal link of harm’ before action is taken 
and at the same time they ensure that the area of science that might provide the proof does 
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not receive funding for investigation (Michaels 2008). Industry representatives on advisory 
panels are emphasizing the uncertainty in the science to ensure that no regulatory action is 
taken. See chapter 6. This was a strategy devised by the tobacco industry for many years 
and now it has been adopted by many other manufacturers (Michaels 2008).  
 
Whilst some scientists have attempted to enforce the precautionary principle in a form that 
states ‘The absence of certainty is not an excuse to do nothing’ the industry representatives 
are reversing this principle to state ‘there is no evidence of harm’ therefore no action is 
required (Michaels 2008 pp60-78). However, the absence of evidence of harm may be due 
to absence of investigation as opposed to evidence that harm is not being caused. Gaps in 
the science can be achieved by a lack of funding in a particular field. This is occurring 
within government regulatory boards for medicines/vaccines because the majority of the 
funding is being directed towards marketing and fast tracking drugs for approval, as 
opposed to adequate safety testing, monitoring and regulation. Other strategies to hide 
causal links involve corporations funding studies that will create confusion and public 
controversy. This scientific literature is referred to as ‘the social production of ignorance’ 
(Frickel et al 2010 p447; Michaels 2008) and it increases public confusion: the public has 
to trust that the government and medical/academic institutions are acting to protect the 
public interest. Another strategy that government and industry have adopted in the current 
era is to ensure that particular knowledge is invisible by producing classified knowledge 
and trade secrets (Krimsky 2003; Frickel et al 2010; Angell 2005). In addition, the evidence 
regarding chemically exposed groups is also obscured to prevent causal relationships from 
being established (Frickel et al 2010 p447). As science has merged with the wider society 
the boundaries between ‘producing knowledge’ and ‘applying knowledge’ have become 
blurred and this has led to the implementation of new technologies with a high degree of 
uncertainty or risk (Gross 2007). Policy-makers, scientists and the public are increasingly 
acknowledging that harmful consequences of new procedures and technologies cannot be 
reliably determined through the usual risk assessment framework. This is because the areas 
of ignorance that result from undone science are increasing (Gross 2007; Hess 2007; 
Frickel et al 2010).  
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8.5 A Case Study of Undone Science: Corby Children Win Landmark 
Toxic Waste Case 
A case study of the rehabilitation of the Corby Steelworks in the town of Corby, Midlands, 
UK, illustrates the political nature of risk assessments and the conclusions that can be made 
about causal links when environmental hazards have not been monitored (Dyer 2009; 
Collins Solicitors). This case was the result of a class action taken by 18 claimants who 
believed their deformities were caused by the rehabilitation of the steel works site in the 
town of Corby (1984–1999). The rehabilitation involved transporting toxic waste in open 
trucks through heavily populated areas. The environmental report stated that the badly 
polluted area had never been effectively assessed, properly permitted, regulated, monitored 
or adequate records maintained.  
The mothers of 18 children claimed that during their pregnancies the exposure to high 
levels of toxins in the atmosphere during the rehabilitation of the Corby steel works site led 
to birth defects in their children. It was submitted by the counsel for the claimants that 
whether Corby Borough Council knew or should have known that the substances being 
transported were potentially hazardous to human health ‘was hardly rocket science’. 
Despite the council’s claim prior to the ruling that there was no causal link between the 
reclamation work and the children’s birth defects because the levels of pollutants had not 
been monitored, the Court ruled that there was a statistically significant cluster of birth 
defects and that the types of contaminants that were being moved could plausibly cause the 
defects that were observed. On this basis, the Court made a ruling in favour of the 
claimants. The council appealed this decision on the basis that ‘a causal link had not been 
proven with scientific evidence’ however this appeal was dropped in April 2010 in favour 
of an out of court settlement and an apology by the council for its negligent activities in not 
monitoring the levels of contaminant exposure. 
8.6 Implications of the Corby Case for Public Health Policy 
Proof of causality of harm to individuals cannot be determined if the possible causal agents 
have not been monitored systematically. A lack of monitoring of harmful agents enhances 
the interests of industry as opposed to the interests of the general public. This commonly 
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occurs in the environmental and health sciences where inadequate monitoring prevents 
industries from concluding that a chemical or procedure is the causal link for an increase in 
a public health problem of significant concern to the community. This situation can prevent 
corporations from being liable for harm and can save companies or government bodies 
from financial loss.  
This case study demonstrates that undone science is an important factor in public health 
policy and that a lack of science sometimes is not a satisfactory defense for a lack of action. 
In addition, a policy that ignores the role of undone science should not be called an 
‘evidence-based policy’. It can be argued that governments are breaching their duty of care 
to the public if they are implementing policies based on a ‘lack of evidence’ of safety and 
efficacy when there is a plausible biological link between the procedure/activity and 
harmful health effects in the population. The implications for this ruling extend to any 
situation where there is the potential for disease to be caused from toxic substances. The 
risk assessment for hazards is a key process and it illustrates how undone science must be 
accounted for in a systematic assessment of the risk. It also demonstrates the necessity for 
including both technical and non-technical information into the framework for risk 
assessment. When there is a lack of evidence resulting from undone science healthy 
outcomes can only be achieved if non-technical values are incorporated into the 
development of public health policy. In other words, in situations where there is a plausible 
causal link between a procedure and harmful effects on the population, the proponent, not 
the general public, must be responsible for taking action to protect public health when there 
is uncertainty in the science. 
The initial court ruling reached in the Corby Toxic Waste Case rejected ‘experimentation’ 
on the human population. Population health is at risk when an absence of evidence can be 
used as a defence for a lack of accountability, that is, authorities stating ‘there is no 
evidence of long-term health effects because we haven’t looked for these effects’ – even 
though there is a plausible link. Undone science can be addressed by adopting the use of the 
precautionary principle that was agreed upon by the Scientific and Environmental Health 
Network (SEHN) in 1998 which states that ‘the onus of proof of harm is on the proponent 
and not the general public’. Public health policies that do not address undone science may 
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be experimenting on humans, which is contrary to the Nuremberg Code of Conduct 
(Holland 2011). This is a result of the uncertainty in the outcomes of these policies caused 
by a lack of relevant research. The traditional method for implementing new 
technologies/procedures into the human population is to perform safety studies in animal 
populations before they are introduced into the human population (Michaels 2008 pp60-78; 
Archibald et al 2011). It is also a requirement that innovative technology is systematically 
monitored and assessed to ensure the outcomes are beneficial to the population after they 
have been implemented (Michaels 2008; AG EHRA 2013). Whilst there is some fallibility 
in testing new technologies in animal populations it is currently the best guide scientists 
have for predicting health outcomes from new technologies or medical procedures 
(Archibald et al 2011).  
 The decision in the Corby Toxic Waste Case did not accept the Corby Council’s defence of 
‘the science has not been done’, that is, a lack of hard evidence because the levels of toxins 
were not monitored. Instead the decision was based on the knowledge of the plausibility of 
the causal link and the negligence of the Council in not ensuring that the levels of these 
known toxic substances were monitored. This ruling has relevance for all government 
health policies. Policies that do not incorporate the precautionary principle in a manner that 
protects the public interest are clearly protecting the interests of industry. Duty of care to 
the public can only be maintained when governments take responsibility for their actions. 
The defence of an absence of evidence demonstrates a lack of accountability and a 
disregard for public health. Governments that place the onus of proof of harmfulness on the 
public and not the proponent after the technology/procedure has been introduced are 
allowing experimentation on human populations. Health outcomes in these policies are 
unknown and in many cases will never be known because governments have not 
established adequate monitoring systems to determine a causal link. This was demonstrated 
in the Corby Toxic Waste Case which in my view should be used as a guiding principle for 
all public health policies.  
8.7 Addressing Undone Science 
Science depends upon the moral integrity of the scientists themselves but it also depends on 
the culture - the accepted norms and values - of each historical period. It is possible for the 
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desire for profit and recognition to become more important and acceptable in cultures that 
do not value integrity and accountability. For example, in societies where there is no 
accountability for the fabrication of data, plagiarism and selective reporting of experimental 
results these practices will flourish and everyone will participate in them to improve their 
status and livelihood. Influence from external agencies on academic institutions can bring 
about this change in values and place public health at risk. In order to redress this situation 
it is necessary for the public to become involved in the decision-making process for public 
health policy (Eduljee 2001; Hess 2009 pp306-327). This is because the public is the 
stakeholder whose primary interest in the policy is the health of the population. Other 
stakeholders, for example, industry, governments and the medical profession, have profit, 
livelihood and status interests tied up in the outcomes of policy-decisions. See Chapter 5. 
This can represent a bias in the value judgments that are made about risk assessment based 
on advice from technical advisory boards. If stakeholders can profit from the decisions that 
are made in public health policy then the only stakeholder whose sole interest is making the 
government accountable for improving health outcomes in the population will be the 
public. In this situation it becomes necessary for the public to have influence in the 
decision-making process to ensure all the science is assessed in policy decisions. 
In the 2000’s civil society movements increasingly countered the foreign domination and 
exploitation of WHO global policies. The People’s Health Movement (PHM) started with a 
People’s Health Assembly as an alternative to the WHO’s World Health Assembly (Baum 
2008 p127). WHO is perceived to be out of touch with global communities and it is 
controlled by the interests of corporations and the World Bank.  PHM established a 
People’s Health Charter that reflects the way political economy is directly linked to the 
health status of communities. This movement promotes democracy and hope to global 
communities whose social welfare and human rights are affected by corporate interests in 
global public health policies. The World Social Forum (WSF) was also established with a 
focus on human rights. This was conceived as an alternative to the World Economic Forum 
(WEF) to discuss concerns and action regarding the direction of global economic policy 
(Baum 2008 p129). The slogan was ‘Another World is Possible’. This illustrates the 
competing value systems and political ideologies that are influencing the social and cultural 
systems of global communities. An ‘ethical seachange’ is needed; controls are needed on 
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the activities of transnational companies and international capital, to distribute resources 
more equitably to global communities so that we do not threaten our own existence (Baum 
2008 pp132-3).  
Krimsky (2003) summarizes the problems associated with the new values in academic-
industry partnerships:  
Policies and legal decisions have created new incentives for research institutions 
with the establishment of academic-industrial complexes. This has led to changes in 
the values of scientific and medical researchers that include secrecy instead of 
openness, the privatization of knowledge and the marketing of discoveries.  
Consequently the idea that university-generated knowledge is a free good no longer 
applies (p79).  
This alters the concept of ‘consensus knowledge’ and explains the gaps that have arisen in 
scientific knowledge regarding the scientific practices and policies that are currently being 
implemented into communities for the ‘public good’. A summary of the political structures 
that result in undone science in government public health policies is provided below. 
8.8 A Summary of the Political Context for Undone Science  
I have provided here the key features of research systems where important areas of research 
are likely to remain undone. This information has been based on analyses by Hess (2007), 
Krimsky (2003) and others:  
• Government advisory boards are dominated by technical experts who ignore and de-
fund research that would prove a causal link of harm to a profitable technology.  
• An alignment is formed between the dominant scientific network and political 
leaders of governments and research/academic institutions.  
• Political and economic leaders support innovative research into applied science and 
technology. Scientific areas that reduce profits in this field are de-funded by 
governments. 
• The funding for different fields in science is chosen by the dominant scientific 
network through control of research agendas and the rewards in science. 
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• Financial control of departmental budgets ensures that the goals of the dominant 
scientific network are enforced in research institutions and in peer-reviewed 
journals. The commercial university ensures that industry can intervene to influence 
research priorities in these institutions. 
• Non-tenured positions reduce the freedom of scientists to speak the truth: behaviour 
of researchers and medical practitioners can be controlled through employment 
opportunities. 
• Science that reduces the profit of innovative technologies is suppressed by 
governments and media or poorly publicised and the scientists are marginalised. 
• Government supported non-profit research institutions that are commercialised lose 
their status as impartial institutions. They can no longer be described as providing 
balanced or consensus knowledge. 
•  Government authorities are requiring proof of harm from the public for a 
technology/procedure before action will be taken to protect public safety. When 
specific areas of science are de-funded this proof cannot be obtained.  
• Industry participates in producing studies that confuse the public about the science. 
This practice is called the ‘social production of ignorance’. See Appendix 5 for an 
example regarding the debate on the universal use of HPV vaccines. 
• Classified knowledge and trade secrets are used to hide causal links. Other tactics 
include obfuscation of data and a lack of transparency in publications. 
• Mainstream media is used to inform the public on scientific issues. Stakeholders do 
not have equal access to voicing their perspectives in the media.  
• Funded lobby groups are used to present ‘disinformation’ campaigns in the media 
and discredit individuals that present findings that reduce industry profit.  
8.9 Undone Science in Australian Vaccination Policies  
The following areas of the Australian Government’s vaccination policies have not been 
supported by evidence from appropriately designed scientific studies. The government has 
not provided this evidence either on the government website, in the Immunisation 
Handbook or in the Australian Academy of Science’s document published in 2012 titled 
The Science of Immunisation: Questions and Answers. See Chapter 9. This evidence is 
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critical to the government’s claim that ‘vaccination is an evidence-based policy’ and that 
‘the benefits of vaccines far outweigh the risks’.   
• The medical literature links the ingredients of vaccines as a plausible causal factor 
in the significant chronic illness that is increasing in Australian children (Greville 
1966; NCIRS Vaccine Components; FDA Thimerosal; Eldred 2006; Shoenfeld and 
Agmon-Levin 2011; Habakus and Holland 2011; Tomljenovic and Shaw 2012). Yet 
the Australian government is not acknowledging or investigating the strong 
correlation between the increased use of vaccines in the 1990’s and the significant 
increase in allergies, asthma, anaphylaxis, autism and other chronic illness that also 
occurred at this time (AIHW 2005).  
• Evidence from formal randomized controlled clinical trials demonstrating   
i) Effectiveness of the vaccines in preventing the disease: only the 
surrogate of seroconversion has been used  or 
ii) The safety of the vaccines using an inert placebo 
Efficacy: Seroconversion (the level of antibody titre in the blood) is used as a 
surrogate in clinical trials to determine the effectiveness of vaccines in preventing 
disease in the population. This surrogate requires a model of seroconversion from 
controlled clinical trials to demonstrate the level of antibody titre that is needed to 
protect against each disease. The Australian government has not provided empirical 
evidence demonstrating that the stated level of antibody titre induced by the vaccine 
(seroconversion) is protective against the disease. Vaccination policies are based on 
the assumption that the induction of a particular level of antibody by a vaccine 
protects the individual against disease. This reductionist thinking about the control 
of infectious diseases was discussed in chapter 2.  
Safety: Clinical trials for vaccines do not compare vaccinated participants with 
unvaccinated participants using an inert placebo. See Chapter 9. In addition, the 
health effects of vaccines are not actively followed up in all participants of clinical 
trials to determine the long-term (4-5 years) health effects of the vaccine. Actively 
following all vaccinated participants would take into account the delayed reactions 
that are known to occur months or years after exposure to the many ingredients of 
vaccines. 
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• The safety of vaccines is based only on evidence from phase 1, 2 and 3 human 
clinical trials (with chosen criteria and parameters) and the evidence does not 
include animal models that demonstrate the safety of vaccines. Long-term health 
outcomes of single vaccines and the combined schedule of vaccines have never 
been done in large-scale animal studies or controlled human clinical trials - 
comparing vaccinated and unvaccinated groups using an inert placebo.  This is 
significant because small–scale animal studies and clinical evidence show there is a 
plausible link between vaccines and adverse events. 
• A demonstrated safe level of the ‘trace’ amounts of excipients (alone or in the 
recommended combination) has not been established in animal studies or human 
studies. 
• The safety of ethylmercury has been extrapolated from the knowledge of the 
neurotoxin methymercury. See Appendix 4. These two neurotoxins are not the same 
and the health effects of ethylmercury in low doses combined with other excipients 
in the vaccine have not been established in studies of the human feotus, infants or 
adults. Many toxins in the past have been found to be more toxic in lower doses 
than originally believed. See Chapter 8. 
• The lack of an active post-vaccination surveillance system to systematically monitor 
the health outcomes of all vaccinated individuals means that definitive evidence of 
vaccine related adverse events and their frequency in the population are unknown.  
• Many vaccinated individuals still get the diseases they are vaccinated against but the 
government does not provide transparent data on the number of vaccinated 
individuals that are still getting the diseases and/or that are hospitalized with these 
diseases. This information is essential for determining the benefits of vaccination 
programs in different populations.    
Government regulators state that studies of diseases in human subjects present logistical 
and ethical problems (Warfel et al 2013 p1). These include the potential for severe disease, 
the lack of effective treatments for cases of disease and the highly contagious nature of 
many diseases. It is also difficult to get a consensus on the efficacy and safety of vaccines 
due to the differences in study designs (Zeigler et al 1991 p16). These problems result from 
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differences in the methodology that is used in studies and the large number of potential 
biases regarding the definitions of disease, socioeconomic conditions and vaccination 
status, that result in different interpretations being drawn by different researchers.  
Vaccines contain active components and excipients (other components) and many of these 
ingredients are known toxins that are not inert. These excipients are stated to be in ‘trace’ 
amounts and it is assumed that these low doses do not cause significant harm in the 
population. The Australian government states that current risk assessment methods cannot 
make accurate quantitative estimates of risk for low levels of exposure to environmental 
hazards (AG EHRA 2013). It is noted that the uncertainties that exist in toxicological and 
exposure data prevent the authorities from providing feasible numerical estimates of the 
risk from many low level exposures.  
The US FDA states that it would be unethical to determine the health effects of different 
doses of ethylmercury (and other toxins) in children because these substances cause 
neurological reactions in humans (FDA Thimerosal). See Appendix 4. This is the stated 
reason why the studies of the health effects of the excipients of vaccines have never been 
tested in children/adults. However, government regulators do not consider it unethical to 
use ethylmercury and other non-inert excipients in the recommended childhood schedule of 
vaccines – without knowing if and how much neurological damage is being caused in the 
population. This has been done for many years without informing doctors or parents of the 
ingredients of vaccines. In some countries it is also done with the use of financial incentives 
to encourage the uptake of vaccines.  
8.10 Case Study: Efficacy and Safety of Whooping Cough Vaccine  
The FDA funded a study in 2013 of infant baboons to test the efficacy of whooping cough 
vaccine in preventing whooping cough disease. This study concluded that the acellular (aP) 
whooping cough vaccine does not prevent infection (colonization) and transmission of the 
whooping cough bacteria in the population (Warfel et al 2013). The authors also concluded 
that ‘the differences in colonization (infection) between the protocol groups [acellular 
vaccine (aP), whole cell vaccine (wP), and naïve (no vaccine)] did not correlate with levels 
of circulating anti-pertussis antibodies’ (p3). In other words, there was no correlation 
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between the antibody titres (seroconversion) and protection from disease. This has been 
known for many years (CDC MMWR 2009). Smith stated in 1999 that the vaccine trials for 
acellular pertussis vaccine show no correlation between antibody responses and vaccine 
efficacy (Ryan et al 1998; Granoff and Rappuoli 1997; Smith A 1999). This is evidence 
that seroconversion (the surrogate for vaccine efficacy) does not equate to immunity in 
individuals against whooping cough infection. 
Yet this is the surrogate for efficacy that governments are using to promote vaccines as 
effective in preventing infectious diseases. This baboon study demonstrated that the 
antibody levels were high even when the vaccinated animals were challenged with the WC 
bacteria and they were still infected (colonised) and were able to transmit the disease to 
unvaccinated baboons (Warfel et al 2013 p3). In contrast the naturally infected baboons 
were not colonised after being re-challenged with the bacteria and they were protected from 
disease. This protection is known to be long-term in contrast to the short-term duration of 
whooping cough vaccine (Zeigler et al 1991; Wendleboe et al 2005). The Australian 
College of Pediatricians (ACP) stated in 1991 that the theory that whooping cough disease 
could be eradicated by achieving a vaccine uptake of 95% was probably wrong (Zeigler et 
al 1998 p16). Two authors of this paper were the founding and current directors of the 
National Centre for Immunisation Research and Surveillance (NCIRS), Margaret Burgess 
and Peter McIntyre, the government body that plays a key role in the development of 
Australia’s vaccination policy through the ATAGI. See section 6.7. 
Whilst Warfel et al (2013) conclude that the vaccine ‘protects against severe disease but not 
colonization and transmission’ this claim is based on a blood count of leukocytosis – as an 
indicator (surrogate) for severe disease in baboons. This surrogate (leukocytosis) is 
considered ‘a significant marker of morbidity in pertussis-infected infants’ (Rowlands et al 
2010 in Warfel et al 2013 p2). However, this conclusion that ‘the whooping cough vaccine 
protects against severe disease’ is again an assumption based on the surrogate of 
leukocytosis as a biomarker for ‘severe disease’. It is not empirical evidence demonstrating 
that the vaccine prevents against ‘severe disease’. In contrast, the historical evidence 
demonstrates that whooping cough was generally not a concern in adolescents and adults 
because most were exposed to natural whooping cough infection in childhood and this 
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confers long-term immunity (Wendleboe et al 2005; NHMRC 1991). It is known that re-
infection at a later age is less severe in individuals who are naturally exposed to pertussis 
bacteria and this maintains a high level of immunity in adolescents and adults (NHMRC 
1991; Wendleboe et al 2005). 
In addition, Warfel et al incorrectly state that whooping cough has only re-emerged as a 
threat in highly vaccinated communities since the whole-cell WC vaccine was replaced 
with the acellular vaccine in the 1990’s (2013 p1). This statement is not supported by 
historical data. Highly vaccinated populations experienced epidemics of whooping cough 
throughout the 1980’s and 1990’s - prior to the introduction of aP vaccine. Whooping 
cough epidemics were recorded regularly in many countries as the push to increase 
vaccination rates continued (Stewart GT 1977; Feery 1981 p174; Behrman et al 1998 p363; 
Zeigler et al 1991; Burgess M et al 1998; Tinnion ON and Hanlon M 1998; Wendleboe 
2005). The acellular vaccine was only introduced in the Australian population from 1997-
1999 (NHMRC IH 2003). The NHMRC states that the whole-cell WC vaccine was never 
tested for efficacy prior to its use in the Australian population (Andrews et al 1997). Small 
studies that have been done since its introduction in 1953 show that efficacy is between 40-
90%. This range of efficacy is due to the differences in the methodology and design of the 
various studies (Zeigler et al 1991 p1).    
The increased use of vaccines in the 1990’s and the emphasis on higher participation rates 
in vaccination programs was an attempt to eliminate infectious diseases through ‘vaccine-
created herd immunity’. See Chapter 2. This evidence of the lack of efficacy of both the 
whole-cell and acellular WC vaccines does not support a theory that vaccines can create 
herd immunity and eliminate infectious diseases. In addition, the Warfel et al (2013) 
primate study, which was funded by the FDA, did not record the health outcomes of the 
vaccinated and unvaccinated infant baboons that were studied in each group. Why not?  It 
would be feasible for the FDA to continue this study for 2 or 3 years to record the health 
outcomes of the vaccinated and unvaccinated baboons. But the FDA is not ensuring that 
this safety data is collected. The FDA and governments should provide evidence about 
safety and efficacy using empirical evidence and properly designed scientific studies.  
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8.11 Conclusion  
Undone science is the research that is not carried out because the likely results would be 
unwelcome to powerful groups. When areas of science are not funded, policies can be 
designed on incomplete knowledge and result in unpredictable health outcomes in the 
population. This is because there are gaps in the scientific knowledge that underpins the 
value judgments that are made in policy decisions. Government policies that are designed 
on incomplete scientific knowledge may not protect the public interest. Areas of undone 
science have expanded in the era of globalization because industry is influencing the 
research agendas of both governments and research institutions. This is a consequence of 
industry being in partnership with universities and being the main sponsor for many private 
research institutions. In addition, government funding agendas have aligned with industry 
goals because the dominant network of scientists is influential on government advisory 
boards. A shift to industrial sources of funding for scientific research is also achieved when 
there is increased scope for the patenting and licensing of scientific discoveries. These 
developments lead to increased conflicts of interest in the production of scientific 
knowledge and in the design of public health policy, along with a lack of transparency. 
They also have the effect of reducing government emphasis on public interest research and 
increasing the pockets of undone science in different fields of science.    
In Australia the federal health minister receives advice on vaccination policies from 
technical experts without consultation with the community. The institutional barriers that 
exist in the Australian political system and in academic and media organizations have 
resulted in the marginalisation of the public’s contribution to vaccination policy, even 
though the public is a main stakeholder in these policies. The Australian government 
justifies current vaccination policies by claiming, in effect, there is no evidence of harm so 
therefore no action is required. However, this claim ignores the lack of evidence due to 
research that has not been funded. The undone science in Australia’s vaccination policies 
includes comprehensive RCT’s for the efficacy and safety of vaccines, either singly or in 
the combined schedule of vaccines in animals and humans. In this situation it becomes 
necessary for the public to have influence in the decision-making process to ensure that all 
relevant research is undertaken and accounted for in policy decisions.  
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The lack of integrity and rigour in the clinical trials and scientific research that is being 
sponsored by industry for global health policies was discussed in chapters 6 and 7. In 
chapters 9 and 10, I have provided case studies illustrating the undone science and industry 
influence in the promotion of global HPV vaccination programs and the pandemic ‘Swine 
Flu’ 2009 vaccine. These case studies illustrate how vaccines can be developed and policies 
implemented on incomplete science due to the political framework that results in undone 
science.  
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CHAPTER 9 
HUMAN PAPILLOMAVIRUS (HPV) VACCINE 
PART 1 HPV AND CERVICAL CANCER PATHOGENESIS  
9.1 Introduction 
HPV vaccines are an example of the technology transfer that is occurring in research 
institutions with industry sponsors. This transfer is facilitated in the 21st century by 
governments that are playing a major role in the marketing of innovative products. 
Public health policies are being designed by technical experts with financial links to 
industry on policy advisory boards. The development of HPV vaccines was based 
largely on research at the US National Institutes of Health (NIH). This government 
body is part of the US Department of Health and Human Services (HHS) which profited 
from the licensing and marketing of this vaccine in 2006. See Section 9.19. HPV 
vaccines have been promoted to the Australian community since 2007 as a vaccine to 
prevent cervical cancer and genital warts in women. However, in 2012, the US FDA 
extended its use to the prevention of anal cancers and genital warts in men. The vaccine 
is now being recommended to all adolescent boys and girls in many countries, including 
Australia. A time-line of events regarding the development and marketing of HPV 
vaccines is presented in Appendix 7.  
This case study will examine the evidence Merck & Co have used to suggest an HPV 
vaccine will protect against cervical cancer. The sequence of events that led to the 
marketing of this vaccine as ‘a prevention’ for cervical cancer will be presented to 
assess the validity of the claims about its safety and efficacy. This will provide the 
context for the discovery that led to a vaccine being marketed for a non-infectious 
disease – cervical cancer – instead of an infectious disease. Traditionally vaccines have 
been developed to prevent infectious diseases because these diseases can spread through 
communities so governments recommend vaccines for ‘community protection’. 
However, this argument does not apply to non-infectious diseases and the involvement 
of HPV infection in the etiology of cervical cancer needs to be examined. Whilst it has 
been established that the human papillomavirus is a necessary transmissible factor in 
most cases of cervical cancer, this research will demonstrate why a vaccine against 
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cervical cancer – a non-communicable disease – is not beneficial as a universal 
preventative strategy for this disease. 
The HPV vaccine has been demonstrated to prevent the transmission of 2 of 15 high-
risk strains of Human Papillomaviruses that are associated with causing cervical cancer 
but it has not been demonstrated to prevent cervical cancer. Consequently, the 
Australian Health Department only refers to this vaccine as an ‘HPV vaccine’ and not a 
‘cervical cancer vaccine’. Yet the Australian Government has allowed this vaccine to be 
promoted to the public as ‘a prevention for cervical cancer’. A causal theory for an 
infectious disease requires that the incidence of the causal agent varies with the 
incidence of the disease. This chapter examines the global incidence of HPV 16/18 and 
the global risk of developing cervical cancer to determine if a correlation exists. It also 
analyses the assumptions that have been made to claim that a quadrivalent HPV vaccine 
will protect against most cervical cancer and that it is cost-effective in countries that 
already have Pap screening programs. The cost-effectiveness of HPV vaccines in many 
countries has been determined using mathematical models that are limited by the 
assumptions they are founded on. These assumptions are described in this chapter. An 
independent and transparent assessment of these assumptions is essential to population 
health and the effective distribution of health resources to the community. This case 
study provides an example of the influence of academic-industry partnerships on the 
production of scientific knowledge. It illustrates the type of evidence that scientists are 
using to claim vaccines are safe and effective and it provides an illustration of the 
communication of risks and benefits of diseases/vaccines to the general public. In 
western countries, such as Australia, health promotion occurs within the capitalist free 
market model of health which is driven by profits. Whilst this can result in good health 
outcomes in many cases it needs to be acknowledged that when doctors promote profit-
making technologies it can conflict with their pledge to prioritise the health and well-
being of their patients. See chapter 5.  
This chapter examines the promotion of this vaccine by medical associations to 
determine how doctors have been educated on the etiology of cervical cancer and 
whether they are promoting it because it is in the best interests of the community. It also 
investigates the design of clinical trials, the rigour of the evidence that conclusions are 
founded on and the communication of risks and benefits to the public. In addition, it 
will observe whether all types of evidence have been used to draw conclusions about 
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the benefits and risks of HPV vaccines. Scientists can obtain valuable scientific 
knowledge from clinical, animal, biological and epidemiological studies and it is 
important that all types of evidence are used to draw conclusions about the risks and 
benefits of vaccines. The manufacturers of the HPV vaccine claimed in 2006 ‘the 
vaccine has the potential to eradicate cervical cancer within a generation’ (NADC). 
Such a claim needs to be supported by evidence. This case study will examine whether 
the conclusions about the benefits of this vaccine have been founded upon 
comprehensive scientific knowledge or whether there are significant areas of undone 
science that throw these conclusions into question. It also provides an example of the 
way in which scientific knowledge and health promotion are being altered by the 
industry-academic partnership that is driving the production of medical knowledge in 
the 21st century. 
This chapter begins with background information regarding the sequence of events that 
led to the identification of HPV DNA in the majority of cervical cancer tumours. I have 
then described the global risk of developing cervical cancer to see whether the risk is 
similar in all countries. This is compared to an overview of the global incidence of HPV 
sub-types to determine whether the risk of cervical cancer correlates with a higher 
incidence of HPV sub-types 16 and 18: the sub-types stated to be the determining and 
independent cause of cervical cancer. Historically scientists believed that cervical 
cancer had a multifactorial etiology involving environmental and lifestyle factors. 
Several factors have been implicated in the cause of this disease for decades and these 
are discussed in this chapter. I have also outlined the strategies that have been used to 
market HPV vaccines to the public. Communication of the risks and benefits of 
vaccines is an important part of public health policies and providing balanced scientific 
information to the public is essential to improving health outcomes. I have provided 
information on the ingredients of HPV vaccines and the adverse events that have been 
associated with these vaccines. This information is compared to the government’s 
claims about the safety and efficacy of HPV vaccines to see whether all the available 
evidence is being included in the government’s assessment of the benefits and risks. 
The methodology for determining the cost-effectiveness of HPV vaccination programs 
in different countries is discussed along with an assessment of the assumptions that 
these models are founded on. Finally I have discussed the conflicts of interest in the 
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production and promotion of HPV vaccines to evaluate their possible influence in the 
decision to use a vaccine in global national vaccination programs.  
Chapter 9 Part 2 outlines the undone science in HPV vaccination programs which 
results in unpredictable health outcomes in the population.  
9.2 Historical Knowledge of the Etiology of Cervical Cancer  
The theory that HPV DNA is the cause of cervical cancer is founded on nascent 
technology that is being used to identify different sub-types of cervical HPV. In this 
section I have discussed the development of this biotechnology to provide background 
information on its sensitivity and specificity in determining the global distribution of 
HPV sub-types from 1995-2003. I have only referenced studies that were available at 
the time the vaccine was developed because my aim is to evaluate the information that 
led to the decision that a vaccine was a suitable management strategy for this disease.  
The information presented in this chapter includes an examination of the correlation 
between the incidence of HPV16/18 and the incidence of cervical cancer to determine 
whether the risk of this disease varies in different populations and regions. This is 
essential to the assessment of whether HPV is an independent cause of cervical cancer 
and whether an HPV vaccine will be effective in preventing this non-communicable 
disease. I have started this section from 1989 because at this time it was unknown 
whether HPV infections were the determining causal factor in the development of 
cervical cancer and I have described the other factors that were believed to be central to 
the etiology this disease. In 1989 the IARC stated there was no clear cut evidence that 
HPV infection is causally related to cancer of the cervix (Munoz et al 1989). This was 
supported by Pfister (1990) who stated ‘the etiology of cervical cancer is still 
unknown.’ He continued ‘vaccination is not yet justified as there is no formal proof for 
HPV causing cancer ...’ (Pfister 1990 p248). At this time the IARC had not excluded the 
possibility that Herpes Simplex Virus-Type 2 (HSV-2) and HPV played a role in the 
causation of cervical cancer (Munoz et al 1989; Bosch et al 2002). 
It was unclear whether HPV was a passenger virus in carcinoma development or 
whether it played a causal role in the progression to ICC (Villa and Franco 1989). 
HPV’s are a group of viruses with strong epitheliotrophic properties (Villa and Franco 
1989). That is, epithelial cells normally harbor the virus and 80% of women are infected 
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with HPV during their lifetime (IARC 1995; Henderson 1989). Therefore you would 
expect that the vast majority of abnormal cervical proliferation was associated with 
HPV infection. The overall evidence in 1988 pointed to a multifactorial cause of 
cervical cancer as other determinants consistently emerged as independent risk factors 
in epidemiological investigations (Villa and Franco 1989). The evidence suggesting an 
etiological role for certain sub-types of HPV in the development of cervical cancer 
stemmed from the following observations (Villa and Franco 1989): 
1. Most genital cancers contain HPV DNA sequences  
2. The viral DNA differs in its physical state 
3. Cervical tumors frequently contain transcriptionally active viral genomes and 
their cell lines are maintained in culture 
4. Malignant transformation can be obtained when viral DNA is introduced into 
mammalian cells in culture (p339) 
In 1989 this evidence was not always consistent (Villa and Franco 1989). Some studies 
demonstrated that the distribution of viral DNA within the specimen and its 
transcriptional activity in cervical tumours showed an inconsistent pattern of 
occurrence. The differences in the physical state and expression of advanced and pre-
cursor lesions could also be a consequence of long-lasting viral infections (Villa and 
Franco 1989). It has also been observed that HPV is present in high frequency in 
women with normal cervices in different populations (Villa and Franco 1989; IARC 
1995) and that cervical cancer is a rare outcome from all HPV infections (NHMRC 
2005; WHO 2008). In other words, HPV infection of any sub-type is not predictive of 
cancer, particularly as ninety percent of HPV infections have no clinical consequences 
at all (IARC 1995; Pfister 1990). That is, there is no development of genital warts or 
progression to cervical cancer. Pfister also stated in 1990 that ‘no papillomavirus is able 
to induce cancer right away and fully on its own which indicates that additional events 
are mandatory to trigger malignant conversion’ (p6). It was observed that carcinomas 
usually develop only after primary lesions are present for several months or even years 
and this indicates other factors are necessary to trigger cancerous tumours.  
New methods for distinguishing different strains of HPV infection became available in 
the 1990’s. Type specific exposure to HPV became available around 1989 due to 
cloning techniques of HPV DNA in bacteria and the development of various 
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hybridization methods but there was uncertainty about the sensitivity and specificity of 
the various analytic methods in detecting HPV DNA in the different tissue types 
(Munoz et al 1989). For example, the detection of HPV sub-types in different tissues, 
such as carcinoma, cervical intraepithelial neoplasia (CIN) and normal tissue, was not 
considered reliable. Pfister (1990) stated that the prevalence of HPV types varies 
considerably in biopsies of cervical lesions depending upon the hybridization detection 
method used. New analytic hybridization techniques for identifying HPV DNA became 
available in the 1990’s and these were believed to be highly sensitive and specific 
(Franco 1995 p779) providing more reliable estimates for the relationship between HPV 
infection and pathogenesis. 
HPV was found to be predictive of cervical intraepithelial lesions (CIN) and associated 
with invasive carcinoma in case-control studies (Franco 1995 p779). Epidemiologists 
claimed there was a highly statistically significant association between HPV and the 
development of cervical intraepithelial neoplasia (CIN) grade 2 or 3, with persistent 
CIN 2/3 and with the development of cervical cancer (Bennett et al 2010). 
Carcinogenicity of HPV16/18 is supported by experimental evidence that proteins of 
these viruses interfere with the functions of cellular regulatory pathways (IARC 1995). 
At this time Bosch et al claimed ‘the association of genital human papillomavirus 
(HPV) with cervical cancer is strong, independent of other risk factors and consistent in 
several countries’ (Bosch et al 1995 p796). In 1995, Bosch et al set out to characterise 
the global distribution of HPV genotypes because they knew this was ‘essential to the 
development of vaccination strategies to curb the burden of cervical cancer’ (Bosch et al 
1995 p797).	  In this study of 1000 cervical cancer tumours it was found that 93% 
contained HPV DNA (Bosch et al 1995). This international study used new polymerase 
chain reaction-based (PCR) assays to detect more than 25 HPV types in 1000 
specimens. In 1999, the 7% of tumours that were originally found to be HPV negative 
in the Bosch et al study of 1,000 tumours were re-analysed using different techniques 
and assumptions (Walboomers et al 1999).  
Whilst PCR methods are more sensitive and specific than liquid hybridization 
techniques and enable the identification of different genotypes, the specificity of this 
technique depends upon the type of primer used: type-specific or broad-spectrum (van 
Doorn et al 2006). The Bosch et al 1995 study used the broad-spectrum MY11/09 
method to genotype HPV-DNA. The re-analysis by Walboomers et al using different 
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primers and assumptions led to the conclusion that ‘a virtual absence of HPV-negative 
carcinomas implies that effective prophylactic vaccination might eliminate cervical 
cancer worldwide’ (Walboomers et al 1999 p18). The nascent technology used in this 
study was only available from the mid-1990’s so the evidence for the causality of 
different HPV genotypes in cervical cancer was based on a small number of studies 
between 1995 and 2002. The limitations of the Bosch et al (1995) study and the 
Walboomers et al (1999) re-analysis have been presented in Appendix 8. 
By 2002 scientists were declaring human papillomavirus (HPV) Type 16 and 18 to be 
the ‘first ever identified necessary cause of human cancer’ (Bosch et al 2002 p244). Yet 
in 1989 CSL had provided funding to Professor Ian Frazer and Dr. Jian Zhou to develop 
a drug that would prevent carcinogenic changes believed to result from HPV infections 
(Uniquest). Frazer and Zou’s research on an HPV vaccine was initiated in the early 
1990’s based on the belief that the illness from genital warts and the association of HPV 
with pre-cursor lesions in the cervix, vulva and penis were sufficient reason to develop a 
vaccine (Pfister 1990). However, it wasn’t known until 1995 that HPV was found in 
most cervical cancer tumours and until 2002 that HPV 16/18 were the most prevalent 
strains in all countries. Uniquest had patented Frazer and Zhou’s HPV vaccine 
technology in 1991 (Uniquest). In 2002 scientists declared human papillomavirus 
(HPV) was associated with virtually all cervical cancer globally and claimed ‘The 
causal role of HPV infections in cervical cancer has been documented beyond 
reasonable doubt’ (Bosch et al 2002 p244). The statement that HPV infection is a 
necessary cause does not say whether it was a sufficient cause of cervical cancer. It had 
been known for decades that persistent infection of the cervix with high-risk HPV was 
not sufficient to cause cervical cancer (Pfistor 1990; IARC 1995; Cogliano 2005; 
Munoz et al 2006 pS3/1). In other words, other factors are also necessary to initiate 
cancer development. This indicates it is not an independent cause of cervical cancer. 
Whilst Bosch (1995) and Walboomers et al (1999) claimed that epidemiological studies 
have shown a strong association of genital HPV with cervical cancer in several 
countries that is independent of other risk factors, they did not demonstrate that HPV 
16/18 are the necessary and determining cause of most cervical cancer by providing 
evidence of a higher incidence of these strains in the countries with the highest risk for 
cervical cancer. The statement of causality was based on the development of new 
biotechnology. Whilst phase 1 and 2 clinical trials had begun for an HPV vaccine in 
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1999, the phase 3 clinical trials to test the efficacy of HPV vaccines against high-grade 
cervical cancer lesions were not begun until 2003 (Future II 2007).  
The plausibility of a causal theory, such as that put forward by Bosch et al, requires 
evidence that the risk of the disease varies with the factors implicated in the cause of the 
disease (Friis and Sellers 2004). It also requires evidence that the disease develops only 
in cases where the virus is present. Prior to 1995 scientists stated that the detection of 
HPV DNA in different tissues had been unreliable but with the development of new 
molecular technology many scientists now claimed that the detection of HPV DNA was 
reliable because the new technology was truly ‘sensitive and specific’ (Franco 1995 
p779).  
Bosch et al (2002) defined a ‘necessary’ cause as the circumstance where the disease 
‘does not and will not develop in the absence of the persistent presence of HPV DNA’ 
(p244) yet they also confirmed in 2002 that HPV DNA had not been detected in 
approximately 10% of specimens of cervical cancer cases (p244). Despite this 
knowledge these scientists claimed that ‘this is the first necessary cause of a human 
cancer ever identified’ (Bosch et al 2002 p244). Although Bosch et al (2002) stated that 
‘proof of cause was elusive’ they believed that scientists had a duty to make causal 
judgements based on the available scientific evidence on the premise that all scientific 
work is incomplete (p260). Hence this network of scientists concluded it was their duty 
to trial an HPV vaccine even though their evidence that HPV 16/18 were the 
determining cause of most cervical cancer was incomplete. It is noteworthy that the 
claims supporting the hypothesis that a vaccine would be effective against cervical 
cancer were made by a dominant group of scientists with financial links to the vaccine 
industry (Bosch et al 1995; Walboomers et al 1999; Munoz et al 2006; Franco 1995).  
9.3 Biotechnology for the Detection of HPV Genotypes 
A causal theory based only on the presence of HPV genotypes is strongly dependent 
upon the accuracy and precision of the biotechnology used for detection. Identification 
of HPV genotypes in the anogenital tract is also complicated by the fact that 40 or more 
different HPV types may be present making it difficult to distinguish the causal agent 
(van Doorn et al 2006). Several methods are used to identify HPV DNA and it is 
essential to know that these methods are unbiased in the amplification of different 
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genotypes (Mori et al 2011). Klug et al (2008) state that genotyping assays that have 
been used in the past decade are known to differ in their ability to amplify and detect 
specific genotypes. A comparison between different studies has been difficult because 
there was no global standardisation of assay performance or methodology for quality 
assurance prior to 2005 (Klug et al 2008).  
The World Health Organisation (WHO) did not establish the global HPV laboratory 
network (LabNet) to standardise assay tests and laboratory procedures until 2005 
(Eklund et al 2012). This is necessary to ensure that assay performances and laboratory 
practices globally can be evaluated against a known and universal standard, with the 
same criteria for accurately determining the incidence of HPV genotypes found in 
different countries. Standardised assays and laboratory practices were established after 
the clinical trials for HPV16/18 vaccines were started.  
9.4 The Global Distribution of HPV Genotypes in Invasive Cervical 
Cancer (ICC) 
The strongest evidence for proving that HPV16/18 are the central etiological factors in 
the majority of cervical cancer would be a correlation between the incidence of 
HPV16/18 worldwide and the incidence of cervical cancer worldwide. This section 
investigates the distribution of HPV genotypes to see whether this correlation exists. An 
important factor in this discussion is the definition of ‘cervical cancer’. This question is 
significant because the incidence rates for cervical cancer include cervical intraepithelial 
neoplasia (CIN) grade 3. These lesions are asymptomatic but they are described as 
‘disease’ and included in the incidence figures for cervical cancer. CIN 3 can only be 
detected by screening and the majority of these lesions do not progress to cancer. This 
section discusses the burden of cervical cancer in different populations and how this is 
affected by Pap screening programs. I have used references that provide evidence of the 
knowledge that was available to scientists at the time the HPV vaccine was developed 
and not the most recent references, to evaluate the strength of evidence on which 
decisions at the time were founded.  
There are over 100 HPV genotypes that have been identified and 40 of these are known 
to more frequently infect the genital tract through sexual contact when a condom or 
diaphragm is not used (Munoz et al 2006; Smith et al 2002). This indicates that the risk 
	  
	  
226	  
of infection with HPV can be reduced by using condoms or a diaphragm even if these 
methods are not 100% effective. Studies of young women who have not had sex show 
that HPV DNA and antibodies to genital types of HPV are not usually detected (IARC 
1995). Although some HPV antibodies are obtained by skin to skin contact during birth 
or childhood these studies provide evidence that HPV infection in childhood is rare and 
that a higher number of sexual partners is an increased risk for HPV infection and 
cervical cancer (IARC 1995). Most strains of HPV are common and harmless, however 
there are at least 20 types associated with cervical cancer: 14 of these are considered 
carcinogenic and these include HPV 16, 18, 31, 33, 35, 39, 45, 51, 56, 58, 52, 26, 53, 66 
(Bosch et al 1995). These types are frequently found in cervical cancer and are 
classified as ‘high-risk’ HPV’s (Bosch et al 1995). Other types such as HPV 6, 11, 42, 
43 and 44 are rarely or never associated with cervical tumours and they are classified as 
low risk HPV types (Bosch et al 1995).  
Study results indicate that high rates of genital HPV infection are sustained in all 
communities throughout the world even in groups that do not have a high partner 
exchange (IARC 1995). As there is not a similar rate of cervical cancer in all these 
communities throughout the world, it has been postulated that the more ‘high-risk’ HPV 
types may be associated with higher grades of CIN and carcinoma (IARC 1995). Whilst 
some scientists are claiming that the variation in the incidence rate between countries is 
due entirely to the implementation of screening practices this does not explain all the 
evidence regarding the incidence and mortality of this disease. Screening has 
significantly reduced the mortality of cervical cancer in many countries through early 
detection and surgery, but prior to Pap screening the mortality from cervical cancer was 
significantly reduced through environmental and lifestyle changes. These co-factors are 
known to influence the variation in cervical cancer incidence rates that are observed 
between countries. Whilst persistent HPV infection is known to be a necessary cause of 
cervical cancer, co-factors (risk factors) are also necessary for pathogenesis to occur 
(IARC 1995). 
An example of the influence of environmental co-factors in the etiology of cervical 
cancer is provided by the cervical cancer statistics for sex workers. The incidence of 
cervical cancer is found to be four times greater in sex workers than in other women 
(Gitsch et al 1991). Yet the study by Gitsch et al did not find any statistically significant 
difference between the distribution of HPV subtypes in the lesions of sex workers and 
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other women. That is, there was no correlation between the incidence of high risk HPV 
subtypes and the incidence of cervical cancer in sex workers. This indicates that 
environmental factors must also play a role in the progression to disease.  
The role of HPV 16 and 18 as the main and determining causal factor in the majority of 
cervical cancer would be confirmed if the countries with the highest incidence of 
cervical cancer (mainly developing countries) also had a higher incidence of HPV 
16/18. If these sub-types are not more prevalent in the general population in these 
countries then there should be no greater incidence of cervical cancer from HPV 
infection in developing countries than in developed countries. Pap screening has 
reduced the mortality and incidence associated with cervical cancer in many countries 
through early detection and intervention but a reduction in the disease burden also 
occurred as a result of environmental changes prior to screening programs.  
Studies have shown that the incidence of the most common HPV subtypes in different 
geographical regions is similar. There are a variety of subtypes in all populations even 
though HPV 16 appears to be the most prevalent in all countries (Bosch et al 1995; 
Clifford et al 2003). Yet cervical cancer incidence is highest in developing countries: 
83% of cervical cancer cases occur in developing countries (IARC 1995). Some 
similarities in the distribution of HPV sub-types have been found in invasive cervical 
carcinomas across regions (Clifford et al 2003). HPV 16 was found to be the dominant 
strain in all countries (51% of cases) and HPV 18 found consistently in 10-14% of cases 
(Clifford et al 2003). This led Clifford et al (2003) to claim that HPV 16 and 18 are 
found in approximately 70% of all ICC cases. Patterns in the prevalence of other HPV 
genotypes in different countries were also observed (Bosch et al 1995; Clifford et al 
2003). These are illustrated in Figure 9.  
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Figure 9: HPV Subtype Prevalence in Carcinomas Globally 
 
Source: Bosch FX, Manos M, Munoz N, Sherman M, Jansen A, Peto J, Schiffman M, 
Moreno V, Kurman R, Shah K, International Biological Study on Cervical Cancer 
(IBSCC), 1995, Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide 
Perspective, Journal of the National Cancer Institute, Vol.87, No. 11  
 
Clifford et al claimed two thirds of ICC was associated with HPV 16 and 18, yet these 
two strains are slightly less common in developing countries where the incidence of 
cervical cancer is the highest (Clifford et al 2003). The prevalence of HPV 16 was 
slightly higher in America, Australia and Europe: the developed countries where the 
risk of cervical cancer is low (Parkin et al 2005). More than 15 high-risk HPV sub-types 
are prevalent in all countries both in regions where the rates of cervical cancer are 
considered high and where they are considered low (Clifford et al 2003). This indicates 
that HPV infection on its own is not pathogenic. These sub-types include 45, 31, 33, 58, 
39, 59 and 52 (Bosch et al 1995; Clifford et al 2003). This can be observed in Figure 12. 
Whilst the incidence of HPV 16 was only slightly higher in developed countries it needs 
to be acknowledged that the evidence does not support the conclusion that HPV 16 is an 
independent cause of this disease, even if HPV infection is a necessary cause.  
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The Australian developer of HPV vaccines, Ian Frazer, stated in 2005, prior to the 
introduction of the vaccine, that 90% of cervical cancer occurs in the developing 
countries not the developed countries (Williamson 2005). The fact that cervical cancer 
is a rare outcome of HPV infection from any strain (Bosch et al 2002) is supported by 
the difference in the prevalence of HPV infection and cervical cancer worldwide. It is 
estimated that the worldwide prevalence of genital HPV infection amongst adult women 
is 326 million and the annual incidence of new cases of cervical cancer worldwide is 
approximately 450,000 (Parkin et al 2005). Approximately eighty percent of all women 
will be infected with HPV yet ninety percent of HPV infections do not lead to cervical 
cancer or warts (IARC 1995). Screening for high-risk HPV infection would identify a 
very large number of women but only a few of these are at risk of cervical cancer 
(NHMRC 2005). This is the same when HPV vaccines are used in universal vaccination 
programs; a large number of women would be using the vaccine but only a few are at 
risk of developing cervical cancer, even when they have a high-risk HPV infection.  
9.5 Overview of the Global Risk of Cervical Cancer  
This section examines the global risk of dying from cervical cancer to investigate the 
severity of the disease in different populations and to determine the most important 
factors in reducing the risk from this disease.  
The two measures of the burden of cancer worldwide are incidence and mortality rates. 
Incidence rates measure the number of new cancer cases each year and can be expressed 
as a rate per 100,000 persons per year (Parkin et al 2005). Figure 9 illustrates the 
incidence and mortality rates for different cancers worldwide. This graph shows that 
cervical cancer (combined with uteri cancer) is placed seventh in importance in women 
in developed countries after breast, colon/rectum, lung, stomach, ovary, and corpus uteri 
cancer. But in developing countries it is placed second in importance in women after 
breast cancer. The graph shows there is a significant difference between the risk of 
cervical cancer in developed and developing countries (Parkin et al 2005).  
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Figure 10: Estimated Numbers of New Cancer Cases (Incidence) and 
Deaths (Mortality) in Developed and Developing Countries in 2002  
 
Data shown in thousands for developing and developed countries by cancer site and sex  
Source: Parkin DM, Bray F, Ferlay J, Pisani P, Global Cancer Statistics 2002, CA: A Cancer 
Journal for Clinicians, 2005; 55; 74-108 
 
In developed countries cervical cancer accounts for 3.6% of new cancers and in the 
developing world it accounts for 15% of new cancers (Parkin et al 2005). This is an 
important distinction to make when educating women about the risks of cervical cancer.  
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Cervical cancer is a disease that has a much lower mortality than incidence rate. It is 
therefore considered to have a good prognosis because the case-fatality rate is low. The 
prognosis is good even in developing countries where many cases present at a relatively 
advanced stage (Parkin et al 2005). This is because cervical cancer can be treated by 
removing the abnormal cells. The high incidence of cervical cancer arises because early 
diagnosis through screening programs enables sub-clinical cases to be detected (Parkin 
et al 2005). CIN 3 is considered a sub-clinical case of ‘disease’. This is because the 
majority of CIN 3 is asymptomatic (Schiffman M et al 2008; McCredie MRE et al 
2008) but it is included in the incidence data because a percentage of CIN 3 will 
progress to cervical cancer. This represents a grey area of diagnosis because not all CIN 
3 is predictive of cancer.	   
The low case-fatality ratio for cervical cancer is a result of two factors: 
i) the inclusion of sub-clinical cases (CIN 3) in the incidence figures that would 
normally go unnoticed in an individual’s lifetime and 
ii) the fact that cancerous cells can be successfully treated with surgery.  
The variation in the incidence rates for cervical cancer between developed and 
developing countries is illustrated in Table 4.  
Table 3: Incidence Rates of Cervical Cancer Worldwide 
Developed Countries  
per 100,000 women 
Developing Countries  
per 100,000 women 
0 – 14.5 14.5- 44 
 
Source: Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global Cancer Statistics 2002, CA: A 
Cancer Journal for Clinicians, 2005; 55; 74-108 
 
The risk of dying from cervical cancer in developed countries is considered very low 
(Parkin et al 2005). For example, the incidence of cervical cancer in Australia is 6.9 
/100,000 women and the mortality rate is 1.9/100,000 women per year (AG NCIRS 
2009). Australia has one of the lowest rates of incidence and mortality for cervical 
cancer in the world and the vast majority of women in Australia (99%) will not be 
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affected by cervical cancer in their lifetime (AG NCIRS 2009). In Australia early 
detection by Pap screening reduced the incidence of cervical cancer by almost 50% in 
the decade from 1991 – 2002 (AIHW 2006).  
The incidence rate has been decreasing in developed nations since the 1950’s (Parkin et 
al 2005). In contrast, the developing countries are considered to have a high risk of 
cervical cancer. The cervical cancer incidence rates in developed countries during the 
1960’s and 1970’s were similar to the rates of cervical cancer in developing countries 
today (Gustafsson et al 1997). This is evidence that environment and lifestyle factors 
play a role in cervical cancer pathogenesis. Table 5 illustrates the mortality rates for 
cervical cancer worldwide. The table shows that mortality rates are much lower than 
incidence rates illustrated in Table 4 and again there is a significant difference between 
the developed and developing countries. 
Table 4: Mortality Rates for Cervical Cancer Worldwide 
Developed Countries  
per 100,000 women 
Developing Countries  
per 100,000 women 
0 - 10 10 - 34 
 
Source: Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global Cancer Statistics 2002, CA: A Cancer 
Journal for Clinicians, 2005; 55; 74-108 
 
The cumulative risk of cervical cancer to women before age 64 in the developed world 
is 0.8% and in the developing world is 1.5% (Parkin et al 2005). This difference in 
incidence rates is observed within Australia when comparing indigenous and non-
indigenous women. In Australia, indigenous women have twice the risk of developing 
cervical cancer and the mortality rate is four to five times that of non-indigenous 
women (AG NCIRS 2009). This is a result of lower socioeconomic conditions which 
are more conducive to the spread of infectious agents. This is evidence of the role of 
environmental and lifestyle factors in the etiology of cervical cancer. The variation of 
risk of cervical cancer between countries can be observed in Figure 11. 
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Figure 11: Age-standardized Incidence and Mortality Rates for Cervix Uteri 
Cancer Worldwide. 
 
Source: Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global Cancer Statistics 2002, CA: A Cancer 
Journal for Clinicians, 2005; 55; 74-108 
 
The developed countries are listed at the bottom of this graph and show that the burden 
cervical cancer in these countries is very low: they have a low case-fatality ratio. Whilst 
the risk of cervical cancer is shown to vary significantly between countries the risk of 
infection with HPV 16/18 is the same in all countries. In addition, there have been 
substantial declines in cervical cancer incidence and mortality rates in many countries 
over the past decades, particularly in the Western world (Parkin et al 2005). Parkin et al 
state co-factors such as high-parity (a high number of births), tobacco smoking and use 
of oral contraceptives are factors that are shown to increase the risk of cervical cancer in 
women who have an HPV infection. Groner et al (2014) state that one of the most 
important risk factors for cervical cancer is the number of lifetime partners. The risk of 
cervical cancer increases four-fold amongst sexually active 14-19 year olds with 3 or 
more partners.  
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9.6 Environmental and Lifestyle Co-factors in Cervical Cancer 
Etiology 
A lack of correlation between HPV 16/18 infection and a higher risk for cervical cancer 
incidence indicates that co-factors are necessary in conjunction with HPV infection for 
pathogenesis to occur. The evidence supporting this conclusion is described here.  
It has been observed that cervical cancer declined in developed countries between 1955 
and 1992 (Parkin et al 2005). Pap screening was not implemented in Australia and many 
other developed countries in a comprehensive way until after 1990 (AIHW 2006). The 
death rate dropped by 74% in the US during this time. Evidence for an association 
between cervical cancer and sexual activity has been available for more than a century 
(Munoz et al 1989). Since 1842 it has been noted that women who do not have sex do 
not get cervical cancer. This has led to the belief that a sexually transmitted virus was 
implicated in the etiology of cervical cancer. For many years the focus was on Herpes 
Simplex Virus Type 2 (HSV–2) as the cause of cervical cancer but as this virus is not 
found in all cervical cancer tumours the focus changed to HPV infection (Munoz et al 
1989). Harald zur Hausen found HPV-DNA in cervical cancers in the 1980’s and was 
awarded the Nobel prize for this discovery in 2008. He was the first to isolate HPV 16 
and 18 from cervical cancer tissue (zur Hausen 2008). The reduction in cervical cancer 
in developed countries from 1955 onwards coincided with improvements in social 
conditions and lifestyle changes (Pfister 1990). There was greater access to healthcare 
facilities, health education and condoms in developed nations. Since 1990 the decline in 
mortality to cervical cancer in Australia has been aided by early detection of neoplasia 
through cervical screening (AIHW 2006). Cervical cancer is nearly always curable (9 
out of 10 cancers) if detected early by Pap screening (NHMRC 2005).  
Studies have shown that early sexual activity, high promiscuity and low socioeconomic 
status are risk factors for the development of cervical cancer (Munoz et al 1989; Gitsch 
et al 1991). Many developing nations have cultures that allow polygamy and the social 
conditions and infrastructure in these countries are poor which increases the 
transmission of infectious agents (Howett and Kuhl 2005). The incidence and mortality 
rate of cervical cancer increases with poverty and varies with socioeconomic status 
(Vetter and Gellor 2007). Educational attainment and access to healthcare significantly 
reduce the incidence of this disease (Vetter and Gellor 2007). Sexually transmitted 
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diseases (STD) are common and increasing in developing countries where there is 
frequent contact with commercial sex workers or where the onset of intercourse occurs 
at an earlier age with increased numbers of partners and sexual acts (Howett and Kuhl 
2005).  
A study by the IARC concluded that women infected with HPV combined with Herpes 
simplex virus – type 2 (HSV-2) are two or three times more likely to get cervical cancer 
than when they are only infected with HPV. Yet women who are infected with HSV-2 
are not at increased risk of cancer if they are not also infected with HPV (Smith et al 
2002). STD organisms represent prolonged and life-long infections in low SES regions 
because antivirals do not represent a cure for STD’s (Howett and Kuhl 2005). 
Therefore, the higher incidence of invasive cervical cancer (ICC) in these regions is 
partly because women are more likely to be infected with a combination of two or more 
STD’s at once and less likely to be regularly screened. Immunosupression is another 
risk factor for cervical cancer and this can be induced by HPV infections that are 
combined with HIV (Bosch et al 2013). Sexual behaviour that is conducive to acquiring 
sexually transmitted diseases represents an increased risk for developing cervical cancer 
and other genital diseases (Munoz et al 1989; Smith et al 2002). Infection rates with 
Herpes Simplex Virus-type 2 (HSV-2) are one in four in the USA and they are the cause 
of acute and recurrent genital herpes (Howett and Kuhl 2005).  
There is a large body of evidence that also implicates sexual practices for males in the 
etiology of cervical cancer (Thomas et al 1996). It has been found that women whose 
husbands were in their twenties or younger when they first visited sex workers were 
found to be at higher risk of cervical cancer than women whose husbands did not visit 
sex workers (Thomas et al 1996). A major predictor of risk among women whose 
husbands visited sex workers was whether they used condoms during their visits. Not 
using a condom is a high risk factor for cervical cancer because it increases the risk of 
exposure to multiple infectious agents. It is believed that the risk of cervical cancer in 
Thailand could be reduced four-fold if men who regularly visit sex workers wore 
condoms (Thomas et al 1996). Contraceptive foams, creams and jellies are also found to 
reduce the risk of cervical cancer (Thomas et al 1996; Howett and Kuhl 2005). Studies 
in Thailand conclude that sex work plays an important role in the development of 
cervical cancer and it is thought that the most likely infectious carcinogenic agent is a 
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combination of some strains of HPV, HSV-2 and HIV (Thomas et al 1996; Smith et al 
2002; Bosch et al 2013). 
It is known that high-risk HPV infections have high resolution rates in young women 
and infections can persist for a lifetime without giving rise to cervical cancer (NHMRC 
2005). This is evidence that environmental and lifestyle factors act in conjunction with 
HPV in the etiology of cervical cancer. In summary the environmental and lifestyle 
factors which are known to increase a person’s risk of persistent infection and the 
progression of high-grade lesions to related cancers include (IARC 1995; Walboomers 
et al 1999; Haverkos 2005):  
a) Multiple partners for the male and female  
b) Presence of HPV plus other sexually transmitted viruses  
c) Sex work (Gitsch et al 1991)  
d) Sex without a condom/microbicides (WHO 2008 p.9)  
e) High parity > 3 children  
f) Cervical tar exposures (Bennett et al 2010)  
g) Low socioeconomic status: poor hygiene/sanitation/nutrition conducive to sexually 
transmitted diseases  
h) Immunosuppression  
i) Smoking  
j) Long-term oral contraceptive use and 
 k) Older age (WHO Biotext 2008 p2).  
When the HPV vaccines were implemented in global populations in 2006/7 it was 
known that most individuals do not develop clinical signs or symptoms of any disease 
after infection from any type of HPV infection. Cervical cancer was known to be a rare 
outcome of HPV infections (IARC 1995; Bosch et al 2002; NHMRC 2005; WHO 
2008). Bennett et al (2010) state ‘..most women who become infected with HPV will 
not develop cervical cancer’ (p331). Yet promotional campaigns for the HPV vaccine 
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create fear about HPV infections by stating that most women will be infected with HPV 
in their lifetime and these infections are the cause of cervical cancer (AG IAP HPV 
2012). HPV vaccines have also been promoted on the information that ‘cervical cancer 
is the second most life threatening cancer world-wide’ (Bennett et al 2010) even though 
this is a misleading statement that ignores the variation in environmental and lifestyle 
factors that significantly affect the risk of this disease in different countries.  
9.7	  Summary of the Evidence for Environmental/ Lifestyle Co-factors 
in Pathogenesis 
The evidence described above demonstrates that the claim by scientists that HPV 16/18 
infections are an independent cause of cervical cancer are false. HPV 16/18 infections 
are a necessary factor in most cases but not sufficient to cause disease. That is, they do 
not cause disease without the presence of environmental co-factors. In addition, it is 
known that cancer can have genetic causes. Evidence for this conclusion is summarised 
below: 
1. HPV infection with any strain is not sufficient to cause cervical cancer 
(Walboomers et al 1999). 
2.  Approximately eighty percent of women are infected with HPV yet ninety percent 
of HPV infections do not lead to cancer or warts (IARC 1995; AG NHMRC 2005).  
3. HPV 16 is identified as the pre-dominant sub-type in all countries yet cervical 
cancer rates vary significantly between countries (Parkin et al 2005). This was the 
case prior to the implementation of Pap screening in many countries so screening 
programs do not fully explain the variation in risk between countries.  
4. Developed countries had the same high rates of cervical cancer in the 1960’s and 
1970’s as the developing countries today but this was reduced by changes in 
environmental and lifestyle factors and with the introduction of Pap screening 
programs in the 1990’s (Parkin et al 2005). 
5. There is an increased risk of cervical cancer with an increased number of sexual 
partners (IARC 1995).  
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6. Sex workers have a four times greater chance of getting cervical cancer even 
though the detection of HPV subtypes is similar to controls (Gitsch et al 1991). 
7. Condoms can reduce the risk of cervical cancer four-fold by preventing many 
infections from HPV (Thomas et al 1996). 
8. Bosch et al (1996) highlight the fact that the sensitivity of new molecular biology 
techniques confirms the plausibility of HPV infection as the pre-cursor event 
leading to cervical cancer (Bosch et al 1995). However, a pre-cursor event is not a 
useful predictor of cancer if the majority of cases do not progress to cancer. 
Environmental factors play a role in the progression of some pre-cursor events to 
cancer.  
9. Some scientists still claim 5-10% of tumors are not associated with any HPV DNA 
(Bosch et al 2002; Schiffman in Kircheimer 2002; Haverkos 2005).  
10. It is stated that HPV 16/18 are present in approximately 70% of tumours but 
improved technology could prove this figure wrong. The 70% figure is dependent 
upon the detection methods used and it is not supported by evidence of a global 
correlation between these subtypes and cervical cancer pathogenesis. This vaccine 
has been founded on evidence of a causal factor for cervical cancer that is 
dependent upon the specificity and sensitivity of the analytical biotechnology that 
is used.  
9.8 The Efficacy of HPV Vaccines in the Prevention of Cervical Cancer 
This section describes the science that underpins the claim that HPV vaccines will be 
effective in preventing cervical cancer. HPV vaccines were not tested against cervical 
cancer outcomes in the clinical trials and this section describes the surrogate that was 
used in the clinical trials and the assumptions that underpin the conclusion that HPV 
vaccines would be effective in preventing cervical cancer.  
HPV DNA is associated with the development of squamous cell cervical cancer and 
cervical adenocarcinoma (FDA Merck Ltd 2006). In 2003 when the WHO consultation 
group was investigating the possibility of developing a prophylactic vaccine to prevent 
these cancers it was decided that a suitable surrogate end-point for the efficacy of the 
vaccine would be the histologic pre-cursor lesions for these cancers (Pagliusi 2004). 
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The histologic pre-cursor lesions are defined as cervical intra-epithelial neoplasia (CIN) 
grade 2/3 lesions and adenocarcinoma in situ (AIS) (FDA Merck Ltd 2006 p2). Cervical 
cancer has a latent period of between 10 and 30 years between HPV exposure and the 
development of cervical cancer and this time period for accruing cases was considered 
unfeasible (Pagliusi 2004). The WHO consultation group decided the virological end-
point of pre-cancerous lesions in women 15-26 years of age was a useful surrogate for 
vaccine efficacy studies (WHO 2008; Pagliusi 2004). This was decided even though 
pre-cursor lesions are common but rarely progress to cancer (WHO 2008 p8) therefore 
they are not a suitable definitive end-point for determining the efficacy of the vaccine in 
preventing cervical cancer.  
 The natural history of HPV infections shows that 90% are not detectable after 2 years. 
In addition, only 5% of HPV infections progress to either CIN 2 or 3 lesions within 3 
years (Schiffman M et al 2008; McCredie MRE et al 2008). Many CIN 3 lesions do not 
lead to invasive cancer later in life. Of the CIN 3 lesions that do progress, only 20% will 
progress to invasive carcinoma within 5 years and only 40% progress to invasive 
carcinoma within 30 years (Schiffman M et al 2008; McCredie MRE et al 2008).This 
suggests that the majority of CIN 2 and 3 pre-cursor lesions in young women do not 
lead to cancer later in life and hence they are not accurately predict how much cervical 
cancer an HPV vaccine can prevent. The decision to use this end-point was based on 
four key features (WHO 2008; FDA 2006; NCIRS 2009):  
1. They are obligate precursors of cervical cancer 
2. They are closely associated in temporal sequence to the development of invasive 
cervical cancer 
3. They are associated with a high risk of development of invasive cervical cancer 
(WHO Biotext 2008 p1). 
4. Treatment or reductions in incidence are shown to result in a reduction in risk of 
invasive cervical cancer. 
The first feature needs qualification. Whilst it is true that lesions grade CIN 3 are 
obligate precursors of cancer, the majority of lesions do not progress to cancer. Most 
high-grade pre-cursor lesions (CIN 2) in young women (~90%) regress quickly and 
without treatment in 2 years and the majority of CIN 3 lesions do not progress to ICC 
(Schiffman M et al 2008; McCredie MRE et al 2008; WHO 2008). The incidence of 
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high-grade squamous intraepithelial lesions (HSIL) is highest in this age-group and 
declines with age (NHMRC 2005; Heitman and Harper 2012). It is stated that cancer is 
an uncommon outcome of these lesions even in the absence of screening. Raffle et al 
(2003) observed that at least 80% of HSIL regresses without intervention or is 
asymptomatic in this age-group (NHMRC 2005 p15).  
Similarly, features two and three are only true when the environmental and lifestyle co-
factors (listed in 10.7 above) are also present (NHMRC 2005). This is demonstrated by 
the variation in the incidence and mortality rates for cervical cancer between developed 
and developing countries and between Australia’s indigenous and non-indigenous 
populations. The fourth feature also needs to be qualified. In countries where the 
environmental risk factors for pathogenesis have been reduced the majority of HPV 
infections are not a risk for cervical cancer. Cervical cancer is a rare outcome of all 
HPV infections with the majority being self-limiting and asymptomatic (IARC 1995; 
NHMRC 2005; WHO 2008). Screening for high-risk HPV infection would identify a 
very large number of women but only a few of them would be at risk of cervical cancer 
(NHMRC 2005 p9). This would be the same if all young women are vaccinated – the 
majority of these women would not be affected by cervical cancer in their lifetime. In 
addition, there are 15 high-risk HPV subtypes that are implicated in causing cervical 
cancer; protecting against just 2 does not prevent infection from the other 13 (AG 
NHMRC 2005). This is why Merck is now producing a vaccine that will include 5 more 
HPV genotypes. Resolved infection from high-risk HPV 16/18 does not protect against 
other high-risk HPV genotypes (Tomljenovic and Shaw 2012). In addition, Gardasil® 
does not prevent cervical cancer from HPV infection 16 and 18 which was already 
present at the time of vaccination (FDA Merck Ltd 2006).  
In 2006 when HPV vaccine was licensed and approved for use in the population there 
was no standard serological assay for detecting HPV antibodies and it was not known 
what level of antibody titre would be protective against HPV infection (WHO 2008; 
NCIRS 2010). An antibody titre against 2 of many oncogenic HPV genotypes (even if a 
protective level is established) is unable to provide accurate information about the 
efficacy of HPV vaccines against the burden of cervical cancer. This is because 
antibody titre is an indication of exposure to the infectious agent which in this case is 
not an independent cause of the disease. In this case the majority of people exposed to 
HPV do not get cervical cancer. There is ‘overwhelming evidence that infection with 
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HPV is necessary, though not sufficient, for development of cancer of the cervix’ 
(NHMRC 2005 p9). The expression of disease from an HPV infection depends upon 
environmental and lifestyle co-factors and most HPV infections are harmless if these 
co-factors are not also present (IARC 1995; WHO 2008; NHMRC 2005). Currently 
there is no technology to predict which CIN 3 lesions will progress to cancer and which 
ones will persist for a lifetime without causing disease (Heitmann and Harper 2012) but 
it is known that the vast majority of CIN 3 lesions do not progress to cancer.  
9.9 The Design of Phase 3 Trials for the Quadrivalent Vaccine: 
Gardasil 
This section describes the evidence that was collected from the clinical trials and the 
assumptions that have been used to market HPV vaccines as a safe and effective 
prevention for cervical cancer.  
The trials investigating the efficacy of an HPV vaccine in preventing cervical cancer 
observed that women (15-26 years old) who were given the vaccine had fewer pre-
cursor lesions than women who were not given the vaccine (FDA Merck Ltd 2006). 
However, this result was dependent upon the protocol of the study group. A significant 
reduction in pre-cursor lesions was only observed in the study group that had not been 
infected with HPV 16/18 at baseline (FDA Merck Ltd 2006). The Australian Health 
Department states that the HPV vaccine does not prevent HPV infection (16 and 18) 
which was already present at the time of vaccination (NHMRC 2005) and the efficacy 
of the vaccine was only 44% in the study group that was infected with HPV 16/18 at 
baseline (Future II 2007). Previous sexual activity is the main reason for infection with 
HPV (NHMRC 2005). In other words, you are still susceptible to cervical cancer if you 
were infected with HPV 16/18 prior to vaccination. This would be a large percentage of 
the population as these are claimed to be the dominant sub-types in all populations. 
Since the vaccine was marketed in 2006 there has been no screening for HPV sub-types 
prior to vaccination so there is no conclusive data on the effectiveness of HPV vaccine 
in preventing pre-cursor lesions due to HPV 16/18. Merck pharmaceutical company, the 
sponsor of the clinical trials, stated the vaccine prevents ‘100% of high-grade disease 
and ‘non-invasive’ cervical cancers associated with HPV infection’ based on its ability 
to prevent pre-cursor lesions (grade 2/3) in women 15-26 years of age (FDA Merck Ltd 
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2006). If CIN 3 does change into invasive cancer the time frame for this to happen 
averages between 8.1 to 12.6 years (ACOG 2005). Yet the longest follow up study for 
the phase 3 clinical trials that examined efficacy against pre-cursor lesions was only 4 
years (FDA Merck Ltd 2006). In addition, ‘the vast majority of women (15-26 years of 
age) clear or suppress HPV to levels not associated with CIN 2 or 3 (high-grade disease) 
and for most women this occurs promptly’ (ACOG 2005). Raffle et al state that 
modelling data from the United Kingdom suggests that eighty percent of high-grade 
intraepithelial abnormalities will regress without intervention (NHMRC 2005). 
Therefore, the correct assumption is that pre-cursor lesions in this age-group are not an 
indication that cervical cancer will develop from high-risk HPV infections. The clinical 
trials do not provide evidence that a reduced number of pre-cursor lesions in women 15-
26 years of age (even if not previously infected with HPV16/18) will reduce the 
incidence of cervical cancer in older women. Therefore there is no evidence of how 
much cervical cancer this vaccine may prevent. The only definitive evidence obtained 
from the clinical trials in this age group was that the drug prevents infection from 2 of 
15 high-risk strains of HPV identified in cervical cancer cases. However the duration of 
this prevention is unknown (WHO 2008).  
It was assumed that fewer HPV associated pre-cursor lesions in the vaccinated group 
indicated a reduction in cervical cancer cases in older women later in life. However, as 
the majority of pre-cursor lesions in this demographic regress naturally and do not lead 
to cancer later in life then it is not predictive of cervical cancer cases in older women. A 
drug to reduce infection from 2 of 15 HPV sub-types may not protect against cervical 
cancer because other HPV sub-types (13+) can infect. Further, the vaccine is not 
beneficial to the majority of women in developed countries because the co-factors for 
pathogenesis are not prevalent and most women are not at risk of cervical cancer.  
9.10 Marketing the HPV Vaccine 
In 2006 when the HPV vaccine was licensed and marketed to females the phase 3 
clinical trials had not been completed (Future II 2007). In other words, the benefit and 
safety of this vaccine against cervical cancer had not been established. Questions that 
still needed answering were (Vettor and Gellor 2007):  
i) Effectiveness of the vaccine as a prevention for cervical cancer  
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ii) Duration of vaccine efficacy  
iii) Efficacy of the vaccine in males and females older than 26 years of age and  
iv) The long-term safety of the vaccine.  
However, the vaccine was already being promoted to the public as a preventative for 
cervical cancer. It was recommended for all women aged 9-26 years old, even though it 
had not been tested for the prevention of pre-cursor lesions in females younger than 15 
years of age (Slade et al 2009). Phase 4 clinical trials of HPV vaccine continued in India 
even after the vaccine was implemented into the NIP’s of many countries in 2007; after 
it was fast tracked for approval outside the guidelines for this process (Sarojini et al 
2010 p29). The phase 4 trials in India were halted after one year when 6 girls died post-
vaccination and many suffered serious adverse reactions that were not being recorded. 
PATH (Program of Appropriate Technology in Health), the organisation responsible for 
the trials and largely funded by the Gates Foundation, was accused of breaches of 
ethical guidelines and the exploitation of children. This organisation had started a two 
year trial called a ‘Demonstration Project’ in paediatric populations/marginalised 
groups, without proper informed consent and without an active adverse event reporting 
system to monitor the health effects in the population. The reporting of adverse events 
by medical practitioners was voluntary (Sarojini et al 2010 pp27-8). This does not allow 
causal relationships or frequency of adverse events to be determined. The vaccine was 
promoted to these participants as giving ‘lifelong protection’ to cervical cancer and no 
side effects were mentioned. They were also not informed that the vaccine only covered 
2 of the 15 plus strains of HPV that are associated with carcinogenesis and therefore 
Pap screening would still be required. The purpose of the study in India was to 
determine the vaccines public health value yet it was already being promoted as 
beneficial in national immunisation programs. The implications of these practices and 
the influence of private-public partnerships on public health priorities are discussed 
further in Part 2 section 9.19.    
By promoting the vaccine as a preventative for cervical cancer, instead of a sexually 
transmitted virus, the HPV vaccine was placed in the non-communicable disease 
category thus enabling the manufacturer to avoid public health officials who would 
have scrutinized a high-risk vaccination campaign (Rothman and Rothman 2009). In 
addition, the US 1986 National Childhood Vaccine Injury Act removes liability from 
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vaccine manufacturers in the US for all design defects including those based on 
negligence (Holland and Krakow 2012 pp39-44). It states that vaccine manufacturers 
do not bear any liability for failing to give accurate or complete information to those 
vaccinated. Manufacturers only have to provide relevant information to doctors who 
must give patients CDC Vaccine Information Statements. In other words, even doctors 
are not required to make judgments about the risks and benefits of vaccines because the 
CDC provides the assessment for them in prepared information sheets. The 1986 
Childhood Vaccine Injury Act created a no-fault compensation program that was 
designed to ensure the stability of the vaccine supply as opposed to the safety of the 
vaccines recommended in government schedules (Holland and Krakow 2012 pp39-44).  
The quadrivalent HPV vaccine was approved by the US Food and Drug Administration 
(FDA) on June 8 2006 and 3 weeks later it was recommended by the US CDC 
Advisory Committee on Immunisation Practices (ACIP) for universal HPV vaccination 
for women 9 – 26 years of age (Blaxhill and Olmsted 2012 p186). The time period 
from clinical trial observing pre-cursor lesions to recommendation against cervical 
cancer was only 4 years. When recommending this drug the committee recognized they 
would need to create a demand for the drug (Vettor and Gellor 2007). In other words, 
cervical cancer was not prominent enough in developed nations for women to request a 
drug for its prevention. Most western women had not thought much about cervical 
cancer when the vaccine was introduced because it was not in the highest 10 most 
serious cancers in many developed countries (AIHW 2006; Rosenthal 2008). The 
public was also largely unaware of the connection between HPV infection and cervical 
cancer (Vettor and Gellor 2007). This causal link was only established in the early 
2000’s (Munoz et al 2006). The ACIP observed that education programs were needed 
to promote this drug and the programs would need to be from a trusted source (Vettor 
and Gellor 2007).  
This vaccine was fast tracked for approval by the FDA due to industry lobbying 
(Rosenthal 2008) and Merck ensured that Gardasil was approved for universal use in all 
women, not just for high-risk groups. The time frame from application to approval of 
the drug by the FDA was only 6 months and the CDC recommended it for universal use 
only weeks later (FDA News Release 2006). Harper, the principal investigator on the 
clinical trials of both HPV vaccines, Gardasil and Cervarix, states ‘Most vaccines take 
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three years to develop and then 5 to 10 more for universal acceptance’ (Rosenthal 2008 
p3). This is necessary to establish the safety and duration of efficacy of the vaccine. 
Many side effects only become apparent after they have been tested on a larger number 
of participants over longer time-periods (Slade et al 2009). The medical director at 
Merck, Richard Haupt, was questioned about the speed with which the HPV vaccine 
had been marketed and he replied ‘Our hope and belief is that this is a remarkable 
vaccine that will have a huge impact on women’ (Rosenthal 2008 p3). ‘Hope’ and 
‘belief’ are not the same as scientific evidence. 
Politicians were lobbied and invited to receptions urging them to legislate against a 
‘global killer’ (Rosenthal 2008 p2). Abramson, the chairman of the committee of the 
CDC that recommended the vaccine for all girls aged 11 or 12, stated ‘there was 
incredible pressure from industry and politics’ to approve this vaccine (Rosenthal 2008 
p2). Harper agrees ‘Merck lobbied every opinion leader, women’s group, medical 
society, politicians and went directly to the people – it created a sense of panic that 
says you have to have this vaccine now’ (Rosenthal 2008 p3). In the US 
pharmaceutical companies are allowed to advertise directly to the public and the 
campaigns for HPV vaccines have been very aggressive. 
 The marketing of drugs is a very important issue. In the following paragraphs I have 
relied largely on Rothman and Rothman (2009) for this information because they have 
provided an in-depth analysis of the health promotion campaigns for HPV vaccines. 
In order to promote HPV vaccines through a trusted source the industry obtained 
government reimbursement and mandates to promote the vaccine to all women, not 
just to high-risk populations. This enabled Merck, the manufacturer of Gardasil, to 
fund the professional medical associations (PMA’s) to promote the vaccine. The 
pharmaceutical companies supplied the medical associations with a Speaker Lecture 
Kit. This included ready-made presentations and letters to promote Gardasil as a 
preventative for cervical cancer, even though the data was incomplete. Much of the 
promotional material did not address the complexity of the issues surrounding the 
vaccine and did not provide balanced advice regarding the risks and benefits of the 
vaccine. It was also presented in a way that obscured the involvement of 
pharmaceutical companies in the marketing campaign. Doctors and nurses were 
recruited for an ‘Educate the Educators’ program created by the pharmaceutical 
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companies to train health professionals to promote the vaccine. The PMA’s maintained 
a registry of educators and participants lectured to thousands of healthcare 
professionals. Hundreds of doctors were paid $4,500 per 50 minute lecture to present 
the information supplied by the pharmaceutical companies at Merck sponsored 
conferences. Health professionals were also paid by the manufacturers to attend 
vaccine advisory board meetings and to educate the public in awareness campaigns. 
The financial support is often indirect so patients are unaware that ‘expert’ advice has 
been paid for by the vaccine makers (Rosenthal 2008). 
The Speaker Lecture Kit enabled the speaker to customize the talk to specific groups, 
for example, pediatricians, gynecologists, patients or parents. One of the medical slides 
stated ‘Cervical cancer screening is described as secondary prevention identifying a 
precursor lesion; the HPV vaccine is primary prevention that would eliminate the cause 
of cervical cancer’ (Speaker Lecture Kit slide 13 in Rothman and Rothman 2009). This 
information is deceptive because it does not inform women that there are more than 15 
other cancer causing strains of HPV, so the vaccine will not eliminate the cause of 
cervical cancer. Whilst the slides acknowledged the uneven distribution of cervical 
cancer rates globally they did not draw attention to the risk factors that make cervical 
cancer a higher risk for women in developing countries. This knowledge is critical to 
women in determining the necessity for the vaccine. When questioned about the cost-
effectiveness of this vaccine the standard company reply was ‘other vaccines exist for 
relatively unusual diseases (for example, rotovirus and meningococcal disease) and 
many newer vaccines are not inexpensive either’ (Speaker Lecture Kit slide 119 in 
Rothman and Rothman 2009). The pharmaceutical company did not attempt to justify 
this vaccine on benefits or the necessity for its use. The HPV vaccine is the most 
expensive vaccine costing $Au 450 per person, with three doses needed for protection 
(Cancer Council Victoria). These vaccines are among the first approved for universal 
use in any age group and Rosenthal (2008) says they will cost the health system more 
money than it will save.  
Education campaigns emphasized the worldwide incidence of this disease whilst 
omitting risk factors for the disease in different countries and cautionary qualifications 
about efficacy and safety of the vaccine. At no time has the public been informed that 
the information they received on this vaccine was designed by pharmaceutical 
companies (Rothman and Rothman 2009; Tomljenovic and Shaw 2013 p190). The 
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pharmaceutically funded promotional campaigns for HPV vaccines have maximized 
the threat of HPV infections and minimised the environmental and lifestyle co-factors 
that are necessary in cervical cancer pathogenesis. The public places its trust in medical 
associations to provide accurate information to health professionals for the promotion 
of medical products to the community. Clearly this trust has been breached. At a 
minimum the public is entitled to be informed openly about relationships with industry 
and precise funding arrangements in order that they can weigh up the credibility of the 
information. This was an intentional deception as the pharmaceutical companies sought 
to present their information through trusted sources and the PMA’s condoned it. 
9.11 Adverse Events associated with HPV Vaccination  
Many adverse events to HPV vaccines were reported during the two and a half years 
following the licensure of the vaccine (Slade et al 2009). The Centers for Disease 
Control and Prevention (CDC) and the Food and Drug Administration (FDA) operate 
the US Adverse Events Reporting System (VAERS). This is a voluntary, national, 
passive surveillance system set up to monitor adverse events from vaccines. 
Manufacturers, health professionals and patients can report reactions to this database. 
There have been three times the rate of reported adverse reactions after HPV vaccine 
than to all other vaccines combined (Slade et al 2009; Tomljenovic and Shaw 2013). 
However, passive pharmacovigilance systems are not designed to determine causal 
relationships to adverse reactions or their frequency in the population (.Tomljenovic and 
Shaw 2013 p186). Although an analysis of the postlicensure safety surveillance data for 
the HPV vaccine has been performed, the analysis only included adverse event data 
from the US (Slade et al 2009). This is despite Gardasil® being licensed in many 
foreign countries. The decision to use only US data was justified on the grounds that it 
offers more complete information and is more feasible for follow up studies for medical 
review. Slade et al indicate that 68% of the adverse reports for the HPV vaccine, in their 
analysis, came from the manufacturer. Of these reports, almost 89% did not provide 
sufficient identifying information to allow medical review of the individual cases. As a 
result of this failure in the system, VAERS data cannot be used to infer causal 
associations between vaccines and adverse events (Slade et al 2009). That the majority 
of the data did not permit follow up for medical review nullifies the stated reason for 
excluding adverse event data from foreign countries.  
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Reporting systems for adverse events also allow the pharmaceutical companies that 
manufacture the vaccine to influence the reporting of adverse events to government 
regulators. The package inserts for HPV vaccines state that suspected adverse events 
should be reported to the manufacturer of the vaccine or to VAERS (Merck & Co Inc 
2006). The manufacturers of the HPV vaccines are pharmaceutical companies that 
benefit financially from the vaccines. It is not in the interest of company profits to be 
vigilant about adverse events. Pharmaceutical companies also fund the clinical trials 
and employ many of the researchers who design the trials and safety studies (Future II 
2007). The only supervision of the clinical trials was performed by the FDA’s Center 
for Biologics Evaluation and Research (CBER) who also granted Merck the first 
Biologics License Application (BLA) for an HPV vaccine (Blaxill and Olmsted 2012 
p186). 
The need for a rigorous long-term surveillance system for vaccines is clear when a 
comparison is made between the pre- and post- licensure adverse events. Slade et al 
comment that rare adverse events following vaccination (AEFV) were observed more 
often in the post licensure data than the pre-licensure data. There are two reasons for 
this:  
I. The longer time period over which the data was collected and  
II.  The larger number of people that were included in the trial.  
In the pre-licensure trials adverse events were only actively reported for 15 days after 
immunization (Future II 2007). However, in the post-licensure passive surveillance 
system events were reported that occurred weeks or months after immunization. For 
example, venous thromboembolic events were diagnosed between 0-306 days after 
vaccination and motor neurone disease was reported some months after vaccination 
(Slade et al 2009). This indicates the inadequacy of the phase 2 and 3 safety data that 
only included events within 15 days of vaccination. It is well established that the 
effects of the chemicals in vaccines may not appear until weeks, months or years after 
the vaccine has been administered (Shoenfeld and Agmon-Levin 2011). The lack of 
adequate surveillance data after vaccination allows the manufacturers to claim there 
was no evidence that the deaths or serious side-effects were caused by the vaccine 
(Slade et al 2009). In other words, if you don’t monitor the events in an appropriate and 
systematic manner then there is no evidence to disprove this statement. Researchers are 
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then able to conclude from the post surveillance data that ‘Gardasil continues to be safe 
and effective and its benefits continue to outweigh the risks’ (Rosenthal 2008 p9). This 
statement is made on the basis of a surveillance system that the researchers themselves 
say is severely limited. The limitations of the system include (Slade et al 2009): 
I. It is a passive system that results in the underreporting of events 
II. Reported events are not always systematically validated.  
III. Inconsistency in the quality and completeness of reported data 
IV. Reporting biases  
The adverse events that have been reported to VAERS from this voluntary reporting 
system include hypersensitivity, anaphylaxis, Guillane-Barre syndrome, transverse 
myelitis, pancreatitis and venous thromboembolic events, deaths and pregnancy 
abnormalities (Slade et al 2009; Tomljenovic and Shaw 2013 p186). An accurate 
comparison of adverse events, including congenital abnormalities and spontaneous 
abortion after vaccination, cannot be made with the unvaccinated group in the clinical 
trials because the placebo was not inert (Slade et al 2009; Tomljenovic and Shaw 
2013). The manufacturer funded clinical trials used a vaccine adjuvant - aluminium 
hydroxyphosphate sulphate - as the placebo in the unvaccinated group (Future II 2007). 
This is a chemical known to be linked to serious adverse events including 
hypersensitivity and autoimmune diseases (Shoenfeld and Agmon-Levin 2011).  
There cannot be an accurate measure of the degree of harm caused by the vaccine if all 
known active ingredients are not removed from the placebo. In one of the clinical trials 
it is stated that the two HPV vaccines being trialled contained 225 micrograms and 395 
micrograms of adjuvant respectively and the two placebos contained 225 micrograms 
and 450 micrograms respectively (Villa et al 2005). The higher amount in the second 
placebo was stated to be for ‘appropriate safety comparisons’ but no explanation was 
provided to explain how it would prove safety. Health authorities often report on the 
number of adverse events for a particular vaccine with respect to the background rate in 
individuals who have never had the vaccine. It is hard to make a true comparison in the 
21st century because children are given multiple vaccines from the first day of life. 
Slade et al (2009) indicate that the FDA and the vaccine manufacturer (Merck & Co) 
agreed to carry out a phase 4 study to determine the safety of simultaneous use of HPV 
vaccine with other recommended vaccines, as well as autoimmune and other serious 
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AE’s. This scientific knowledge is essential because 5 newly licensed adolescent 
vaccines have been introduced at age 12 and 13: meningococcal, tetanus, diphtheria, 
and acellular pertussis vaccine (Slade et al 2009). When these vaccines were introduced 
in the US, there was an increase in the number of females 11-18 fainting (syncope) after 
vaccination. The scientific literature reports seizure-like activity in children during 
syncope (Slade et al 2009) so it is important to have an accurate assessment of reactions 
before parents are informed this practice is safe. Between 2006 and November 2013 
there have been approximately 155 deaths and 32,995 adverse events reported to 
VAERS (CDC). Of these events 6,549 have resulted in permanent damage. The VAERS 
statistics are believed to represent only one-tenth of the population damaged by the 
vaccine because this is a passive reporting system (Slade et al 2009). There has been no 
systematic, active, long-term surveillance of the adverse events resulting from this 
vaccine since it was marketed six years ago. Whilst the WHO states the vaccine is 
‘generally safe and well-tolerated’ (WHO 2008 p17) this claim does not include a true 
comparison of vaccinated and unvaccinated (non-adjuvanated) females and there has 
been no active follow up of vaccinated individuals.  
This illustrates that the risks and benefits of HPV vaccines have not been founded on 
sufficient evidence. It also demonstrates that the manufacturer was not required to prove 
the vaccine was effective or safe before it was approved by the FDA and marketed to all 
women in 2006.  
9.12 The Ingredients of HPV Vaccines  
This is a genetically engineered, recombinant vaccine produced in yeast cells (Villa et al 
2005). HPV itself is a non-enveloped, encapsulated, double-stranded DNA virus. In 
yeast cells the L1 protein generates virus-like-particles (VLP) that resemble HPV virons 
but are non-infectious. These are the particles included in the HPV vaccine (Villa et al 
2005). There are 2 HPV vaccines on the market - Cerverix and Gardasil - and they 
contain different ingredients (CDC Vaccine Excipients): 
I. ‘Cerverix: 3-0-desacyl-4’-monophosphorl lipid A (MPL), 225 micrograms 
aluminium hydroxide, amino acids, insect cell protein, mineral salts, sodium 
dihydrogen phosphate dehydrate, vitamins, 20 micrograms HPV -16 L1 protein, 
20 micrograms HPV 18 L1 protein (recombinant VLP’s)  
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II. Gardasil: Contains 4 recombinant VLP’s: HPV types – 40 micrograms VLP 
16, 20 micrograms VLP 18, 40 micrograms VLP 11 and 20 micrograms VLP 6. 
Other ingredients include amino acids, 225 micrograms amorphous aluminium 
hydroxyphosphate sulphate, carbohydrates, L-histidine hydrochloride, mineral 
salts, polysorbate 80, sodium borate, vitamins’. 
Polysorbate 80 and sodium borate found in the Gardasil vaccine are known to be linked 
to infertility (WAVE). The World Association for Vaccine Education (WAVE) states 
sodium borate is linked to infertility, seizures (twitching), convulsions and paralysis. 
This chemical is a dangerous poison which the National Library of Medicine states ‘is 
no longer commonly used in medical preparations’ (WAVE). This statement was made 
in 2005 and the vaccine was licenced in 2006. Polysorbate 80 is an emulsifier that can 
sometimes have fatal effects when given through a needle (WAVE). Changes in heart 
function can be immediate. The blood-brain-barrier can be penetrated followed by 
seizures and death. Anaphylaxis is known to be caused by this chemical. It demonstrates 
synergistic toxicity with a range of other chemicals that can be found in vaccines. It 
needs to be asked why it is necessary to put this chemical into many 
children’s/adolescent vaccines, given that other stabilizers can be used. Cerverix does 
not contain this chemical.  
Aluminium hydroxyphosphate sulphate is the adjuvant used in HPV vaccines to 
stimulate the immune system. Aluminium is a heavy metal that is known to have 
neurotoxic effects in humans and animals (Klish and Baker 1996). In 1996 the 
American Academy of Pediatrics stated aluminium is implicated in the interference of a 
variety of cellular and metabolic processes in the nervous system and other human 
tissues (Klish and Baker 1996). Scientists have known for many years that this chemical 
is associated with autoimmune diseases and hypersensitivity (Shoenfeld and Agmon-
Levin 2011; Greville 1966). In addition, aluminium adjuvants may lead to macrophagic 
myofascitis which is a syndrome where aluminium macrophages infiltrate muscle tissue 
and may be accompanied by myalgia, arthralgia and fatigue (Eldred et al 2006). In the 
clinical trials 0.1% of women did not complete the trials due to adverse events and 3.6% 
of pregnant women from both the vaccinated and the placebo groups experienced a 
serious adverse event (WHO 2008 p17). There were 15 to 16 congenital anomalies born 
in each group (WHO 2008). The common factor in these trial groups was aluminium 
adjuvant and it is an indication that many adverse events may not have been causally 
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related to the vaccine in the trials because the trials did not compare vaccinated 
participants to an inert placebo group. 
The WHO states that background information about the health status of adolescents 
including acute, chronic and autoimmune diseases should be collected before broad 
HPV vaccination programs are established (WHO 2008 p6). This would ensure that the 
risks of the vaccine can be properly evaluated. Broad vaccination programs have been 
rapidly implemented into many countries and the true health effects of this vaccine may 
never be known if this information has not been collected and if government regulators 
are using passive post-vaccination surveillance systems.  
9.13 Evaluating the Cost-Effectiveness of HPV Vaccination Programs 
Government policy-makers in many countries are using epidemiological and economic 
models to determine the cost-effectiveness of HPV vaccines (Brisson et al 2009). There 
are over 20 different models with considerable variations between them (WHO 2008; 
Brisson et al 2009). This is due to the significant gaps in the scientific literature 
regarding many aspects of HPV natural history and also due to the subjectivity of 
individual scientists in deciding the level of detail to include in the mathematical models 
(WHO 2008; Brisson et al 2009). The HPV vaccine is being utilised in many countries 
even though it is known that there are many uncertainties in the health outcomes 
predicted by the models because of the use of simplified assumptions (WHO 2008; Choi 
et al 2012). Mathematical models depend upon the equations used and the parameter 
values chosen. Modelling involves many assumptions so good judgment and disciplined 
integrity by the investigative scientists are vital (Michaels 2008 p61). Results can be 
manipulated intentionally or inadvertently so it is important that there is an independent 
assessment of the models and data used (Michaels 2008). Almost all HPV models 
assume that infection, clearance, progression and regression for each HPV type are 
independent of infection from other types (Choi et al 2012). Although some scientists 
are now claiming infection from one type influences the chance of infection by another 
type, more sophisticated multi-type individual based models are needed to properly 
analyse this possibility (Choi et al 2012). HPV vaccines have been deemed cost-
effective for many countries, using mathematical models, even though scientists are 
claiming that the effects of the vaccine on high-grade lesions and invasive cancer will 
not be clear for many years (WHO 2008 p5; Choi et al 2012).  
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In 2008, Brisson et al stated that the HPV vaccine trials were showing ‘promising’ 
results. The cost-effectiveness models of HPV prevention in developed countries prior 
to 2008 concluded that vaccinating girls is ‘likely’ to be cost-effective if the duration of 
vaccine protection is greater than 30 years or if booster doses are given when the 
duration of efficacy is short-term (Brisson et al 2008). Other scientists claim that the 
duration needs to be at least 15 years with 90% efficacy against at least HPV 16 to be 
cost-effective (Heitmann and Harper 2012). Yet the duration of the vaccine was 
unknown when the vaccine was marketed to women in 2007 (NCIRS 2010) as an 
effective prevention for cancer (NADC 2006). Mathematical models present cost-
effectiveness as a ratio (CER) defined as the incremental cost of obtaining a unit of 
health effect from an intervention when compared to an alternative (Brisson et al 2009). 
Models for HPV vaccine can only produce speculative health outcomes because of the 
assumptions made about HPV pathogenesis. In the developed countries the majority of 
HPV infections (90%) are not a high risk for cervical cancer (WHO 2008). Empirical 
evidence of the benefits of the vaccine will not be determined for decades due to the 
long latent period (10-30 years) between HPV infection and cervical cancer incidence 
(WHO 2008 p5). 
The assumptions that have been used in the CER models for HPV vaccines include: 
1. HPV DNA on its own is a cause of cervical cancer. 
2. HPV 16 and 18 infections are a high risk for developing cervical cancer. 
3. High-grade pre-cursor lesions (CIN 2/3) in 15-26 year old women are a 
surrogate for cervical cancer.  
4. The other 13 + strains of HPV will not infect and progress to cervical cancer. 
5. The duration of the vaccine is longer than 10 years.  
6. There are few serious side-effects produced by the vaccine 
HPV vaccine is not proven safer or more effective than Pap screening combined with 
loop electrosurgical excision procedure (Heitmann and Harper 2012; Tomljenovic and 
Shaw 2012) therefore it is important to assess the validity of each assumption regarding 
pathogenesis and vaccine safety that has been used in the CE models. This knowledge 
plus the fact that vaccinated women will still need Pap screening must be factored into 
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the CE assessment. The HPV vaccine costs $Au450 per vaccinated individual (3 doses 
of vaccine) (Cancer Council Victoria) and this must also be compared to the cost of a 
Pap test every 2 or 3 years, as HPV vaccine does not protect against all oncogenic HPV 
infections. Pap screening is believed to detect 9 out of 10 cervical cancer cases (Cancer 
Council Victoria) and it is virtually risk free. As vaccinated women will still need this 
program HPV vaccination programs cannot be cost-effective.  
9.14 Assumptions in HPV Vaccination Programs 
The introduction of the HPV vaccine was based on a number of questionable 
assumptions that are summarised here:  
HPV DNA is an independent cause of cervical cancer 
When scientist’s trialled this vaccine against pre-cursor lesions in 2003 it was known 
that HPV 16 and 18 could persist for a lifetime without causing cervical cancer. It was 
also observed that 5–10 % of tumours did not contain HPV DNA. Genetic and 
environmental factors were known to be a cause of all types of cancer and many co-
factors were identified in the etiology of cervical cancer prior to the development of 
HPV vaccines. There were significant gaps in the scientific knowledge regarding the 
interaction of these co-factors with numerous oncogenic HPV genotypes in 
pathogenesis.  
HPV 16/18 infections do not lead to cancer without co-factors being present. The 
majority of HPV 16/18 infections (90%) are harmless, self-limiting and asymptomatic 
and are not a high risk of cervical cancer or warts. Environmental and lifestyle factors 
are known to influence the global incidence and mortality of cervical cancer and this is 
demonstrated by the lack of correlation between the presence of HPV 16 and 18 and the 
incidence of cervical cancer. Current biotechnology has identified that HPV 16 and 18 
infections are a necessary causal factor in approximately 70% of cervical cancer, but 
these infections are not sufficient to cause disease and future developments in 
biotechnology may prove this percentage wrong. 
Pre-cursor lesions in young women as a cervical cancer surrogate.  
 The natural history of HPV 16/18 infection in the 15–26 year demographic does not 
support the conclusion that HPV precancerous lesions are a precursor for cervical 
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cancer: the opposite is true. The majority of pre-cancerous lesions in this demographic 
regress naturally and do not lead to cancer later in life. This indicates that a measure of 
efficacy against pre-cancerous lesions (CIN 2 and 3) in young women is an inadequate 
surrogate for determining how much cervical cancer can be prevented with a 
quadrivalent HPV vaccine.  
HPV genotypes and progression to cervical cancer 
It is believed that this vaccine will protect against ~70% of cervical cancer. The 
assumption is that vaccinated women will not be infected with the 13 other HPV 
subtypes that are associated with carcinogenesis. Approximately 30% of cervical cancer 
is linked to HPV genotypes that are not covered in the vaccine. Therefore it is 
recommended that all vaccinated women should still have regular Pap screening to 
ensure they are protected. Preventing infection from HPV 16 and 18 assumes that it will 
prevent some cervical cancer but there is no empirical evidence to indicate how much 
cancer it can prevent in developed countries where cervical cancer is already a low risk 
due to Pap screening programs and where 13+ other genotypes can also infect.  
Duration of the vaccine 
The duration of this vaccine was unknown when it was approved by the FDA in 2006 
and it is still unknown years later. Duration of the vaccine is believed to be at least 5 
years as predicted by mathematical modelling performed by the manufacturer. In 
addition, duration of the vaccine is not an indication of the protection against cervical 
cancer – only against infection from 2 subtypes of 15+ high-risk HPV infections.  
Adverse Events 
Safety was not adequately investigated in the clinical trials for this vaccine. The trials 
for this vaccine did not use an inert placebo in the unvaccinated group and they did not 
study the latent effects of the vaccine components for a year or more after exposure. In 
addition, there is a lack of knowledge about the harm this vaccine will cause in the 
population because there is no active surveillance system to monitor adverse events. 
This allows scientists to claim there is no indication that the adverse events reported 
after HPV vaccination are caused by the vaccine. It is often claimed that these events 
are a ‘coincidence’, enabling government regulators to state the vaccine is safe and 
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effective based on insufficient evidence. Models for the cost-effectiveness of HPV 
vaccines do not include an estimate of serious side-effects due to the vaccine. 
Vaccination programs are targeting 11-12 year olds at an age when the risk of cervical 
cancer death is zero and for which a trial for a vaccine for efficacy against cervical 
cancer would be unethical. In comparison, the risk of vaccine injury or death for this 
demographic is very real. This risk may be small or large but it is necessary to have an 
accurate estimate before broad vaccination programs are implemented for healthy 
adolescents who have a low lifetime risk of developing cervical cancer.  
Costs 
Vaccination programs are very expensive compared to the cost of screening programs. 
Pap screening is effective in preventing 9 out of 10 cervical cancer cases and virtually 
risk free. In contrast, the HPV vaccine is very expensive and it cannot prevent at least 
30 % of cervical cancer. In addition, Pap screening will still be required by all 
vaccinated women. Vaccinating all women in developed countries results in the 
majority of women using a vaccine for a disease they are not at risk of getting but they 
are now at risk from the vaccine.  
9.15 Conclusion to Part 1 
The promotional campaigns for HPV vaccine misrepresented the risk of HPV infections 
and cervical cancer to women in different countries. This was done in order to create a 
market for the vaccine. Currently the benefit of HPV vaccines against the burden of 
cervical cancer is unknown and the risk of injury or death associated with the vaccines 
has not been accurately determined in different populations. Universal HPV vaccination 
programs that target infection from HPV 16 and 18 are not beneficial to the majority of 
women in developed countries because these infections will not progress to cancer 
without specific environmental and genetic factors (risk factors) also being present. 
HPV infections do not progress to carcinoma in the majority of cases and there are 
currently 13+ oncogenic strains of HPV that the vaccine does not protect against.  
HPV vaccines are not demonstrated to be safer or more effective than Pap screening 
combined with surgical procedures. Hence it follows that implementing broad HPV 
vaccination programs is not necessary or cost-effective because Pap screening programs 
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combined with surgery are the most effective prevention and are still required by 
vaccinated women. HPV vaccines are offering uncertain benefits in reducing the burden 
of cervical cancer and may cause more harm than good due to the lack of investigation 
of their long-term safety.  
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PART 2 UNDONE SCIENCE IN HPV VACCINATION PROGRAMS 
9.16 Introduction 
The global policy of using HPV vaccines to prevent cervical cancer has been formed on 
incomplete evidence resulting from undone science. In the following sections I will 
present the undone science in HPV vaccination programs and explain why this science 
is important and why funding has not been provided to carry out this research. The 
Political Framework for Undone Science that is summarised in chapter 8 illustrates the 
cultural values found in governments and research institutions that result in conclusions 
being formed on a lack of evidence. This allows public health priorities to be 
determined on political decisions. The political decisions made in the development of 
HPV vaccines reveal the role that industry now plays in developing vaccines for the 
market and approving them for national immunisation programs. This has been 
facilitated by the private-public partnerships in the GAVI alliance that determines 
global public health priorities through the WHO.  
This chapter illustrates how conflicts of interest within research institutions, doctor’s 
education and government advisory boards are institutional barriers that allow biased 
and incomplete knowledge to be used in government policy. These structural barriers 
are hidden from the public but they are accepted practice by governments. In the next 
section I will present seven areas of undone science that represent incomplete 
knowledge relevant to global HPV vaccination programs. In each area I describe the 
significance of the undone research to knowledge about the safety and efficacy of the 
HPV vaccine. A consequence of industry influence in research and academic 
institutions is that the production of knowledge is no longer impartial therefore it is 
necessary to ensure that policies founded on industry-funded science include value 
judgments that are made on all the health risks involved. See chapters 4, 6 and 8. 
Government policies can be founded on selective evidence to serve the interests of 
industry when the public is not involved in decisions about policy development. In 
many health and environment issues, industry interests do not synergise with the best 
interests of the public. This case study also indicates the ways in which the Australian 
government’s NIP may include other vaccines about which there is incomplete 
evidence. The discussion and references for the evidence presented in this section are 
provided in Part 1 of this chapter. 
	  
	  
259	  
9.17 Undone Research on the Efficacy of HPV Vaccines 
UHPVR#1 Research has not been carried out to demonstrate that the 
quadrivalent HPV vaccine can prevent cervical cancer. There are 
15+ high risk strains of HPV that are associated with causing 
cervical cancer when influenced by environmental and lifestyle 
factors. The clinical trials for the efficacy of this vaccine used a 
surrogate for cervical cancer: high-grade CIN lesions (CIN 2/3) in 
women 15-26 years of age. This end-point was an inadequate 
indicator of cervical cancer.  
Why is this Undone Research Important? 
This undone science is important because it is necessary to have complete knowledge 
about the efficacy of the drug before it is recommended for universal use. The fact that 
there are 15+ strains of HPV that are associated with cervical cancer and only 2 
oncogenic strains are covered by the HPV vaccine places doubt on the premise that the 
vaccine can prevent the burden of cervical cancer, particularly as co-factors are also 
required. The vaccine is not proven to be safer or more effective than Pap screening and 
surgery in preventing cervical cancer therefore it is essential to know that the drug can 
achieve the desired outcome before it is implemented into the population. An accurate 
risk/benefit assessment of the drug cannot be performed if it is not demonstrated to 
prevent any cervical cancer.  
If conclusions about efficacy are based on a surrogate for cervical cancer it must be 
demonstrated that the surrogate is predictive of cervical cancer development. The 
surrogate used in the clinical trials for HPV vaccine was not predictive of cancer in the 
demographic that was studied (See Section 9.8). Therefore the trials could not provide 
evidence of ‘how much’ cervical cancer the drug could prevent. 
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UHPVR#2 HPV 16/18 is a common infection in all populations but cervical 
cancer is a low risk in many populations. Research has not been 
done to correlate a causal factor with a high risk of developing 
cervical cancer.  
Why is this Undone Research Important? 
Scientists have not found a correlation between the stated causal agent of most cervical 
cancer - HPV16/18 - and a high risk of cervical cancer. Therefore it is unknown whether 
this vaccine will target the majority of cervical cancer. Lifestyle changes such as regular 
Pap screening have been observed to significantly reduce the risk of this disease and 
environmental co-factors also play a role in the progression of HPV infections to 
cancer. Research needs to be done to demonstrate a correlation between the main causal 
factors with a high risk of cervical cancer before it is decided that a vaccine will be 
effective in preventing this disease. 
What would it involve to carry out undone research #1, and #2? 
A trial of a vaccine with cervical cancer as the end-point would take 20-30 years 
because of the latent period for cancer development. This is the only method for proving 
that an HPV vaccine against 2 oncogenic HPV strains will be effective in preventing the 
majority of cervical cancer when there is no correlation between the stated cause of the 
disease and the risk of the disease. The fact that HPV infections rarely progress to 
cancer indicates that an HPV vaccine is not the solution for preventing cervical cancer. 
This is because the majority of women would be put at risk from the vaccine when they 
are not at risk from the disease. Research that focuses on the environmental factors that 
correlate with the high risk of cervical cancer in developing countries could be easily 
carried out, as many co-factors have been identified, and would be effective in reducing 
the burden of this disease.  
9.18 Undone Research on the Safety of HPV Vaccines 
UHPVR#3 Research has not been carried out to determine the safety of the 
HPV vaccine using a saline inert placebo in an unvaccinated group. 
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Why is this Undone Research Important? 
This research is necessary to determine the effects of the vaccine in healthy individuals. 
An inert placebo means that the placebo will not react in the human body to cause 
adverse events. Definitive conclusions about the types and frequency of adverse events 
that will result from the vaccine can only be made if the placebo that is used does not 
react in the human body. The clinical trials for Gardasil, the quadrivalent HPV vaccine, 
used the aluminium adjuvant contained in the vaccine however this comparison will not 
provide conclusive safety data about the vaccine because this adjuvant itself is linked to 
causing autoimmune and other neurological reactions (See section 9.9). 
UHPVR#4 Research has not been carried out to establish the long-term adverse 
events caused by the vaccine.  
Why is this Undone Research Important? 
The clinical trials for the efficacy of quadrivalent HPV vaccine in preventing pre-cursor 
lesions were carried out for 4 years from 2003-2007. However, safety data on the 
outcomes for each participant in these trials was not followed for this time period. This 
data would have provided significant evidence for the long-term safety of using this 
vaccine in women because the health of vaccinated and unvaccinated women could 
have been compared for at least 4 years in the clinical trials. Yet this data was not 
collected during this trial. Ideally the long-term health effects should be actively 
followed for decades to determine the long-term health risks and benefits of using this 
vaccine to prevent cervical cancer. 
UHPVR#5 Research was not carried out to observe the health effects of HPV 
vaccine in animal studies. There are no animal models 
demonstrating the safety of HPV vaccines in animals.  
Why is this Undone Research Important? 
A study of the quadrivalent HPV vaccine in animals for 4 years or longer could provide 
significant data on the possible long-term harm from the vaccine. This could be done by 
comparing vaccinated and unvaccinated animals. Whilst animal studies do not provide 
conclusive evidence for adverse events in humans they are considered to be good 
indicators of the possible harm a drug might cause in the population.  
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What would it involve to carry out the undone safety research #3, #4 and #5? 
This undone research provides knowledge about the types and frequency of adverse 
events that have been observed after HPV vaccination. This research could have been 
done easily by using an appropriate inert placebo in the 4 year clinical trial for 
quadrivalent HPV vaccine. If the health outcomes of all the participants of the trial had 
been followed actively for 4 years, instead of 15 days, this would have provided 
valuable information on the long-term safety of the vaccine compared to an 
unvaccinated control group. Similar data could have been collected in a 4 year (or 
ideally longer) animal study of vaccinated and unvaccinated animals using an inert 
placebo to provide a rigorous safety profile of the vaccine before it was implemented in 
the population. 
UHPVR#6 The Australian government did not carry out research to determine 
the baseline health of adolescent girls prior to the introduction of the 
vaccine with an emphasis on the adverse events (AE’s) observed in 
the clinical trials for HPV vaccines. 
Why is this Undone Research Important? 
This research would provide valuable information for evaluating the long-term safety of 
the vaccine in the population. Baseline data of health outcomes in the population (prior 
to implementing the vaccine) specifically focusing on the adverse events observed in 
the clinical trials is essential for determining the harm the vaccine will cause after 
universal HPV vaccination programs have been implemented.  
What would it involve to carry out the undone safety research #6? 
Performing this research would involve collecting information on the frequency of 
certain conditions and illnesses in the population prior to HPV vaccination programs. 
The type of baseline data that should be available prior to vaccination includes events 
such as encephalopathy, seizures, allergies, anaphylaxis, autoimmune diseases and 
death that were observed in the clinical trials for the vaccine from 2003-2007. The trial 
researchers concluded these were rare events even though it is known that clinical trials 
are not representative of the frequency of the events in the population. This is because 
of the greater genetic diversity of populations compared to trial groups. In order to 
accurately evaluate the benefits and risks of vaccines it is necessary to compare the 
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incidence of these diseases/conditions in the general population before and after the 
vaccination program has been implemented.  
UHPVR#7 Research has not been conducted to establish the type and frequency 
of AE’s causally linked to the vaccine post-vaccination.  
Why is this Undone Research Important? 
Although many AE’s were observed in the clinical trials researchers were not able to 
provide accurate information on the frequency of these events in the larger population. 
This is due to the size and genetic diversity of populations. Yet government regulators 
have implemented HPV vaccination programs into populations without providing post-
vaccination surveillance systems that can causally relate the types and frequency of 
adverse events that are associated with this vaccine. This is because regulators are using 
passive surveillance systems that depend upon voluntary reporting of adverse events. 
These systems do not follow the health outcomes of all vaccinated individuals and 
therefore cannot be used to make causal links to the vaccine. Passive surveillance 
systems also depend upon the authorities acknowledging that an event is associated with 
the vaccine. In the current passive system it is known that many adverse events (~90%) 
are not reported by doctors and patients and it is also possible for government regulators 
to claim that an event is not associated with the vaccine. The assessment of adverse 
events is a subjective process that is being performed by government regulatory bodies 
that are 100% funded by industry. See chapter 6.  
Since 2007, when HPV vaccines were introduced globally, parents whose children have 
been injured or have died after vaccination have set up a database and website to record 
the adverse events (AE’s) that are occurring after vaccination. The types and frequency 
of these AE’s that are being recorded by parents on this website are linked to the CDC’s 
Vaccine Adverse Event Reporting System (VAERS) (SaneVax website). Although 
these reactions are being associated with the vaccine government regulators have 
dismissed these reactions as being ‘psychosomatic’ and unrelated to the vaccine 
(Erikson 2014). In this way many reactions are not being acknowledged and this signal 
of possible harm to many recipients is being ignored.  
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What would it involve to carry out undone research #7? 
This data can be easily collected and recorded using the government ACIR database. 
Mandatory bi-annual or annual follow-up of the health outcomes of all vaccinated 
individuals can be recorded on the ACIR database. The ACIR is set up to monitor the 
timely vaccination of children and it can also be used to record the health outcomes of 
vaccinated children/adults. This would ensure that safety signals associated with the 
vaccine can be detected and evaluated early. It is necessary to actively follow the health 
outcomes of all vaccinated individuals to make causal links between adverse health 
outcomes and the vaccine.  
 Assessment  
This undone research is essential to a rigorous assessment of the safety and efficacy of 
the HPV vaccine yet governments have not ensured this research is done prior to 
implementing a policy that is claimed to be for the health of the community. A public 
health policy that is not implemented on complete scientific knowledge of the effects of 
the policy on the majority of individuals may produce more harm than good in the 
population. 
9.19 Why is this Undone Research Unwelcome? 
The undone research summarised above would be unwelcome to academic institutions, 
scientists, industry and governments that are profiting from the patenting and marketing 
of this vaccine. The way in which governments are profiting from this arrangement is 
discussed below. Merck is the pharmaceutical company that made the quadrivalent 
HPV vaccine and funded the only clinical trials for safety and efficacy that were 
performed before its approval in the US in 2006 (FDA Merck Ltd 2006). The clinical 
trials were designed by Merck employees with clinical-site investigators and employees 
of Merck who were responsible for collecting and analysing the data (Villa et al 2005). 
The main researchers in the phase 2 and 3 clinical trials for the quadrivalent HPV 
vaccine were paid current or former employees of Merck (Villa et al 2005 p278; Future 
II 2007 p1925). Many had an equity interest or held stock in the company or they 
received consulting fees for serving on advisory boards for Merck and other 
pharmaceutical companies such as GlaxoSmithKline (GSK). This arrangement was 
similar for many of the main researchers in all the clinical trials for this vaccine. The 
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academic institutions, governments and pharmaceutical companies involved with 
developing HPV vaccines received large royalty payments for their contribution to its 
development. In 1995, when HPV subtypes 16 and 18 were identified as being the pre-
dominant types in all countries, based on a study of 1000 tumours (See Appendix 8), the 
Gardasil HPV vaccine was licensed to CSL, the Australian developer of the HPV 
vaccine, and sub-licensed to Merck & Co (Uniquest; CSL Ltd). CSL received royalties 
and milestone payments and retained the right to market the vaccine in Australia and 
New Zealand in return for providing Merck with exclusive worldwide rights to market 
the vaccine (Williamson 2005). A time-line of these events is provided in Appendix 7. 
The US government FDA supervised the phase 3 clinical trials for this vaccine from 
2003-2007 and approved the license for the two pharmaceutical companies – Merck and 
GlaxoSmithKline – to manufacture the vaccines. The US government’s Advisory 
Committee on Immunization Practices (ACIP), an advisory board for the CDC, 
recommended the HPV vaccine for inclusion in the US national vaccination program 
shortly after it was approved by the FDA in 2006. In the US the CDC purchased $51 
million of Gardasil (HPV4) for the strategic national stockpile (Merck & Co 2011) and 
they continue to purchase $10 million doses of HP4 annually (CDC 2008). In 2007-8, 
the first year of promoting Gardasil in Australia, CSL received $227 million from its 
inclusion in the national immunisation program (NIP) and it received royalty payments 
of $167 million from international sales of the vaccine (CSL 2008). The vaccine has 
made > $6 million for Merck since it was marketed in 2006 (Blaxill and Olmsted 2012 
p188).  
There are mechanisms in the Australian and US political process that allow industry to 
influence policy development (Levinson HHS 2009; Baxter 2010). It is noted that the 
inclusion of HPV vaccines in the Australian NIP has been influenced by political 
advisors with COI with industry and a government regulator, the Therapeutic Goods 
Association (TGA), that is 100% funded by industry. This vaccine was fast tracked for 
market approval by the industry funded US FDA in 2006 (See section 9.10). At the time 
HPV vaccines were approved for the national immunisation programs in Australia and 
the US, there were COI within the vaccine advisory committees in both countries: 
ATAGI and the US CDC. It is noted that senior officials in the US government health 
department move from government employment to lucrative corporate consulting jobs 
for the companies whose products they have approved while employed by the 
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government, a practice called the revolving door. (Blaxill and Olmsted 2012 p202; 
Angell 2005; Haberkus and Holland 2011).  
The US government Department of Health and Human Services (HHS) shared directly 
in the profits that are made from approving HPV vaccines for the market (Blaxill and 
Olmsted 2012 pp188-196). This is a clear conflict of interest in the role of the US Food 
and Drug Administration (FDA), the government regulator of medicines and biological 
products. The FDA was responsible for supervising the clinical trials for the HPV 
vaccine and approving the application to market the drug. It is also worth noting that the 
industry funded regulators, both the Australian TGA and US FDA, can decide which 
AE’s and deaths they will acknowledge as being associated with the vaccine and which 
AE’s they will not associate with the vaccine: the process is subjective and is similar to 
the documentation of AE’s in the Merck funded clinical trials (Blaxill and Olmsted 
2012 pp188-196).  
Conflicts of interest within the CDC for policy decisions regarding HPV vaccines were 
reported in a CDC report (Levinson HHS 2009). The report states that of special 
government employees hired by the CDC in 2007 for service on panels to evaluate flu 
and cervical cancer vaccines, 97% had potential conflicts of interest that were not fully 
declared and resolved (Levinson CDC 2009). Conflicts of interest of representatives on 
government advisory boards raise the question of whose interests these individuals are 
representing – industry or the public. A cultural ethos accepting of COI has become 
prevalent in most research institutions globally and within the governing bodies of 
many countries and organisations. The governing body of the World Health 
Organisation (WHO) that directs public health policy for 194 United Nations member 
countries also has consultation boards that are dominated by industry representatives 
(European Parliamentary Council 2010). See chapters 3 and 10.  
Financial ties to industry provide an explanation for why important research has not 
been completed to assess the claims that HPV vaccines will be safe and effective in 
preventing cervical cancer. Research that might provide evidence that the vaccine is not 
effective against cervical cancer or research that enables causal links to be made 
between the vaccine and adverse events would harm the profits of industry, and this is 
research that remains undone in HPV vaccination policies. This also explains why the 
PATH run phase 4 clinical trials in India from 2009-2010 were not designed to conform 
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with the declaration of Helsinki with respect to ethical standards in medical research 
(Sarojini et al 2010 p28). There is a lack of transparency in the promotion of drugs in 
national and global health policies and in many cases the uncritical acceptance by 
medical practitioners of these practices is a consequence of the registration requirements 
for doctors. Even when independent bodies request the evidence for the design of 
clinical trials for drugs/licensing under the Right to Information Act 2005, they are 
being refused on the grounds that the data is a trade secret and exempted from 
disclosure under this Act (Sarojini et al 2010 p32). Private-public partnerships 
providing funding for public health research have been introduced without any 
mechanisms to enforce transparency and accountability. In the phase 4 clinical trials in 
India (‘Demonstration Projects’) medical practitioners were given certificates of safety 
and worthiness for HPV vaccines from the Indian Academy of Paediatrics even while 
the safety and benefits of the vaccines were still being determined. These unethical 
practices are the responsibility of all health authorities – government, private and non-
government (Sarojini et al 2010 p32).  
Some of the national and international trials for HPV programs violated ethical 
guidelines and were of questionable scientific value. Regulatory authorities in many 
countries are 100% funded by industry (see chapter 6) and are approving trials that are 
performed with sponsorship from pharmaceutical and biomedical companies without 
requiring ethical protocols to be followed. National regulations need to be revised to 
enforce ethical standards and transparency in medical research (Sarojini et al 2010 p33).  
National interests should be addressed before market interests and this was clearly not 
the case with the rapid introduction of HPV vaccines into national vaccination 
programs. The hidden influence of corporations and their aggressive marketing 
strategies in public health policies were discussed in detail in chapter 6.     
9.20 Conclusion to Part 2 
It is important that comprehensive research on the safety and efficacy of drugs is 
completed prior to their implementation. When crucial research is left unfunded, policy 
decisions are founded on incomplete evidence (selective science). In addition, it is 
essential that any research that is performed and funded by industry is open to 
assessment by independent scientists before the conclusions are accepted in public 
health policies. Research that is performed by scientists with ties to industry may result 
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in biased results and this has significant implications for population health when the 
findings are recommended to policy advisors by representatives who also have financial 
ties to industry.  
 
Hidden COI in all areas of research and policy development are institutional barriers 
that prevent the government from being accountable to the public. This is because 
industry agendas influence the research and industry employees double as 
representatives on government and professional decision-making bodies. Ultimately, the 
price that is paid for adopting private-public sponsorship of global health policies and 
the academic-industry model for research institutions is an increased risk to the health 
of populations because the profit motive contaminates the search for knowledge. This 
health model is a faith-based system and not an evidence-based system because it is 
dependent upon trade secrets and political decisions that are based on biases that are not 
transparent to the public.  
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CHAPTER 10 CASE STUDY: ‘SWINE FLU’ 2009 PANDEMIC 
10.1 Introduction  
This case study illustrates the influence of industry in the design of public health policies that are 
promoted to global populations by the WHO. In chapter 3 I described how public-private 
partnerships have influenced global and national health policies since the 1990’s and how the 
influence of the GAVI alliance dominated these policies from 2000 onwards. The partners in the 
GAVI alliance have influence in the design of WHO directives for global policies and GAVI 
assists in advocating and implementing these policies into WHO member countries. The partners 
of the alliance include pharmaceutical companies, the biomedical industry, the World Bank, 
International Monetary Fund, the Rockefeller Foundation and the BM Gates Foundation in a 
partnership with WHO/UNICEF. All partners in this alliance have an influence in global policy 
decisions and they provide financial assistance to governments to implement the 
recommendations in national public health programs. The involvement of industry in the 
development of public health policies breaches the WHO charter and it puts public health at risk. 
Industry influence in WHO policy decisions is a deceptive practice that is not transparent to the 
global population. In 2000 industry generated statistics from the Global Outbreak Alert and 
Response Network (GOARN) were already being used by GAVI/WHO to monitor outbreaks of 
disease and promote vaccines to the public. This chapter describes how the influence of the 
GAVI alliance changed the governance of the WHO and altered the International Health 
Regulations to orchestrate a global influenza pandemic in 2009 using a sophisticated media 
campaign.    
10.2 Influenza Disease 
This section provides background information on the case history of influenza disease and its 
pathogenicity and case-fatality rates in the population. 
Influenza is a widespread viral disease that has been present almost continually somewhere in the 
world for the last few centuries (Hays 2000). It shares symptoms with the common cold and 
these can vary in severity. However, even in epidemic and pandemic times most people recover 
from influenza within a few days and without complications (AG DHAi; Hays 2000; Jefferson et 
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al 2007). The disease is characterized by frequent high illness rates and relatively low mortality. 
Seasonal flu and human swine flu are known to cause mild illness in most people (GWAc 2009). 
In the tropics, influenza can occur all year around but in temperate climates most activity occurs 
in autumn and winter (AG DHAi). The main symptoms of influenza include fever/chills, myalgia 
(muscle aches), headache, malaise (tiredness), upper respiratory tract infection with a non-
productive cough, sore throat and rhinitis (runny nose). In typical cases, the illness resolves for 
within several days to a week. In a minority of cases, generally those with underlying medical 
conditions, influenza can result in secondary bacterial pneumonia or viral infections (AG DHAi). 
Influenza-associated illness can also be present in children. This includes lower respiratory tract 
infection with symptoms such as croup and bronchiolitis (AG DHAi). Complications such as 
primary viral or secondary bacterial pneumonia, otitis media, diarrheal illness and febrile 
seizures are rare but may occur in children with underlying medical conditions (Heikkinen et al 
2006).  
The great majority of deaths to influenza occur in the 65 years and older age group (AG DHAi). 
Other symptoms in this age group can include loss of appetite, confusion, shortness of breath and 
increasing Chronic Obstructive Airway Disease symptoms. Influenza is highly contagious and 
passed from person to person in droplets in the air by sneezing and coughing. Individuals are 
contagious 1-2 days before symptoms appear and 3-4 days after infection (AG DHAi). Although 
there are many influenza viruses that cause this respiratory disease there are two main types that 
are responsible for causing epidemics in humans. These are influenza Type A and Type B 
viruses (AG DHAi). Type B viruses are found in humans only but Type A viruses are found in 
several species. Water birds are the natural host of influenza Type A viruses (AG DHAi). 
Influenza A viruses have been known to jump the species barrier and become established in 
other animals. Hence, Type A viruses are the most likely cause of new epidemics. These viruses 
are further sub-typed on the basis of two surface antigens: hemagglutinin (H) and neuraminidase 
(N). Influenza B is not sub-typed even though it contains the same surface antigens that change 
regularly.  The most common influenza Type A strains circulating since 1977 are A (H1N1) and 
A (H3N2). Only H1, H2 and H3 have been transmitted easily between humans (AG DHAi).  
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The influenza virus is extremely contagious and unstable. This means it changes its structure 
frequently through antigenic drift. New strains of influenza A and B continually emerge because 
of changes to the neuraminidase and hemagglutinin antigens (AG DHAi). As a result of these 
changes influenza viruses present a constant challenge to our immune systems and also to the 
production of a vaccine. This is the basis for seasonal epidemics and the reason why it is 
necessary to reassess the recommended strains each year.  Infection with influenza one year may 
not ensure immunity the next year.   
It is believed that immunity to hemagglutinin and other surface antigens reduces the chances of 
infection. Therefore the influenza vaccine is an inoculation of antigen prepared from inactivated 
influenza virus which will stimulate the antibody response (AG DHAi ). The measure of the 
antibody response is referred to as the hemagglutination inhibition (HI) antibody titre. It is 
known that soreness, fever, fatigue, muscle soreness (symptoms that mimic the flu) and allergies 
including hives, asthma, breathlessness and collapsing are side-effects of the vaccine (AG 
DHAi). Allergies are known to occur due to the egg protein, antibiotics, thimerosal and other 
ingredients of the vaccines. Therefore a contraindication to being vaccinated with influenza 
vaccine is a family history of hypersensitivity to any of the ingredients or high fever due to 
another illness (AG DHAi). People with specific chronic diseases and older people often develop 
lower post-vaccination antibody titres than healthy young adults, hence they can remain 
susceptible to infection after vaccination (AG DHAi).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
10.3 Discovery of the Influenza Virus 
I describe here the progress in science and technology that led to the development of a vaccine as 
a strategy for the prevention of influenza disease.  
The discovery of the influenza virus in 1933 led to the possibility of a preventative vaccine 
(Hays 2000). In 1918 the mortality rates to influenza were higher than we would expect today 
because there were no remedies for a viral illness or a bacterial infection once it took hold of the 
body.  Biomedicine was still a developing field at this time. Although different strains of viruses 
could be identified in the 1940’s preventative therapies remained elusive due to the changing 
nature of the virus. Serum therapies were not highly successful and many failed or resulted in 
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persistent problems (Hays 2000). In predicting a pandemic today, authorities remind the public 
of the pandemic of 1918 to illustrate the dangers of new strains of influenza viruses. This was the 
case for the false prediction of a swine flu pandemic in 1976 in America. Scientists wrongly 
identified the new strain of influenza in 1976 as being similar to the 1918 strain. It was identified 
as ‘swine flu’ (H1N1) which scientists claimed ‘had not circulated for 50 years’ (HSA). In fact, it 
is thought by the US Centers for Disease Control (CDC) that the 1918 strain was derived from an 
avian species of the flu virus and not a ‘swine’ virus at all (HSA). On the basis of this false 
identification the CDC claimed ‘This new flu strain might conceivably become as big a killer as 
the flu of 1918, the worst ever’ (HSA). 
The fallacy of this way of thinking is that the conditions of 1918 were unique to the social, 
economic and political influences of the time. The poor social conditions, vaccination for small 
pox and typhoid (with poorly tested vaccines), mass movement of troops, the stress of war, lack 
of medicines and shortages of food are not present in developed countries today. The strong 
correlation between these conditions and a greater mortality to influenza is well known. See 
chapter 2. Public health officials use the epidemiological triangle to assist in determining the 
causality of disease (Friis et al 2004). This model recognizes three major factors as being 
important in pathogenesis – host, pathogen and environment. Environmental conditions and host 
characteristics, due to better nutrition, in many countries today are not as conducive to influenza 
pandemics as they were in 1918. In Australia and other developed nations sanitation, hygiene, 
nutrition and living standards had all improved by 1950 (CoA 1953). At this time the NHMRC 
altered the list of notifiable diseases and removed influenza, as well as whooping cough and 
measles, because mortality and morbidity from these diseases had been significantly reduced. 
This was prior to the use of any vaccines for these diseases (CoA 1953). Antibiotics were 
discovered in the 1940’s and this assisted in the reduction of mortality from these diseases by 
1950 (O’Connor 1989). 
10.4 The Global Influenza Surveillance Network (GISN) 
The World Health Organization (WHO) set up the Global Influenza Surveillance Network 
(GISN) in 1952 to monitor the global circulation of influenza viruses and to serve as a global 
alert mechanism for the emergence of influenza viruses with pandemic potential (WHO GISN). 
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The GISN advises members on the best control measures for influenza through a network of 
international laboratories. Samples are collected from national influenza centres and sent to one 
of five WHO Collaborating Centres, where antigenic and genetic analyses of isolates are done 
and repositories of different strains of virus maintained. Improvements in biotechnology over 
past decades have enabled scientists to identify influenza viruses through new techniques in sub-
typing (HSA). This has changed the surveillance of influenza and has given governments the 
opportunity to predict pandemics based on the surveillance of different sub-types (strains) of 
influenza. The ‘pandemics’ that have been predicted on this technology are: 
I. 1957 Asian Flu 
II. 1968 Hong Kong Flu 
III. 1976 Swine Flu America 
IV. 2009 Swine Flu 
The predictions for the pandemics listed above were based upon the identification of a new strain 
of influenza virus and the assumption that the public would have little or no immunity to the 
virus (HSA). The death rates predicted for these pandemics did not occur but in all cases a 
vaccine was rushed onto the market within 3 months of the virus being identified (HSA). The 
appearance of a ‘pandemic’ can be created by increased global surveillance and sub-typing of 
influenza viruses which results in an ‘incidence’ of the new strain of flu that is identified.  If the 
definition of a pandemic refers only to the spread of this new strain and not the severity then it is 
a ‘pandemic’ of influenza that will be no more serious than the many other strains of influenza 
that circulate each year. The only difference is that new technology has enabled scientists to 
identify sub-types of the influenza virus.  
In the case of the Asian Flu 1957, the H2N2 virus was identified in February 1957 and a vaccine 
was produced by August 1957 (HSA). The vaccine was produced rapidly on the assumption that 
the community would have little immunity to this new strain. Interestingly, there were no 
community outbreaks of this strain of influenza (H2N2) in America until August 1957 when the 
vaccine was first used (HSA). The first wave of illness peaked in October 1957. The H2N2 virus 
sub-type stopped circulating in 1968. This prediction of a pandemic in 1957 was similar to the 
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1976 and 2009 influenza ‘pandemics’; both were predicted on the basis of a new strain of flu that 
was claimed to be spreading rapidly and authorities feared a repeat of the 1918 pandemic (AG 
OHP; HSA). The vaccine was made available rapidly after the new strain was identified based on 
the assumption that the community would have little or no immunity to the new strain.  
10.5 Pandemic Influenza 
Pandemics of influenza have occurred since the eighteenth century and they are believed to have 
certain characteristics (Hays 2000).  
1. Pandemics can occur when a new sub-type of the virus appears which meets little or no 
resistance from human antibodies. 
2. Crowded conditions are conducive to pandemics particularly in poverty stricken areas. 
3. Domestic animals can play a role in transmission. 
4. Illness is very high in outbreaks but most cases are not severe. The young and the very 
old are most at risk. 
5. Death is usually a result of a combination of influenza and some bacteria – most often 
pneumonia. 
The Australian Health Department also emphasises that the influenza virus is spread easily 
and rapidly between humans infecting large numbers of people around the world and causing 
many deaths. However, it is known that influenza disease is characterized by an extremely 
high incidence of infection and relatively small mortality.   
The occurrence of influenza pandemics coincides with improvements in global mass 
transportation systems. One of the most serious pandemics occurred in 1889–90 when steam 
transportation by sea resulted in large numbers of people being transported around the world 
(Hays 2000). The combination of crowded areas and poor living standards is known to 
correlate with infectious disease in general. Poor living conditions facilitated serious 
outbreaks of cholera, plague, measles and influenza in 1889. Poor nutrition, poor housing 
and less supportive care are associated with secondary bacterial infections that worsen the 
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effects of influenza. Although influenza affected millions of people in 1889 most individuals 
had little reason to fear death. Influenza quietly kills thousands of vulnerable elderly people 
during a pandemic but this figure is small relative to the millions that get infected (Hays 
2000).  
10.6 Influenza Pandemic 1918-1919 (Spanish Flu)  
This section provides a comparison of the patterns of influenza pandemics that have occurred 
during the 20th century. The information is drawn largely from Hays’ 2000 book The Burden 
of Disease: Epidemics and Human Response in Western History which provides a 
comprehensive description of the historical context of infectious diseases. I describe the 
similarities in the way these pandemics have been declared at different times in history and 
the government responses to these situations. 
It is believed that the pandemic of 1918-19 was caused by a more virulent sub-type of 
influenza that was particularly dangerous for young adults. This virus seriously 
compromised people’s lungs which resulted in many deaths from respiratory complications. 
Crowded troopships were believed to be responsible for transporting the virus around the 
world. This virus was observed to diminish during the summer months and was followed by 
a more virulent second wave during the winter months. It is known that the social, economic 
and political circumstances of World War I contributed to the severity of influenza in the 
pandemic of 1918-19. Young men were brought together in crowded camps, ships and 
during rallies. In many areas there was social chaos in addition to poor nutrition, sanitation 
and stress which leads to a greater chance of contracting a bacterial infection combined with 
influenza. It is also observed that many areas unaffected by war were also hit by the 
influenza pandemic. This is the case in India where poverty played a much greater role in 
influenza’s mortality. Whilst war has helped spread influenza through communities, poverty 
or poor social conditions plays a much greater role in the deaths associated with influenza. 
These characteristics of influenza disease were reflected in the definition of a pandemic that 
existed prior to May 2009. See section 10.9.  
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In 1918-19 physicians tried many remedies including antitoxins and vaccines but none had a 
noticeable effect. Approximately thirty percent of the US population was affected by 
influenza in 1918-19 but despite this, its impact passed quickly in the US and other 
developed countries. In comparison, mortality rates in the developing countries were much 
higher. These are illustrated in Table 3.  
Table 5: Mortality Rates to Influenza in Different Regions (1918) 
Region  Mortality Rate per infected cases 
Europe  5 / 1,000 
USA 5 / 1,000 
Latin America 10 / 1,000 
Africa 15 / 1,000 
Asia Approx. 25 / 1,000 
India Approx. 60 / 1,000 
Tahiti 100 / 1,000 
 
Reference: Hays JN, 2000, The Burdens of Disease: Epidemics and Human Response in Western 
History, Rutgers University Press, New Jersey/London p.273. 
 This indicates that social conditions are a major factor in the mortality associated with influenza 
and this is because poor living standards are conducive to secondary bacterial infections.  The 
most severe effects of the influenza pandemic occurred in developing regions in Latin America, 
Africa and Asia. Many of these regions were densely populated or had poor social conditions in 
1918. Whilst millions of people are affected during pandemics of influenza the majority of 
people recover without permanent scarring or chronic illness. Poverty increases the opportunity 
for individuals who are weakened by influenza to be infected with pneumonia and other bacterial 
infections. Correlations have also been observed between high mortality rates for influenza and 
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damage to crops. Poor nutrition results in decreased immunity and greater susceptibility to 
infections. The effects of war in some regions also resulted in increased mortality to influenza 
due to a shortage of medical staff, provisions and poorer social conditions. 
 The question remains as to why young adults were so susceptible to this virus in 1918 and some 
suggestions are that military generations were subject to more stress. They were required to 
move around a lot during troop movements and often in unsanitary or crowded conditions. Stress 
may also have been enhanced in 1918 by the vaccinations provided to the troops before 
departing or as a result of the trauma of the military situation (Hays 2000; Allen 2007).  The 
vaccines for smallpox and typhoid may have caused stress on the constitution of soldiers and in 
combination with the stressful conditions, poor nutrition and hygiene this could have resulted in 
the higher number of deaths due to a greater susceptibility to secondary infections (Allen 2007). 
In 1914 the manufacturing and testing of vaccines was in the early stages of development (Allen 
2007). In America during the early nineteen hundreds, a report commissioned by the Royal 
Army College established that the unsanitary conditions of the camps led to the easy spread of 
typhoid. It was known at this time that the biggest decrease in typhoid fever in both the military 
and civilian life had come from better hygiene. Despite this fact, it was recommended that all 
soldiers be vaccinated against typhoid in case the hygienic reforms failed (Allen 2007). A new 
typhoid vaccine produced by Almroth Wright was being made available at this time and the 
argument for adopting this preventative strategy was that men in active service often experience 
unsanitary conditions and this made the vaccine worthwhile.  
Wright happened to be the professor of pathology at the Royal Army College at the time. In 1912 
typhoid vaccine was made mandatory even though the vaccine was known to have serious side-
effects (Allen 2007). During World War I the vaccinated United States force suffered 1,500 
cases of typhoid, 227 deaths to typhoid and more than 35,000 soldiers were made ill from the 
vaccine (Allen 2007). It is possible that vaccinating the troops in 1918 reduced their vitality and 
made them more susceptible to the pandemic flu. American soldiers who were vaccinated 
against typhoid and small pox were significantly affected by influenza in September 1918 when 
43,000 men died (Allen 2007). The Navy reported that 40 percent of its members were flu-
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stricken and the Army had 36 percent flu stricken. These soldiers were vaccinated with a reactive 
typhoid vaccine which was never put into widespread civilian use in America (Allen 2007).    
10.7 Swine Flu Pandemic 1976 
Whilst influenza vaccines are commonly used it is difficult to make them effective because the 
virus continually changes its structure. New influenza antigens appear and major shifts in two of 
the viruses’ key proteins occur every few decades (HSA). There were major antigen shifts in 
1957 and 1968. This complicates the production of the vaccine which has to be produced a 
season in advance on guesswork. The flu vaccine is promoted annually to elderly people because 
they have the highest mortality rate yet their immune systems do not respond well to the 
influenza vaccine (GWA 2009c). 
In 1976 CDC scientists identified a strain of influenza in a soldier that appeared to be similar to 
the deadly flu virus of 1918-19 (HSA). The outbreak resulted in 4 cases of flu with pneumonia 
and one death. The strain was identified as ‘swine’ influenza H1N1 that the CDC claimed had 
not circulated for 50 years (HSA). On this basis, on 24 March 1976, the CDC sent a memo to the 
secretary of Health and Human Services predicting a pandemic. A news conference was held by 
Sabin and Salk, creators of the polio vaccines. The support of these high profile scientists 
provided additional credibility to the public health campaign promoting the influenza vaccine. At 
this time President Ford asked Congress to spend $135 million to produce enough vaccine for 
every ‘man, women and child’ in the United States (HSA). The four main vaccine manufacturers 
were asked to rush out 200 million doses (10 times the usual number) of the new vaccine.  
However, the insurance companies became concerned because they assumed that a massive 
campaign using rapidly produced vaccine would result in side-effects and lawsuits. The 
pharmaceutical companies stopped production of the vaccine and demanded that Congress 
assume the risk (HSA). A swine flu bill was rushed through Congress making the government 
liable for the program. By mid-August there had not been a single extra case of swine flu in 
America and none of the known cases had been seriously ill from this strain. In fact, there was 
not a single case of swine flu around the world in June 1976. The vaccine was made available 
only after the new legislation was implemented on 1 October 1976 (HSA). 
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In October 1976, three people died after receiving the flu vaccine and by late November the first 
reports of Guillane-Barre syndrome were received (HSA). Guillane-Barre syndrome is a rare 
inflammation of the nerves that usually follows viral infection, injury, surgery, vaccination or a 
period of stress (Carter and Bowen 1991). The muscles that the nerves supply become paralysed 
and sensation is lost. Twenty percent of people are left with a permanent disability (Carter and 
Bowen 1991). The government set up a special branch of the Federal Court of Appeals to deal 
with 4,000 injury claims and 1,384 lawsuits (HSA). The government ultimately paid out $100 
million in compensation and the risk of developing Guillane-Barre syndrome appeared to be 11 
times greater in the vaccinated than the unvaccinated. The program was suspended on 16 
December 1976 and the influenza pandemic never eventuated (HSA). This incident opened the 
public health authorities to criticism and ridicule. One skeptical journalist stated ‘something had 
gone out of American life – our unbridled faith in science ……for too long we believed 
uncritically in science, swallowing whole what we’ve been told. Any program conceived by 
politicians and administered by scientists comes to us doubly plagued’ (Allen 2007 p261).  This 
scenario was repeated globally in 2009. 
 10.8 Pandemic Influenza 2009: A New Strain of Influenza H1N1  
This section describes the steps that led to the declaration of a global influenza pandemic in 
2009. Infectious disease pandemics are considered an issue of international concern and the 
GAVI alliance was instrumental in developing the new IHR’s that came into force in 2007. 
These included pandemic preparedness plans (PPP) that required governments to enact a set of 
policies if a pandemic was declared. See chapter 3.5. It is noted that there were also two 
milestones WHO member countries were required to achieve under the PPP that came into force 
in 2007: 
i) the assessment of their surveillance and response capacities by June 2009 (the global 
pandemic was declared on June 11 2009)  
ii) the development and implementation of plans of action to ensure that these core 
capacities are functioning by 2012 (WHO IHR 2008).  
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The information provided below is a description of the unfolding of the 2009 pandemic and 
should be considered within the context of the IHR’s and the PPP’s. 
In April 2009, a new strain of influenza A was first detected in North America (CDC 2009a). 
Two cases of febrile respiratory illness in children were identified in Southern California on 
April 17, 2009 and although these 2 cases resolved uneventfully within a week, the swabs were 
sent to reference laboratories for extra testing and identification. This would seem unnecessary if 
the cases were uneventful. Further testing identified a new strain of flu with a unique 
combination of gene segments (CDC 2009a). This combination of genes in a flu strain had not 
been identified in either pigs or humans prior to these cases and neither child had been in contact 
with pigs.  The CDC stated that ‘this is not a new subtype of influenza A in humans’ but they 
were concerned that this new strain of influenza A (H1N1) was substantially different to the A 
(H1N1) from previous years. Scientists postulated that the community may have less immunity 
to this strain because of the lack of exposure (CDC 2009a).  The reason this new strain was 
detected was because two sick children presented at outpatient clinics that were participating in a 
clinical study actively obtaining influenza surveillance. If these children had presented to a GP 
and no test for the sub-type of the virus made, there would have been no concerns as both cases 
were uneventful. Despite the fact that influenza activity in California and Texas was declining at 
the time, it was still decided that surveillance for this new strain of virus should be enhanced.  
The new influenza strain was identified as being a recombination of genetic material from human 
influenza Type A H1N1, and swine and bird gene segments. The majority of genes were from 
swine influenza viruses that have circulated in pigs in America since 1999 but swine influenza 
genes from the Eurasian lineage were also identified (CDC 2009a; WHO 2009a). The WHO 
stated that this strain is not known to be endemic in pigs. Despite this fact the new flu strain was 
promoted to the public as ‘swine flu’ (WHO 2009a). The very few cases of swine flu that have 
been found in pigs since the outbreak are believed to have been transferred from humans (CFIA 
2009). In the past there has been no national surveillance of pigs for influenza in America but a 
pilot swine surveillance program was recently established to determine the efficiency of 
transmission of new viruses in swine and in humans (CDC 2009a). 
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Influenza is a disease that is caused by many strains of virus. These viruses spread easily and 
new strains develop regularly. The CDC reports that there are approximately 1-2 new human 
swine influenza viruses appearing every couple of years (CDC 2009a). These novel influenza A 
viruses became nationally notifiable in America in 2007 and this explains the increase in the 
number of reported cases that have occurred in recent times. Prior to 2007 sub-types of influenza 
A were not monitored systematically (WHO GISN; GWA IFS 2009). Cases were recorded as 
influenza A or B or Influenza-like-illness (ILI) (GWA IFS 2009).  The CDC stated on the 24 
April 2009 ‘there is no information currently available regarding the efficiency of transmission 
(of this virus) in swine or in humans’ (CDC 2009a). At the same time the World Organisation for 
Animal Health stated ‘no link between an animal and the first cases (of this virus) has been 
established’ (Vallet 2009). Although the two Californian cases of swine influenza observed in 
children were uneventful and were not transmitted from pigs, the public health authorities 
requested that clinicians consider notifying any observed cases of animal or seasonal influenza 
infection (CDC 2009a). Clinicians were particularly asked to monitor those individuals who had 
been in contact with pigs even though there was no evidence of a connection with pigs. They 
were asked to send any suspected cases of swine influenza to the laboratory for confirmation and 
the CDC was to receive any influenza A specimens that could not be sub-typed. 
Diagnosing ‘Swine’ 2009 Influenza     
Mexico also experienced outbreaks of influenza-like-illness (ILI) in several regions in early 
April 2009 (CDC 2009b). On 17 April an atypical case of pneumonia prompted the authorities to 
increase surveillance of influenza viruses in Mexico. Laboratory testing of several cases of 
respiratory illness confirmed infection with ‘swine-origin’ influenza A. Analysis revealed they 
were the same as the two cases in California and this led the General Directorate of 
Epidemiology (GDE) in Mexico to issue a national alert to all influenza-monitoring units and 
hospitals. Hospitals were required to collect specimens from all infected cases within 72 hours 
(CDC 2009b).   
There were three definitions for cases of ‘swine-flu’: 
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I. A suspected case: severe respiratory illness with fever, cough and difficulty 
breathing. 
II. A probable case: a suspected case in a patient from whom a specimen tested positive 
for influenza A. 
III. A confirmed case: a probable case that tested positive for swine origin influenza 
virus (S-OIV) by real-time reverse-transcription polymerase chain reaction (RT-
PCR). 
In accordance with these criteria health care providers were contacted to provide retrospective 
data to 1 March, as well as ongoing data for persons with the above descriptions. Surveillance 
was concentrated on hospitals and 1,918 suspected cases were reported. It is stated that these 
suspected cases included 286 probable cases and 97 confirmed cases (CDC 2009b). In other 
words, only 97 cases were confirmed as the new strain of influenza – the others were only 
suspected. Other data was mainly collected from sites conducting routine surveillance of patients 
with influenza-like-illness (ILI) (CDC 2009a). This data was collected from clinical studies 
investigating the transmission of influenza in the community. Suspected or probable cases were 
reported from all 31 states of Mexico (CDC 2009b). Again these were suspected cases, not 
confirmed ‘swine flu’ and there was no evidence at this time that animals were playing any part 
in the transmission of this virus (Vallet 2009). If there had been no monitoring for subtype A 
influenza then the incidence of this strain would have remained unknown – as it was in previous 
years.  This type of surveillance can be seen as a method of creating an incidence of disease. It 
was reported that 97 patients were confirmed with swine origin influenza virus (S-OIV) and 7 
had died by 30 April (CDC 2009b). Of this number there were only 24 cases (out of 97), for 
which there was demographic and clinical information. They ranged in age from 1-59 years with 
79% aged 5 to 59. Only 16 of the cases had full clinical records and they reported symptoms of 
fever, coughing, tachypnea (rapid breathing), dyspnea (labored breathing), vomiting and diarrhea 
(CDC 2009b). Of the 16 cases with records 12 had confirmed pneumonia from radiography 
records and 3 of the 16 had underlying health problems. 7 of the 24 cases died.  
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On April 24, the president of Mexico was advised to close all schools in the Federal District and 
metropolitan area of Mexico City. Warnings were issued to travelers to seek medical advice if 
they experienced symptoms of ILI. Educational messages, masks and sanitizers were distributed 
to the public which raised the anxiety of the population (CDC 2009b). Authorities announced a 
national decree for house-isolation for any person with a suspected case – even if the case wasn’t 
confirmed at this early stage of surveillance. By April 27 school closures were mandated 
throughout the country. At this time the CDC stated ‘The clinical spectrum of S-OIV illness is 
not yet well characterized in Mexico ……evidence suggests that S-OIV transmission is 
widespread and that less severe (uncomplicated) illness is common’ (CDC 2009b). If less severe 
cases of influenza were most common it would have been appropriate to monitor the virus 
without undue concern to the community until virulence was established. This involves a 
comparison of hospitalization and mortality data due to influenza in previous years. At this time 
it was stated that ‘patients with confirmed cases had been identified in several states and 
suspected cases have been identified in all states’. The CDC concludes that ‘this suggests that S-
OIV transmission is widespread’ (CDC 2009b). Considering that ‘suspected’ cases refer to 
influenza A and not S-OIV then the only evidence was some confirmed cases in several states. 
Influenza A has been covered in the influenza vaccine for many years because it is a 
predominant strain (GWA 2009c). If the technology to subtype this strain had not been available 
there would have been no evidence of this new H1N1 infection only an incidence of influenza A. 
This incidence and mortality should have been compared to previous years to establish virulence 
prior to creating a vaccine and promoting anxiety in the population.  
Is it a ‘Swine’ Flu? 
It was stated by the WHO in June 2009 that ‘swine’ influenza  A (H1N1) was a new virus and 
one to which most people have no or little immunity (WHO 2009b). Influenza Type A (H1N1) is 
a strain of flu that has been covered in the flu vaccine for many years yet the WHO stated ‘this 
virus is not related to previous or current human seasonal influenza viruses’ (WHO 2009b). This 
statement was contradicted by the CDC which claimed ‘this is not a new subtype of influenza A 
in humans’ (CDC 2009a). The CDC was concerned the population might have less immunity to 
this strain because it was substantially different to previous strains but it stated the genetic 
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makeup does contain human, avian and swine virus components (CDC 2009b). Therefore, it was 
not completely unrelated to previous human Type A (H1N1) as the WHO stated. The seasonal 
influenza vaccine from previous years covered three strains of influenza - A (H1N1), A (H3N2) 
and Type B (GWA 2009c). Despite the fact that in April 2009 there were no known cases of this 
strain in pigs (Vallet 2009), the WHO and CDC labeled this influenza strain as ‘swine flu’ (CDC 
2009a). A ‘swine flu’ is defined as a highly contagious pathogen endemic in pigs (Kothalawala 
et al 2006). Human infection with swine influenza viruses is uncommon and usually associated 
with close contact with live pigs (Vallet 2009). To refer to swine flu in humans normally implies 
an ongoing role of pigs in the transmission of the virus and yet there were no cases of this 
influenza strain being transferred from contact with pigs (Vallet 2009). The first case of this 
influenza strain being identified in a pig was in May 2009 in Canada (CFIA 2009). It was 
believed that the pig was infected from contact with a human.  
 If this strain of influenza had been promoted to the public in the media as ‘human influenza 
Type A, H1N1 2009’- the official name – it would not have created as much fear in the 
community. This is because humans have been exposed to a related strain for many years. 
Influenza pandemics are traditionally named after the region where they are first identified 
(Vallet 2009). Authorities disagreed over the naming of this virus. The WHO suggested the virus 
should be called ‘North American influenza’ and others suggested ‘Mexican influenza’ because 
this is where the epicentre appeared to be (CDC 2009b). These names were disputed because the 
genetic material in the virus included elements from a swine influenza virus of Eurasian origin 
(CDC 2009a). The majority of the swine genes in the virus appeared to be related to an American 
pig virus but the virus itself was unknown in pigs. Therefore, it was scientifically and factually 
inaccurate to name this human disease ‘swine influenza’ as it was predominantly a human 
disease (Vallet 2009). The virus was labelled ‘A/California/7/2009-v like H1N1’ in the vaccines 
that were developed for use against this 2009 virus and marketed to populations in 2010/11 
(Nolan et al 2009). 
10.9 Surveillance of Influenza in 2009 
 There was little evidence of this strain being more virulent when it first emerged in April but in 
June 2009 the WHO was speculating that this virus could cause more infections than are seen 
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with seasonal flu (WHO 2009a). This was stated two months after identifying the new strain. At 
this time the WHO stated ‘large outbreaks of disease have not yet been reported in many 
countries and the full clinical spectrum of disease is not yet known’ (WHO 2009a). Despite this 
fact and the fact that this strain had not yet shown itself to be more virulent than other new 
strains, the WHO stated it was already working closely with pharmaceutical companies to 
develop a vaccine to protect against this virus.  
In other words, the WHO admitted that this strain of flu was mild in the majority of cases and 
new strains appear regularly but they had already initiated plans to develop a vaccine before its 
virulence was established. At this time the WHO claimed that this strain of influenza was 
spreading fast among young people aged 10 to 45 (WHO 2009b). The WHO admitted that the 
majority of hospitalized cases in this age group had underlying health problems or weak immune 
systems. The WHO’s decision to develop a vaccine was based on the assumption that most 
people would have no immunity to this new strain. The WHO stated that this H1N1 strain was 
unrelated to the human seasonal H1N1 viruses that had been in circulation since 1977 (WHO 
2009b). This is contradicted by the fact that the new virus contained human strain A H1N1 and a 
study conducted by the CDC found that individuals between the ages of 18-64 had antibodies 
present that reacted to the ‘swine’ H1N1 virus (CDC 2009c). Whilst this evidence doesn’t 
indicate clinical protection it does suggest that some individuals may have had immunity from 
previous exposure to H1N1 (CDC 2009c). The WHO was very quick to assume that the 
population would have no immunity to this new strain even though it was immunologically 
similar to previous H1N1 viruses. Further studies have shown that a significant proportion of 
people over the age of 65 also had some immunity against this new strain (AG OHP 2009).  
In August 2009 the Australian government prioritized the implementation of a vaccine against 
this new strain of influenza H1N1 (AG OHP 2009). This preventative action was notable 
because there was little evidence in the community that this new influenza strain was more 
virulent than other new strains of flu which occur regularly. In fact, prior to a vaccine being 
produced, the WHO stated the majority of people who contract this disease experience the milder 
form of influenza and recover without requiring treatment (WHO 2009b). The Therapeutic 
Goods Association stated ‘the experience in Australia of the disease is mild in most cases’ (AG 
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TGA 2009). In addition, the Australian Health Department did not produce statistics showing 
that the overall death rate for influenza in 2009 was significantly worse than in previous years 
before it considered buying a vaccine (AG OHP 2009). Analysis of the case-fatality data at the 
end of the pandemic (2010) in Australia and other countries showed the excess mortality from 
influenza and pneumonia to be lower than in recent influenza seasons (NSW PHN 2009; Laurell 
2010). In 2009 many cases of the new strain - Type A H1N1 2009 - were identified in 
comparison to sub-types for previous years because national and international surveillance 
centres were actively and systematically sub-typing cases of influenza A (GWA 2009c). In 
previous years many of these cases would have gone unnoticed and been recorded as ‘Influenza 
Type A’ or ‘respiratory infection’. This is because few national or international surveillance 
systems distinguish between influenza and influenza-like-illness (ILI) (Jefferson et al 2009). ILI 
refers to other respiratory viruses that are not laboratory confirmed or sub-typed. Prior to 2009 
surveillance systems in most countries were not distinguishing between these viruses because it 
was not considered important and systems were not geared up for it. 
10.10 Declaring a Pandemic 
In 2005, the newly established International Health Regulations (IHR) board stipulated that the 
WHO Director-General (DG) was to appoint an Emergency Committee (EC) for advice on 
matters relating to global pandemics of disease. It was stated in the IHR that membership of this 
committee was not to be made public and therefore conflicts of interest would not be declared or 
publicised (Flynn 2010). Further, the composition of the board with respect to stakeholder 
representation would also be unknown to the public. This secret committee was given the power 
to make decisions about vaccination policies in global pandemics without consultation with the 
Strategic Advisory Group of Experts (SAGE), the principal advisory group within the WHO for 
the development of policies related to vaccines and immunization strategy (WHO 2009i). The 
SAGE board comprises 15 members who have to sign a declaration of interests they have with 
professional activities that might conflict with their advisory function for the WHO. This is done 
with the purpose of excluding representatives with conflicts from the decision making process. 
The establishment of the secret EC did not require any declaration of COI or stakeholder 
representation in decisions to declare a global pandemic. 
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Some experts noted from an early stage that the new sub-type of influenza virus was causing less 
harm than other strains of the virus in previous years (Flynn 2010; Rosella et al 2013). In this 
regard the definition of a pandemic is of great significance. In 2009, some scientists became 
concerned when WHO raised the pandemic to level 6 when the influenza virus was causing mild 
symptoms in most cases of the disease. It was noted that the WHO Emergency Committee 
changed the definition of a pandemic just prior to calling the level 6 pandemic (Flynn 2010). It 
would not have been possible to call a pandemic if the definition of the pandemic had not been 
changed. Whilst the WHO claims that the definition was finalized in February 2009 as part of the 
current pandemic preparedness plans, the fact remains that after 10 years of PPP the change in 
definition made it possible to call a pandemic (O’Dowd 2010). There was a lot of time and 
money invested in planning for a pandemic. 
The important change to the definition that occurred in May 2009 was the removal of the need to 
show how severe the impact of the virus would be on the population. For many years prior to 
2009 the WHO defined pandemics as causing ‘enormous numbers of deaths and illness’ but this 
phrase was removed in 2009 (Cohen and Carter 2010). Both definitions of a pandemic are listed 
below (Flynn 2010): 
1. Before 4th May 2009:  
“An influenza pandemic may occur when a new influenza virus appears against 
which the human population has no immunity, resulting in epidemics worldwide with 
enormous numbers of deaths and illness. With the increase in global transport, as 
well as urbanization and overcrowded conditions, epidemics due to the new influenza 
virus are likely to quickly take hold around the world”.  
2. After 4th may 2009:  
“A disease epidemic occurs when there are more cases of that disease than normal. A 
pandemic is a worldwide epidemic of a disease. An influenza pandemic may occur 
when a new influenza virus appears against which the human population has no 
immunity ….Pandemics can be either mild or severe in the illness and death they 
cause and the severity of a pandemic can change over the course of the pandemic”. 
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It is clear that pandemic planning requires that all stakeholders agree on a common definition of 
what an influenza pandemic actually represents (Flynn 2010). The Parliamentary Assembly of 
the European Council (PA) believes that the changes made to the pandemic definition were 
highly inappropriate at a time when a major influenza infection was occurring. These changes 
affected disease descriptions and indicators and they were made in a non-transparent manner. It 
also meant that because of the PPP’s that locked governments into prescribed actions when a 
pandemic was called, authorities were constrained in their actions – even when the evidence 
didn’t match the actions they were required to implement (Rosella et al 2013). Once the 
pandemic was declared governments had no choice but to buy up the required vaccines 
according to quantities and prices set in the PPP’s.     
10.11 Conflicts of Interest in the WHO     
In 1993 the World Health Assembly encouraged the participation of public-private partnerships 
in health development in the governance system of the WHO. The intention was to improve 
funding and resources for public health whilst improving the corporate image and thereby 
attracting new investors and establishing new markets (Buse and Waxman 2001). This means 
that many of the members of WHO advisory boards now have financial and professional links to 
pharmaceutical and biotechnology companies that are involved in identifying and monitoring 
viruses and manufacturing vaccines. Whilst the WHO states that safeguards were put in place to 
protect the public interest there are many scientists who believe the safeguards lack substance 
and process (Buse and Waxman 2001). The safeguards were also not evidenced in the 
establishment of a secret Emergency Committee (EC) in 2009 to advise the WHO when to call a 
pandemic. The Parliamentary Assembly has expressed concern that this lack of transparency and 
unregulated or secret lobbying, as occurred with the PPP’s, has undermined the democratic 
principles and good governance provided by the WHO. In particular there is concern about the 
systematic recruitment of key opinion leaders by specific image and communication agencies in 
the pharmaceutical industry (Flynn 2010; Krimsky 2003; Angell 2005). See chapter 6. 
In order to counter the effects of individuals with a conflict of interest, the WHO describes some 
routine safeguards that are in place. WHO believes transparency regarding conflicts of interest is 
ensured by requiring external experts to declare any relevant commercial interests or activities, 
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including funding, that they have received from pharmaceutical companies or consultancies 
(Flynn 2010). WHO officials state that experts with perceived conflicts of interest are excluded 
from making recommendations and they believe this removes bias from the decision-making 
process. This did not occur in the 2009 decision to declare a pandemic as was evidenced when 
the composition of the secret emergency committee (EC) was eventually revealed. WHO claims 
that when individuals with COI participate in discussions their views are weighted according to 
their declared conflict of interest (Flynn 2010). This is a very subjective method of dealing with 
conflicts of interest and it is not transparent to consumers. Individuals have their own 
interpretations of a ‘perceived’ or ‘real’ conflict of interest and how much it will affect their 
advice. For example, many experts insist their ties to pharmaceutical companies have no 
influence on their recommendations (Bita 2010). This system remains non-transparent to 
consumers due to the subjective nature of a perceived conflict of interest. In addition, the public 
has no evidence of how effectively safeguards are enforced. The public is expected to trust the 
WHO to enforce the safeguards but the WHO itself has admitted that there are some 
inconsistencies regarding its policies on conflicts of interests (Kmietowicz 2010). It admitted that 
safeguards surrounding engagements with industry need to be tightened. It can be argued that 
consumers without COI must be properly represented on vaccine advisory boards to ensure the 
discussions include a diversity of arguments and are not dominated by ‘groupthink’. This is the 
situation where members of an advisory board present the same perspective and other 
perspectives are not discussed.  
Margaret Chan defends the non-transparency of the EC as a desire to protect the experts from 
commercial or other influences (Chan 2010). Yet the primary objective of the WHO is its 
mandate to protect public health and this policy is not consistent with COI policies in all other 
areas of government decision-making. Scientists and decision-makers are always at risk of being 
pressured by lobby groups and they are expected to make professional decisions under these 
conditions. The lack of transparency in the EC board protects industry interests in decisions 
made about global health policies: transparency can protect the public interest. Even when the 
PA attempted to find out if the members of the EC had COI with industry the WHO refused to 
publish this information (Flynn 2010). WHO only agreed to release the names of the members of 
this committee after the pandemic was over, in August 2010. It was then revealed that 5 of the 15 
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members, including the chief advisor, had direct professional connections to pharmaceutical 
companies (WHO 2009iii). The chief advisor had received payment for previous work with 
Roche and GlaxoSmithKline – the two companies that were due to profit from the advice they 
provided to the WHO (Cohen and Carter 2010). Indirect links to industry in this board were not 
publicised. It is of note that a key milestone of the PPP that was pre-established in the IHR was 
the assessment of the surveillance and response capacity of the member countries by June 2009. 
This is of note because the EC declared a global pandemic on June 11 2009. The EC held its first 
meeting on 25 April 2009 to provide advice to the Director-General and a pandemic was 
declared on 11 June 2009. A level 6 pandemic could not have been declared if the EC had not 
been given the power under the IHR to change the definition of a pandemic (Flynn 2010). This 
power given to a secret committee enabled the pharmaceutical companies to secure substantial 
profits that led to an investigation into the governance of the WHO.  
The vaccine manufacturers had a vested interest in the declaration of a pandemic because of the 
billion dollar ‘silent’ contractual agreements with member countries regarding vaccination 
campaigns that were put in place in 2006/7 (Flynn 2010). Viewed in this light the change in 
definition of a pandemic that occurred a month before the declaration is significant. 
Pharmaceutical companies could make huge profits because of this change. Estimations from the 
international investment bank JP Morgan indicate that sales of H1N1 vaccines in 2009 were 
expected to result in profits of approximately 7-10 billion dollars to pharmaceutical laboratories 
(Flynn 2010). Figures from Sanofi-Aventis at the beginning of 2010 show a record year of anti-
flu sales that produced a net profit of 7.8 billion Euros (+11%) (Flynn 2010). It was observed 
that H1N1 vaccines were being sold to national governments at significantly inflated prices 
compared to the usual influenza vaccines. This is because they were using new patented 
technology to speed up the production of vaccines (Flynn 2010). Countries were even informed 
that double doses of vaccine were necessary leading to many countries overstocking and wasting 
large amounts of public money. The Parliamentary Assembly  questioned whether this was 
justified particularly as some experts have wondered whether the new strain could have been 
treated with normal seasonal flu vaccine which has contained a human strain A of H1N1 since 
2007 (Flynn 2010).  
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10.12 Summary of the Evidence for an Orchestrated Pandemic in 2009 
• Key scientists advising the WHO on planning for a flu pandemic had done paid work for 
drug firms that would benefit from the advice they were giving.  
• The establishment of a secret emergency committee (EC) to advise the DG was 
implemented by a board fully funded by pharmaceutical companies (ESWI) (Cohen and 
Carter 2010).  
• The EC was given the power under the IHR to change the definition of a pandemic and 
many of the members of this board, including the chief-advisor had COI with 
pharmaceutical companies. 
• The advice from the non-transparent EC to the WHO led to governments around the 
world stockpiling billions of dollars worth of antiviral drugs and vaccines. This advice 
was given without the WHO declaring conflicts of interest of the representatives on the 
secret committee at the time. 
• The assessment of the severity of the influenza virus was removed from the definition of 
a pandemic by the EC but the ‘sleeping contracts’ that governments had with 
pharmaceutical companies, adopted in their PPP’s for a severe pandemic, remained tied 
to the declaration of a pandemic.  
• Pressure was put on governments to buy more expensive vaccines that were evaluated 
through accelerated authorization procedures.   
• The communication of risk to the public did not include the changes to surveillance of 
influenza viruses that enhanced the incidence of this ‘new’ sub-type or the mild nature of 
the pandemic that was unfolding (Cohen and Carter 2010). It has been stated that there 
was no scientific basis for the claim that there would be 2 billion cases of H1N1 and also 
that scientists knew little about the benefits and harm of the vaccines (section 8.13). Yet 
this uncertainty in the science was not communicated to the public in the media 
campaigns.  
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10.13 Conclusion 
The ‘Swine Flu’ pandemic of 2009 was declared by a secret WHO committee that had ties to 
pharmaceutical companies that stood to make excessive profits from the pandemic. This situation 
was facilitated by the lack of effective regulations and transparency regarding COI, within the 
WHO and national governments, to prevent pharmaceutical companies from exploiting global 
health policies to their advantage. The pattern of this pandemic was similar to that of the ‘swine’ 
flu pandemic of 1976 which also did not eventuate. Scientists are using industry funded research 
to predict the occurrence of influenza pandemics and these are based upon questionable premises 
and assumptions linked to the profits that can be made if a pandemic is declared. Under the 
influence of GAVI significant changes were made to the governance of global health policies 
through the implementation of the International Health Regulations (IHR) in 2005. These 
changes required all WHO member countries to increase surveillance systems for all infectious 
diseases to create extensive national surveillance systems: not just at the entry and exit points for 
countries. GAVI/WHO also spent 10 years developing Pandemic Preparedness Plans (PPP) with 
all member countries to ensure that if a global pandemic was declared all countries would be 
required to buy vaccines at prices that were set in ‘silent contracts’. By 2005 nascent 
technologies had enhanced the surveillance of diseases by enabling greater sub-typing of 
infectious agents. Whilst increased surveillance of a disease can give the appearance of a greater 
risk due to more cases, this is not always the case. For many diseases, such as influenza, the 
majority of cases are mild and without complications, and would otherwise have gone unnoticed. 
This risk assessment of disease incidence and severity needs to be characterised for each disease 
because it is the severity of a disease and not the incidence that presents a risk to population 
health (Burnet 1956; Cumpston 1989). This characteristic of risk assessment for infectious 
diseases was discussed in chapter 4.  
Influenza is a common respiratory virus that mutates regularly. Whilst a new strain of virus may 
be more virulent it is important to establish the risk prior to introducing a new vaccine because 
vaccines themselves produce a risk to individuals and the efficacy and safety of influenza 
vaccines are still being debated. The interpretation of the PP used in government policies is a 
political decision that is linked to the desired outcomes of the policy. An interpretation that does 
	  
	  
293	  
not put the onus of proof on the proponent does not protect the public interest in health policies.  
The information about the risks of vaccines is significant to public health but it is not 
communicated to the public by governments or the mass media. In the case of the 2009 ‘Swine 
Flu’ pandemic, a level 6 pandemic could not have been declared if the WHO secret Emergency 
Committee had not been given the power to change the definition of a pandemic. This power was 
given to the EC by the European Scientific Working Group on Influenza that was 100% funded 
by industry. Public health is at risk if authorities and the media are not accurately informing the 
public about the risks of both diseases and vaccines. For many diseases increased surveillance 
results in a large number of identified cases that do not present a greater threat to public health. 
This was the case for the increased surveillance of ‘Swine Flu’ in 2009 and it resulted in an 
excessive waste of government funds and endangered public health.  
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CHAPTER 11  
CONCLUSION 
11.1 Introduction 
In Australia vaccination is not compulsory however the financial and workplace requirements 
that are linked to using vaccines make it difficult for Australian consumers to refuse vaccines 
in practice. The aim of this thesis was to assess the Australian government’s rationale for its 
vaccination policies and to determine whether the government’s policies have been 
implemented in response to the needs of the Australian community. It was useful to examine 
the historical decline of infectious diseases in Australia and to investigate the cultural and 
political influences that have led to the introduction of mass vaccination campaigns for many 
infectious diseases in the last two decades. An investigation of the methodology that is used 
for determining health risk assessment was also important. These risks need to be assessed in 
the Australian context – a genetically diverse population in a developed country.  
The data collected was used to assess the following claims by the Australian government 
(section 7.3): 
I. Vaccines are proven to be a safe, effective and necessary management strategy for 
infectious diseases and 
II. The benefits of vaccines to the community far outweigh the risks of vaccines to 
individuals. 
11.2 The Development of the Australian Government’s Vaccination Policy  
The historical evidence of the decline of infectious diseases in the 20th century shows that 
most of the reduction in deaths and illnesses due to infectious diseases occurred before the 
introduction of the majority of mass vaccination campaigns. The reduction in disease by 1950 
was due to the natural adaption of humans to the environment, including naturally acquired 
herd immunity, and to the effects of social medicine (environmental and lifestyle changes) 
that were promoted to the public through mass media campaigns. Prominent public health 
officials of the 20th century stated that the most important factors in the reduction of deaths 
and illness from infectious diseases were adaptation to the environment, nutrition, sanitation, 
hygiene, smaller family sizes (exposure to the infectious agent at an older age), less 
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crowding, maternal education and improved infrastructure and healthcare facilities. This was 
discussed in sections 2.3 and 2.4.  
Genetics, gender, age, socio-economic status and maternal education all interact in the 
expression of disease outcomes from infectious agents. Hence there is a diverse range of 
health outcomes that occur after exposure to any infectious agent. These vary from sub-
clinical (asymptomatic) or mild infection to serious disease and death, and severity is 
determined by the specific characteristics of each environment, host and agent interaction: the 
ecological context. See sections 4.1 and 4.6. This has been described for decades in the 
Epidemiological Triad (section 2.3). Infectious agents on their own are not a sufficient cause 
of disease, that is, they do not produce disease in all individuals because of a diverse range of 
environmental and host characteristics. Hence it cannot be assumed that all individuals in a 
community (or all communities) are at the same risk of disease from any infectious agent, just 
as we cannot assume that all individuals are at the same risk from a vaccine. Vaccines are 
used in genetically and environmentally diverse populations; therefore implementation on a 
‘one size fits all’ basis is questionable. A risk/benefit assessment for vaccines and diseases 
needs to consider the specific ecological context of each geographical community due to the 
diversity of many factors. See chapter 2.  
The key measures of health that the Australian government has used to evaluate community 
health over the last century have been i) the reduction of infant mortality rates and ii) 
vaccination coverage in the population (section 2.8). However, these provide an incomplete 
picture of the health and wellbeing of communities. Quality of life and chronic illness cannot 
be accurately determined from the infant mortality rates of populations or from vaccination 
coverage when evidence for the safety and efficacy of vaccines is incomplete. Public health 
authorities who evaluate the success of health policies using only these outcomes are limited 
in their ability to recognise other safety signals regarding the health of populations. If a 
specific adverse event or chronic illness is not acknowledged as being plausibly linked to 
vaccines and investigated, it will not be identified as a causal link for those outcomes. For 
example, the correlation between the significant increase in chronic illness in Australian 
children and the increasing use of vaccines in the NIP (section 1.1) has not been 
acknowledged as a plausible causal link by the Australian government and therefore it has not 
been investigated. The Australian government is claiming the NIP is safe without 
investigating the long-term health outcomes, 5 years or more, of using the combined schedule 
of 16 vaccines in infant animals or humans (sections 7.4 and 7.5). In Australia, infants are 
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recommended to have vaccines to protect against 7 diseases by 2 months of age and 12 
vaccines by 12 months of age. A government that is assessing ‘health’ by measuring 
vaccination coverage and infant mortality rates will not be looking for, or detect,  a link 
between an increase in chronic illness in children and the continually expanding childhood 
vaccination schedule.  
In the mid 20th century, Western countries adopted the scientific medical model of health as 
the foundation for government public health policies (chapter 2, 3 and 5). This model of 
health focuses on causes of infectious disease that arise from biological processes within the 
individual and is based on the germ theory of disease: a single external cause. This allows for 
a biomedical solution to disease prevention - vaccines - but it downplays the significance of 
environmental and lifestyle factors in the expression of infectious diseases and it downplays 
the risks of vaccines (section 5.3). Scientists in the 1950’s and 1960’s believed it was 
possible to prevent deaths and illness to infectious diseases by artificially raising the antibody 
level of the blood to fight the antigen without experiencing a serious case of the disease. At 
this time vaccines were only being used in voluntary mass vaccination programs for a few 
diseases. The belief in using vaccines as a method of prevention for many infectious diseases 
became most entrenched after the threat from infectious diseases significantly declined in 
developed countries. 
The theory of vaccine-induced immunity is based on the assumption that immunity is gained 
solely from the presence of antibodies to combat the pathogen and not on the interaction of 
complex body systems. It also assumes that adverse events and deaths due to each vaccine, 
and the combination of childhood vaccines are rare, something that has never been 
demonstrated with systematically collected data over many years. The ecological evidence of 
the significant increase in chronic illness in Australian children is a signal that this might not 
be the case (chapter 7). Since 1960 many new vaccines have been introduced into national 
vaccination programs in developed countries for infectious diseases that were not a serious 
risk to the majority of children. Most vaccines have not been implemented because of 
epidemics of disease in Australia or because of a serious threat of death or disability to the 
majority of the community, but to see if the diseases could be eliminated. Many vaccines 
have been introduced on this rationale even though some public health authorities stated that 
this theory was flawed (sections 3.2 and 3.10). The expansion of Australia’s vaccination 
program was not in response to a serious risk from infectious diseases in Australia, but in 
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response to directives from the WHO/GAVI alliance under global public health policies 
(section 3.2 to 3.5).  
The Australian Government adopted a free market model of healthcare in the 1980’s: a model 
that is underpinned by neoliberalism, the current capitalist economic model. This model is 
driven by profit, hence it encourages the production and consumption of health products and 
drugs in the community. A free market model of health is not necessarily a negative for 
public health, however the influence of financial rewards for all healthcare professionals and 
medical researchers must be recognised and appropriate measures must be taken to protect 
the public interest if policies are being promoted to the public for the good of the community 
(sections 5.4 and 6.2). Australia’s adoption of this model of health was in line with the 
WHO’s international program to vaccinate all the children of the world. The program, known 
as the Expanded Program on Immunisation (EPI), was launched in 1974. In 1983 all WHO 
member countries committed to achieving vaccination rates of 80% by 1990. This was to be 
achieved for all vaccines in use at this time even though the majority of the populations in 
developed countries were not at risk from these diseases. After 1990 the WHO re-set the 
standard to achieving 90% vaccination coverage by 2000 with many new vaccines being 
added to the schedule. This included both developed and developing countries irrespective of 
the ecological context of the disease in each country. In 1990, even though infectious diseases 
were not of significant concern in Australia and expenditure on infectious diseases was low 
(section 2.6), the Australian government complied with the WHO directive to raise the 
vaccination rate of the population by introducing financial incentives to doctors and parents 
to encourage the use of all the recommended vaccines (sections 3.10 and 3.11). This included 
a push for high vaccination rates for the many new vaccines that were introduced at this time 
without a transparent risk/benefit assessment for each vaccine. Infant mortality rates to 
infectious diseases were low (8.2/1000 live births) before the new vaccines and strategies for 
increased participation rates were implemented in the 1990’s.   
The Australian Government claimed at the time that the need to increase the vaccination rate 
of the population was to see if these diseases could be eliminated and not because the 
diseases posed a serious risk of death and illness to the majority of children (section 3.10). 
Infectious diseases were re-named vaccine-preventable diseases at this time implying that the 
diseases could be prevented with vaccines. The rationale for the government’s requirement 
for high participation rates in vaccination programs was the need to create herd immunity 
with vaccines and the claim that high vaccination rates (90% and above) would lead to the 
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elimination of these diseases. It is well established that infectious diseases declined in part 
because of the effect of natural herd immunity created after exposure to the infectious agents 
when children are at the right age (section 2.5). This produces long-term immunity in 
individuals and communities but this is not addressed by the government in the promotion of 
vaccination policies to the public (section 4.7 and chapter 7).  
Australia’s vaccination policy was formalized in 1997 as the Immunise Australia Program 
(IAP) and the expanded schedule of vaccines was linked to welfare benefits and school entry 
to encourage (pressure) parents to vaccinate (section 3.11). At this time children could not be 
prevented from attending school but the emphasis on vaccination suggested it was the 
responsible thing to do and financial incentives for doctors and patients were used to 
encourage vaccination. Many parents depend on welfare and childcare benefits and this 
policy limits their choices regarding employment and health. Although parents could choose 
not to vaccinate based on philosophical or religious exemption, this required a doctor’s 
signature; a requirement that coerces parents to participate in this medical practice. This is a 
reversal of the guidelines for informed consent set by the Medical Board of Australia (MBA) 
and stated in section 2.1.3 of the Australian Immunisation Handbook (Ed.10 2015). This 
guideline states informed consent ‘must be given voluntarily in the absence of undue 
pressure, coercion and manipulation’ (section 5.6). The Australian government’s adoption of 
strategies in public health policy that pressure the community to vaccinate represents a 
paternalistic attitude to health that promotes the recommendation of a medical intervention on 
the basis that it is in the community/individual’s best interest. This system effectively 
removes the autonomy of individuals over their own health, that is, the individual’s right to 
choose how they care for their own bodies. Australians are expected to accept vaccination, 
and the government’s public health policies, without question or debate, because doctors are 
the ‘experts’ who know best. See chapter 5. 
The ethical code of conduct for Australian practitioners is controlled by the Australian 
Medical Association (AMA) under the Good Medical Practice guidelines designed by the 
Medical Board of Australia (section 5.6). This system allows the AMA, a powerful 
institution, to influence doctors’ education and behaviour through the registration procedures 
for practitioners.  This ethical code was adopted from the guidelines set by the World 
Medical Association in the Declaration of Geneva and they replace the Hippocratic Oath. 
Medical practitioners in Australia vow to abide by these ethical guidelines that include the 
following commitments:  
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• The health of my patients will be my first consideration. 
• I will not use my medical knowledge to violate human rights and civil liberties even 
under threat.  
Informed consent to medical interventions is protected in the Good Medical Practice 
guidelines. Doctors are required to get signed consent from consumers/patients before a 
medical intervention is accepted. This guideline also requires that doctors present all the risks 
and benefits of a medical intervention before consent is given. Yet this is not the case for 
vaccination in Australia: a medical intervention for healthy people. Doctors are not required 
to provide Australian parents with a list of the ingredients of vaccines and the government 
does not publish this data on the IAP website where parents are directed to obtain information 
about Australia’s vaccination program. Few parents are informed, either by doctors or the 
Australian government, of the serious adverse events that are listed on the Product 
Information for each vaccine. In addition, they are required to get a doctor’s signature to 
refuse this medical intervention. Australian vaccination policies are violating human rights by 
linking this medical procedure to social welfare benefits (section 5.7). The International 
Covenant on Economic and Cultural and Social Rights (ICECSR) protects an individual’s 
right to individual autonomy over their own bodies (bodily integrity) with respect to medical 
interventions. This covenant also protects the community’s right to non-discriminatory social 
welfare policies. The removal of these rights in a government public health policy must be 
justified as being ‘appropriate to the risk and no more intrusive or invasive than reasonably 
available alternatives that would achieve the desired level of health protection’ (Fidler and 
Gostin 2006 p87). The Australian Human Rights Commission states that governments can 
infringe on human rights if the infringement is done for a legitimate purpose (including 
public health), is proportionate to the risk and is done by law. However, the Australian 
government has not provided adequate evidence that the use of multiple vaccines in infants is 
appropriate to the risk from these infectious agents, and there is no legislation or regulations 
in any Health Acts that compel Australians to accept a vaccine (section 5.7). In the disclaimer 
on the government’s IAP website the government states that members of the public should 
seek independent advice from an appropriate professional relevant to their own particular 
circumstances. The Commonwealth of Australia does not warrant that the information 
contained on the IAP website is accurate, current or complete.  
In 2012, the Australian government decided to increase the incentives to vaccinate by 
increasing the welfare and childcare benefits that are linked to vaccines (section 3.13). At the 
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same time the government increased the number of vaccines listed on the recommended NIP: 
three new vaccines were added to the schedule even though there was no increased risk from 
these diseases. The government emphasized the need for all children to receive the new 
vaccines by providing childcare and welfare benefits only to children who were ‘fully’ 
vaccinated. This change meant that parents would not receive the benefit if they selectively 
vaccinated or did not have a valid exemption form signed by a doctor. Hence the default 
position in Australia is to vaccinate and pressure is placed on parents to be responsible for the 
good of the community. In 2015 the Australian government proposed removing religious and 
philosophical exemption to vaccination and only allowing medical exemptions. These 
coercive policies using financial incentives effectively mandate vaccines for all parents who 
rely on childcare and welfare benefits. In 2006 the NSW Health Department issued a Policy 
Directive mandating the use of the recommended vaccines for some clinical positions and for 
tertiary health students. This was expanded to other states by 2008. Many Australian 
institutions, such as hospitals and general practices, now require employees to be fully 
vaccinated even though there is no regulation or legislation under Australian health acts to 
compel individuals to use vaccines (AG IAP 2013). This policy was introduced without the 
government providing evidence for its necessity and whilst still claiming that vaccination in 
Australia is not compulsory. Employees in some institutions are threatened with losing their 
jobs if they choose not to update with the recommended vaccines (section 3.15).   
In this paternalistic system, the public is expected to place their trust in the directives 
provided by the government and the medical profession regarding this medical intervention. 
Governments implement public health policies on the premise that they are in the public’s 
best interest and they will promote health in the community. Yet government vaccination 
policies are not underpinned by the ethical principles used to guide decisions in health 
promotion. These principles are described in the Seedhouse Ethical Grid (section 5.5). The 
underlying ethical principle of health promotion in the Seedhouse Ethical Grid is to create 
individual autonomy. This is stated in the code of conduct for health professionals as the right 
for a patient to be fully informed of the risks and benefits of a medical intervention without 
coercion before giving their consent to the procedure.  Australian vaccination policies restrict 
individual autonomy in the use of vaccines. Seedhouse (2009) states ‘All plausible theories of 
health equate work for health in some way with the creation of autonomy’ (p144). In other 
words, when autonomy is not promoted in the use of a medical intervention, health is not 
assured. Individual ‘autonomy’ in vaccination policies refers to the right to informed consent 
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without coercion’, as stated in the Australian Immunisation Handbook (ed.10). If this 
guideline is violated a medical intervention can be promoted through indoctrination and this 
puts public health at risk. Linking the professional registration of doctors to supporting 
government vaccination policies also puts public health at risk because it prevents doctors 
speaking freely about the risks and benefits of the procedure to their patients. 
The generally accepted ethical principles for health promotion include (Seedhouse 2009): 
1.  Respect for autonomy: a respect for the rights of individuals and their right to 
determine their lives. 
2. Beneficence: doing good 
3. Non-malfeasance: doing no harm 
4. Justice: being fair and equitable  
5. Duty to care 
6. Duty to be truthful 
Government public health policies are founded on political decisions and value judgments 
concerning the scientific evidence available. Scientific evidence is not static; it evolves over 
time and can be produced under different cultural practices that alter its integrity and rigour. 
If the ethical guidelines for health promotion are not adopted in the design of government 
health policies it is possible for these policies to do more harm than good in the population. 
This is particularly the case if policies are designed on non-transparent decisions/evidence 
and if the government is not accountable for the decisions it makes. Australians, who depend 
on government welfare benefits and some employment situations, are pressured to vaccinate 
to receive financial benefits. This discriminatory policy exposes these individuals to a greater 
risk from vaccines without a compensation scheme for those who suffer adverse events. The 
requirements for implementing Australian vaccination policies are contrary to the ethical 
guidelines for promoting health in communities and they are being implemented without 
community involvement in debate or decision-making.  
11.3 Industry Influence and Undone Science in Public Policy 
In the current political climate of neoliberalism, global health policies are being formed by 
partnerships with corporations. The WHO/GAVI alliance is a partnership that includes 
pharmaceutical and biotechnology companies, the Rockefeller and Gates Foundations, the 
World Bank and the International Monetary Fund, etc, and all these players are influential in 
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determining global health policy directives for all WHO member countries. These public-
private partnerships are designing global public health policies that are promoted by the 
WHO as being in the interests of community health (sections 3.2 and 3.3). The WHO/GAVI 
alliance is also involved in advocacy for these directives with national governments and 
providing financial incentives to countries that cannot afford to implement vaccination 
programs (section 3.4). Sponsorship of programs allows GAVI to influence the agendas that 
are promoted in national public health policies of many countries. WHO/GAVI policy 
directives are being justified on evidence-based policy-making (EBPM), however the type of 
evidence used in the assessment of risks and benefits is not transparent to the global 
community (chapter 6). Many national governments are relying on international donations 
that require them to prioritise global health initiatives (influenced by industry) over local 
health issues and requirements. Financial incentives are being used to induce governments to 
pursue global goals for an increasing number of vaccination programs, even when these 
policies do not match the needs of the country. This trend is observed in the development of 
the Australian government’s NIP. See chapter 3 and the case studies in chapters 9 and 10.   
Public health policies for infectious diseases in Australia are determined on the advice 
provided to the health minister by the Australian Technical Advisory Group on Immunisation 
(ATAGI) (sections 3.4 and 6.7). This body relies on technical advice provided by the WHO/ 
industry and the medical profession, with only one public representative. There are many 
interests other than health that can be protected in government health policies, even though 
the stated goal of these policies is to protect public health. This is why all stakeholders should 
be properly represented in the decision-making process, particularly the public upon whom 
the policy is enforced. The Environmental Health Risk Assessment (EHRA) framework 
emphasises the need for a transparent and systematic assessment of the risks of health hazards 
and the importance of public involvement in debates/decisions on public health policy but the 
Australian government has not adopted the EHRA framework for the foundation of 
vaccination policies (sections 4.4 and 4.5). Vaccination policies are being designed using 
generic computer modeling of diseases by the GAVI/WHO alliance for broad communities 
without accounting for the specific environmental and lifestyle factors of different 
communities. Generic modeling for the implementation of vaccines is modified with local 
factors for some countries but many countries adopt the recommendations made by 
WHO/GAVI. The cost-effectiveness of these programs is determined using industry 
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generated statistics with underlying assumptions that are not transparent to the public. See 
chapters 3, 9 and 10. 
When technical experts dominate political systems, their values and beliefs can play a role in 
framing government health agendas. The value judgments made by the representatives of the 
ATAGI advisory board help determine which information should be prioritised in 
government policy. In the Australian political system health ministers are dependent upon the 
recommendations of this board. If the minister is not informed about the significance of a gap 
in the scientific knowledge it is possible for government policy to be formed despite relevant 
studies not being undertaken (section 8.2). The status quo can be maintained in this system 
because authorities can claim ‘there is no evidence of harm therefore no action needs to be 
taken.’ When the public is not consulted about their perspectives on the risk of a procedure 
and when the science used in policy decisions is not transparent, it is possible for the 
dominant network of scientists to shape policy priorities in ways that may not be in the 
public’s best interest. See chapter 8. 
 In section 6.7 I described the representation of stakeholders on the Australian government’s 
vaccination advisory board (ATAGI). There are many representatives on this board who have 
financial ties to industry, including the chairman of the committee from 2005-2014, and there 
is only one consumer representative. Biased or selective science can be used in government 
policy when industry interests dominate the decision-making process. COI in the political 
system assists industry to dominate the design of public policy and this can synchronise with 
a powerful voice in the media. This underscores the need for governments to maintain 
individual autonomy in public health policies as special interest groups can promote their 
agendas in these policies. In the era of globalization and neoliberalism, decisions regarding 
research agendas and public health policy are being influenced by industry via industry 
sponsorship of medical research and representatives on government and institutional advisory 
boards. This reinforces a dominant network of scientists in academic institutions that controls 
the finances and resources in the field as well as the allocation of rewards (section 8.8). The 
funding arrangements in academic/industry institutions can appear fair but they can be 
designed to enhance some areas and neglect others due to the drive for industry profits. 
Scientists who wish to pursue public interest science that is not aligned with industry 
outcomes can experience a lack of funding, less prestige and suppression of their research. 
Academic institutions can no longer be considered independent and impartial educational 
facilities because of industry sponsorship and because of the equity that researchers and 
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departments hold in the research they perform. This influences Australian public policy 
because industry has influence in ATAGI decisions and the scientific evidence that underpins 
these decisions is performed at academic/industry research institutions. See chapter 8.   
Industry sponsorship in academic institutions can influence the direction and outcomes of the 
scientific research that is produced. Industry can influence which areas of science will remain 
unfunded and therefore ‘undone’, resulting in a lack of evidence in policy development. This 
often occurs in areas that would reduce company profits. Examples of this have been 
provided in chapters 6, 7 and 8. It is also important that science remains open for all 
stakeholders to debate because this ensures that it is produced with the values that result in 
scientific rigor and integrity. When scientific data is not shared and openly assessed by the 
scientific community it is more susceptible to fraudulent practices and manipulation while the 
community is expected to trust that the scientific knowledge has been produced with 
integrity. In the capitalist model of health where doctors and scientists are financially 
dependent on their research/work for their livelihood, it is important that they are free to 
speak the truth. Loyalty to the health of society should take precedence over jobs, careers, 
research grants and professional memberships. The public interest is not protected if 
scientists can lose their jobs if they do not produce results that support their 
sponsor/employer’s interests. Job security is needed for scientists who present findings that 
are contrary to the interests of their employer.   
Governments that place the onus of proof of harmfulness on the public and not the proponent 
after a technology/procedure is introduced into the population are allowing experimentation 
on human populations. This is contrary to the precautionary principle that is intended to 
protect human and environmental health when there are significant gaps or uncertainty in the 
science. Health outcomes in these policies are unknown and in many cases will never be 
known, because governments are not establishing adequate monitoring systems to determine 
causal links. This is the case with government vaccination policies and it has been illustrated 
with the examples of the HPV vaccine and the ‘Swine Flu’ 2009 vaccine in chapters 9 and 
10. Undone science can be addressed in public health policies to protect the public interest by 
adopting the form of the precautionary principle that was agreed upon by the Scientific and 
Environmental Health Network (SEHN) in 1998. This principle is stated as: 
 ‘The burden of proof of harmlessness of any procedure/technology is on the proponent and 
not the general public’.  
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Public health policies that do not address significant undone science violate the Nuremberg 
Code of Conduct and the Geneva Declaration (Physicians Oath) adopted by the General 
Assembly for the World Medical Association in 1948 and by the Australian Medical 
Association (AMA) in the Code of Ethics and Good Medical Practice guidelines for health 
practitioners (section 5.6). 
The Undone Science in Australian Vaccination Polices  
Here is some of the research that has not been funded but is needed to justify the Australian 
government’s vaccination policies (chapters 6, 7 and 8):  
• Evidence from formal randomized controlled clinical trials is needed to demonstrate  
i) Effectiveness of the vaccines in preventing the disease (and not just the 
surrogate end-point of seroconversion)  
ii) The safety of the vaccines using an inert placebo 
• The safety of vaccines is based on evidence from phase 1, 2 and 3 human clinical 
trials (with chosen criteria and parameters) and the evidence does not include animal 
models that demonstrate the safety of vaccines. Long-term health outcomes of single 
vaccines and the combined schedule of vaccines have never been investigated in 
large-scale animal studies or controlled human clinical trials, comparing vaccinated 
and unvaccinated groups using an inert placebo. This is significant because small–
scale animal studies and clinical evidence show there is a plausible link between 
vaccines and the chronic illness that is increasing in Australian children (section 7.4).  
• A demonstrated safe level of the ‘trace’ amounts of excipients (alone or in the 
recommended combination) has not been established in animal studies or human 
studies (AG EHRA 2012) (section 4.5).  
• The safety of ethylmercury has been extrapolated from the knowledge of the 
neurotoxin methylmercury. These two neurotoxins are not the same and the health 
effects of ethylmercury in low doses combined with other excipients in the vaccine 
have not been established in studies of the human feotus, infants or adults. Many 
toxins in the past have been found to be more toxic in lower doses than originally 
believed.  
• The lack of an active post-vaccination surveillance system to systematically monitor 
all the health outcomes of vaccinated individuals means that definitive evidence of 
vaccine related adverse events and their frequency in the population is not available.  
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• Many vaccinated individuals still get the diseases they are vaccinated against but the 
government does not provide transparent data on the number of vaccinated 
individuals that are still getting the diseases and/or that are hospitalized with these 
diseases. This information needs to be presented with the socioeconomic status of the 
case to evaluate the benefits of vaccination programs in different populations.  
11.4 CONCLUSION 
In chapter 1 I stated that the aim of this thesis is to examine the following claims made by the 
Australian government (section 1.3): 
1. Vaccines are proven to be a safe, effective and necessary management strategy for 
infectious diseases and 
2. The benefits of vaccines to the community far outweigh the risks of vaccines to 
individuals and population health. 
This thesis has demonstrated that there is inadequate evidence from independent studies to 
support these claims about vaccines.  
Claim 1: Most mass vaccination campaigns were introduced into developed countries after 
1950 in an attempt to eliminate infectious diseases, not because infectious diseases were a 
serious risk to the majority of Australian children. In addition, many vaccines were 
introduced after 1980 on a directive from the WHO at a time when infant mortality rates and 
the risk of infectious diseases in Australia were very low. There is a lack of evidence to 
support the claim that vaccine-induced herd immunity can eliminate infectious diseases. The 
Australian government has not provided evidence from formal controlled clinical trials that 
demonstrate the efficacy of vaccines in preventing disease nor has it provided transparent, 
independent data on the vaccination status, socioeconomic status, and severity of reported 
cases of disease that would demonstrate the influence of vaccines in preventing disease.  
There is a lack of evidence to claim that vaccines are a safe and effective management 
strategy in diverse genetic populations because the appropriate scientific studies have not 
been funded to determine the types and frequency of adverse events that are occurring in 
different communities.   
Claim 2: The government’s claim that the benefits of vaccines to the community far 
outweigh the risks of vaccines to individuals cannot be sustained because the government has 
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not established an active surveillance system that can provide data on the long-term health 
effects of single or multiple vaccines in the Australian population. The correlation between 
the increased use of vaccines in the NIP and the significant increase in chronic illness in 
children has not been acknowledged or investigated by the Australian government. 
Furthermore, the Australian government claims that the benefit of using vaccines is to create 
herd immunity to protect the community. Yet the criterion for recommending a vaccine for 
approval in the NIP does not include the necessity to demonstrate that the vaccine has 
implications for herd immunity in the population (Nolan 2010 A79).   
Summary: 
The undone science in Australian government vaccination policies results in unpredictable 
health outcomes in the population. It needs to be acknowledged by the Australian government 
that increased morbidity in the Australian population is a possible outcome if vaccination 
policies are being implemented on a lack of comprehensive scientific evidence. Infectious 
diseases had declined in severity in Australia before most vaccines were introduced. Vaccines 
were not introduced to reduce the deaths and illness due to infectious diseases but to see if 
they could be eliminated. Infectious diseases were re-labeled vaccine-preventable diseases to 
imply that vaccines are the key to preventing disease, which contradicts the historical decline 
of infectious diseases. The contribution that vaccines may have made to the decline of 
infectious diseases is unknown because there has been no systematic assessment of their 
efficacy in preventing disease. Australian government vaccination policies have been 
founded on global directives from the WHO/GAVI that were designed by an alliance with 
industry. They have not been recommended as a result of an independent assessment of the 
need for vaccines in the ecological context of Australia. This is significant because 
environmental and host characteristics play a role in disease expression. Infectious agents on 
their own do not cause disease and this explains why many infectious diseases are not severe 
in countries with improved environmental and social conditions. The Australian government 
has not provided a risk/benefit assessment for each vaccine in the Australian context to 
support the claims that are made in vaccination policies.  
Finally it must also be acknowledged that industry influence is pervasive and is affecting 
research findings as well as the research topics that are being investigated and the decisions 
being made in policy. Undone research in the government’s vaccination policies includes the 
absence of studies of vaccination by scientists who are completely independent of industry 
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influence. In addition, decisions are being made by policy decision-makers with COI with 
industry that are not transparent to the Australian public, even if they are required to be 
declared before a meeting. The public is also not informed that directives for Australia’s 
public health policies are provided by the WHO/GAVI alliance that includes partnerships 
with pharmaceutical companies. This synchronises with government vaccine advisory boards 
that do not have adequate representation of public members to present the public perspective 
in these policies. In this situation, the public is left to trust that officials are using evidence 
that is produced with integrity and rigour to develop policies that protect the public interest. 
Biomedical research produced in academic/industry research institutions contains trade 
secrets that prevent collaboration and an independent assessment of the science. There is also 
a lack of independent studies to assess the accuracy of the conclusions that are drawn. This 
leads to institutional biases in the political decisions that are made in national and global 
public health policies. Government policies are being promoted to the public in the interests 
of the community yet they are being designed and driven by industry interests. This misleads 
the public and endangers public health. Governments are also informing the public that they 
should seek their advice on vaccination from medical practitioners. Yet health professionals 
are unable to speak freely about the risks and benefits of vaccines because they are required 
to support government vaccination polices for their professional registration.   
These conclusions emphasise the need for maintaining voluntary participation, without 
coercion, in public health policies that include a medical intervention. This is particularly the 
case for preventative health policies that promote a medical intervention to healthy 
individuals. Healthy communities are achieved by increasing individual autonomy, that is, the 
individual’s right to choose how they care for their own bodies in the prevention of disease. 
This prevents indoctrination and it must be respected and promoted in public health policies 
to ensure that better health is the primary outcome of these policies. 
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Appendix 1 
 The Ingredients of Vaccines 
Reference: The Australian Immunisation Handbook 10th Edition. 2013. Australian 
Technical Advisory Group on Immunisation (ATAGI). 
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handboo
k10-home  (Updated 30th May 2013).  
Table A3.1: Components of vaccines used in the National Immunisation Program 
Vaccine component* Vaccine brand† Antigen 
Albumin/serum 
Avaxim Hepatitis A (HAV) 
ProQuad Measles-mumps-rubella-varicella (MMRV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Vaqta Hepatitis A (HAV) paediatric/adolescent 
Varilrix Varicella (VV) 
Varivax 
Refrigerated Varicella (VV) 
Aluminium 
hydroxide 
Avaxim Hepatitis A (HAV) 
Cervarix Human papillomavirus (HPV) 
Engerix-B Hepatitis B (HBV) adult and paediatric 
Havrix Junior Hepatitis A (HAV) paediatric 
H-B-Vax II Hepatitis B (HBV) adult and paediatric 
Infanrix IPV Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Menjugate 
Syringe 
Serogroup C meningococcal conjugate 
(MenCCV) 
NeisVac-C Serogroup C meningococcal conjugate (MenCCV) 
Vaqta Hepatitis A (HAV) paediatric/adolescent 
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Vaccine component* Vaccine brand† Antigen 
Aluminium 
hydroxide/ 
phosphate 
Boostrix Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Gardasil Human papillomavirus (HPV) 
Infanrix hexa 
Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
influenzae type b  
(DTPa-hepB-IPV-Hib) 
Aluminium 
phosphate 
Adacel Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Meningitec Serogroup C meningococcal conjugate (MenCCV) 
Prevenar 13 13-valent pneumococcal conjugate (13vPCV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Borax/sodium 
borate 
Gardasil Human papillomavirus (HPV) 
Vaqta Hepatitis A (HAV) paediatric/adolescent 
Egg protein 
All influenza 
vaccines 
Agrippal 
Influenza 
Fluarix Influenza 
Fluvax Influenza 
Influvac Influenza 
Vaxigrip Influenza 
Formaldehyde 
Adacel Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Agrippal Influenza 
Avaxim Hepatitis A (HAV) 
Boostrix Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Fluarix Influenza 
Havrix Junior Hepatitis A (HAV) paediatric 
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Vaccine component* Vaccine brand† Antigen 
Infanrix hexa 
Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
influenzae type b (DTPa-hepB-IPV-Hib) 
Infanrix IPV Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Influvac Influenza 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Vaqta Hepatitis A (HAV) paediatric/adolescent 
Vaxigrip Influenza 
Gelatin 
ProQuad Measles-mumps-rubella-varicella (MMRV) 
Varivax 
Refrigerated Varicella (VV) 
Gentamicin 
Fluarix Influenza 
Influvac Influenza 
Glutaraldehyde 
Adacel Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Kanamycin Agrippal Influenza 
Mannitol 
Priorix Measles-mumps-rubella (MMR) 
Priorix-tetra Measles-mumps-rubella-varicella (MMRV) 
Monosodium 
glutamate (MSG) 
ProQuad Measles-mumps-rubella-varicella (MMRV) 
Varivax 
Refrigerated Varicella (VV) 
Neomycin 
Agrippal Influenza 
Avaxim Hepatitis A (HAV) 
Fluvax Influenza 
Havrix Junior Hepatitis A (HAV) paediatric 
Infanrix hexa Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
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Vaccine component* Vaccine brand† Antigen 
influenzae type b (DTPa-hepB-IPV-Hib) 
Infanrix IPV Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Priorix Measles-mumps-rubella (MMR) 
Priorix-tetra Measles-mumps-rubella-varicella (MMRV) 
ProQuad Measles-mumps-rubella-varicella (MMRV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Vaqta Hepatitis A (HAV) paediatric/adolescent 
Varilrix Varicella (VV) 
Varivax 
Refrigerated Varicella (VV) 
Vaxigrip Influenza 
Phenol Pneumovax 23 
23-valent pneumococcal polysaccharide 
(23vPPV) 
Phenoxyethanol 
Adacel Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
Avaxim Hepatitis A (HAV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Polymyxin 
Fluvax Influenza 
Infanrix hexa 
Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
influenzae type b (DTPa-hepB-IPV-Hib) 
Infanrix IPV Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Polysorbate or 
sorbitol 
Agrippal Influenza 
Boostrix Diphtheria-tetanus-acellular pertussis (dTpa) reduced antigen 
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Vaccine component* Vaccine brand† Antigen 
Fluarix Influenza 
Gardasil Human papillomavirus (HPV) 
Havrix Junior Hepatitis A (HAV) paediatric 
Infanrix hexa 
Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
influenzae type b (DTPa-hepB-IPV-Hib) 
Infanrix IPV Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
Influvac Influenza 
Prevenar 13 13-valent pneumococcal conjugate (13vPCV) 
Priorix Measles-mumps-rubella (MMR) 
Priorix-tetra Measles-mumps-rubella-varicella (MMRV) 
ProQuad Measles-mumps-rubella-varicella (MMRV) 
Quadracel Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis (DTPa-IPV) 
RotaTeq Rotavirus 
Yeast 
Engerix-B Hepatitis B (HBV) adult and paediatric 
Gardasil Human papillomavirus (HPV) 
H-B-Vax II Hepatitis B (HBV) adult and paediatric 
Infanrix hexa 
Diphtheria-tetanus-acellular pertussis-hepatitis 
B-inactivated poliomyelitis-Haemophilus 
influenzae type b (DTPa-hepB-IPV-Hib) 
* If the person to be vaccinated has had an anaphylactic reaction to any of the vaccine 
components, administration of that vaccine may be contraindicated. Specialist advice 
should be sought to identify the component and to review if the person can be 
vaccinated in future. 
† Please also refer to Appendix 4 Commonly asked questions about vaccination for 
more specific information about these various constituents. 
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Thimerosal was listed as an ingredient of some vaccines in March 2013 in The 
Australian Immunisation Handbook 9th Edition. Components of Vaccines. Appendix 4. 
Australian Technical Advisory Group on Immunisation (ATAGI). Page 343.  
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/78CDF4
1C283426A8CA2574E40020CCAB/$File/handbook-9.pdf (accessed March 2013). 
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Appendix 2 
Case Study: Thimerosal and Mercury Toxicity in Humans 
The Preservative Thimerosal 
Thimerosal is a preservative that was invented in 1920 by the chemist, Eli Lilly, the 
founder of the pharmaceutical company of the same name (Kirby 2005 p48). It is an 
organomercurial compound that is almost 50% mercury by weight and metabolises to 
ethylmercury and thiosalicylate. Its brand name is Merthiolate and it is a cream-
coloured water soluble crystalline powder (Kirby 2005). This preservative has never 
been tested for safety and effectiveness since it was first used in the 1930’s (FDA p1). 
The first requirement for preservatives to be included in the US Code of Federal 
Regulations (CFR) was in 1968 but preservatives were present in many products prior 
to this time. The CFR requires that ‘the preservative shall be sufficiently non-toxic so 
that the amount present in the recommended dose of the product will not be toxic to the 
recipient…’ (FDA p1). Yet the FDA does not test preservatives for safety and efficacy. 
FDA safety and effectiveness standards only apply to collecting safety and effectiveness 
data on the product that is being licensed not on the preservative that is in the product 
for licensing.  
Whilst the FDA states that the concentration of thimerosal in vaccines meets the 
preservative standards set by the United States Pharmacopeia these standards do not 
refer to the safety of the preservative – only to its effectiveness. In other words, it kills 
the specified challenge organisms and is able to prevent the growth of the fungi when it 
is at a concentration in the range of 0.001% - 0.01%. Thimerosal at a concentration of 
0.01% contains 50 micrograms of thimerosal per 0.5 ml dose or 25 micrograms of 
mercury in a 0.25 ml dose. A trace amount of thimerosal is considered to contain 1 
microgram or less of mercury per dose. Whilst the FDA claims several studies have 
indicated thimerosal has a ‘long record of safe and effective use’ (p2) these studies are 
mostly for the effectiveness of thimerosal in topical products and not for the safety and 
effectiveness of thimerosal injected into the tissues (FDA p7). During the 1990’s many 
thimerosal-containing vaccines were added to the childhood schedule in all countries. 
Yet there is no safety data on the health effects of trace amounts of thimerosal in 
vaccines or accumulated or synergistic effects of thimerosal with other vaccine 
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ingredients (FDA 2012 p3). It is also known that organomercurial compounds have the 
potential for neurotoxicity even at low levels in the human body.  
Cases of mercury poisoning that occurred from the administration of  thiomersal-
containing products in the 1970-1990’s (including the administration of immune 
globulin) reported necrosis, acute hemalysis, disseminated intravascular coagulation, 
acute renal tubular necrosis and central nervous system injury including obtundation, 
coma and death (IOM in FDA p3). Animal studies prior to 1990 demonstrated that the 
maximum dose of thimerosal that could be tolerated without causing death was 20 
micrograms of thimerosal/kg in rabbits and 45 micrograms/kg in rats (FDA p3). There 
is no mention of the health effects that occur in these animals (prior to death) when 
exposed to these levels of mercury. In addition, the FDA has not established definitive 
data on the time it takes to remove ethyl mercury from the body of animals or humans. 
The FDA uses the Magos et al (1985) study of rats to make the claim that ‘ethylmercury 
is less neurotoxic than methylmercury’, the organomercury compound that the safety 
guidelines are based on. There is no evidence provided by the FDA to support this 
statement and no description of the health effects in the rats after exposure to 5 daily 
doses of ethyl and methyl mercury to illustrate the conclusion that ‘it is less neurotoxic’ 
(FDA p3). Instead the FDA uses other studies to observe that there are differences in the 
way thimerosal and methyl mercury are distributed, metabolized and excreted in the 
body, therefore the FDA concludes ‘Thimerosal appears to be removed from the blood 
and body more rapidly than methyl mercury’ (FDA p3). This is not a definitive 
statement about the removal of thimerosal.         
The guidelines that do exist for the health effects of mercury in humans have been 
established from accidents with the related organomercury compound, methylmercury 
and its consumption in the diet - not injection into the body (FDA p2; TEACH). The 
FDA states that ethyl and methyl mercury are expected to have different toxicological 
profiles but as there is a ‘lack of definitive data on the comparative toxicities’ the FDA 
has considered them equivalent in its risk evaluation (p2). It is also known that exposure 
from ingestion is very different to exposure from injection of the substances into the 
tissues (Gilbert 2004). Ethyl and methylmercury are both organic compounds which 
mean they contain carbon and are easily absorbed by lipids and fatty membranes (Kirby 
2005 p48). The difference between the compounds is that ethylmercury has one extra 
carbon molecule making it a larger structure (Kirby 2005). Organomercury is more 
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dangerous than inorganic mercury because inorganic mercury can dissolve in water and 
be more easily excreted by the kidneys in urine (Gilbert 2004). Ethylmercury is less 
readily eliminated from the body because it is an organic mercury compound. 
FDA Guidelines for the Use of Methyl and Ethyl Mercury 
Several agencies have developed guidelines for safe exposure to methyl mercury 
including the US Environmental Protection Agency (EPA) (1997) 0.1 mg/kg/day, the 
Agency for Toxic Substances and Disease Registry (ATSDR) (1999) 0.3 mg/kg/day, the 
FDA (1979) 0.4 mg/kg/day and WHO (1996) 0.47 mg/kg/day (FDA p2). These 
exposure levels range from 0.1 micrograms/kg body weight/day (EPA) to 0.47 
micrograms/kg body weight /day (WHO). The FDA claims that the figures vary 
between agencies due to: 
I. Varying safety margins 
II. The different emphasis placed upon various sources of data 
III. The different missions of the agencies and  
IV. The population that the guideline is intended to protect. For example, adult or 
child.  
The FDA’s guideline has been based partly on an adult who ingests 30 micrograms/day 
of methyl mercury in the diet. This is equivalent to 0.43 micrograms/kg/day for a 70kg 
adult. Although there are variations in the guidelines between the different agencies the 
FDA considers that they all fall within the same order of magnitude. However, if this 
data is assessed in the perspective in which it is used i.e. the safety of toxins in a new 
born infant compared to a mature adult of 70kg then these guidelines vary considerably 
between the agencies. The 0.1 mg/kg body weight recommended by the EPA is 
significantly less than 0.43 (FDA) and 0.47 mg/kg body weight (WHO) – particularly as 
the FDA’s standard is based on a 70 kg adult. Toxins are known to have a 10 fold 
increased effect in infants compared to adults (Gilbert 2004).    
Ideally the guidelines should also describe the route of entry of the exposure: ingestion 
(diet), inhalation or injection. This is essential because injection ensures that most of the 
substance is absorbed into the circulatory system and is accessible to all organs whereas 
ingestion via the diet results in a large proportion of the mercury being excreted in the 
faeces (Gilbert 2004). In animal studies methylmercury has been shown to cross the 
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placenta and accumulate in foetal brain, kidney and liver of mice, hamsters, rats and 
monkeys. Methyl mercury is transferred to infants via breast milk in both rats and 
hamsters but it transfers more efficiently across the placenta (TEACH p8).  
Based on the FDA’s guidelines it recommends that pregnant women, nursing mothers 
and young children do not consume certain kinds of fish that may contain high levels of 
methyl mercury (FDA p7; TEACH p1), in particular, shark, swordfish, king mackerel 
and tilefish which are the higher order consumers. In contrast, governments in 2013 are 
recommending the influenza vaccine to pregnant women (DHA IAP 2013) even though 
some influenza vaccines contain thimerosal and other non-inert excipients that are 
injected into the tissues and have access to the foetus and body organs. Every dose of 
influenza vaccine that comes from a multi-dose vial contains 24.5 micrograms of 
mercury (CSL PI). This is recommended even though the FDA has not established a 
safe dose of ethyl mercury in the foetus, infants, adults or pregnant women (FDA p3).  
The Health Effects of Ethyl and Methyl Mercury 
Ethyl and methyl mercury are classified as neurotoxins that destroy cells in key centers 
of the brain and nervous system. Mercury is especially hazardous to foetuses and small 
children. This is of concern when it is also known that the majority of substances that 
are taken in by a pregnant woman will cross the placental membrane ensuring that the 
foetus will experience the same level of any drug that the mother is exposed to (Gilbert 
2004 p28). However, compounds such as methylmercury are found in higher 
concentrations in the foetus than in the mother because the developing infant is a 
storage site for maternal mercury (Gilbert 2004 p28). Further protection is provided to 
the adult brain by the blood-brain barrier to filter out hazardous substances however the 
foetus and infant up to 6 months of age do not have this protection (Gilbert 2004). The 
blood-brain barrier is able to prevent large molecules from passing into the brain tissue 
but it cannot stop water soluble agents from entering the brain (Gilbert 2004 p28). 
Mercury is known to affect the central nervous system, skin and kidneys (FDA; NCIRS 
THIM FS p1). As the body systems of infants are still developing even a ‘trace’ amount 
of a toxin (particularly in combination with other substances) could affect the proper 
development of the kidneys and therefore inhibit the removal of mercury from an 
infant’s body. The NCIRS states that ‘ethyl mercury is rapidly converted in the body to 
inorganic mercury which is excreted in the stool’ (p1). This statement is unreferenced 
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and may not apply to infants whose systems are still developing. In addition, it may also 
give the mercury greater access to the brain when the blood-brain barrier is not 
developed. The effects of mercury exposure in adults include kidney damage and 
digestive tract problems including diarrhea, nausea and ulcers (TEACH p4). 
Mercury is known to inhibit cell division and migration within the forming brain and 
has been shown to bind to DNA thereby interrupting chromosomal reproduction and 
blocking several essential proteins (Kirby 2005 p48). The uptake of a chemical by 
different tissues and organs is also known to be affected by exposure to multiple 
chemicals at the same time (Gilbert 2004 p28). A combination of chemicals (such as the 
excipients in multiple vaccines or exposures to pesticides and other chemicals in the 
environment) can interact to affect absorption of the substance or to affect the body’s 
reaction to a specific chemical. Knowledge of these interactions on the metabolism and 
elimination of substances from the human body is limited (Gilbert 2004 p28). This is 
particularly the case for the foetus and infants because their body systems are still 
developing. Most detoxification occurs in the liver by breaking down toxic substances 
into less toxic substances. Heavy metals such as mercury are unable to be degraded so 
removal is dependent upon the functioning of the kidneys (Gilbert 2004 p29). Mercury 
is removed from the body by the kidneys which concentrate the toxin in the urine ready 
for excretion. A significant factor in the ability of a toxin to cause harm is the half-life 
of the substance.   
Methyl mercury has a half life of approximately 70 days but it is believed to be slightly 
less for ethyl mercury (PHAC 2002 p6). This is not a definitive statement supported 
with evidence. The Australian NCIRS states that the half-life of methyl mercury is 50 
days and for ethyl mercury is considerably less at 7-10 days but this statement is not 
referenced (NCIRS THIM p1). The half-life of any substance will be influenced by the 
genetics of the individual and the variations that occur in physiology at different ages or 
under different conditions. For example, metabolism varies considerably between 
individuals and in response to hormonal changes at different stages in life – infant, adult 
or pregnant mother (Gilbert 2004 p29). The half-life of a toxin can increase 
considerably during pregnancy due to physiological changes that affect the absorption, 
distribution and metabolism of an agent (Gilbert 2004 p 31). A compromised immune 
system or genetic trait can result in low level exposures being completely intolerable to 
some individuals (Gilbert 2004 p31). In addition, rapid weight loss can cause excess 
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toxins to be redistributed into the blood as fat is metabolised. Young people are 
particularly susceptible to health effects from toxins because the organs are rapidly 
developing and the dividing cells are more easily harmed than mature cells (Gilbert 
2004 p31).  
The brain grows rapidly in the first 7 years of life and mercury is a neurotoxin that 
specifically targets the nervous system and brain (TEACH). When children have been 
exposed to methyl mercury during pregnancy (in utero) it has been associated with 
delays in reaching developmental milestones and decreases in intelligence (TEACH p2). 
The foetus is found to be more sensitive to the effects of mercury and conditions such as 
severe neurologic injury including a condition similar to cerebral palsy have been 
acquired even when the mother has shown few or no symptoms (FDA p2). The larger 
the dose the greater the severity of the neurological condition (TEACH). When children 
in utero were exposed to low levels of methyl mercury they experienced sensory and 
motor neurological dysfunction and developmental delays (FDA p2). Children exposed 
to high doses of methyl mercury may experience mental retardation, cerebral palsy, 
reduced muscle coordination, blindness, deafness, seizures, muscle weakness and an 
inability to speak (TEACH p2 and 4). Studies from the Faroe Islands reported subtle 
cognitive disabilities including, impaired performance on attention, language and 
memory tests, associated with levels of methyl mercury that were previously thought to 
be safe (Grandjean et al 1997 in FDA p3). 
Children and adults exposed to high levels of methylmercury can also develop a 
disorder called acrodynia or pink disease (TEACH p4). Symptoms of this disorder 
include leg cramps, irritability, redness, peeling of hands and skin, nose and soles of 
feet, fever, itching, sweating, salivating, rashes, sleeplessness, weakness and 
neurological tics (TEACH). Pink disease is another name for mercury poisoning and the 
symptoms are consistent with autism spectrum disorders (American Psychiatric Assoc 
in PHAC 2002 p3). 
Mercury Toxicity and Autism 
Some epidemiological studies have also linked ethylmercury exposure with autism and 
other neurological disorders in children (TEACH p4; PHAC 2002 p3). However, due to 
variations in methodology the results from different studies have been inconsistent. 
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Evidence is also available that demonstrates autism is a common disorder in vaccinated 
children but a rare disorder in unvaccinated children (Vaccine Injury). This evidence is 
consistent with the fact, that neurodevelopmental disorders such as autism have similar 
symptoms to those of mercury poisoning (Coulter 1990; Kirby 2005 p73; PHAC 2002 
p3; US Congressional Record).  
Autism is characterised by impaired social interaction and communication, repetitive 
and stereotypic behaviours, interests and activities (PHAC 2002 p3). Symptoms 
generally appear at 18 to 30 months of age and range from mild to severe resulting in 
the term Autism Spectrum Disorders (ASD) (PHAC 2002 p3). Causes that have been 
implicated in this disorder are genetics, exposure to heavy metals such as lead and 
mercury, nutritional deficiencies and metabolic disease. One theory is that a genetic pre-
disposition to metallothionein protein dysfunction could cause autism in children after 
exposure to heavy metals (PHAC 2002 p3). Some children have a genetic problem with 
expelling mercury from the body and these predisposed children are more at risk of 
permanent neurological damage particularly when exposed to the live-virus MMR 
vaccine at eighteen months of age (Kirby 2005). This genetic predisposition appears to 
be four times more common in boys than girls (El-Dahr in 2001 in Kirby 2005 p143) 
This correlates with the statistics on autism, Attention Deficit Disorder (ADD), tics, 
speech delay and most other neurological disorders, which are also higher in boys 
compared to girls in the same ratio (American Psychiatric Association 1994 in PHAC 
2002). The sulfur-based protein metallothionein (MT) which performs many key 
functions in the human body is dysfunctional or depleted in autistic children.  
The History of Mercury as a Preservative in Vaccines 
In 1982, the FDA Register stated mercury compounds used in medicinal products 
should be classified as ‘not generally recognized as safe and effective’ (Burton 2003). 
At this time, the FDA independent panel also described mercury as an unreliable 
preservative. It was described as more bacteriostatic than bactericidal – it slowed the 
growth of new bacteria but did not kill them altogether. In fact, it was found to be more 
deadly to healthy cells than it was to harmful bacteria e.g. 35.3 times more toxic for 
embryonic heart tissue than for Staphylococcus aureus (FDA 1982 in Kirby 2005 p83).  
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Studies indicated that thimerosal was one of the most toxic and highly allergenic of 
twenty or more mercury compounds that the panel examined (FDA 1982 in Kirby 
2005). Whilst the FDA knew in 1982 of mercury’s potential to cause cell damage and 
delayed allergenic responses, it did not use caution by insisting that it was removed 
from vaccines (Burton 2003). Instead the FDA called for the removal of all mercury-
based preservatives, including thimerosal from over-the-counter topical products, such 
as eardrops, eyedrops, nasal sprays and mercurochrome but it did not call for its 
removal from vaccines that are injected into the tissues of infants. It wasn’t required to 
be removed from vaccines until 1998 after parents began investigating the ingredients 
of vaccines. Many parents were associating the escalation of chronic illness in children 
during the 1990’s with the increase in the number of vaccines being used and the 
increase in the vaccination rates in children (Bernard et al 2001 in FDA p3; Burton 
2003). In particular the reported cases of autism increased dramatically in the 1990’s 
(10 to 17 percent per year) and the exposure of infants to ethylmercury increased 
threefold (Burton 2003).  
It was estimated that children in the 1990’s were receiving many times more than the 
daily limit of mercury because of the addition of many new thimerosal-containing 
vaccines (FDA p1). When Hepatitis B and Haemophilus Influenza Type B vaccines 
were added to the schedule in the early 1990’s the cumulative levels of ethylmercury 
that children were exposed to increased almost 3 fold (Burton 2003). Parents informed 
Congress of these concerns in 1997 and the FDA was mandated to evaluate the human 
exposure to mercury that children were receiving (Burton 2003). Due to the variations 
in safety standards that existed between agencies the National Academy of Sciences was 
asked by Congress to provide a recommendation for a justifiable level of mercury for 
protecting human health (FDA p3). It was agreed that the EPA’s guide of 0.1 
microgram/kg/day was considered scientifically justifiable (Burton 2003; FDA p3). 
Consequently the FDA discovered that the amount of ethyl mercury that infants were 
exposed to in the first 6 months of life through mandatory vaccinations was higher than 
the recommended standard for organomercury compounds (Burton 2003). 
A ‘safe’ cumulative level of mercury in infants depends upon the standard that is used 
and the size of the infant (Gilbert 2004; Halsey 1999). Halsey (1999) observed that 
using the EPA guideline of 0.1 microgram/kg/day ‘many children at 2 months of age 
received almost 90 times the daily limit in a single doctor’s visit. And the smallest 
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babies were given approximately eight months worth of daily exposures (240 times the 
daily limit) in a single day’ (Halsey 1999 in Kirby 2005 p81). Halsey (1999) the 
Director of Vaccine Safety in America, is quoted as saying in an American Academy of 
Pediatrics (AAP) committee report ‘doctors should be told soon about the amount of 
mercury in vaccines and the conflict with a federal health guideline’ (Halsey 1999 (57 
and 59) in Kirby D 2005 p70). Halsey N, (1999) also stated ‘no-one knows what dose of 
mercury, if any is safe, and we can claim there is no evidence of harm but the truth is 
no-one has looked’ (Kirby 2005 p71). 
After parents and researchers highlighted the correlation between vaccines and 
increased neurodevelopmental disorders in children the FDA reviewed the list of 
regulated products containing mercury that were listed under the FDA Modernization 
Act of 1997. The review was conducted in 1999 and concluded that ‘there was no 
evidence of harm from the use of thimerosal as a vaccine preservative, other than local 
hypersensitivity reactions (Bell et al 2001 in FDA p4). The FDA stated that as a 
precaution vaccines would be reformulated without thimerosal. In 2001 the Institute of 
Medicine (IOM) stated that an association between mercury exposure and 
neurodevelopmental disorders including autism, attention deficit hyper-activity disorder 
(ADHD) and speech or language delay was biologically plausible (FDA p3). However it 
was considered that further studies were needed to prove a causal link. After assessing 
further epidemiological studies, the IOM in 2004 rejected a causal relationship between 
thiomersal containing vaccines and neurodevelopmental disorders (FDA p3). Many of 
the epidemiological studies conducted or funded by the CDC have been claimed to be 
of poor design, under-powered and fatally flawed (Burton 2003).  
The statement made by the Institute of Medicine (IOM) Immunisation Safety Review 
Committee in 2004 made the following conclusion: 
The body of evidence favoured rejection of a causal relationship between 
thimerosal-containing vaccines and autism and that the hypothesis generated to 
date, concerning the biological mechanism for such causality, are theoretical 
only. The committee also stated that the benefits of vaccination are proven and 
the hypothesis of susceptible populations is presently speculative and that 
widespread rejection of vaccines would lead to increases in incidences of serious 
infectious diseases (FDA p3).     
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  It is claimed by the FDA that ‘there is only a theoretical potential of toxicity from trace 
amounts of thimerosal in vaccines’ (IOM, FDA, NCIRS THIM). This is a value 
judgment   made without definitive knowledge of a safe level of mercury in children or 
adults. Mercury is classified as a neurotoxin and exposure to organic mercury is known 
to target the nervous system resulting in a disease similar to autism (TEACH p4; PHAC 
2002 p3). Whilst the FDA considered that it was unethical to determine a safety profile 
of ethyl mercury in infants it did not consider it unethical to use ethyl mercury in 
vaccines for many years without knowing what level was harmful to an infant. 
The FDA has used ethylmercury in vaccines for many years and it has been detected in 
the blood, urine, and faeces of vaccinated infants (PHAC 2002; Kirby 2005). These 
infants present a good opportunity to study the effects of different levels of mercury in 
children but the FDA has not used this opportunity to systematically study the health 
outcomes of ethyl mercury after 60 years of using thimerosal-containing vaccines. In 
1999 the US Federal health officials conceded that the amount of thimerosal in vaccines 
exceeded 2 safety thresholds (Burton 2003). They also conceded that the amount of 
mercury in one dose of DTaP or Hepatitis B vaccines (25 micrograms each) was many 
times above the threshold set by the EPA (Burton 2003). Whilst there is inadequate 
research on the neurotoxicity and nephrotoxicity of ethyl mercury in infants, there is a 
large body of evidence indicating the dangers to health of ethyl mercury in animals and 
humans. Yet the FDA did not consider it unethical to use this preservative in numerous 
vaccines for children when it did not have empirical evidence of its safety.  
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Appendix 3  
The Australian Government’s Recommended Schedule of Vaccines 
This information is referenced from the Australian Government’s Immunise Australia 
Program (IAP) website 2013, Frequently asked questions related to payments and 
immunisation  
http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/faq-related-
payments#immunised (accessed July 2013). 
Definition of ‘fully immunised’ for the Family Tax Benefit Part A Supplement 
From 1 July 2012 
 
Age Disease immunised against 
2 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib 
Hepatitis B 
4 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib 
Hepatitis B 
6 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib 
Hepatitis B (or at 12 months) 
12 months Measles 
Mumps 
Rubella 
Hib 
Hepatitis B (or at 6 months) 
4 years Diphtheria 
Tetanus 
Pertussis 
Polio 
Measles 
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Mumps 
Rubella 
  
 
 
Definition of ‘fully immunised’ for the Family Tax Benefit Part A Supplement 
From 1 July 2013 
 
Age Disease immunised against 
2 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib 
Hepatitis B 
Pneumococcal 
4 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib 
Hepatitis B 
Pneumococcal 
6 months Diphtheria 
Tetanus 
Pertussis 
Polio 
Hib  
Hepatitis B (or at 12 months) 
Pneumococcal 
12 months Measles 
Mumps 
Rubella 
Hib 
Hepatitis B (or at 6 months) 
Meningococcal C 
18 months Measles 
Mumps 
Rubella 
Varicella 
Pneumococcal* 
4 years Diphtheria 
Tetanus 
Pertussis 
Polio 
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 Vaccines for Occupational Groups	  
Reference: The Australian Immunisation Handbook 10th Edition. 2013. Australian 
Technical Advisory Group on Immunisation (ATAGI). 
Table 3.3.7 Recommended vaccinations for persons at increased risk of certain 
occupationally acquired vaccine-preventable diseases 
Occupation Vaccine 
Healthcare workers (Hcw) 
All HCW 
Includes all workers and students directly involved in 
patient care or the handling of human tissues 
Hepatitis B 
Influenza 
MMR (if non-immune)‡ 
Pertussis (dTpa) 
Varicella (if non-
immune) 
HCW who work in remote Indigenous communities or with 
Indigenous children in NT, Qld, SA and WA, and other 
specified healthcare workers in some jurisdictions 
Vaccines listed for ‘All 
HCW’, plus hepatitis A 
HCW who may be at high risk of exposure to drug-resistant 
cases of tuberculosis (dependent on state or territory 
guidelines) 
Vaccines listed for ‘All 
HCW’, plus consider 
BCG 
 
 
 
Persons who work with children 
 
 
 
All persons working with children, including: 
• staff and students working in early childhood 
education and care 
• correctional staff working where infants/children 
cohabitate with mothers 
• school teachers (including student teachers) 
• outside school hours carers 
• child counselling services workers 
• youth services workers 
 
 
 
Influenza 
MMR (if non-immune)‡ 
Pertussis (dTpa) 
Varicella (if non-
immune) 
Staff working in early childhood education and care 
Vaccines listed for 
‘Persons who work with 
children’, plus hepatitis 
A 
Carers 
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Occupation Vaccine 
Carers of persons with developmental disabilities§ 
Hepatitis A 
Hepatitis B 
Influenza 
Staff of nursing homes and long-term care facilities for 
persons of any age§ 
Influenza 
MMR (if non-immune)‡ 
Varicella (if non-
immune) 
Providers of home care to persons at risk of high influenza 
morbidity Influenza 
Emergency and essential service workers 
Police and emergency workers 
Hepatitis B 
Influenza  
Tetanus (dT or dTpa) 
Armed forces personnel 
Hepatitis B 
Influenza 
MMR (if non-immune)‡ 
Tetanus (dT or dTpa) 
Other vaccines relevant 
to deployment 
Staff of correctional facilities 
Hepatitis B 
Influenza 
MMR (if non-immune)‡  
Tetanus (dT or dTpa) 
Staff of detention and immigration centres 
Hepatitis B 
Influenza 
MMR (if non-immune)‡  
Tetanus (dT or dTpa) 
 
 
Laboratory personnel 
 
Laboratory personnel handling veterinary specimens or 
working with Q fever organism (Coxiella burnetii) 
 
Q fever 
Laboratory personnel handling either bat tissues or 
lyssaviruses (including rabies virus and Australian bat 
lyssavirus) 
Rabies 
 
 
Laboratory personnel routinely working with these 
organisms:  
Bacillus anthracis 
Vaccinia poxviruses 
Poliomyelitis virus 
Salmonella enterica subspecies enterica serovar Typhi 
(S. Typhi) 
Yellow fever virus 
Neisseria meningitidis 
 
 
 
 
Anthrax  
Smallpox 
Poliomyelitis (IPV) 
Typhoid 
 
Yellow fever 
Quadrivalent 
meningococcal 
conjugate vaccine 
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Occupation Vaccine 
 
 
Japanese encephalitis virus 
(4vMenCV) 
 
Japanese encephalitis 
Persons who work with specific communities 
Workers who live with, or make frequent visits to, remote 
Indigenous communities in NT, Qld, SA and WA Hepatitis A 
Workers assigned to the outer Torres Strait Islands for a 
total of 30 days or more during the wet season Japanese encephalitis 
Persons who work with animals 
Veterinarians, veterinary students, veterinary nurses# 
Influenza 
Q fever 
Rabies 
Agricultural college staff and students (aged >15 years) 
exposed to high-risk animals# Q fever 
Abattoir workers and contract workers in abattoirs 
(excluding pig abattoirs) 
Livestock transporters 
Sheep shearers and cattle, sheep and dairy farmers 
Those culling or processing kangaroos or camels 
Tanning and hide workers 
Goat farmers 
Livestock saleyard workers 
Those handling animal products of conception 
Q fever 
Wildlife and zoo workers who have contact with at-risk 
animals, including kangaroos and bandicoots Q fever 
Persons who come into regular contact with bats (both 
‘flying foxes’ and microbats), bat handlers, bat scientists, 
wildlife officers, zoo curators 
Rabies 
Poultry workers and others handling poultry, including 
those who may be involved in culling during an outbreak of 
avian influenza, and swine industry workers 
Influenza 
Other persons exposed to human tissue, blood, body fluids or sewage 
Embalmers Hepatitis B 
Workers who perform skin penetration procedures (e.g. 
tattooists, body-piercers) Hepatitis B 
Funeral workers and other workers who have regular 
contact with human tissue, blood or body fluids and/or used 
needles or syringes 
Hepatitis B 
Plumbers or other workers in regular contact with untreated 
sewage 
Hepatitis A 
Tetanus (dT or dTpa) 
	  
  
National Immunisation Program Schedule
From 20 April 2015
Child programs 
Age Vaccine
Birth •	Hepatitis	B	(hepB)	a
2 months •	 Hepatitis	B,	diphtheria,	tetanus,	acellular	pertussis	(whooping	cough),	Haemophilus 
influenzae	type	b,	inactivated	poliomyelitis	(polio)	(hepB-DTPa-Hib-IPV)
•	 Pneumococcal	conjugate	(13vPCV)	
•	 Rotavirus
4 months •	 Hepatitis	B,	diphtheria,	tetanus,	acellular	pertussis	(whooping	cough),	Haemophilus 
influenzae	type	b,	inactivated	poliomyelitis	(polio)	(hepB-DTPa-Hib-IPV)
•	 Pneumococcal	conjugate	(13vPCV)	
•	 Rotavirus
6 months •	 Hepatitis	B,	diphtheria,	tetanus,	acellular	pertussis	(whooping	cough),	Haemophilus 
influenzae	type	b,	inactivated	poliomyelitis	(polio)	(hepB-DTPa-Hib-IPV)
•	 Pneumococcal	conjugate	(13vPCV)	
•	 Rotavirus	b
12 months • Haemophilus influenzae	type	b	and	meningococcal	C	(Hib-MenC)
•	 Measles,	mumps	and	rubella	(MMR)	
18 months •	 Measles,	mumps,	rubella	and	varicella	(chickenpox)	(MMRV)
4 years •	 Diphtheria,	tetanus,	acellular	pertussis	(whooping	cough)	and	inactivated		
poliomyelitis	(polio)	(DTPa-IPV)	
•	 Measles,	mumps	and	rubella	(MMR)	(to	be	given	only	if	MMRV	vaccine	was	not		
given	at	18	months)	
School programs 
10–15 years (contact	your	State	
or	Territory	Health	Department	for	
details)	
•	 Varicella	(chickenpox)	c
•	 Human	papillomavirus	(HPV)	d
•	 Diphtheria,	tetanus	and	acellular	pertussis	(whooping	cough)	(dTpa)
At-risk groups
Aboriginal and Torres Strait Islanders
12–18 months (in	high	risk	areas)e •	 Pneumococcal	conjugate	(13vPCV)
12–24 months (in	high	risk	areas)f •	 Hepatitis	A
6 months to less than 5 years •	 Influenza	(flu)
15 years and over •	 Influenza	(flu)
•	 Pneumococcal	polysaccharide	(23vPPV)	(medically	at	risk)
50 years and over •	 Pneumococcal	polysaccharide	(23vPPV)
Other at-risk groups
6 months and over (people	with	
medical	conditions	placing	them	
at	risk	of	serious	complications	of	
influenza)
•	 Influenza	(flu)	
12 months (medically	at	risk)e •	 Pneumococcal	conjugate	(13vPCV)
4 years (medically	at	risk)e •	 Pneumococcal	polysaccharide	(23vPPV)
Pregnant women (at	any	stage	of	
pregnancy)
•	 Influenza	(flu)	
65 years and over •	 Influenza	(flu)	
•	 Pneumococcal	polysaccharide	(23vPPV)
*	Please	refer	to	reverse	for	footnotes
Footnotes to the National Immunisation Program (NIP) Schedule
a.	 Hepatitis	B	vaccine:	should	be	given	to	all	infants	as	soon	as	practicable	after	birth.	The	greatest	
benefit	is	if	given	within	24	hours,	and	must	be	given	within	7	days.
b.	 Rotavirus	vaccine:	third	dose	of	vaccine	is	dependent	on	vaccine	brand	used.	Contact	your	State	or	
Territory	Health	Department	for	details.
c.	 Varicella	vaccine:	contact	your	State	or	Territory	Health	Department	for	details	on	the	school	grade	
eligible	for	vaccination.
d.	 HPV	vaccine:	is	for	all	adolescents	aged	between	12	and	13	years.	Contact	your	State	or	Territory	
Health	Department	for	details	on	the	school	grade	eligible	for	vaccination.
e.	 Pneumococcal	vaccine:	
i.	 Medically	at	risk	children	require	a	fourth	dose	of	13vPCV	at	12	months	of	age	and	a	booster	dose	
of	23vPPV	at	4	years	of	age.
ii.	 Aboriginal	and	Torres	Strait	Islander	children	require	a	fourth	dose	of	pneumococcal	vaccine	
(13vPCV)	at	12-18	months	of	age	for	children	living	in	high	risk	areas	(Queensland,	Northern	
Territory,	Western	Australia	and	South	Australia).	Contact	your	State	or	Territory	Health	
Department	for	details.
f.	 Hepatitis	A	vaccine:	two	doses	of	Hepatitis	A	vaccine	for	Aboriginal	and	Torres	Strait	Islander	children	
living	in	high	risk	areas	(Queensland,	Northern	Territory,	Western	Australia	and	South	Australia).	
Contact	your	State	or	Territory	Health	Department	for	details.
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Further information
Further	information	and	immunisation	resources	are	available	from	the	Immunise	Australia	Program	
website	at	www.immunise.health.gov.au	or	by	contacting	the	infoline	on	1800 671 811.
You	should	contact	your	State	or	Territory	Health	Department	for	further	information	on	the	program	
specific	to	your	State	or	Territory:
State/Territory  Contact Number
Australian	Capital	Territory	 (02)	6205	2300
New	South	Wales		 1300	066	055
Northern	Territory		 (08)	8922	8044
Queensland		 13	HEALTH	(13	4325	84)
South	Australia		 1300	232	272
Tasmania		 1800	671	738
Victoria		 1300	882	008
Western	Australia		 (08)	9321	1312
www.immunise.health.gov.au
All	information	in	this	publication	is	correct	as	at	June	2015
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Appendix 4 
 Governance of the National Immunisation Program (NIP) 
This information is referenced from the Australian Government’s Immunise Australia 
Program (IAP) website 2014.  
An overview of the main committees and advisory boards involved in designing 
Australia’s vaccination policies is provided here. Further details of their roles and the 
stakeholder composition of some of these boards are provided in chapter 6. The 
National Immunisation Committee (NIC) is the body that is responsible for the 
development, implementation and delivery of the Immunise Australia Program (IAP). 
This body reports to the Australian Health Protection Committee (AHPC) within the 
Communicable Diseases Network Australia (CDNA).  
Members of the NIC include: 
• National, state and territory government agencies;  
• Australian General Practice Network (AGPN);  
• Australian Medical Association (AMA);  
• Consumer Health Forum (CHF);  
• National Centre for Immunisation Research and Surveillance (NCIRS);  
• Royal Australian College of General Practitioners (RACGP);  
• Rural Doctors Association of Australia (RDAA)  
• National Indigenous Immunisation Coordinator (NIIC) 
The Australian Technical Advisory Group on Immunisation (ATAGI) works within the 
NIC and provides advice to the Minister for Health and Ageing. In addition to technical 
experts on the ATAGI committee, membership includes a consumer, a nurse and 
general practitioners. The Terms of Reference of ATAGI as stated on the government 
website are to (AG IAP 2012):  
• ‘provide technical advice to the Minister for Health and Ageing on the medical 
administration of vaccines available in Australia, including those on the National 
Immunisation Program;  
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• through the department provide advice to research funding bodies regarding the 
status of current immunisation research and areas where additional research is 
required.   
• advise the Pharmaceutical Benefits Advisory Committee on matters relating to 
the ongoing strength of evidence pertaining to existing, new and emerging 
vaccines in relation to their effectiveness and use in Australian populations;  
• produce the Australian Immunisation Handbook for the approval of the National 
Health and Medical Research Council;  
• consult with the National Immunisation Committee (NIC) on the content and 
format of the Australian Immunisation Handbook and implementation strategies; 
and  
• consult with the Communicable Diseases Network Australia (CDNA), the 
Australian Drug Evaluation Committee (ADEC) and the Adverse Drug 
Reactions Advisory Committee (ADRAC) on matters relating to the 
implementation of immunisation policies, procedures and vaccine safety.’ 
The Population Health Division, within the Department of Health and Ageing, is 
responsible for the development, implementation and evaluation of national 
immunisation policies and programs. There are several bodies within this division that 
are involved with implementing and managing the policy.  
The Therapeutic Goods Administration (TGA) 
The Therapeutic Goods Administration is the Australian regulator of vaccines and is 
responsible for both approving medicines/vaccines for the Australian market and 
monitoring their safety in the population. The board is operated on a cost-recovery 
system that requires the manufacturers of the products to provide 100% of the funding 
for the regulatory functions that it performs. A more detailed description of the role of 
this government organisation is described in chapter 7. 
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The Pharmaceutical Benefits Advisory Committee (PBAC) 
This board has the responsibility of evaluating the cost-effectiveness of vaccines to 
determine whether they should be funded under the NIP. This is a legislated process and 
the government cannot recommend a vaccine unless this board agrees that it is cost-
effective to the community. The cost-effectiveness of vaccines is determined by 
examining the evidence of the benefit of the vaccine from large clinical trials. This can 
then be used to estimate the cost of saving one quality-adjusted life year (QALY) which 
translates to the number of doses that need to be given at the vaccine cost to gain one 
extra year of full quality life (McIntyre 2012).  
Commencing 1 July 2009 the essential vaccines for the State and Territory 
Governments were being purchased directly by the Commonwealth under the National 
Immunisation Program. These arrangements are described in the document titled 
National Partnership Agreement on Essential Vaccines. Nolan concludes that 
Australian vaccination policy development is founded on ‘high-quality scientific 
foundations embedded in a national health funding model founded on equity and access 
for all’ (Nolan 2010 A82).  
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Appendix 5 
Comment on the Hawke, Lea and Berryman Paper 
Answering human papillomavirus concerns; a matter of science and time 
In June 2013 the journal Infectious Agents and Cancer published two papers that made 
opposing conclusions about the safety and efficacy of HPV vaccines. These papers were 
titled ‘Answering human papillomavirus concerns; a matter of science and time’ 
(Hawkes, Lea and Berryman 2013) and ‘HPV vaccines have not been demonstrated to 
be cost-effective in countries with comprehensive Pap screening and surgery’ (Wilyman 
2013). Whilst the first paper claimed HPV vaccines have been demonstrated to be safe 
and effective in preventing cervical cancer the second paper claimed that HPV vaccines 
have not been demonstrated to be safe and effective in preventing cervical cancer. It is 
necessary to investigate the type of evidence being used in both papers to see how the 
different conclusions have been drawn. 
Below is a critique of the evidence provided by Hawkes et al to illustrate how claims 
about the safety and efficacy of HPV vaccines can be made on a lack of scientific 
evidence.  
1. HPV vaccines have not been tested for efficacy in preventing cervical cancer. 
HPV vaccines have been tested for efficacy by investigating the effect of the 
vaccine in preventing pre-cancerous lesions (CIN 2 and 3) in young women 15-
26 years old. The authors of this paper state ‘this is a good predictor of cervical 
cancer risk’ yet they have not provided evidence that pre-cancerous lesions in 
this age-group are a good predictor of the risk of cervical cancer later in life. 
It is known that the majority of pre-cancerous lesions in this age-group clear 
naturally and never progress to cancer later in life so this end-point is inadequate 
for predicting the efficacy of this vaccine in preventing cervical cancer.    
2. The authors also inform the reader that ‘HPV infection rates’ are a good 
predictor of cervical cancer’. Yet the majority of women with high-grade HPV 
infections in developed countries are not at risk of cervical cancer because an 
HPV infection on its own does not cause cervical cancer. Co-factors are required 
for an HPV infection to progress to cervical cancer and these co-factors are not 
prevalent in developed countries such as Australia, UK, and the US. In other 
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words, an HPV infection on its own is not the only factor needed for the 
development of cervical cancer. 
3. The data in Table 1 of the Hawkes et al paper is incorrectly labelled as data from 
‘Phase III Trials’. This table contains data from phase 1, 2 and 3 trials. The only 
data collected from phase III trials for Gardasil (quadrivalent) vaccine was the 
Future II study conducted from 2003-2007. This study was the first trial of the 
efficacy of Gardasil vaccine in preventing pre-cancerous lesions in 15-26 year 
old women.  
This fact needs to be clarified by the authors because this 4 year study was the 
only trial for the efficacy of this vaccine in the prevention of cervical cancer. As 
it is known that the majority of pre-cancerous lesions in this age-group (15-26 
years) will never lead to cervical cancer then this end-point cannot be considered 
a good predictor of the efficacy of the vaccine in preventing cervical cancer. 
4. The authors incorrectly suggest that there is conclusive evidence of cross-
protection against the other 13+ HPV types that are not covered in the vaccine 
but are associated with cancer development. Scientists do not agree that HPV 
vaccines will protect against other high-grade HPV strains that are not included 
in the vaccine. 
5. The authors claim ‘CIN 2/3 are pathological signs of an HPV infection’. This is 
misleading because these lesions (CIN 2/3) associated with an HPV infection do 
not produce disease symptoms and may never progress to disease. An HPV 
infection does not produce disease on its own – co-factors are required. This 
point is not clarified in the paper.   
6. Hawkes et al state “HPV vaccination reduces CIN lesion incidence” (p.7).               
This needs to be qualified because the ability of the vaccine to reduce lesions 
depends upon an individual receiving all 3 doses of the vaccine and being naive 
for HPV 16/18. The correct statement is “HPV vaccine may reduce CIN lesions 
if specific criteria are met”. If these criteria are not met then efficacy is variable 
and unknown in different populations.  
In addition, reducing CIN in the majority of women in developed countries 
where the risk factors for pathogenesis are not common is not reducing the 
burden of disease (either warts or cancer) because HPV infection (and CIN 2/3) 
in most women does not progress to disease. This needs to be clarified by 
Hawkes et al. 
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7. Hawkes et al incorrectly stated that “Overall HPV can be associated with 99.7% 
of cervical cancers and can be considered as a necessary cause of cancer”.  
This figure comes from a small study of 1,000 tumours (Bosch et al 1995) which 
were re-analysed using different assay techniques by Walboomers et al in 1999. 
The figure cannot be extrapolated to ‘all cancers worldwide’.  
In addition, HPV infection is considered a necessary cause of ‘most’ cervical 
cancer but not all cervical cancer. Some scientists claim 5-10% of cervical 
cancer does not contain HPV infection (Haverkos 2005; Schiffman 2002). 
8. Hawkes et al state that ‘the safety of the ingredients has been well established’ 
yet they have not provided definitive evidence to support this claim. The authors 
have provided only a single reference for this claim and they have ignored all the 
adverse events and deaths that have been documented as linked to this vaccine 
by VAERS. Slade et al (2009) indicate that these cases cannot be properly 
reviewed because the vaccine manufacturers did not collect enough medical 
information to allow a review of the reported cases and therefore the VAERS 
database cannot establish causal links with the vaccine. 
In addition, Slade et al agree that a passive post-vaccination surveillance system 
is inadequate for determining causal events and their frequency in the 
population. Hawkes et al have also not discussed the evidence produced by 
Tomljenovic et al, Harper, Haug, Slade et al and others that questions the safety 
of this vaccine. 
9. Hawkes et al have made the following claim ‘there was no increase in relative 
risk (RR) of experiencing an autoimmune event compared with a control group 
that containing nonadjuvanted, or aluminium-/aluminium hydroxide-adjuvanted 
vaccines (RR 0.98, confidence intervals 0.8, 1.21).’ [sic] (p.7) 
The authors do not clearly state whether the vaccinated group was compared to a 
‘non-adjuvanated’ group or an ‘adjuvanated’ group – it refers to both and gives 
no clear discussion or evidence. Table 2 indicates that Cervarix was compared to 
the Hepatitis A vaccine and the AS04 adjuvant and not an inactive placebo. 
There is no evidence provided that systemic adverse events were compared to an 
unvaccinated group with a true inert placebo. The discussion is not clear and it 
mixes data for Gardasil with data for Cervarix.  
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10. Hawke et al state ‘However when systemic adverse events were examined there 
was no difference between vaccine and placebo’ (p.7).  
The authors do not explain that a true inert placebo was not used in the clinical 
trials to obtain this data. This data was obtained for Gardasil using the 
aluminium adjuvant that was present in the vaccine. This adjuvant has been 
linked to causing autoimmune diseases and it is not a suitable inert placebo for 
establishing the safety of the vaccine. It is important to clearly describe the 
placebo that was used for each vaccine and to clarify the reactions that occurred 
in a transparent manner. 
11. The paper describes the inadequacies of the passive monitoring system with an 
example of the significant disparity between the number of adverse events 
(AE’s) reported in the US compared to Australia (p.8) yet the authors conclude:  
‘The benefits of HPV vaccines far outweigh the risk and the mechanisms are in 
place to continue monitoring possible adverse events into the future.’  
The claim that ‘the benefits of HPV vaccines far outweigh the risks’ is 
unsubstantiated and adequate mechanisms for monitoring adverse events into the 
future are not in place. 
12. The conclusions drawn by Hawkes et al (2013) and quoted below have not been 
sustained or discussed with evidence in this paper: 
‘This review describes studies that have demonstrated the safety of vaccines and 
answered the very specific concerns raised particularly in regards to nervous 
system reactions, interactions with other vaccines and HPV vaccine influencing 
the course of existing lesions.’ [sic]. 
.  
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  Appendix 6 
Frequently Asked Questions about Immunisation  
This information is referenced from the Australian Government’s Immunise Australia 
Program (IAP) Website 2014: 
What is immunisation? 
Immunisation protects people against harmful infections before they come into contact 
with them in the community. Immunisation uses the body’s natural defence mechanism 
- the immune response - to build resistance to specific infections. Immunisation helps 
people stay healthy by preventing serious infections.  
 
What’s the difference between immunisation and vaccination? 
• Vaccination means having a vaccine - that is actually getting the injection.  
• Immunisation means both receiving a vaccine and becoming immune to a 
disease, as a result of being vaccinated.  
Most people use the terms 'vaccination' and 'immunisation' interchangeably but their 
meanings are not exactly the same.  
 
The term 'immunisation' is used in this website, as it's most commonly used in the 
community.  
 
How does immunisation work? 
All forms of immunisation work in the same way. 
 
When a person is vaccinated, their body produces an immune response in the same way 
their body would after exposure to a disease, but without the person suffering symptoms 
of the disease. When a person comes in contact with that disease in the future, their 
immune system will respond fast enough to prevent the person developing the disease. 
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What is in vaccines? 
Vaccines contain either:  
• a very small dose of a live, but weakened form of a virus;  
• a very small dose of killed bacteria or virus or small parts of bacteria; or  
• a small dose of a modified toxin produced by bacteria.  
Vaccines may also contain either a small amount of preservative or a small amount of 
an antibiotic to preserve the vaccine. 
 
Some vaccines may also contain a small amount of an aluminium salt which helps 
produce a better immune response. 
 
What childhood vaccines contain thiomersal? 
Thiomersal is a compound used in small amounts to prevent bacterial and fungal 
contamination of vaccines. Thiomersal is partly composed of mercury in the form of 
ethylmercury. Mercury causes a toxic effect after it reaches a certain level in the body. 
Whether or not it reaches a toxic level depends on the amount of mercury consumed and 
the person’s body weight. As a result of these concerns, in particular for newborn babies 
and very young children, thiomersal was removed or reduced from vaccines. 
 
Currently, all vaccines on the National Immunisation Program for children under 5 
years of age are now either thiomersal free or have only trace amounts of thiomersal. 
 
It is not possible to completely remove thiomersal from all vaccines, some vaccines like 
Energix-B are still most effectively manufactured using a trace amount of thiomersal as 
a preservative. 
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How long do immunisations take to work? 
In general, the normal immune response takes approximately two weeks to work. This 
means protection from an infection will not occur immediately after immunisation.  
 
Most immunisations need to be given several times to build long lasting protection. For 
example, a child who has been given only one or two doses of diphtheria-tetanus-
pertussis vaccine (DTPa) is only partially protected against diphtheria, whooping cough 
(pertussis) and tetanus, and may become sick if exposed to these diseases. However, 
some vaccines give protection after only one dose. 
 
How long do immunisations last? 
The protective effect of immunisations is not always for a lifetime. Some can last up to 
30 years. Due to frequent changes to the influenza virus, annual influenza vaccination is 
needed to provide protection against the most recent virus. 
 
Is everyone protected from disease by immunisation? 
Even when all the doses of a vaccine have been given, not everyone is protected against 
the disease.  
 
Measles, mumps, rubella, tetanus, polio and Hib vaccines protect more than 95% of 
children who have completed the course. One dose of meningococcal C vaccine at 12 
months protects over 90% of children. Three doses of whooping cough (pertussis) 
vaccine protects about 85% of children who have been immunised, and will reduce the 
severity of the disease in the other 15% if they do catch whooping cough.  
 
The protection levels provided by vaccines differ. For example, if 100 children are 
vaccinated with MMR, 5-10 of the fully immunised children might still catch measles, 
mumps or rubella (although the disease will often be milder in immunised children). 
However, if you do not immunise 100 children with MMR vaccine, and the children are 
exposed to measles, most of them will catch the disease with a high risk of 
complications like lung infection (pneumonia) or inflammation of the brain 
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(encephalitis). 
Booster doses are needed because immunity decreases over time. 
Why do children get so many immunisations? 
A number of immunisations are required in the first few years of a child’s life to protect 
the child against the most serious infections of childhood. The immune system in young 
children does not work as well as the immune system in older children and adults, 
because it is still immature. Therefore more doses of vaccine are needed.  
 
In the first months of life, a baby is protected from most infectious diseases by 
antibodies from her or his mother, which are transferred to the baby during pregnancy. 
When these antibodies wear off, the baby is at risk of serious infections and so the first 
immunisations are given before these antibodies have gone.  
 
Another reason why children get many immunisations is that new vaccines against 
serious infections continue to be developed. The number of injections is reduced by the 
use of combination vaccines, where several vaccines are combined into one shot. 
Why should children be immunised? 
There are two reasons for immunising every child in Australia:  
1. Immunisation is the safest and most effective way of giving protection against 
the disease. After immunisation, your child is far less likely to catch the disease 
if there are cases in the community. The benefit of protection against the disease 
far outweighs the very small risks of immunisation.  
2. If enough people in the community are immunised, the infection can no longer 
be spread from person to person and the disease dies out altogether. This is how 
smallpox was eliminated from the world and polio has disappeared from many 
countries. 
Where can I find more information on childhood immunisation? 
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Parents and guardians are able to find information on routine childhood immunisation in 
the Understanding Childhood Immunisation booklet. This is a detailed booklet which 
informs parents and guardians on why child/ren should be immunised against vaccine 
preventable diseases, common side effects of immunisation, how long immunisations 
last, vaccines their child/ten require at specific ages including the diseases they prevent 
and frequently asked questions. A handy quick guide to understanding childhood 
immunisation is also available. 
Should parents be immunised? 
Parents and other people (including grandparents, carers, etc) who come into contact 
with young children are commonly carriers of some childhood infections and should be 
vaccinated against these diseases. For example, several studies of infant pertussis 
(whooping cough) cases have indicated that family members, and parents in particular, 
were identified as the source of infection in more than 50% of cases. For more 
information on immunisations against childhood diseases, visit your local doctor or 
immunisation provider. 
 
Are there any reasons to delay immunisation? 
There are very few medical reasons to delay immunisation. If a child is sick with a high 
temperature (over 38ºC) then immunisation should be postponed until the child is 
recovering. A child who has a runny nose, but is not ill can be immunised, as can a child 
who is on antibiotics and obviously recovering from an illness. 
What are the side-effects of immunisation? 
Many children experience minor side effects following immunisation. Most side effects 
last a short time and the child recovers without any problems. Common side-effects of 
immunisation are redness, soreness and swelling at the site of an injection, mild fever 
and being grizzly or unsettled. You should give extra fluids to drink, not overdress the 
baby if hot and may consider using paracetamol to help ease the fever and soreness.  
 
Serious reactions to immunisation are very rare, however if they do occur consult your 
doctor immediately. It is important to remember that vaccines are many times safer than 
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the diseases they prevent. 
 
What about natural immunity? 
 
Natural immunity and vaccine-induced immunity are both natural responses of the 
body’s immune system. The body’s immune response in both circumstances is the 
same. In some cases, vaccine-induced immunity may diminish with time; natural 
immunity, acquired by catching the disease is usually life-long. The problem is that the 
wild or natural disease has a high risk of serious illness and occasionally death. Children 
or adults can be re-immunised (required with some vaccines but not all) if their 
immunity falls to a low level. It is important to remember that vaccines are many times 
safer than the diseases they prevent. 
Can immunisation overload the immune system? 
No. Children and adults come into contact with many antigens (substances that provoke 
a reaction from the immune system) each day, and the immune system responds to each 
antigen in specific ways to protect the body. Without a vaccine, a child can only become 
immune to a disease by being exposed to infection, with the risk of severe illness. If 
illness occurs after vaccination, it is usually insignificant. 
Why is immunisation still necessary in this day and age? 
Many diseases prevented by immunisation are spread directly from person to person, so 
good food, water and hygiene do not stop infection. Despite excellent hospital care, 
significant illness, disability and death can still be caused by diseases which can be 
prevented by immunisation. 
 
What does the Australian Government do for immunisation? 
 
A number of Australian Government initiatives in the past decade have led to the 
immunisation success story. They include funding immunisation-related financial 
incentives for parents and providers and the National Childhood Immunisation Register. 
The Government also funds state and territory governments to purchase vaccines.  
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The National Immunisation Program (NIP) Schedule lists the diseases for which 
immunisation is available and the ages at which doses should be given for those 
currently funded under the National Immunisation Program. 
 
Although vaccines are provided free under the National Immunisation Program for the 
ages outlined in the Schedule, a GP consultation fee may be charged for the 
immunisation visit. 
Where can I find information about travel vaccinations? 
Some health problems associated with international travel are vaccine preventable. 
Travellers should consult a travel medical centre, or their local doctor, at least 6 - 12 
weeks before departure, for a check-up and to discuss required and recommended 
vaccinations for specific regions. 
 
The websites below provide information about vaccinations and tips for staying healthy 
while overseas:  
• Travel Clinics Australia (Travel Clinic Australia)  
• Smartraveller (Department of Foreign Affairs and Trade);  
• International travel and health (World Health Organization)  
• Travelers’ health (US Center for Disease Control & Prevention). 
How do I get a copy of my child’s vaccination history? 
Records are kept by the Australian Childhood Immunisation Register (ACIR) which is 
run by Medicare Australia.  
 
ACIR was established in 1996 and is a national register administered by Medicare 
Australia that records details of vaccinations given to children under seven years of age 
who live in Australia. You can obtain a record of your child’s immunisation history 
from ACIR through the Medicare Australia website. You will need to register for online 
services at the following link, and then you will be able to request a history statement.  
 
	   344	  
Department of Human Services Website  
 
Alternatively, you can call ACIR on 1800 653 809 and request a statement be sent to 
you. 
 
If your child was born before 1989 you will need to get in contact with the general 
practice, health centre or immunisation provider your child attended for the first two 
years of their life. They will be able to provide you with a copy of their medical records, 
including all immunisations they have had. 
Page last modified: 10 February 2014  
 
Prior to February 2014 the following Q & A was also provided by the 
Australian Government on the IAP website: 
 
How safe are vaccines? 
 
All vaccines currently available in Australia must pass stringent safety testing before 
being approved for use by the Therapeutic Goods Administration (TGA). This testing is 
required by law and is usually done over many years during the vaccine’s development. 
In addition, the safety of vaccines is monitored once they are in use, by the Adverse 
Drug Reactions Advisory Committee (ADRAC) and other organisations. 
 
Before vaccines are made available for use they are rigorously tested in thousands of 
people in progressively larger clinical trials. These trials are strictly monitored for 
safety. The approval process can take up to 10 years. As a result of such detailed testing, 
a number of vaccines that failed in these early tests have never been released.  
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Appendix 7 
Timeline of Events in the Development of HPV Vaccination Policies 
Date Events 
1989 Haruld zur Hausen discovered HPV-DNA in cervical cancer tumors. He found 
HPV 16 in ~50% of tumours and HPV 18 in ~20% of tumours (zur Hausen 
2008). At this time it was believed that cervical cancer had a multifactorial 
etiology and it was not known whether HPV was a causal or a passenger virus in 
cervical epithelial tissue (Henderson 1989; Pfister 1990). 
 IARC stated there is no clear evidence that HPV infection is causally related to 
cancer of the cervix (Munoz et al 1989; Pfister 1990 p248). 
 CSL provided funding for Professor Ian Frazer and Dr. Jian Zhou to develop a 
drug at University of Queensland using new biotechnology that would prevent 
carcinogenic changes believed to result from HPV infections (Uniquest). 
1990 Pfister stated that there are no strains of HPV that are able to induce cancer right 
away and fully on their own; co-factors are required.   
1991  Frazer and Zhou successfully produced a recombinant virus-like particle (VLP) 
of the capsid protein L1 and L2 implicated in the cause of HPV pathogenesis. 
Uniquest patented this vaccine technology in 1991. The role of HPV in cervical 
cancer pathogenesis wasn’t established until 1995. 
1995 New hybridization techniques for identifying HPV DNA were described as 
being highly sensitive and specific and Bosch et al found HPV-DNA in 93% of 
their study of 1,000 tumours. These scientists claimed ‘the association of genital 
human papillomavirus (HPV) with cervical cancer is strong, independent of 
other risk factors and consistent in several countries’ (p796). 
 The IARC stated HPV DNA is not predictive of cancer because 90% of HPV 
infections have no clinical consequences. This indicates they are not an 
independent cause of cervical cancer. Lifestyle and environmental factors have 
been known to be risk factors for cervical cancer for decades (Haverkos 2005)  
Carcinogenicity of HPV 16/18 is supported by experimental evidence that 
proteins of these viruses interfere with the functions of cellular regulatory 
pathways (IARC 1995). Prior to 1995 it was not known whether HPV 16 and 18 
were the most common strains worldwide. 
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1995 The recombinant technology developed by Frazer and Zhou was licensed to CSL 
and sub-licensed to Merck & Co whilst still retaining the rights to market the 
technology in Australia and New Zealand (Uniquest; CSL Ltd). CSL received 
royalties and milestone payments in return for providing Merck with exclusive 
worldwide rights to market the vaccine (Williamson 2005). 
1999 Walboomers et al (1999) re-analysed the Bosch et al (1995) results using 
different techniques and assumptions and found 99.7% of the 1,000 tumors had 
HPV DNA. Scientists declared human papillomavirus (HPV) was associated 
with virtually all cervical cancer tumors. 
2002 Bosch et al (2002) claimed ‘The causal role of HPV infections in cervical cancer 
has been documented beyond reasonable doubt’ (p244). These scientists also 
stated that cervical cancer is a rare outcome from any strain of HPV infection. 
2003 Clifford et al (2003) state there are at least 16 high-risk oncogenic HPV sub-
types but ~70% of ICC is associated with HPV16/18. This figure is dependent 
upon the technology used to identify HPV in different studies. It was suggested 
that a multivalent vaccine could prevent the global burden of ICC. This was 
stated even though the Global Cancer Statistics for 2002 did not show a 
correlation between the incidence of HPV16/18 infections and a higher risk for 
cervical cancer (Parkin et al 2005). 
  Phase 3 trials to test the HPV-16/-18 vaccine for efficacy in preventing high-
grade CIN lesions (grade 2/3) in women 15-26 years of age were started. This 
surrogate for cervical cancer was chosen even though it was known that CIN 2/3 
lesions in this age-group mostly (95%) clear naturally and never lead to cervical 
cancer (WHO 2008). 
2005 CSL entered into a cross-licensing agreement with GaxoSmithKline, the 
pharmaceutical company producing the competitor HPV vaccine Cervarix 
(Uniquest) 
 Merck, Sharp and Dohme Corporation (MSD) (a subsidiary of the company 
Merck and Co Inc that is based in the US) is a member of Medicines Australia 
(MSD). Merck & Co Inc established an external licensing system in Australia in 
2005 and Gardasil was licensed in Australia in 2006 (MSD) 
 Prof Ian Frazer:  ‘90% of ICC occurs in the developing world’ (Williamson 
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2005). 
 The World Health Organisation (WHO) established the global HPV laboratory 
network (LabNet) to standardize assay tests and laboratory procedures. Prior to 
2005 a comparison between different studies of HPV subtypes was difficult 
because there was no global standardisation of assay performance or 
methodology for quality assurance (Eklund et al 2012). 
2006  The US FDA supervised the safety and efficacy clinical trials for quadrivalent 
HPV vaccine and fast-tracked the vaccine for market approval. The HPV 
vaccine was approved in 2006 for all women 9-26 years of age even though the 
risk of cervical cancer is significantly higher in the developing world, indicating 
that there are clear risk factors that are necessary for cervical cancer 
development.  
 
 Within 3 weeks of the US FDA approving the marketing of the vaccine the US 
CDC recommended the HPV vaccine for inclusion in the US National Schedule 
of Vaccines. The FDA monitors the post-vaccination surveillance program with 
the CDC – both of these government agencies have financial ties to the 
marketing of the vaccine and to Merck pharmaceutical company (Blaxill and 
Olmsted 2013). 
 Promotional campaigns stated that ‘cervical cancer is the second most common 
cancer in women worldwide’ even though this statistic is not representative of 
the risk of cervical cancer in all countries.  
 In 2006 the vaccine was still being trialled for efficacy against warts and pre-
cursor lesions (O’Neill 2006). Frazer stated ‘we are fairly optimistic that this 
vaccine will protect against HPV6 and 11 (warts) and if trials go well we are 
optimistic it will work against HPV16 and 18 (cervical cancer)’ (O’Neill 2006). 
 MSD claimed Gardasil was 100% successful in preventing pre-cursor lesions 
and non-invasive cervical cancers associated with HPV infection (MSD). 
Gardasil was licensed in Australia in 2006 (MSD). 
 Ian Frazer was awarded ‘Australian of the Year’ in 2006 for creating a vaccine 
that had the potential to wipe out cervical cancer within a generation (NADC). 
Between 2006-2008, the US and Australian inventors of the vaccine - Frazer, 
Lowry and Schiller - were bestowed with prestigious awards for their role in 
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developing VLP’s (Blaxill and Olmsted 2013 p183). Frazer credited his partner 
Jian Zhou with suggesting the idea for the new capsid technology underpinning 
the development of HPV vaccines (AG, Dept. Innovation and Industry 2008).   
2007 The marketing campaign for Gardasil began in Australia and the global 
campaign made US $1.5 billion for this year (Uniquest).  
 The Phase 3 clinical trials determining the efficacy and safety of HPV vaccines 
in preventing high-grade CIN lesions (2 and 3) were published (Future II 2007). 
These trials concluded the vaccine may prevent some cervical cancer. Scientists 
stated the vaccine was ‘expected’ to reduce cervical cancer rates because HPV 
infects all sexually active women. This ignores the fact that the majority of HPV 
infections (90%) are asymptomatic and never progress to disease because 
environmental factors are also required. Consequently the majority of women 
receiving the vaccine are not at risk from cervical cancer. 
2008 Haruld zur Hausen won the Nobel Prize for discovering HPV DNA in ICC. 
CSL’s profits increased by 63% from the previous year. CSL received royalty 
payments of $161 million from international sales of Gardasil and $159 million 
from the Australian government’s vaccination program. 
2009 The US FDA approved Gardasil for use in males aged 9–26 years of age (CSL 
2009). At this time it was approved for males for genital warts that are caused by 
HPV subtypes 6 and 11. Further data supporting the use of the vaccine against 
anal cancer and its pre-cursor anal intraepithelial neoplasia (AIN) was provided 
in 2012. Use of the vaccine was expanded to women 27-45 years of age (CSL 
Ltd) even though this demographic is most likely to have previous exposure to 
HPV16/18 and will not be protected by the vaccine.  
 CSL was granted an extended patent for the vaccine that will be effective until 
2026 (CSL Ltd). 
2010 Gardasil vaccine has been a blockbuster success for Merck &Co making $6 
billion from 2007-2010 (Blaxill and Olmsted 2013).  
2012 
HPV vaccines recommended for all boys (12-13 years) in Australia in subsidised 
school vaccination programs (AG IAP 2012). 
2013 HPV vaccines recommended for boys in subsidised programs in the US (CDC 
2013).  
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Appendix 8 
 The Limitations of the Bosch et al (1995) Study and the Re-Analysis 
by Walboomers et al (1999) 
Whilst Bosch et al, (1995), claim their international study of 1000 tumors confirms the 
role of HPV’s as the central etiological factor in cervical cancer worldwide, their 
evidence does not explain why there is a higher risk of cervical cancer in developing 
nations than developed nations. They claim that “HPV prevalence was remarkably 
homogonous among the countries’ (Bosch et al 1995). These authors claim “our results 
confirm the role of genital HPV’s as the central etiological factor in cervical cancer 
worldwide” (Bosch et al 1995 p796). This statement relies upon the detection methods 
used for HPV DNA and can only be made by ignoring the 5-10% of tumours that were 
known to be HPV negative in 1995. It should be noted that the primary researchers 
involved with the studies making this claim have links to pharmaceutical companies 
which make significant profits from vaccines (Bosch et al 1995; Walboomers 1999; 
Franco 1995; Munoz et al 2006).  
The limitations of this study Bosch et al (1995) study include:  
1. This study only included 10 of 18 regions for which cervical cancer incidence 
has been recorded 
2. It did not include a representative number of Asian countries which have very 
high rates of cervical cancer 
3. In each country the size of the study is limited and the cases cannot be claimed 
to be representative. 
4. The results vary according to the method of detection used. For example, 
analysis of the 66 HPV-negative specimens using additional HPV detection 
methods (e.g. other primers) alters the number of negative tumors to fewer than 
5%. 
5. In the final analysis HPV-negative results were only accepted from specimens 
with adjacent, confirmed tumor tissue. ‘This was to avoid false-negative results’. 
However, by doing this the researchers were missing some genuine HPV-
negative results. 
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6. The researchers state that their prevalence estimate of 93% maybe slightly 
inflated because the only restrictions for HPV-positive specimens were 
diagnostic confirmation and PCR sufficiency. 
7. Whilst it is stated that all HPV detection was carried out by one expert 
laboratory and by one histological reviewer, it would be important for the results 
to be confirmed by another reviewer to ensure there is agreement. This is 
because there is subjectivity in assessing specimens. The study does not state 
that the specimens were checked by another independent researcher.  
The Strength of Evidence for HPV genotypes in Cervical Carcinomas 
Despite the significant evidence illustrating environmental and lifestyle factors are 
necessary in the etiology of this cancer, Bosch et al stated in 1995 that epidemiological 
studies have shown that the association of genital human papillomavirus with cervical 
cancer is ‘strong, independent of other risk factors and consistent in several countries’ 
(Bosch et al 1995 p796). This contradicts all the evidence of previous studies. Prior to 
1995 most scientists were claiming a multifactorial etiology for cervical cancer. At this 
time Bosch et al, realized it was necessary to show that HPV is present in all cases of 
cervical cancer in order to prove that HPV is the main factor in cancer etiology. With 
the new technology they set out to conduct an international study of HPV sub-types in 
cervical cancer. The aim of this study was to characterize the distribution of HPV types 
in cervical cancer in different geographical regions. They state ‘this is essential to the 
development of vaccination strategies to curb the burden of cervical cancer’ (Bosch et al 
1995 p797). So even though studies were indicating HPV on its own does not result in 
cervical cancer, Bosch et al were already thinking of a vaccine to prevent this disease.  
Prior to this study it was believed that HPV DNA rates in tumor specimens were about 
60-90% (Franc 1995).  By 1995 it was believed that the filter in situ hybridization 
technique used to identify HPV DNA in epidemiological studies in the 1980’s had 
inadequate specificity and sensitivity (Franco 1995).  There was great concern regarding 
the variation in laboratory methods with different levels of specificity and sensitivity for 
detecting HPV DNA. Therefore a new technique was used in the 1995 study that was 
believed to be highly specific and sensitive (Franco 1995). The technique used by 
Bosch et al was a polymerase chain reaction (PCR) protocol based on consensus 
primers flanking a relative conserved region in the L1 gene of HPV. This technique is 
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also called MY09/11. Bosch et al (1995) concluded from their study that new molecular 
biology techniques are ‘truly sensitive and specific’ and they believed their result 
confirmed the plausibility of HPV infection as the pre-cursor event leading to cervical 
cancer. It is interesting that this claim has been made based upon cases using a 
particular biological test when the IARC states that these case series only provide 
suggestive results and can never serve as a basis for causal inferences (IARC 1995). 
Causality of infectious diseases should be based upon the epidemiological triangle - 
agent, host and environment. A claim of causality based on PCR tests ignores these 
factors. It is known that there are 35 + distinct HPV types and these complicate the 
ability to attribute causality to different types (Bosch et al 1995).  
The Bosch et al (1995) study tested nearly 1000 tumors and the negative-HPV tumors 
were re-tested using different methods and assumptions in 1999 (Walboomers 1999). 
Franco believes that the article by Bosch et al (1995) can be viewed as a critical 
contribution to our understanding of the etiology of cervical cancer.  He claimed that on 
the basis that traces of HPV were detected in 95% of the 1,000 tumours studied that 
HPV infection might ‘be the first cause of a human cancer shown to be a necessary one’ 
(p780). This was stated even though >5% of tumours were HPV negative and the claim 
was dependent upon the technology that was used. In addition, it ignored that fact that it 
was known that HPV on its own was not sufficient to cause disease. This is consistent 
with the epidemiological triad of causality that has been used for decades to determine 
causality. At this time (1995) the recombinant technology for the HPV vaccine that was 
developed by Frazer and Zhou was being licensed to CSL and sub-licensed to Merck & 
Co whilst still retaining the rights to market the technology in Australia and New 
Zealand (Uniquest; CSL Ltd). CSL received royalties and milestone payments in return 
for providing Merck with exclusive worldwide rights to market the vaccine (Williamson 
2005) – before it was tested for efficacy against pre-cursor lesions (2003-2007). This 
was also before it was established that HPV DNA 16 and 18 were found in 70% of 
tumours worldwide and it was known that HPV was not an independent cause of 
cervical cancer – environmental co-factors area also necessary (IARC 1995).  
On the evidence of the Bosch et al study, Franco (1995) questions the existence of 
cervical cancers that are induced by carcinogenic routes other than HPV infection. He 
suggests HPV free cancers might be reflecting loss of the HPV genome as the disease 
progresses (p780). This is speculation. Rather than accepting that it’s possible some 
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tumors are induced by factors other than HPV, he suggests researchers will have to 
demonstrate that ‘failure to detect HPV DNA is not due to insufficient sensitivity’ of the 
test (p780). Franco has taken the position that an absence of HPV genome is not 
because there is an absence of HPV genome but rather a loss due to disease progression 
and he is assuming the HPV was there in the first place. This is called interpreting the 
results to produce the desired picture. In addition, if HPV DNA is found in organs and 
tissues where it is not expected to be found he claims ‘researchers will have to prove 
that an occasional HPV- tissue association is not due to insufficient specificity or 
contamination’ (p790). Franco is suggesting that the reason for not getting the result 
they expected was again because the test was inadequate and therefore the result should 
not be accepted.  
Franco states earlier in his article that ‘an easily diagnosed viral infection as the pre-
cursor event leading to cervical cancer calls for action on 2 fronts’ (p779):  
1. Primary prevention by immunisation against HPV and  
2. Secondary prevention by cytology screening with testing for cervical HPV 
infection.  
It would appear that the researchers were pre-empting the result in order to find 
evidence to support the preventative measures listed above.  
Analysis of the Evidence from the ‘Worldwide’ Study of HPV 
Prevalence (Bosch et al 1995) 
Despite the limitations of the study and the fact that the study found the prevalence of 
HPV 16 was the pre-dominant sub-type in all countries whilst other high-risk sub-types 
varied between countries, these authors still claimed that the results confirmed that 
genital HPV’s were the central causal factor in cervical cancer globally. Yet this 
distribution of HPV sub-types did not explain the higher risk of cervical cancer in 
developing countries than developed countries. Bosch et al attempt to explain the 
geographical distribution of cervical cancer by suggesting that HPV sub-types might 
need to be studied in conjunction with host genetics. Again this is suggesting that the 
etiology of cervical cancer may be dependent upon host genetics in combination with 
HPV. This is not evidence for a disease that can be treated by vaccination and it does 
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not support their claim that HPV is the central etiological factor in most cervical cancer 
worldwide. 
In 1999, Walboomers et al re-analysed the 66 HPV negative carcinomas found in the 
Bosch et al 1995 study. After re-analysis Walboomers et al claimed the HPV- negative 
tumors were mostly a result of ‘sample inadequacy or integration events affecting the 
HPV L1 gene, which is the target of the polymerase chain reaction (PCR)-based test 
which was used’. The re-analysis was on 49 of the 66 cases using a different detection 
method to that used in 1995. The results were compared with 48 of the 866 carcinoma 
cases that were originally positive for HPV DNA. After re-analysis 38 of the negative 
cases were now declared positive. Another 21 cases were considered ‘qualitatively 
inadequate’ and these were not included in the final result. Walboomers et al (1999) 
then concluded that 99.7% of the 1000 cervical tumors in the worldwide study were 
now positive for HPV DNA.  This led to the claim by Walboomers et al that HPV-
negative cancers are an ‘extreme rarity’ – this was despite the limitations of this 
‘worldwide study’ and despite the fact that the samples were not considered to be 
representative of each country. The sample size and lack of representation of all global 
regions are insufficient to give this study statistical significance in a worldwide context. 
Yet it is this study that has been quoted in future papers as being the evidence for the 
conclusion that HPV is the main cause of cervical cancer (Munoz et al 2006).  
Walboomers et al go on to claim that the virtual absence of HPV-negative cancers (in 
this small unrepresentative worldwide study) implies that effective prophylactic 
vaccination might almost eliminate cervical cancer worldwide. They continue ‘This is 
especially relevant in developing countries, where screening may not be economically 
feasible’ (Walboomers et al 1999 p18). This conclusion has been made by ignoring all 
the lifestyle factors that have been suggested as risk factors in the etiology of cervical 
cancer for one hundred years. It also ignores the fact that developing countries have a 
higher incidence of other high-risk HPV types that would not be covered by the 
quadrivalent HPV vaccine. 
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